## **EXHIBIT A**

## To

## Declaration of Jeffrey B. Coopersmith

1			
2	UNITED STATES DISTRICT COURT		
3	NORTHERN DISTRICT OF CALIFORNIA		
4	SAN JOSE DIVISION		
5			
6	UNITED STATES OF AMERICA, )  OR-18-00258-EJD		
7	PLAINTIFF, ) ) SAN JOSE, CALIFORNIA		
8	VS. ) DECEMBER 7, 2022 RAMESH "SUNNY" BALWANI, )		
9	DEFENDANT. )		
10			
11			
12	TRANSCRIPT OF PROCEEDINGS BEFORE THE HONORABLE EDWARD J. DAVILA		
13	UNITED STATES DISTRICT JUDGE		
14	APPEARANCES:		
15	FOR THE PLAINTIFF: UNITED STATES ATTORNEY'S OFFICE BY: JOHN C. BOSTIC		
16	JEFFREY B. SCHENK 150 ALMADEN BOULEVARD, SUITE 900		
17	SAN JOSE, CALIFORNIA 95113		
18	BY: ROBERT S. LEACH 1301 CLAY STREET, SUITE 340S		
19	OAKLAND, CALIFORNIA 94612		
20	(APPEARANCES CONTINUED ON THE NEXT PAGE.)		
21	OFFICIAL COURT REPORTER:		
22	IRENE L. RODRIGUEZ, CSR, RMR, CRR CERTIFICATE NUMBER 8074		
23			
24	PROCEEDINGS RECORDED BY MECHANICAL STENOGRAPHY TRANSCRIPT PRODUCED WITH COMPUTER		
25			

1	APPEARANCES:	(CONT'D)
2		
3	FOR DEFENDANT BALWANI:	ORRICK, HERRINGTON & SUTCLIFFE LLP BY: SHAWN ESTRADA REESE ONATE
4		SERENA NICHOLS
5		THE ORRICK BUILDING 405 HOWARD STREET SAN FRANCISCO, CALIFORNIA 94105
6		
7		BY: JEFFREY COOPERSMITH  AARON BRECHER  AMANDA MCDOWELL
8		701 FIFTH AVENUE, SUITE 5600 SEATTLE, WASHINGTON 98104
9		BY: STEPHEN CAZARES
10		77 SOUTH FIGUEROA STREET, SUITE 3200 LOS ANGELES, CALIFORNIA 90017
11		BY: AMY WALSH
12		51 W 52ND STREET NEW YORK, NEW YORK 10019
13	FOR II C. DRODAHIOM.	
14	FOR U.S. PROBATION:	JESSICA GOLDSBERRY
15	ALSO PRESENT:	OFFICE OF THE U.S. ATTORNEY BY: MADDI WACHS, PARALEGAL
16		UNITED STATES POSTAL INSPECTION SERVICE
17		BY: CHRISTOPHER MCCOLLOW
18		FEDERAL BUREAU OF INVESTIGATION BY: MARIO C. SCUSSEL
19		UNITED STATES FOOD & DRUG
20		ADMINISTRATION
21		BY: GEORGE SCAVDIS
22		
23		
24		
25		

	1	SAN JOSE, CALIFORNIA	DECEMBER 7, 2022
10:09AM	2	PROCEE	I D I N G S
10:09AM	3	(COURT CONVENED AT 10:09 A	.M.)
10:09AM	4	THE COURT: LET'S CAI	LL OUR MORNING MATTER.
10:09AM	5	THIS IS 18-258, UNITED STA	TES VERSUS
10:09AM	6	RAMESH "SUNNY" BALWANI.	
10:09AM	7	LET ME FIRST CAPTURE THE A	PPEARANCES OF THE PARTIES.
10:09AM	8	WHO APPEARS FOR THE GOVERN	MENT?
10:09AM	9	MR. LEACH: GOOD MORN	NING, YOUR HONOR.
10:09AM	10	ROBERT LEACH ON BEHALF OF '	THE UNITED STATES.
10:09AM	11	I'M JOINED BY JOHN BOSTIC	AND JEFF SCHENK
10:09AM	12	THE COURT: THANK YO	OU. GOOD MORNING.
10:09AM	13	AND FOR THE DEFENDANT?	
10:09AM	14	MR. COOPERSMITH: GOO	DD MORNING, YOUR HONOR.
10:09AM	15	JEFF COOPERSMITH FOR MR. B.	ALWANI.
10:09AM	16	MR. BALWANI IS PRESENT.	
10:09AM	17	I'M JOINED BY MY COLLEAGUE	S, AMY WALSH, STEPHEN CAZARES,
10:09AM	18	AND MOST OF OUR TEAM, AMANDA, S	HAWN ESTRADA, REESE ONATE,
10:09AM	19	AARON BRECHER, SERENA NICHOLS,	AND MOST OF MR. BALWANI'S FAMILY
10:09AM	20	IS SEATED BEHIND THAT ROW.	
10:10AM	21	THE COURT: THANK YOU	J. GOOD MORNING. IT'S NICE TO
10:10AM	22	SEE EVERYONE.	
10:10AM	23	MR. COOPERSMITH: THA	ANK YOU, YOUR HONOR.
10:10AM	24	THE COURT: WE ARE HE	ERE THIS MORNING FOR THE
10:10AM	25	SENTENCING IN THIS MATTER HAVIN	G HEARD THE JURY'S VERDICT THAT

10:10AM	1	WAS RETURNED AND SUBSEQUENT TO THE TRIAL IN THIS MATTER.
10:10AM	2	LET ME INDICATE AND ASK FIRST, ARE ALL PARTIES READY TO
10:10AM	3	PROCEED?
10:10AM	4	MR. LEACH: YES, YOUR HONOR.
10:10AM	5	MR. COOPERSMITH: YES, YOUR HONOR.
10:10AM	6	THE COURT: ALL RIGHT. THANK YOU.
10:10AM	7	AND WHO APPEARS FOR PROBATION?
10:10AM	8	PROBATION OFFICER: GOOD MORNING, YOUR HONOR.
10:10AM	9	JESSICA GOLDSBERRY FOR U.S. PROBATION.
10:10AM	10	THE COURT: THANK YOU. GOOD MORNING.
10:10AM	11	LET ME INDICATE THE DOCKETS THAT I HAVE REVIEWED IN THIS
10:10AM	12	MATTER IN ANTICIPATION OF PREPARATION OF THE SENTENCING.
10:10AM	13	FIRST OF ALL, I HAVE REVIEWED THE PSR, WHICH IS DOCKET
10:10AM	14	1647; I'VE REVIEWED THE GOVERNMENT'S SENTENCING MEMORANDUM,
10:10AM	15	1661; THE DEFENSE MEMORANDUM, 1662, I BELIEVE IT IS. THERE WAS
10:11AM	16	A DEFENDANT'S APPENDIX A THAT WAS LET'S SEE. THAT WAS FILED
10:11AM	17	ON NOVEMBER 30TH, YES.
10:11AM	18	AND 1665 WERE DEFENDANT'S EXHIBITS; 1671 WAS THE DEFENSE
10:11AM	19	RESPONSE TO THE GOVERNMENT'S MEMO WITH EXHIBITS; 1674 WAS THE
10:11AM	20	GOVERNMENT'S RESPONSE TO DEFENDANT'S MEMO; AND THEN AS RECENTLY
10:11AM	21	AS YESTERDAY AT 1:34 P.M., 1677 I BELIEVE IT WAS 100 PAGE
10:11AM	22	DOCUMENT, SUPPLEMENTAL EXPERT REPORT THAT WAS FILED BY THE
10:11AM	23	DEFENSE.
10:11AM	24	DID THE GOVERNMENT GET THAT SUPPLEMENTAL REPORT?
10:11AM	25	MR. LEACH: WE DID, YOUR HONOR. THANK YOU.

10:11AM	1	THE COURT: ALL RIGHT. THANK YOU.
10:11AM	2	THOSE ARE THE DOCUMENTS THAT THE COURT RECEIVED AND
10:11AM	3	CONSIDERED, INCLUDING THE EXHIBITS.
10:11AM	4	LET ME INDICATE THAT THERE WERE MANY, MANY LETTERS OF
10:11AM	5	SUPPORT OF MR. BALWANI THAT WERE ALSO CONTAINED IN THOSE
10:12AM	6	EXHIBITS, AND THE COURT HAS READ AND REVIEWED THOSE AS WELL.
10:12AM	7	ARE THERE ANY OTHER DOCUMENTS THAT THE PARTIES WANT TO
10:12AM	8	BRING TO MY ATTENTION?
10:12AM	9	MR. LEACH: NO, YOUR HONOR.
10:12AM	10	MR. COOPERSMITH: NO, YOUR HONOR. YOU'VE COVERED
10:12AM	11	IT. THANK YOU.
10:12AM	12	THE COURT: THANK YOU.
10:12AM	13	LET ME ASK PROBATION THEN AS TO THE PSR, ARE THERE ANY
10:12AM	14	CHANGES, ADDITIONS, DELETIONS TO THE PRESENTENCE REPORT?
10:12AM	15	MR. COOPERSMITH: NO, YOUR HONOR.
10:12AM	16	THE COURT: ALL RIGHT. THANK YOU.
10:12AM	17	AND THE PARTIES DID RECEIVE THAT IN A TIMELY MATTER.
10:12AM	18	WHAT I'D LIKE TO DO INITIALLY IS TO REVIEW THE OBJECTIONS.
10:12AM	19	THERE WERE OBJECTIONS MADE TO THE PSR.
10:12AM	20	WHAT I THOUGHT I WOULD DO, I BELIEVE THERE WERE A TOTAL OF
10:12AM	21	39 OBJECTIONS FILED BY THE DEFENSE AS TO THE PSR, INCLUDING
10:12AM	22	OBJECTIONS IN THE APPENDIX A THAT WAS ATTACHED TO THE DEFENSE
10:12AM	23	SENTENCING MEMORANDUM.
10:13AM	24	AND GIVEN THE QUANTITY OF THOSE OBJECTIONS, I HAVE DIVIDED
10:13AM	25	THOSE INTO TWO CATEGORIES THAT I TITLED CONTEXTUAL AND

10:13AM	1
10:13AM	2
10:13AM	3
10:13AM	4
10:13AM	5
10:13AM	6
10:13AM	7
10:13AM	8
10:13AM	9
10:13AM	10
10:13AM	11
10:13AM	12
10:14AM	13
10:14AM	14
10:14AM	15
10:14AM	16
10:14AM	17
10:14AM	18
10:14AM	19
10:14AM	20
10:14AM	21
10:14AM	22
10:14AM	23
10:14AM	24
10:14AM	25

SUBSTANTIVE.

THE SUBSTANTIVE OBJECTIONS, LET ME PARSE THOSE OUT FIRST,

THOSE ARE -- AND I'VE IDENTIFIED THOSE AS OBJECTIONS, AND THESE

ARE DEFENSE OBJECTIONS THIRTEEN, TWENTY-TWO, TWENTY-THREE, AND

TWENTY-FOUR, AND I'LL TALK ABOUT THOSE SEPARATELY.

THE BALANCE I'VE LABELLED CONTEXTUAL. AND WHAT I WOULD LIKE TO DO IS GO THROUGH THOSE INITIALLY, AND THEN WE'LL GO THROUGH THE SUBSTANTIVE.

IN THIS ANALYSIS, I THINK YOU'LL FIND THAT THE SUBSTANTIVE OBJECTIONS REALLY RELATE TO LOSS AND GUIDELINE CALCULATIONS, WHICH ARE OF INTEREST TO THE PARTIES.

I NOTE THAT THE GOVERNMENT ALSO FILED AN OBJECTION, AND I HAVE THAT HERE.

LET ME ASK, IS THERE ANYTHING ELSE THAT YOU WOULD LIKE ME TO KNOW, MR. LEACH, IN REGARDS TO THE GOVERNMENT'S OBJECTION?

MR. LEACH: NO, YOUR HONOR.

I THINK AS WE RELAY IN THE BRIEF THAT IN PREPARING THE PSR, IT APPEARED THAT PROBATION RESOLVED SOME OBJECTIONS BY PUTTING IN ARGUMENT WHERE -- WE'VE HIGHLIGHTED TWO OF THOSE PARAGRAPHS FOR THE COURT.

WE DON'T THINK IT'S NECESSARY TO PARSE THE PSR IN QUITE THAT WAY.

I THINK THE COURT SAT THROUGH TWO TRIALS WITH A LENGTHY RECORD, AND WE WANTED TO HIGHLIGHT THOSE TO THE COURT BECAUSE THERE WERE ELEMENTS THAT WE DISAGREED WITH, BUT AS WE SAY IN

10:14AM	1
10:14AM	2
10:14AM	3
10:14AM	4
10:15AM	5
10:15AM	6
10:15AM	7
10:15AM	8
10:15AM	9
10:15AM	10
10:15AM	11
10:15AM	12
10:15AM	13
10:15AM	14
10:15AM	15
10:15AM	16
10:15AM	17
10:15AM	18
10:15AM	19
10:15AM	20
10:15AM	21
10:15AM	22
10:15AM	23
10:15AM	24
10:16AM	25

OUR PAPERS, I DON'T THINK IT'S NECESSARY FOR THE COURT TO
RESOLVE THOSE OBJECTIONS FOR PURPOSES OF SENTENCING. AND I
WOULD IMAGINE THEY FALL INTO THE CATEGORY OUTSIDE OF THIRTEEN,
TWENTY-TWO, TWENTY-THREE, AND TWENTY-FOUR THAT YOUR HONOR JUST
DESCRIBED.

THE COURT: OKAY. THANK YOU.

MR. COOPERSMITH, YOU'RE AT THE LECTERN.

MR. COOPERSMITH: OH, I JUST THOUGHT IT WOULD BE
ABOUT THAT TIME TO APPROACH, BUT I HAVE NOTHING TO ADD AT THIS
PARTICULAR MOMENT.

THE COURT: WELL, THANK YOU.

THE GOVERNMENT'S OBJECTIONS WERE, AS YOU STATED,

MR. LEACH, TO -- I THINK YOUR OPINION IS THAT THE DEFENSE

SEEMED TO -- AND THEIR INTENT AND REQUEST WAS TO ADD CERTAIN

LANGUAGE TO VARIOUS PARAGRAPHS. AND I'VE LOOKED AT THOSE,

INCLUDING THE EXAMPLES 17, 23 AND OTHERS THAT YOU SUGGEST.

AND LET ME JUST INDICATE THAT YOU ARE RIGHT, AND YOU HAVE

A GOOD MEMORY, I DID SIT THROUGH BOTH TRIALS, AND I WAS ABLE TO

HEAR THE EVIDENCE IN THAT.

THE STATEMENTS THAT YOU'VE RAISED THERE, I'M GOING TO INVOKE FEDERAL RULE OF CRIMINAL PROCEDURE 32(I)(3)(B) AND INDICATE THAT THE COURT NEED NOT RULE ON THOSE OBJECTIONS BECAUSE THE COURT IS NOT GOING TO CONSIDER THAT TYPE OF INFORMATION AS YOU'VE INDICATED. AND I THINK PART OF THIS --- IN ITS SENTENCING DECISION.

10:16AM	1	AND PART OF THIS WILL COME OUT IN OUR DISCUSSION ABOUT THE
10:16AM	2	BALANCE OF THE OBJECTIONS. SO THANK YOU FOR THAT.
10:16AM	3	ANYTHING FURTHER ON THAT?
10:16AM	4	MR. LEACH: NO, YOUR HONOR.
10:16AM	5	MR. COOPERSMITH: NO, YOUR HONOR.
10:16AM	6	THE COURT: GREAT. THANK YOU.
10:16AM	7	WELL, LET'S GO THROUGH WHAT I'VE IDENTIFIED AS CONTEXTUAL
10:16AM	8	OBJECTIONS. AND THESE ARE CONTAINED, FIRST OF ALL, IN THE PSR
10:16AM	9	ITSELF BEGINNING IN THE ADDENDUM TO THE PRESENTENCE REPORT AND
10:16AM	10	THEN IN APPENDIX A SENTENCING MEMORANDUM THAT CONTAINED 24
10:16AM	11	THROUGH 39 I THINK THE BALANCE OF THE OBJECTIONS.
10:16AM	12	LET ME FIRST SAY THAT I HAVE READ AND REVIEWED THE
10:16AM	13	OBJECTIONS THAT ARE CONTAINED IN THE PSR. THOSE ARE 1 THROUGH
10:17AM	14	24, I BELIEVE.
10:17AM	15	LET ME ASK, MS. GOLDSBERRY, IS THERE ANYTHING ELSE YOU
10:17AM	16	WOULD LIKE TO ADD TO ANY OF PROBATION'S RESPONSES TO THOSE
10:17AM	17	OBJECTIONS?
10:17AM	18	PROBATION OFFICER: NO, YOUR HONOR.
10:17AM	19	THE COURT: ALL RIGHT. THANK YOU.
10:17AM	20	ANYTHING FURTHER YOU WOULD LIKE TO ADD TO THE OBJECTIONS,
10:17AM	21	MR. COOPERSMITH?
10:17AM	22	MR. COOPERSMITH: NOT ON THOSE, YOUR HONOR. WE PUT
10:17AM	23	THAT IN THE RECORD, AND WE THINK THE COURT IS FAMILIAR WITH THE
10:17AM	24	CASE OBVIOUSLY. WE STAND BY THOSE, BUT WE DON'T THINK IT'S
10:17AM	25	NECESSARY TO ARGUE THOSE ONE BY ONE.

10:17AM	1	THE COURT: OKAY. ANYTHING FURTHER
10:17AM	2	MR. LEACH: NO, YOUR HONOR.
10:17AM	3	THE COURT: ON THOSE OBJECTIONS?
10:17AM	4	MR. LEACH: NO, YOUR HONOR.
10:17AM	5	THE COURT: ALL RIGHT. THANK YOU.
10:17AM	6	WHAT I INTEND TO DO IS JUST TO GO THROUGH AND INFORM YOU
10:17AM	7	OF THE COURT'S DECISION AS TO THOSE OBJECTIONS.
10:17AM	8	OBJECTION NUMBER ONE IS THE OBJECTION TO PARAGRAPH NUMBER
10:17AM	9	18 OF THE PSR, AND THAT OBJECTION IS OVERRULED. THE COURT
10:18AM	10	FINDS THAT THIS SUMMARY IS SUBSTANTIVELY THE SAME AS THE SCHEME
10:18AM	11	TO DEFRAUD IN THE THIRD SUPERSEDING INDICTMENT, AND I'LL ALLOW
10:18AM	12	THAT TO REMAIN.
10:18AM	13	OBJECTION NUMBER TWO GOES TOWARDS THE PARAGRAPH 19, AND
10:18AM	14	THE COURT FINDS THAT THE OBJECTION OR THE RULING ON THIS IS
10:18AM	15	UNNECESSARY, AGAIN, CITING FEDERAL RULE OF CRIMINAL PROCEDURE
10:18AM	16	32(I)(3)(B), AND THE COURT WILL NOT CONSIDER PRE-2010
10:18AM	17	PRE-CONSPIRACY SAFEWAY RELATIONSHIP IN THE DEFENDANT'S
10:18AM	18	SENTENCING.
10:18AM	19	MR. COOPERSMITH: YOUR HONOR, JUST TO CLARIFY.
10:18AM	20	OBJECTION NUMBER TWO I BELIEVE RELATES TO FINAL PSR PARAGRAPH
10:18AM	21	20?
10:18AM	22	THE COURT: 20, YES.
10:18AM	23	MR. COOPERSMITH: YES, YOUR HONOR.
10:18AM	24	THE COURT: YES. IF I SAID 19, I MEANT 20, YES.
10:18AM	25	MR. COOPERSMITH: YES.

10:18AM	1	THE COURT: IT'S 20 IN THE FINAL PARAGRAPH. IT'S 19
10:18AM	2	IN THE DRAFT.
10:18AM	3	MR. COOPERSMITH: YES, YOUR HONOR. THANK YOU.
10:19AM	4	THE COURT: OBJECTION THREE RELATES TO PARAGRAPH 21,
10:19AM	5	AND I'M GOING TO SUSTAIN IN PART THIS OBJECTION.
10:19AM	6	AND I WILL THE THIRD BOLD REFERENCE IN THIS PARAGRAPH
10:19AM	7	THAT REFERENCES BALWANI, THE NAME BALWANI, WE'LL STRIKE THAT.
10:19AM	8	AND THE FOLLOWING SENTENCE, I THINK IT'S FIVE LINES DOWN,
10:19AM	9	MS. GOLDSBERRY, THE WORD, THE FOURTH WORD IN THAT IS "THEY,"
10:19AM	10	THAT SHOULD BE CHANGED TO "WAS."
10:19AM	11	PROBATION OFFICER: COULD THE COURT TELL ME THE
10:19AM	12	WHOLE SENTENCE?
10:19AM	13	THE COURT: "IF YOU SEE." LET ME SAY, THERE ARE
10:20AM	14	SOME CHANGES HERE WE'RE GOING TO HAVE TO DO. THE PSR, AS YOU
10:20AM	15	KNOW, IS CONFIDENTIAL.
10:20AM	16	MR. COOPERSMITH: YES.
10:20AM	17	THE COURT: SO I'M RETICENT TO READ WHOLESALE
10:20AM	18	INFORMATION.
10:20AM	19	PROBATION OFFICER: I UNDERSTAND.
10:20AM	20	THE COURT: BUT I'M TRYING TO GIVE YOU GUIDANCE ON
10:20AM	21	WHERE IT IS, AND, OF COURSE, I'LL HAVE TO READ SOME WORDS IN.
10:20AM	22	BUT IF YOU'LL GO DOWN ONE, TWO, THREE, FOUR FIVE LINES
10:20AM	23	DOWN, THAT SENTENCE BEGINS WITH THE WORD "THERANOS."
10:20AM	24	PROBATION OFFICER: YES.
10:20AM	25	THE COURT: AND THE WORD "THEY" IN THAT SENTENCE

10:20AM	1	WILL BE CHANGED TO "WAS."
10:20AM	2	PROBATION OFFICER: "WAS."
10:20AM	3	THE COURT: AND IN THE PRECEDING SENTENCE FOLLOWING
10:20AM	4	THE WORD "HOLMES," THE NEXT TWO WORDS WILL BE STRICKEN,
10:20AM	5	INCLUDING MR. BALWANI'S NAME IN BOLD.
10:20AM	6	PROBATION OFFICER: THE SENTENCE BEFORE?
10:20AM	7	THE COURT: CORRECT.
10:20AM	8	PROBATION OFFICER: OKAY.
10:20AM	9	THE COURT: SO THE WORDS "AND BALWANI," FOLLOWING
10:20AM	10	THE WORD "HOLMES," WILL BE DELETED.
10:21AM	11	PROBATION OFFICER: OKAY. GOT IT.
10:21AM	12	THE COURT: OBJECTION FOUR IS OVERRULED. THIS IS AN
10:21AM	13	ACCURATE DESCRIPTION, AND IT DOES PROVIDE CONTEXT.
10:21AM	14	OBJECTION FIVE IS OVERRULED. THIS RELATES TO PARAGRAPH
10:21AM	15	26. THE COURT FINDS THAT THIS PARAGRAPH CORRECTLY STATES THE
10:21AM	16	EVIDENCE THAT WAS INTRODUCED AT TRIAL.
10:21AM	17	OBJECTION SIX IS OVERRULED. I'LL NOTE THAT AT THE THIS
10:21AM	18	IS ONE OF THOSE PARAGRAPHS WHERE AT THE DEFENSE REQUEST I
10:21AM	19	BELIEVE PROBATION ACTUALLY INCLUDED SENTENCES THAT THE
10:21AM	20	DEFENDANT REQUESTED TO PROVIDE CONTEXT. SO I'LL OVERRULE THE
10:21AM	21	OBJECTION TO THAT MATERIAL.
10:21AM	22	OBJECTION SEVEN, THIS RELATES TO PARAGRAPHS 36 AND 37,
10:21AM	23	THAT IS OVERRULED. THE COURT FINDS THIS PARAGRAPH ACCURATE,
10:22AM	24	AND AGAIN, IT PROVIDES HELPFUL CONTEXT FOR THE OVERALL COMPANY
10:22AM	25	HISTORY AND SPECIFICALLY ITS RELATIONSHIP WITH PFIZER.

10:22AM	1	I'LL ALSO NOTE THAT PROBATION DID ADD LANGUAGE AT THE
10:22AM	2	DEFENSE REQUEST REGARDING HIS KNOWLEDGE OF THE PFIZER REPORT.
10:22AM	3	OBJECTION EIGHT AS TO PARAGRAPH 39 IS OVERRULED. THIS
10:22AM	4	PARAGRAPH DOES PROVIDE CONTEXT AND PROBATION DID, AS I
10:22AM	5	UNDERSTAND IT, REMOVE A SENTENCE AT THE DEFENSE REQUEST.
10:22AM	6	OBJECTION NINE AS TO PARAGRAPH 40 IS SUSTAINED IN PART,
10:22AM	7	AND THE COURT WILL STRIKE THE INTRODUCTORY CLAUSE IN THE
10:22AM	8	SENTENCE.
10:22AM	9	AND LET ME GET THAT FOR YOU, MS. GOLDSBERRY.
10:22AM	10	IT'S PROBABLY EASIER TO TELL YOU THAT THE SECOND SENTENCE
10:22AM	11	UP FROM THE BOTTOM THAT BEGINS WITH THE WORD "DESPITE."
10:23AM	12	PROBATION OFFICER: YES.
10:23AM	13	THE COURT: THAT WILL BE STRICKEN, THE WORD
10:23AM	14	"DESPITE" WILL BE STRICKEN AS WILL THE NEXT FOUR WORDS,
10:23AM	15	INCLUDING THE COMMA.
10:23AM	16	PROBATION OFFICER: OKAY. SO EVERYTHING UP UNTIL
10:23AM	17	THE COMMA?
10:23AM	18	THE COURT: INCLUDING THE COMMA. AND THE SENTENCE
10:23AM	19	WILL BEGIN WITH "HOLMES."
10:23AM	20	PROBATION OFFICER: GOT IT.
10:23AM	21	THE COURT: OBJECTION TEN, THIS OBJECTION IS
10:23AM	22	OVERRULED. THIS DESCRIPTION IS ACCURATE. IT DOES PROVIDE
10:23AM	23	RELEVANT TESTIMONY FROM A FORMER EMPLOYEE.
10:23AM	24	AND I'LL NOTE AGAIN AT THE DEFENSE REQUEST, THE PROBATION
10:23AM	25	INCLUDED SENTENCES IN REGARDS TO THE DEFENDANT'S, PARDON ME,

1 10:23AM 10:23AM 2 10:24AM 3 10:24AM 4 10:24AM 10:24AM 6 10:24AM 7 10:24AM 8 10:24AM 9 10:24AM 10 10:24AM 11 10:24AM 12 10:25AM 13 10:25AM 14 10:25AM 15 10:25AM 16 10:25AM 17 10:25AM 18 10:25AM 19 10:25AM 20 10:26AM 21 10:26AM 22 10:26AM 23 10:26AM 24 10:26AM 25

RELIANCE ON OPINIONS.

OBJECTION ELEVEN IS OVERRULED. THE COURT FINDS THAT THIS
PARAGRAPH IS ACCURATE AS WRITTEN, AND IT SEEMS THAT THE
DEFENDANT SEEKS TO ADD INFORMATION THAT ENCOMPASSES THE SPIRIT
OF PERHAPS A CLOSING ARGUMENT HERE, BUT THAT'S PART OF THE
RECORD, AND THE JURY HEARD THAT AND CONSIDERED ALL OF THAT. SO
THE OBJECTION IS OVERRULED.

TWELVE IS AN OBJECTION TO PSR PARAGRAPHS 25, 26, 35, 36, 37, 38, 39, 40, 41, 42, AND 44, AND THIS OBJECTION AS TO THOSE PARAGRAPHS IS OVERRULED. I WILL NOTE THAT MANY OF THE PARAGRAPHS ALSO CONTAIN STATEMENTS THAT WERE ADDED BY PROBATION AT DEFENSE REQUEST INDICATING THAT MR. BALWANI'S POSITION AS TO THOSE PARAGRAPHS AS WELL AS HIS DISAGREEMENT WITH THOSE PARAGRAPHS WERE NOTED. SO THE COURT WILL OVERRULE THAT OBJECTION.

LET'S SEE. I BELIEVE OBJECTION FOURTEEN, AND I'M AT PARAGRAPH 47, IS OVERRULED. AND THIS DETAILS INVESTOR MENDENHALL.

I'M NOT CERTAIN -- I WAS NOT ABLE TO DETERMINE WHAT THAT OBJECTION REALLY ENTAILED, SO I'M GOING TO LEAVE IT AS IS.

MR. COOPERSMITH, I NOTE THE OBJECTION. I DON'T SEE HOW

IT'S INCOMPLETE OR MISLEADING, SO I'M GOING TO OVERRULE THE

OBJECTION AND LEAVE IT AS IT IS.

OBJECTION FIFTEEN RELATES TO PARAGRAPH 49, AND THE COURT AGREES WITH THE PROBATION OFFICER'S RESPONSE TO THIS PARAGRAPH.

1 10:26AM 10:26AM 2 3 10:26AM 10:26AM 4 10:26AM 5 10:26AM 6 10:26AM 7 10:26AM 8 10:27AM 9 10:27AM 10 10:27AM 11 10:27AM 12 10:27AM 13 10:27AM 14 10:27AM 15 10:27AM 16 10:27AM 17 10:27AM 18 10:28AM 19 10:28AM 20 10:28AM 21 10:28AM 22 10:28AM 23 10:28AM 24 10:28AM 25

IT DOES NOT PURPORT TO TALLY THE NUMBER OF PATIENT VICTIMS. IT ONLY STATES WITH ACCURACY THAT HUNDREDS OF PATIENTS PAID FOR THE BLOOD TEST, IRRESPECTIVE OF WHETHER THEY PAID OUT OF POCKET OR THROUGH AN INSURED. IT'S JUST A STATEMENT OF A FACT THAT THE COURT WILL NOT DISTURB, AND THAT OBJECTION IS OVERRULED.

OBJECTION SIXTEEN RELATES TO PARAGRAPH 49 AND 50. AND THE COURT OVERRULES THIS. THE COURT FINDS THAT THE EVIDENCE AT TRIAL REVEALED MR. BALWANI'S KNOWLEDGE OF THE FACTS AS INDICATED AND ADOPTS PROBATION'S EXPLANATION.

OBJECTION SEVENTEEN RELATED TO PARAGRAPH 52 IS OVERRULED.

THIS PARAGRAPH IS AN ACCURATE DESCRIPTION OF THE FACTS IN THE

CASE, AND THE COURT WILL OVERRULE THAT OBJECTION.

OBJECTION EIGHTEEN RELATES TO PARAGRAPH 53, PARDON ME,
THROUGH 58. THE COURT WILL OVERRULE THIS IN PART. PARAGRAPHS
53, 54, AND 58 REFLECT THE EXPERIENCE OF PATIENTS WHO DID
TESTIFY AT TRIAL, AND THEREFORE, THE OBJECTIONS TO THOSE
PATIENTS ARE OVERRULED.

NOW, AS TO THE REMAINING PATIENTS THAT ARE LISTED IN

THOSE -- IN THAT PARAGRAPH, THE COURT AGAIN WILL INVOKE FEDERAL

RULE OF CRIMINAL PROCEDURE 32(I)(3)(B) BECAUSE THE COURT WILL

NOT CONSIDER THOSE PATIENTS IN THE DEFENDANT'S SENTENCING.

OBJECTION NINETEEN RELATES TO PARAGRAPH 60. THE COURT FINDS THAT THIS INFORMATION IS RELEVANT, IT PROVIDES CONTEXT, AND THE COURT WILL OVERRULE THAT OBJECTION.

OBJECTION TWENTY RELATES TO PARAGRAPH 66 AND 67, AND

10:28AM	1	THOSE THAT OBJECTION IS OVERRULED. THE STATEMENTS, THE
10:28AM	2	COURT CONSIDERS THEM APPROPRIATE AS VICTIM IMPACT STATEMENTS.
10:28AM	3	THE COURT, OF COURSE THE PARTIES ARE AWARE, MAY CONSIDER THE
10:29AM	4	CONSPIRATORIAL CONDUCT WITHIN THE SCOPE OF THE CONSPIRACY, EVEN
10:29AM	5	IF THERE WASN'T PERSONAL OR INTERACTION WITH SPECIFIC INVESTORS
10:29AM	6	BY THE DEFENDANT.
10:29AM	7	OBJECTION TWENTY-ONE RELATES TO PARAGRAPH 61, AND THAT'S
10:29AM	8	OVERRULED. THE COURT FINDS THAT THE PROBATION OFFICER'S
10:29AM	9	EXPLANATION TO THIS OBJECTION IS APPROPRIATE.
10:29AM	10	OBJECTION TWENTY-FIVE IS OVERRULED. THIS RELATES TO
10:29AM	11	PARAGRAPH 14, AND THIS PARAGRAPH IS ACCURATE AND IS SUPPORTED
10:29AM	12	BY THE RECORD IN THE MATTER.
10:29AM	13	OBJECTION TWENTY-SIX RELATES TO PARAGRAPH 19, AND THIS IS
10:29AM	14	SUSTAINED IN PART. THE COURT WILL SUSTAIN IN PART THIS
10:29AM	15	OBJECTION.
10:30AM	16	THIS IS ON PAGE 8, MS. GOLDSBERRY, AND IT'S IN THE LAST
10:30AM	17	THREE SENTENCES OF THIS PARAGRAPH.
10:30AM	18	AND THE THIRD SENTENCE UP FROM THE BOTTOM AT THE END OF
10:30AM	19	THAT SENTENCE FOLLOWING THE WORD THE COURT WILL STRIKE THE
10:30AM	20	WORDS "REVIEW AND APPROVAL," AND IN PLACE OF THAT WILL INSERT
10:30AM	21	THE WORD "KNOWLEDGE."
10:31AM	22	DID YOU GET THAT?
10:31AM	23	PROBATION OFFICER: GOT IT.
10:31AM	24	THE COURT: OKAY. THANK YOU.
10:31AM	25	OBJECTION TWENTY-SEVEN IS OVERRULED. THIS LANGUAGE

1 10:31AM 2 10:31AM 3 10:31AM 10:31AM 4 10:31AM 10:31AM 6 10:31AM 7 10:31AM 8 10:31AM 9 10:31AM 10 10:32AM 11 10:32AM 12 10:32AM 13 10:32AM 14 10:32AM 15 10:32AM 16 10:32AM 17 10:32AM 18 10:32AM 19 10:32AM 20 10:32AM 21 10:32AM 22 10:33AM 23 10:33AM 24 10:33AM 25

ADEQUATELY REFLECTS DR. ROSENDORFF'S TESTIMONY AND THE
PARAGRAPH NOTES THAT THE DEFENSE DISAGREEMENT WITH THE
CHARACTERIZATION OF KNOWLEDGE. SO IT DOES CAPTURE THE DEFENSE
OPINIONS, SO I'LL OVERRULE THE OBJECTION.

OBJECTION TWENTY-EIGHT REFERS TO PARAGRAPH 37, AND THAT IS

OVERRULED. THE COURT FINDS THAT THIS PARAGRAPH, INCLUDING THE

LAST SENTENCE, IS ACCURATE AND DOES PROVIDE CONTEXT.

OBJECTION TWENTY-NINE IS -- RELATES TO PARAGRAPH 44, AND
THIS IS OVERRULED. THE COURT NOTES THAT THESE OBJECTIONS TO
THIS PARAGRAPH FOR THE SAME REASONS HE OBJECTS TO PARAGRAPH 40,
WHICH WAS OBJECTION NINE. THIS PARAGRAPH ACCURATELY SUMMARIZES
MS. PETERSON'S TESTIMONY AT TRIAL AND THE CONVICTIONS OF
MR. BALWANI REGARDING THE WIRE FRAUD AGAINST RDV CORPORATION,
WHICH WAS COUNT SEVEN. SO I'LL OVERRULE THAT OBJECTION.

OBJECTION THIRTY RELATES TO PARAGRAPH 50. THAT OBJECTION IS OVERRULED. THIS PARAGRAPH IS SUPPORTED BY THE JURY'S FINDINGS. THE COURT FINDS THAT IT IS ACCURATE.

OBJECTIONS THIRTY-ONE THROUGH THIRTY-TWO RELATE TO

PARAGRAPHS 55 AND 56, AND THE COURT WILL REFER, AS TO THESE

OBJECTIONS, REFER TO ITS DECISION IN OBJECTION EIGHTEEN, AND IT

IS VERY SIMILAR, AND THE COURT'S FINDING IN OBJECTION EIGHTEEN

WILL ALSO RELATE TO THESE OBJECTIONS.

OBJECTION THIRTY-THREE RELATES TO PARAGRAPH 57 OF THE PSR.

AND THE COURT WILL, AGAIN, CITE FEDERAL RULE OF CRIMINAL

PROCEDURE 32(I)(3)(B). THE COURT WILL NOT CONSIDER THIS

INFORMATION AND THIS PARAGRAPH IN RELATION TO THE DEFENDANT'S 1 10:33AM SENTENCING. 10:33AM 2 OBJECTION THIRTY-FOUR RELATES TO PARAGRAPH 59, AND THIS 3 10:33AM 10:33AM 4 INFORMATION THAT IS IN THIS PARAGRAPH IS ACCURATE, AND THE 10:33AM 5 LANGUAGE IN THIS PARAGRAPH INDICATES THAT THE DEFENDANT'S 10:33AM 6 CONCERNS WERE ADDRESSED BY PROBATION. THAT OBJECTION IS 10:33AM 7 OVERRULED. OBJECTION THIRTY-FIVE RELATES TO PARAGRAPH 62, AND THE 10:33AM 8 COURT WILL PERHAPS SUSTAIN THIS IN PART. I BELIEVE THE DEFENSE 10:33AM 9 10:34AM 10 OBJECTS TO PARAGRAPH 62. BUT, MR. COOPERSMITH, MY SENSE IS THAT YOU'RE -- YOU 10:34AM 11 10:34AM 12 INTEND TO INSERT THIS PROPOSED LANGUAGE PERHAPS AT THE END OF PARAGRAPH 60, IN PARAGRAPH 60 BUT AT THE END. 10:34AM 13 WOULD THAT BE A BETTER PLACEMENT FOR THIS? 10:34AM 14 10:34AM 15 MR. COOPERSMITH: YOU MEAN IN PARAGRAPH 60 RATHER THAN PARAGRAPH 62, YOUR HONOR? 10:34AM 16 10:34AM 17 THE COURT: YES. 10:34AM 18 YOUR SENTENCE BEGINS WITH "FOR COMPARISON," AND IT ENDS 10:34AM 19 WITH "TEST RESULTS," AND THAT LANGUAGE, I LOOKED AT THAT AND THOUGHT IF THAT IS GOING TO BE APPROPRIATE, IT MIGHT BE MORE 10:34AM 20 APPROPRIATE TO ADD IT AT THE TAIL END OF 60. IT'S CONTEXTUAL 10:34AM 21 10:34AM 22 AND RELATES TO THAT SENTENCE. 10:34AM 23 MR. COOPERSMITH: YOUR HONOR, I GUESS I DON'T HAVE 10:34AM 24 VERY STRONG FEELINGS ABOUT IT, AS LONG AS IT'S IN. 10:34AM 25 BUT IT RELATES MORE TO PARAGRAPH 62 BECAUSE PARAGRAPH 60

10:34AM	1	RELATES TO THIS ARIZONA MATTER SEEMS LIKE A DIFFERENT ISSUE.
10:35AM	2	BUT EITHER WAY, AGAIN, YOUR HONOR, IT'S THE POINT WOULD
10:35AM	3	STILL BE IN THE PSR EITHER WAY.
10:35AM	4	THE COURT: WELL, I SUPPOSE THAT WAS THE CONFUSION
10:35AM	5	AS TO WHERE IT SHOULD GO.
10:35AM	6	LET'S ADD IT IN 60. IT SEEMS TO ME 60 IS ONLY TWO
10:35AM	7	SENTENCES NOW, AND IF YOU WOULD LIKE THIS TO HAVE SOME
10:35AM	8	RECOGNITION, PERHAPS IT'S BETTER PLACED THERE AND IT WON'T GET
10:35AM	9	LOST IN ALL OF THE LANGUAGE OF 62.
10:35AM	10	MR. COOPERSMITH: THAT'S FINE, YOUR HONOR.
10:35AM	11	THE COURT: SO THAT WILL BE INSERTED AT THE END, THE
10:35AM	12	END OF PARAGRAPH 60.
10:35AM	13	PROBATION OFFICER: AND THAT SENTENCE IS IN THE
10:35AM	14	APPENDIX, OBJECTION NUMBER THIRTY-FIVE DID THE COURT SAY?
10:35AM	15	THE COURT: LET'S SEE. I THINK THAT'S WHERE IT IS.
10:35AM	16	PROBATION OFFICER: OKAY.
10:35AM	17	(PAUSE IN PROCEEDINGS.)
10:36AM	18	THE COURT: THE FIRST SENTENCE IS WHAT I WAS
10:36AM	19	FOCUSSED ON, NOT THE SECOND SENTENCE.
10:36AM	20	SO THAT FIRST SENTENCE THAT ENDS IN "RESULTS"?
10:36AM	21	PROBATION OFFICER: YES.
10:36AM	22	THE COURT: THAT WILL BE PLACED IN 60. THE SECOND
10:36AM	23	SENTENCE IS NOT NECESSARY.
10:36AM	24	PROBATION OFFICER: GOT IT.
10:36AM	25	THE COURT: AND OBJECTIONS THIRTY-SIX THROUGH

10:36AM	1	THIRTY-NINE ARE OVERRULED TO SAY THAT THE COURT WILL DISCUSS
10:36AM	2	THESE THIS IS PART OF OUR GUIDELINE DISCUSSION, SO I SUPPOSE
10:36AM	3	I COULD DEFER THOSE OBJECTIONS. THEY WILL BE, THEY WILL BE
10:37AM	4	TAKEN UP IN OUR CONVERSATION ABOUT GUIDELINE CALCULATIONS.
10:37AM	5	MR. COOPERSMITH: THANK YOU, YOUR HONOR.
10:37AM	6	THE COURT: ALL RIGHT. ANY QUESTIONS?
10:37AM	7	MS. GOLDSBERRY, DID YOU GET EVERYTHING?
10:37AM	8	PROBATION OFFICER: I DID, YOUR HONOR.
10:37AM	9	THE COURT: ALL RIGHT. THANK YOU.
10:37AM	10	ALSO. LET ME MOVE NOW, IF I MAY, TO WHAT I'VE CALLED AND
10:37AM	11	CATEGORIZED THE SUBSTANTIVE OBJECTIONS.
10:37AM	12	LET'S START WITH OBJECTION THIRTEEN, WHICH IS THE INVESTOR
10:37AM	13	VICTIM COUNT. I BELIEVE IT'S PARAGRAPH 48 THAT THE DEFENSE
10:37AM	14	OBJECTS TO. IT RELATES TO THE INVESTOR COUNT.
10:37AM	15	I JUST WANTED TO SAY AS TO THIS PARAGRAPH, THE COURT WOULD
10:38AM	16	SUSTAIN THE OBJECTION IF THE OBJECTION IS INDICATING THAT THE
10:38AM	17	COURT SHOULD NOT ESTIMATE THE VICTIMS, AND I THINK THAT'S THE
10:38AM	18	IMPORT OF WHAT THIS OBJECTION IS.
10:38AM	19	THE DEFENDANT ASSERTS THAT THE COURT CANNOT ESTIMATE THE
10:38AM	20	NUMBER OF VICTIMS, AND THE COURT WILL NOT ESTIMATE THE NUMBER
10:38AM	21	OF VICTIMS, USING THE ENTIRE BODY OF THE C INVESTORS, NOR WILL
10:38AM	22	IT ANALYZE C1, C2 INVESTORS IN THE AGGREGATE.
10:38AM	23	THE COURT WILL CONSIDER THE EVIDENCE THAT IS PRESENTED AND
10:38AM	24	AVAILABLE FOR EACH INVESTOR VICTIM AND IDENTIFY THE VICTIMS AND
10:38AM	25	THOSE LOSS CALCULATIONS THAT FLOW FROM.

10:38AM	1	SO PERHAPS I'M TAKING TOO FINE A NOTE OF IT, BUT IF THE
10:38AM	2	OBJECTION WAS, JUDGE, YOU CAN'T ESTIMATE, I AGREE WITH THAT,
10:38AM	3	AND THE COURT DOESN'T INTEND TO ESTIMATE.
10:38AM	4	OBJECTION TWENTY-TWO IS THE LOSS CALCULATION AND
10:39AM	5	CAUSATION. EXCUSE ME. SO LET'S TALK ABOUT THAT.
10:39AM	6	THERE'S A NUMBER OF OBJECTIONS, DIFFERENT LEVEL OF
10:39AM	7	OBJECTIONS, I THINK, THAT THE DEFENSE IMPOSED HERE.
10:39AM	8	MR. COOPERSMITH: YES, YOUR HONOR.
10:39AM	9	AND MY COLLEAGUE, AMY WALSH, WILL SPEAK ON THE LOSS AMOUNT
10:39AM	10	ISSUES.
10:39AM	11	THE COURT: OKAY. WELL, THEN IT'S TIME FOR A
10:39AM	12	PITCHING CHANGE.
10:39AM	13	MR. COOPERSMITH: YES, YOUR HONOR.
10:39AM	14	THE COURT: GOOD MORNING, MS. WALSH.
10:39AM	15	MS. WALSH: GOOD MORNING, YOUR HONOR. NICE TO SEE
10:39AM	16	YOU AGAIN.
10:39AM	17	THE COURT: THANK YOU. LIKEWISE.
10:39AM	18	SO AS TO THE LOSS CALCULATION HERE, I NOTE THAT THE
10:39AM	19	DEFENDANT OBJECTS TO LISTING ANY VICTIM OR ANY LOSS ASSERTING
10:39AM	20	THAT NO VICTIM SUSTAINED ANY LOSS.
10:40AM	21	LET ME ASK YOU, DO YOU WANT TO MAKE A DO YOU WANT TO
10:40AM	22	PUT ANYTHING ON THE RECORD BEFORE I GO FORWARD HERE? WOULD YOU
10:40AM	23	LIKE ME TO HEAR SOMETHING?
10:40AM	24	MS. WALSH: YES, YES, PLEASE.
10:40AM	25	THE COURT: GO RIGHT AHEAD. PLEASE.

10:40AM	1	MS. WALSH: SO, YOUR HONOR, WHAT I HAD PLANNED TO
10:40AM	2	ADDRESS THE COURT ON TODAY WERE ALL OF THE ISSUES CONNECTED TO
10:40AM	3	OUR OBJECTIONS REGARDING LOSS, INCLUDING THE BURDEN OF PROOF,
10:40AM	4	THE NUMBER OF VICTIMS, CAUSATION, ET CETERA.
10:40AM	5	THE COURT: OKAY.
10:40AM	6	MS. WALSH: AND THE SABA REPORT.
10:40AM	7	THE COURT: SURE.
10:40AM	8	MS. WALSH: AND I'LL JUST RUN THROUGH THAT, AND
10:40AM	9	OBVIOUSLY IF THE COURT HAS QUESTIONS, I'LL ANSWER THAT.
10:40AM	10	THE COURT: SURE. OF COURSE.
10:40AM	11	MS. WALSH: SO LET'S START WITH THE BURDEN OF PROOF.
10:40AM	12	OBVIOUSLY THE COURT APPLIED IN MS. HOLMES'S SENTENCING THE
10:40AM	13	PREPONDERANCE BURDEN OR STANDARD OF PROOF, AND WE RESPECT THAT
10:40AM	14	RULING. WE DO DISAGREE WITH IT.
10:40AM	15	WE DO BELIEVE THAT THE CLEAR AND CONVINCING STANDARD
10:40AM	16	SHOULD APPLY HERE. WE THINK <u>UNITED STATES VERSUS LONICH</u> IS THE
10:41AM	17	OPERATIVE CASE THAT SHOULD APPLY TO THESE CIRCUMSTANCES.
10:41AM	18	AND THE ISSUE, OF COURSE, IS WHAT STANDARD OF PROOF SHOULD
10:41AM	19	APPLY TO THE GOVERNMENT WHO HAS THE BURDEN OF PROVING LOSS IN A
10:41AM	20	FRAUD CASE.
10:41AM	21	THE TWO FACTORS THAT REALLY ANIMATED THE COURT'S OPINION
10:41AM	22	IN <u>LONICH</u> , WHICH WAS A 2822 CASE, AS YOU KNOW, WERE, FIRST,
10:41AM	23	WHETHER THE DISPUTED ENHANCEMENTS DRAMATICALLY INCREASED THE
10:41AM	24	LOSS AMOUNT OR THE LEVELS, THE OFFENSE LEVEL THAT APPLIED.
10:41AM	25	AND THE COURT IN <u>LONICH</u> APPLIED THE VALENCIA FACTORS FIVE

AND SIX AND THAT IS IF THE ENHANCEMENT WAS 4 OR MORE LEVELS 10:41AM 1 ABOVE WHAT IT OTHERWISE WOULD BE, AND THE OFFENSE LEVEL 10:41AM 2 PROVIDED FOR A DOUBLING OF THE SENTENCING RANGE, THEN THAT WAS 3 10:41AM 10:42AM 4 ONE -- TWO FACTORS THAT WEIGHED HEAVILY IN FAVOR OF APPLYING THE CLEAR AND CONVINCING STANDARD OF PROOF. 10:42AM THERE'S NO DISPUTE HERE THAT THOSE TWO FACTORS ARE MET. 10:42AM 6 10:42AM 7 WHAT THE GOVERNMENT PROPOSES IN ITS LOSS CALCULATION DRAMATICALLY INCREASES THE OFFENSE LEVEL. 10:42AM 8 10:42AM 9 WHAT THE PSR ALSO RECOMMENDS DOES THE SAME. AND EVEN IF 10:42AM 10 YOU TAKE THE COURT'S FINDINGS IN THE HOLMES CASE, IT STILL 10:42AM 11 DRAMATICALLY INCREASES THE OFFENSE LEVELS BY THE LEVELS OF 10:42AM 12 LOSS. THE GOVERNMENT WOULD BE 30 LEVELS. THE COURT'S 10:42AM 13 APPLICATION WAS 24 LEVELS. AND IF YOU TAKE MR. SABA'S PROPOSED 10:42AM 14 10:42AM 15 LOSS, THAT'S AN ADJUSTMENT OF 26 OR 28 LEVELS. SO I DON'T THINK THERE'S ANY QUESTION THAT ANY PROPOSED 10:43AM 16 10:43AM 17 LOSS CALCULATION, AT LEAST WHAT WE HAVE HEARD SO FAR IN THE 10:43AM 18 HOLMES CASE AND IN OUR CASE, DRAMATICALLY INCREASES THE 10:43AM 19 DISCLOSURE. 10:43AM 20 THE SECOND FACTOR THAT THE LONICH COURT FOCUSSED ON WAS 10:43AM 21 WHETHER THE INCREASE WAS BASED ON THE EXTENT OF THE CONSPIRACY. 10:43AM 22 AND, OF COURSE, THIS IS AN EXTREMELY -- IT CAN BE A DIFFICULT 10:43AM 23 FACT TO ASCERTAIN. 10:43AM 24 THE LONICH COURT ITSELF RECOGNIZED THAT IN CONSPIRACY 10:43AM 25 CASES, THERE CAN BE THESE BORDERLINE CASES WHERE THE LOSS

AMOUNT DOES NOT FALL WITHIN THE CONSPIRACY.

AND WHAT WAS IMPORTANT TO THE COURT AND REALLY DROVE THE COURT'S OPINION WAS WHETHER THE DEFENDANT HAD THE OPPORTUNITY TO CHALLENGE THE LOSS AMOUNT THAT WAS BEING APPLIED AND CHALLENGE THE EVIDENCE SUPPORTING THAT LOSS AMOUNT, AND THE COURT REALLY FOCUSSED ON THE DUE PROCESS CONCERNS THAT WERE AT PLAY IN LONICH, YOU KNOW, THE FAILURE OF THE BANK WAS BEING PEGGED AS THE LOSS AMOUNT AND WHAT THE GOVERNMENT WAS PROPOSING, AND THERE WERE REAL DUE PROCESS CONCERNS BECAUSE THE DEFENDANTS NEVER REALLY GOT TO CHALLENGE THAT AMOUNT.

AND SO HERE WE HAVE A SIMILAR SITUATION.

THOSE DUE PROCESS CONCERNS THAT WERE AT PLAY IN LONICH
APPLY HERE AND REQUIRE A HIGHER BURDEN OF PROOF.

NONE OF THE FACTS UNDERLINE THE LOSS AMOUNT HERE AND REALLY CAUSATION OF THE LOSS WERE PRESENTED TO THE JURY.

THE JURY WAS NOT INSTRUCTED ON RELIANCE. THERE WERE TIMES WHEN TO THE EXTENT THAT THE DEFENSE WANTED TO ASK QUESTIONS ABOUT RELIANCE OR GET INTO RELIANCE, THE GOVERNMENT OBJECTED TO THOSE QUESTIONS, UNDERSTANDABLY BECAUSE RELIANCE IS NOT AN ELEMENT, BUT NEVERTHELESS THE JURY DID NOT HEAR THAT EVIDENCE.

THE JURY CAME BACK WITH A GENERAL VERDICT, MAKING NO FINDINGS WHATSOEVER ON CAUSATION OR RELIANCE OR LOSS.

AND IN THE CIRCUMSTANCES OF THIS CASE, I RECOGNIZE THAT

THERE ARE SOME CASES WHERE, GIVEN THE NATURE OF THE CONSPIRACY,

IT'S EASY TO FIGURE OUT WHETHER THE CONDUCT FALLS WITHIN THE

1

2

3

4

8

10:43AM

10:43AM

10:43AM

10:43AM

10:43AM

10:43AM

10:44AM

10:44AM 7

10:44AM 9

10:44AM 10

10:44AM 11

10:44AM 12

10:44AM 13

10:44AM 14

10:44AM 15

10:44AM 16

10:44AM 17

10:44AM 18

10:44AM 19

10:44AM 20

10:45AM 21

10:45AM 22

10:45AM 23

10:45AM 24

1 10:45AM 10:45AM 2 3 10:45AM 10:45AM 4 10:45AM 10:45AM 6 10:45AM 7 10:45AM 8 10:46AM 9 10:46AM 10 10:46AM 11 10:46AM 12 10:46AM 13 10:46AM 14 10:46AM 15 10:46AM 16 10:46AM 17 10:46AM 18 10:46AM 19 10:46AM 20 10:46AM 21 10:47AM 22 10:47AM 23 10:47AM 24 10:47AM 25

SCOPE OF THE CONSPIRACY AND THE LOSS CAN JUST BE CALCULATED.

IN THIS CASE IT'S JUST NOT SO. IT'S A VERY COMPLICATED

CAUSATION AND LOSS METHODOLOGY THAT NEEDS TO BE APPLIED OR THAT

HAS BEEN APPLIED BY VARIOUS EXPERTS. IT'S NOT -- IT WAS NOT A

SHAM COMPANY. THERANOS WAS A REAL COMPANY. IT WASN'T A PONZI

SCHEME, WHICH MAY MAKE IT EASIER TO FIGURE OUT LOSS.

IT REALLY -- WHAT THESE INVESTORS AND OTHER INVESTORS THAT
THE GOVERNMENT WANTS TO INCLUDE RELIED ON IN MAKING THEIR
DECISIONS TO INVEST IS A SERIOUS QUESTION, AND IT'S A QUESTION
THAT YIELDS MANY, MANY YEARS OF EXPOSURE AND POTENTIALLY TIME
IN JAIL AND BECAUSE OF THAT, WE BELIEVE THAT THE CLEAR AND
CONVINCING STANDARD SHOULD APPLY.

SO, YOUR HONOR, I WAS GOING TO MOVE ON TO THE GOVERNMENT'S LOSS AMOUNT.

THE COURT: YES.

MS. WALSH: SO THE GOVERNMENT IS ADVOCATING FOR AN \$800 MILLION LOSS AMOUNT ROUGHLY, AND IT HAS NOT PROVEN CAUSATION FOR THAT AMOUNT.

IT DOES NOT PROVE CAUSATION FOR THE LONG LIST OF VICTIMS

THAT IT PROVIDED TO THE COURT. IT DOES NOT -- IT HAS NOT

PROVEN, EITHER BY CLEAR AND CONVINCING EVIDENCE OR BY A

PREPONDERANCE THAT EACH ONE OF THOSE VICTIMS INDIVIDUALLY

RELIED ON THE REPRESENTATIONS THAT WERE BEFORE THE JURY IN THIS

CASE IN MAKING THEIR DECISIONS ABOUT WHETHER TO INVEST, AND I'M

GOING TO COME BACK TO THAT IN A SECOND.

1 10:47AM 2 10:47AM 3 10:47AM 10:47AM 4 10:47AM 10:47AM 6 10:47AM 7 10:47AM 8 10:47AM 9 10:47AM 10 10:47AM 11 10:48AM 12 10:48AM 13 10:48AM 14 10:48AM 15 10:48AM 16 10:48AM 17 10:48AM 18 10:48AM 19 10:48AM 20 10:48AM 21 10:48AM 22 10:48AM 23 10:48AM 24 10:48AM 25

BUT ANOTHER REASON THAT THE GOVERNMENT'S PROPOSED LOSS

AMOUNT FAILS IS THAT WE HAVE A SERIES OF EVENTS THAT ARE

INTERVENING CAUSES THAT BREAK THE CAUSAL CHAIN AFTER

MR. BALWANI LEAVES THERANOS.

AND I'M GOING TO ADDRESS THAT SEPARATELY, BUT THAT IS THE SECOND REASON. MR. BALWANI IS IN A VERY DIFFERENT SITUATION FROM MS. HOLMES. HE LEFT THERANOS IN MAY OF 2016. SO I WILL COME BACK TO THAT LATER.

BUT THE FINAL REASON THAT THE GOVERNMENT'S LOSS AMOUNT

FAILS IS THAT THE GOVERNMENT DOES NOT DISENTANGLE AS THE COURT

POINTED OUT IN MS. HOLMES'S SENTENCING. THE GOVERNMENT DOES

NOT DISENTANGLE THE VALUE OF THERANOS FROM THE PRICE THAT

INVESTORS PAID FOR STOCK IN THERANOS, AND THEY HAVE TO DO THAT

UNDER ZOLP.

THE GOVERNMENT TRIED TO DO IT WITH THE SABA REPORT, BUT AS I'M GOING TO GO THROUGH, THAT REPORT, AND AS EVIDENCED BY THE EXPERT REPORTS THAT WE SUBMITTED, HAS SERIOUS ERRORS THAT CALL INTO QUESTION THE RELIABILITY OF MR. SABA'S ANALYSIS, SO I WANT TO GO THROUGH EACH ONE OF THOSE.

THE COURT: OKAY.

MS. WALSH: SO ON THE RELIANCE ISSUE, THE GOVERNMENT HAS NOT PROVEN THAT EACH OF THE PROPOSED VICTIMS RELIED ON THE STATEMENTS THAT WERE THE SUBJECT OF THE TRIAL.

THERANOS HAD MANY, MANY INVESTORS. THOSE INVESTORS INVESTED IN THERANOS FOR MANY DIFFERENT REASONS, VARIOUS

1 10:48AM 2 10:49AM 3 10:49AM 4 10:49AM 10:49AM 10:49AM 6 10:49AM 7 10:49AM 8 10:49AM 9 10:49AM 10 10:49AM 11 10:49AM 12 10:49AM 13 10:49AM 14 10:49AM 15 10:50AM 16 10:50AM 17 10:50AM 18 10:50AM 19 10:50AM 20 10:50AM 21 10:50AM 22 10:50AM 23 10:50AM 24 10:50AM 25

REASONS. SOME MAY HAVE INVESTED BECAUSE THEY THOUGHT

ELIZABETH HOLMES WAS BRILLIANT AND WAS A DYNAMIC LEADER AND

BELIEVED IN HER MISSION. OTHERS MAY HAVE INVESTED BECAUSE

EVERYONE ELSE WAS INVESTING AND THEY HAD THIS FEAR OF MISSING

OUT ON A GREAT OPPORTUNITY.

AND, IN FACT, YOUR HONOR CITED A SIMILAR TYPE OF INVESTOR IN MS. HOLMES'S SENTENCING, AND I THINK IT WAS MS. FADIL WHO INVESTED BECAUSE SHE NOTICED SOME BIG NAMES INVESTING. AND THE COURT RIGHTLY POINTED OUT THAT THERE HAS TO BE SOME RELIANCE BY A PARTICULAR INVESTOR ON THE STATEMENTS THAT WERE AT ISSUE IN THE TRIAL.

THE VERDICT ALONE, SINCE IT WAS A GENERAL VERDICT, CANNOT ESTABLISH THAT RELIANCE AND NEITHER THE GOVERNMENT NOR THE PSR PROVIDES SUFFICIENT EVIDENCE FROM WHICH THE COURT CAN REASONABLY CONCLUDE THAT EACH ONE OF THESE DIFFERENT VICTIMS RELIED ON THE MISREPRESENTATIONS, AND, THEREFORE, THEIR LOSSES WERE CAUSED BY THEM.

AND I WANT TO TALK ABOUT ONE VERY GLARING EXAMPLE, AND THIS IS ONE OF THE INVESTORS THAT YOUR HONOR INCLUDED IN THE TEN THAT APPLIED DURING MS. HOLMES'S SENTENCING, AND THAT INVESTOR IS RUPERT MURDOCH.

SO MR. MURDOCH INVESTED \$125 MILLION IN FEBRUARY 2015.

THE GOVERNMENT NEVER INTERVIEWED MR. MURDOCH ABOUT WHAT HE

RELIED ON, AND HE DID NOT SUBMIT A VICTIM IMPACT STATEMENT. SO

WE DON'T KNOW WHY HE INVESTED IN THERANOS.

1 10:50AM 2 10:50AM 3 10:50AM 10:51AM 4 10:51AM 10:51AM 6 10:51AM 7 10:51AM 8 10:51AM 9 10:51AM 10 10:51AM 11 10:51AM 12 10:51AM 13 10:51AM 14 10:51AM 15 10:52AM 16 10:52AM 17 10:52AM 18 10:52AM 19 10:52AM 20 10:52AM 21 10:52AM 22 10:52AM 23 10:52AM 24 10:52AM 25

HE MAY HAVE BEEN LIKE MS. FADIL AND INVESTED IN THERANOS BECAUSE EVERYONE ELSE WAS, WE JUST DON'T KNOW.

WHAT WE DO KNOW IS FROM HIS CHIEF OF STAFF,

NATALIE RAVITZ, WHO TESTIFIED IN FRONT OF THE S.E.C., AND WHAT

SHE SAID UNDER OATH IN FRONT OF THE S.E.C. IS THAT SHE

UNDERSTOOD THAT THERANOS'S HISTORICAL REVENUES WERE LOW. SHE

WAS SKEPTICAL ABOUT THE INVESTMENT FOR THAT REASON. SHE

DESCRIBED HOW MS. HOLMES TOLD HER THAT THE DEVICE, THE THERANOS

DEVICE COULD BE USED IN MILITARY FIELD OPERATIONS AND ON

MEDEVAC HELICOPTERS, BUT SHE DIDN'T SAY THEY WERE ON THE

HELICOPTERS OR THEY WERE IN THE FIELD, JUST THAT THEY COULD BE.

AND IMPORTANTLY, MS. RAVITZ TESTIFIED IN THE S.E.C. THAT

SHE ACTUALLY DIDN'T DO THE WORK THAT SHE WOULD NORMALLY DO, THE

DUE DILIGENCE OR EXAMINING THE BINDER THAT WAS RECEIVED FROM

THERANOS BECAUSE MR. MURDOCH HAD ALREADY AGREED TO INVEST IN

THERANOS BEFORE SHE GOT A CHANCE TO DO IT. HE ALREADY HAD AN

ORAL AGREEMENT WITH MS. HOLMES TO INVEST.

SO THIS IS THE CLEAREST EXAMPLE OF WE HAVE NO IDEA WHY RUPERT MURDOCH INVESTED IN THERANOS, AND BECAUSE OF THAT THE GOVERNMENT HAS NOT MET ITS BURDEN OF PROOF ON CAUSATION.

ANOTHER INVESTOR THAT FALLS INTO THAT SAME CATEGORY IS

PEER VENTURES. PEER VENTURES -- THE REPRESENTATIVES OF

PEER VENTURES WERE INTERVIEWED, THEY GAVE STATEMENTS ABOUT WHAT

STATEMENTS WERE MADE TO THEM ABOUT THERANOS, BUT THERE'S

NOTHING ABOUT WHAT THEY ACTUALLY RELIED ON AND WHY THEY

1 10:52AM 2 10:52AM 3 10:52AM 10:52AM 4 10:53AM 10:53AM 6 10:53AM 7 10:53AM 8 10:53AM 9 10:53AM 10 10:53AM 11 10:53AM 12 10:53AM 13 10:54AM 14 10:54AM 15 10:54AM 16 10:54AM 17 10:54AM 18 10:54AM 19 10:54AM 20 10:54AM 21 10:54AM 22 10:54AM 23 10:54AM 24 10:54AM 25

INVESTED, AND THAT ABSENCE OF EVIDENCE MEANS THAT WE CANNOT PUT
THEM IN THE CATEGORY OF A VICTIM WHOSE LOSSES WERE CAUSED BY
THE MISREPRESENTATIONS.

OKAY. WHAT THE GOVERNMENT ALSO OFFERS TO THE COURT, AND THE COURT USED THIS DURING MS. HOLMES'S TESTIMONY, IS AN EXPERT REPORT THAT WOULD ESTABLISH LOSS UNDER ZOLP BY ESTABLISHING ALSO THE VALUE OF THERANOS AT VARIOUS DIFFERENT DATES. AND THE COURT, I KNOW, RELIED ON THAT REPORT DURING THE HOLMES'S SENTENCING, BUT AS EVIDENCED BY THE EXPERT REPORTS THAT WE SUBMITTED, THE SABA REPORT IS NOT RELIABLE, AND IT'S NOT RELIABLE FOR SEVERAL DIFFERENT REASONS.

ONE, IS ON ITS OWN IT PROVIDES A RANGE OF INVESTOR LOSSES,
AND THAT RANGE IS 237 MILLION TO 316 MILLION, WHICH IS AN
\$80 MILLION RANGE. THAT RANGE IS FAR TOO BROAD FOR THE COURT
TO BE ABLE TO RELY ON IT AS CONSTITUTING A REASONABLE ESTIMATE
OF LOSS.

AND I THINK THE COURT RECOGNIZED THAT IN THE HOLMES

SENTENCING, SO WE WOULD JUST REITERATE THAT ARGUMENT HERE. THE

SAME THING APPLIES HERE. IT'S TOO BROAD A RANGE, AND THE COURT

CANNOT USE IT.

THE SECOND ISSUE IS THAT EACH OF THE TWO APPROACHES USED BY MR. SABA CONTAINS SERIOUS FLAWS, BOTH THE INCOME APPROACH AND THE ASSET APPROACH.

SINCE THE COURT RELIED ON THE INCOME APPROACH, I WANT TO ADDRESS THAT FIRST.

SO THE FLAW IN MR. SABA'S INCOME APPROACH RELATES TO THE 1 10:54AM DISCOUNT RATE THAT HE APPLIED TO ASCERTAIN THE PRESENT VALUE OF 2 10:54AM THE CASH FLOWS. AND THIS IS ALL LAID OUT IN MR. WEINGUST'S 3 10:55AM 10:55AM 4 DECLARATION. AND THE DISCOUNT RATE MATTERS BECAUSE IT'S WHAT IS USED TO REDUCE FUTURE CASH FLOWS TO PRESENT VALUE. 10:55AM USING A HIGHER DISCOUNT RATE MEANS THE PRESENT VALUE WILL 10:55AM 6 10:55AM 7 BE LOWER. AND WHAT MR. WEINGUST POINTS OUT IS THAT MR. SABA'S RATE IS INAPPROPRIATELY HIGH. SO WHY IS THAT? 10:55AM 8 ACCORDING TO MR. WEINGUST, MR. SABA RELIED ON OLD DATA IN 10:55AM 9 10:55AM 10 REACHING THAT 44 PERCENT DISCOUNT RATE, AND WHAT HE SHOULD HAVE 10:55AM 11 DONE IS USED THE DATA THAT EXISTED CLOSER IN TIME TO THE 10:55AM 12 VALUATION DATE, WHICH WAS DECEMBER 31ST, 2014, THE DATE THAT THE COURT CHOSE. 10:55AM 13 NOW, WHEN YOU USE THAT DISCOUNT RATE, WHEN YOU USE THE 10:55AM 14 10:56AM 15 DATA THAT IS CLOSER IN TIME, YOU COME UP WITH YOUR DISCOUNT RATE, IT GOES DOWN TO 27 PERCENT, AND THIS IS ALL LAID OUT IN 10:56AM 16 10:56AM 17 THE WEINGUST DECLARATION. 10:56AM 18 THE COURT: DID HE TALK ABOUT THE -- HIS CRITICISM, 10:56AM 19 I THINK, WAS ABOUT THE USE OF THE PEPPERDINE STUDY. HE TALKED 10:56AM 20 ABOUT THE PEPPERDINE STUDY. MS. WALSH: HE DID. 10:56AM 21 10:56AM 22 THE COURT: AND I THINK HE WAS CRITICAL SAYING THAT 10:56AM 23 MR. SABA DID NOT PROPERLY USE THAT PEPPERDINE STUDY IN THE 10:56AM 24 SENSE THAT -- I THINK -- DIDN'T HE SAY THAT THE INFORMATION IN 10:56AM 25 THAT STUDY WAS SOMEHOW DATED AND HE SHOULD HAVE DONE MORE?

MS. WALSH: RIGHT. SO PEPPERDINE CREATES THE STUDY 1 10:56AM EVERY YEAR AND INSTEAD OF USING THE YEAR THAT WAS CLOSE IN TIME 2 10:56AM TO THE VALUATION DATE, MR. SABA INCLUDED MANY, MANY YEARS GOING 3 10:56AM 10:56AM 4 BACK PRETTY FAR IN TIME, AND MR. WEINGUST SAYS THAT'S NOT AN APPROPRIATE WAY TO CALCULATE THE DISCOUNT RATE. YOU SHOULD USE 10:56AM 10:57AM 6 THE DATA THAT EXISTS AS CLOSE IN TIME AS POSSIBLE TO THE 10:57AM 7 VALUATION DATE. THE COURT: AND THERE WAS ALSO SOME DISCUSSION IN 10:57AM 8 BOTH OF THE REPORTS ABOUT THE VARIABILITY OF VC CONDUCT. VC'S 10:57AM 9 10:57AM 10 INVEST IN VERY STRANGE WAYS. IT'S NOT A 3 PERCENT GUARANTEED RETURN, IT'S NOT A TREASURY BILL. 10:57AM 11 10:57AM 12 MS. WALSH: NO. THE COURT: IT'S A CREATURE OF THEIR OWN DESIGN AND 10:57AM 13 ACTIONS, AND, THEREFORE, I THINK THEY BOTH OBSERVED THAT VC 10:57AM 14 10:57AM 15 INVESTMENTS ARE DIFFICULT TO TRACK. 10:57AM 16 MS. WALSH: THEY ARE DIFFICULT -- WELL, PEPPERDINE IS A STUDY THAT TRACKS THEM EVERY YEAR. SO THAT IS THE DATA 10:57AM 17 10:57AM 18 THAT EXISTS. 10:57AM 19 THE COURT: COLLECTS THOSE INVESTMENTS AND OFFERS 10:57AM 20 THAT HISTORY? MS. WALSH: RIGHT. BUT JUST SINCE YOU RAISED IT, 10:57AM 21 10:57AM 22 YOUR HONOR, VC INVESTMENTS OR I GUESS PROJECTIONS OR RATES OF 10:58AM 23 RETURN THAT APPEAR THERE, THEY ACCOUNT FOR THE RISK THAT THEY 10:58AM 24 KNOW THEY'RE GETTING INTO. AND THERE ARE PARTS, AND I THINK 10:58AM 25 MR. WEINGUST POINTED THIS OUT, THERE ARE PARTS OF MR. SABA'S --

1 10:58AM 2 10:58AM 3 10:58AM 10:58AM 4 10:58AM 10:58AM 6 10:58AM 7 10:58AM 8 10:58AM 9 10:58AM 10 10:58AM 11 10:58AM 12 10:59AM 13 10:59AM 14 10:59AM 15 10:59AM 16 10:59AM 17 10:59AM 18 10:59AM 19 10:59AM 20 10:59AM 21 10:59AM 22 10:59AM 23 10:59AM 24 10:59AM 25

I THINK IT'S MORE IN THE SUPPLEMENTAL DECLARATION WHERE

MR. SABA SAYS, YOU KNOW, THESE RATES ARE TOO OPTIMISTIC, AND

THEY DON'T ACCOUNT FOR THE RISK THAT EXISTED AT THERANOS.

WELL, THESE ARE VENTURE CAPITAL FIRMS. THEY ACCOUNT FOR RISK. THIS IS A MARKET FULL OF RISK. SO THAT IS ANOTHER ONE OF MR. WEINGUST'S POINTS THAT MR. SABA IS KIND OF AFTER THE FACT SAYING THAT THESE RATES ARE TOO OPTIMISTIC BECAUSE THEY HAVEN'T ACCOUNTED FOR RISK, BUT THEY HAVE. THAT'S WHAT THEY DO.

THE COURT: THANK YOU. YOU KNOW, WHAT WAS

INTERESTING, AS I LOOKED AT THESE REPORTS AND THINGS, I DIDN'T

LOOK AT AN APPENDIX OF THE PEPPERDINE REPORT OR ANY OF THESE

OTHER REPORTS, AND WHEN THEY TALK ABOUT RISK, AND THAT'S WHAT

WE'RE TALKING ABOUT FOR THIS ANALYSIS, WAS THERE ANY SPECIFIC

FACTOR THAT WAS IDENTIFIED IN THE RISK TAKING FOR THE RISK OF

FRAUD IN AN INVESTMENT?

IT DIDN'T SEEM THAT THAT'S A COLUMN THAT IS CHECKED OFF,
TICKED BY A PEPPERDINE STUDY OR SOMEONE ELSE. IT SAYS RISK,
AND I SUPPOSE FROM AN INVESTOR STANDPOINT, I DON'T KNOW, BUT
DOES THAT MEAN, WELL, YOU KNOW, COMPANIES FAIL. SOMEONE
INVENTS A NEW MOUSETRAP AND IT MIGHT WORK, BUT IT MIGHT NOT AS
OPPOSED TO IS THERE A RISK THAT THIS IS A FRAUDULENT ENDEAVOR?

MS. WALSH: SO WHEN WE'RE TALKING ABOUT ECONOMIC
RISK AND VALUATION, FIRST, VALUATION IS DONE ONLY BASED ON WHAT
IS KNOWN OR KNOWABLE, RIGHT?

SO TYPICALLY IF THERE IS A FRAUD, IT'S NOT KNOWN 1 10:59AM 2 TYPICALLY. 11:00AM THE COURT: NO ONE WOULD INVEST IN THAT, WOULD THEY? 3 11:00AM 11:00AM 4 MS. WALSH: RIGHT. BUT THIS IS ALSO AN ECONOMIC ANALYSIS, AND WHETHER -- IT'S ABOUT LOSING YOUR MONEY. SO 11:00AM WHETHER YOU LOSE YOUR MONEY BECAUSE THE COMPANY FAILED OR 11:00AM 11:00AM 7 BECAUSE IT -- FRAUD IS AFOOT, AND THE FRAUD COMES OUT AND YOU LOSE YOUR INVESTMENT, FROM AN ECONOMIC STANDPOINT, THOSE TWO 8 11:00AM THINGS ARE NOT GOING TO BE DIFFERENT. YOU'RE GOING TO LOSE 11:00AM 9 11:00AM 10 YOUR MONEY. 11:00AM 11 SO TO ANSWER YOUR QUESTION, I DON'T THINK THOSE -- THE 11:00AM 12 PEPPERDINE STUDY ACCOUNTED FOR FRAUD, BUT I'M NOT SURE IT 11:00AM 13 MATTERS. 11:00AM 14 THE ISSUE IS WHAT IS THE RISK THAT YOU ARE GOING TO LOSE 11:00AM 15 YOUR INVESTMENT. OKAY. SO MR. WEINGUST, WHEN HE APPLIES THE DATA THAT HE 11:00AM 16 11:00AM 17 THINKS IS APPROPRIATE, COMES UP WITH A MUCH LOWER DISCOUNT 11:01AM 18 RATE, AND IT'S A 27 PERCENT DISCOUNT RATE. AND HE LAYS THAT 11:01AM 19 OUT IN HIS TABLE 2 TO HIS DECLARATION. 11:01AM 20 AND MR. WEINGUST IS NOT JUST PICKING THIS OUT OF THIN AIR. 11:01AM 21 HE BASES IT ON DATA THAT EXISTS AT THE TIME OF THE VALUATION 11:01AM 22 DATE, BUT IT'S ALSO CORROBORATED BY OTHER EVIDENCE IN THE CASE. 11:01AM 23 FOR EXAMPLE, ARANCA USED A DISCOUNT RATE ON DECEMBER 31ST, 11:01AM 24 2014 THAT WAS 20 PERCENT, MUCH CLOSER TO MR. WEINGUST AND MUCH, 11:01AM 25 MUCH LOWER THAN MR. SOLACE. AND THE LONG FILING THAT YOU

11:01AM	1	REFERENCED THIS MORNING, YOUR HONOR, I THINK IT WAS SO LONG
11:01AM	2	BECAUSE MR. WEINGUST ATTACHED THAT ARANCA REPORT.
11:01AM	3	THE COURT: I THINK HIS SUMMARY, WAS IT 14 PAGES OR
11:01AM	4	SOMETHING LIKE THAT?
11:01AM	5	MS. WALSH: YEAH, RIGHT.
11:01AM	6	THE COURT: RIGHT. BUT OF COURSE HE WANTED ME TO
11:02AM	7	READ THOSE 14 PAGES TO GET CONTEXT OF HIS 14 PAGES I THINK.
11:02AM	8	MS. WALSH: WELL, I THINK HE JUST WANTED TO GIVE YOU
11:02AM	9	THE BASIS FOR WHAT HE WAS SAYING.
11:02AM	10	SO THAT ARANCA REPORT DOES CONTAIN THE DISCOUNT RATE AND
11:02AM	11	ITS DISCOUNT RATE IS 20 PERCENT.
11:02AM	12	ANOTHER CORROBORATING FACT IS FORTRESS IN 2017, LATE IN
11:02AM	13	2017 WHEN "THE WALL STREET JOURNAL" HAS WRITTEN ALL OF ITS
11:02AM	14	ARTICLES ABOUT THERANOS AND THE FRAUD IS POTENTIALLY OUT IN THE
11:02AM	15	MARKETPLACE, VERY RISKY INVESTMENT FOR ARANCA I'M SORRY, FOR
11:02AM	16	FORTRESS, AND FORTRESS ASSIGNED A DISCOUNT RATE OF 25 PERCENT,
11:02AM	17	A RATE OF RETURN OF 25 PERCENT, ALSO MUCH CLOSER TO
11:02AM	18	MR. WEINGUST AND MUCH LOWER THAN MR. SABA.
11:02AM	19	FINALLY, RDV IN ONE OF ITS EXHIBITS THAT IS A TRIAL
11:02AM	20	EXHIBIT, AND THIS IS TRIAL EXHIBIT 2192, ASSIGNED A RATE OF
11:03AM	21	RETURN FOR THERANOS OF 30 PERCENT.
11:03AM	22	SO MR. WEINGUST'S AFTER-THE-FACT ANALYSIS IS ACTUALLY
11:03AM	23	CORROBORATED BY SEVERAL PIECES OF EVIDENCE IN THE CASE. AND
11:03AM	24	WHAT IT SHOWS IS MR. SABA'S DISCOUNT RATE IS TOO HIGH AND
11:03AM	25	CORRECTING IT MAKES A HUGE DIFFERENCE IN THE AMOUNT OF VALUE

1 11:03AM 2 11:03AM 3 11:03AM 11:03AM 4 11:03AM 11:03AM 6 11:03AM 7 11:03AM 8 11:04AM 9 11:04AM 10 11:04AM 11 11:04AM 12 11:04AM 13 11:04AM 14 11:04AM 15 11:04AM 16 11:04AM 17 11:04AM 18 11:04AM 19 11:04AM 20 11:04AM 21 11:04AM 22 11:05AM 23 11:05AM 24 11:05AM 25

THAT EXISTED IN THERANOS ON THAT VALUATION DATE, A HUGE DIFFERENCE, AND THOSE DIFFERENCES ARE LAID OUT IN MR. WEINGUST'S TABLE 2.

MR. WEINGUST ALSO FOUND THAT MR. SABA'S ASSET APPROACH WAS FLAWED.

AND SINCE THE COURT DIDN'T APPLY THE ASSET APPROACH, I'D LIKE TO GO THROUGH IT, BUT I RECOGNIZE THAT IT WASN'T APPLIED TO MS. HOLMES.

BUT JUST QUICKLY, MR. WEINGUST NOTICED THAT MR. SABA DID

NOT APPLY AN OPPORTUNITY COST, WHICH IS A STANDARD FACTOR THAT

IS APPLIED IN ASSESSING VALUE USING THIS ASSET APPROACH. AND

MR. SABA APPEARS TO HAVE IGNORED THAT FACTOR. I DON'T KNOW IF

HE FORGOT TO APPLY IT OR WHY HE DIDN'T MENTION IT.

HE SAYS IN HIS SUPPLEMENTAL DECLARATION THAT HE DID CONSIDER IT, BUT HE DECIDED NOT TO APPLY IT.

I THINK -- I'M NOT QUITE SURE THAT IS CREDIBLE BECAUSE

THERE WERE OTHER THINGS IN HIS ORIGINAL REPORT THAT HE

CONSIDERED AND DECIDED NOT TO APPLY, AND HE GOES THROUGH THEM

VERY CAREFULLY. SO IT SEEMS HE WOULD DO THE SAME THING WITH

OPPORTUNITY CAUSED IF HE HAD REALLY CONSIDERED IT. BUT IN ANY

EVENT, IT SHOULD BE APPLIED ACCORDING TO MR. WEINGUST, AND THAT

ALSO GREATLY AFFECTS THE VALUE OF THERANOS.

FINALLY, THE ALLOCATION METHOD THAT MR. SABA USES, SO THIS
IS WHEN HE HAS THE ENTIRE VALUE AND HE NEEDS TO ALLOCATE IT TO
THE DIFFERENT SHAREHOLDERS BASED ON THEIR LEVELS WITHIN THE

COMPANY, HE USED AN ALLOCATION METHOD THAT IS ACCEPTED IN THE 1 11:05AM INDUSTRY, BUT IT'S THE OPC METHOD, BUT THERE ARE TWO INPUTS 2 11:05AM THAT GO INTO THAT METHOD THAT ARE EXTREMELY SPECULATIVE. 3 11:05AM 11:05AM 4 THE TWO INPUTS ARE VOLATILITY AND THE OCCURRENCE OF A HYPOTHETICAL LIQUIDITY EVENT. 11:05AM 11:05AM 6 AND WITH A PUBLIC COMPANY, THAT'S EASILY ASCERTAINABLE. 11:05AM 7 AND WITH A PRIVATE COMPANY AND LIMITED SHAREHOLDERS, IT IS REALLY GUESSWORK TO ASCERTAIN THE LIQUIDITY OF PRIVATE STOCK OR 8 11:05AM WHAT THE TIME PERIOD SHOULD BE BEFORE A LIQUIDITY EVENT HAPPENS 11:06AM 9 11:06AM 10 IN THE FUTURE. THERE ARE UNKNOWNS, AND THEY REALLY INVOLVE A LOT OF 11:06AM 11 11:06AM 12 GUESSWORK. THAT WOULD BE -- MAYBE THAT WOULD BE OKAY. THE 11:06AM 13 PROBLEM IS IF YOU CHANGE EITHER ONE OF THESE INPUTS, IT GREATLY IMPACTS THE VALUE THAT YOU END UP WITH PER SHAREHOLDER, AND 11:06AM 14 11:06AM 15 THESE HUGE SWINGS ARE JUST NOT APPROPRIATE FOR THE COURT TO USE WHEN WE'RE TALKING ABOUT A CRIMINAL CASE AND SENTENCING AN 11:06AM 16 11:06AM 17 INDIVIDUAL TO WHAT COULD BE A LONG PERIOD OF TIME IN JAIL TO 11:06AM 18 RELY ON A METHOD WHERE IF YOU TWEAK ONE THING, IT SWINGS BY 11:06AM 19 HUNDREDS OF MILLIONS OF DOLLARS. IT JUST DOESN'T SEEM 11:06AM 20 REASONABLE TO RELY ON THAT METHODOLOGY. 11:07AM 21 SO WHERE DOES THAT LEAVE US WITH MR. SABA? 11:07AM 22 11:07AM 23 CASE, BUT IT'S NOT RELIABLE ENOUGH TO MAKE A REASONABLE ESTIMATE IN THESE CIRCUMSTANCES IN SENTENCING. 11:07AM 24 11:07AM 25 MR. SABA IS ALSO INCONSISTENT WITH HOW HE USES

1 11:07AM 2 11:07AM 3 11:07AM 11:07AM 4 11:07AM 11:07AM 11:07AM 7 11:08AM 8 11:08AM 9 11:08AM 10 11:08AM 11 11:08AM 12 11:08AM 13 11:08AM 14 11:08AM 15 11:08AM 16 11:08AM 17 11:08AM 18 11:08AM 19 11:08AM 20 11:09AM 21 11:09AM 22 11:09AM 23 11:09AM 24 11:09AM 25

INFORMATION. FOR EXAMPLE, HE USES THE TIME PERIOD UNTIL A LIQUIDITY EVENT. HE BASES THAT ON THE ARANCA REPORT, BUT HE REJECTS THE ARANCA'S RATE OF RETURN. AND THERE'S NO REASON WHY HE'S PICKING AND CHOOSING CERTAIN THINGS TO USE FROM ARANCA AND NOT WITHOUT ANY EXPLANATION.

SO NO MATTER WHAT APPROACH MR. SABA USES, THE PROBLEM IS,

AS I JUST SAID, THE VALUE THAT HE LANDS ON IF YOU TWEAK ONE

THING ABOUT HIS APPROACH, WHICH MR. WEINGUST BELIEVES SHOULD BE

DONE TO BE ACCURATE, THE VALUE OF THERANOS GOES UP BY HUNDREDS

OF MILLIONS OF DOLLARS AND THE LOSS GOES DOWN BY HUNDREDS OF

MILLIONS OF DOLLARS.

SO WHAT IT SHOWS IS THAT IT'S NOT A RELIABLE METHODOLOGY
TO USE WHEN ASSESSING LOSS.

SO WE DON'T THINK THE GOVERNMENT HAS PROVEN EVEN BY A PREPONDERANCE LOSS IN THIS CASE. EVEN WITH THE BENEFIT OF MR. SABA'S REPORT, IT'S TOO SPECULATIVE. AND WHEN YOU LOOK AT THE ECONOMIC REALITY OF WHAT HAPPENED HERE, IT'S A TOTALLY DIFFERENT PICTURE.

WHAT HAPPENED IS MR. BALWANI LEFT THERANOS IN MAY 2016.

WHEN HE LEFT THERANOS, THERE WAS \$350,000 IN THE BANK, THERE

WAS IP THAT THERANOS OWNED WORTH HUNDREDS OF MILLIONS OF

DOLLARS, AND THAT'S EVIDENCED BY FORTRESS'S LOAN OF

\$100 MILLION THAT IT EXTENDED TO THERANOS. AS A PRACTICE, THE

VALUE OF THE COLLATERAL IS GOING TO BE WORTH MULTIPLES OF THE

FACE AMOUNT OF THE LOAN. THE PERKINS COIE REPORT VALUED

1 11:09AM 2 11:09AM 3 11:09AM 11:09AM 4 11:09AM 11:09AM 6 11:09AM 7 11:10AM 8 11:10AM 9 11:10AM 10 11:10AM 11 11:10AM 12 11:10AM 13 11:10AM 14 11:10AM 15 11:10AM 16 11:10AM 17 11:10AM 18 11:10AM 19 11:10AM 20 11:10AM 21 11:11AM 22 11:11AM 23 11:11AM 24 11:11AM 25

THERANOS'S IP AS POTENTIALLY GENERATING HUNDREDS OF MILLIONS OF DOLLARS. AND AFTER MR. BALWANI LEFT THERANOS -- I THINK I JUST MISSPOKE. I SAID 350,000 IN THE BANK. IT'S 350 MILLION. APOLOGIES. A BIG DIFFERENCE.

SO THERE'S A HUGE AMOUNT OF CASH IN THE BANK AND A HUGE VALUE OF IP THAT THE COMPANY OWNS.

AND WHEN MR. BALWANI LEAVES THERANOS, THERANOS HAS TO DECIDE WHAT TO DO WITH THOSE ASSETS. IS IT GOING TO CONTINUE ITS BUSINESS OF TESTING BLOOD? IS IT GOING TO PUT A PAUSE ON ITS BUSINESS AND SHUT DOWN AND REPAY ALL OF ITS INVESTORS? IS IT GOING TO LICENSE ITS IP AND TRY TO GENERATE REVENUE THAT WAY TO GIVE ITS INVESTORS A RETURN ON THEIR INVESTMENTS? ALL OF THOSE ARE DECISIONS THAT HAD TO BE ANALYZED AND MADE.

MR. BALWANI WAS NO PART OF THAT. HE WAS GONE FROM THE COMPANY. HE HAD NO CONTROL OVER THOSE DECISIONS. THOSE DECISIONS WERE BEING MADE BY ELIZABETH HOLMES, THE BOARD OF DIRECTORS, AND INVESTORS WHO WERE COMMUNICATING WITH THEM AT THE TIME.

SO THE GOVERNMENT'S PROPOSITION THAT, WELL, THE INVESTORS
LOST EVERYTHING AND MR. BALWANI SHOULD BE ON THE HOOK FOR THAT
LOSS IS -- IT CANNOT BE SUSTAINED BECAUSE MR. BALWANI LEFT
THERANOS BEFORE THE INVESTORS LOST THEIR MONEY. THERE WERE SO
MANY INTERVENING FACTORS THAT BREAK THE CHAIN OF CAUSATION
BETWEEN THE INVESTORS BUYING THERANOS STOCK AND THEN AT THE END
OF THE DAY LOSING THEIR MONEY WHEN THERANOS SHUT ITS DOORS.

1 11:11AM 11:11AM 2 3 11:11AM 11:11AM 4 11:11AM 5 11:11AM 6 11:11AM 7 11:12AM 8 11:12AM 9 11:12AM 10 11:12AM 11 11:12AM 12 11:12AM 13 11:12AM 14 11:12AM 15 11:12AM 16 11:12AM 17 11:12AM 18 11:12AM 19 11:12AM 20 11:12AM 21 11:12AM 22 11:12AM 23 11:13AM 24 11:13AM 25

AND ONE OF THOSE INVESTORS WAS MR. BALWANI. HE LOST THE MILLIONS OF DOLLARS THAT HE USED TO BUY THERANOS STOCK. AND HE HAD NO CONTROL OVER THAT.

SO, YOUR HONOR, JUST TO SUM UP ON LOSS, THE GOVERNMENT HAS NOT MET ITS BURDEN BY CLEAR AND CONVINCING EVIDENCE OR BY A PREPONDERANCE TO SHOW THAT THE LOSSES THAT THE INVESTORS SUSTAINED WERE CAUSED BY MR. BALWANI'S CONDUCT.

THE WAY THEY APPROACH LOSS USING THE SABA REPORT IS SO SPECULATIVE AND UNRELIABLE THAT THE COURT SHOULD NOT USE IT. IT CANNOT YIELD A REASONABLE ESTIMATE OF LOSS. IT'S WAY TOO COMPLICATED.

AND, IN FACT, I WOULD JUST NOTE THAT THE GOVERNMENT

DOESN'T CITE ANY NINTH CIRCUIT CASE WHERE THE COURT USES A

METHODOLOGY TO ASSESS SHARE PRICE OR VALUE FOR A PRIVATE

COMPANY.

THEY CITE TO THE LEONARD CASE IN THE SECOND CIRCUIT AND OTHER SECOND CIRCUIT CASES. AND THE LEONARD CASE, I MEAN THE LEONARD CASE ACTUALLY REVERSED THE DISTRICT COURT FOR DOING EXACTLY WHAT THE GOVERNMENT IS RECOMMENDING TO THIS COURT.

THE <u>LEONARD</u> DISTRICT COURT SAID THE WHOLE LOSS -- THAT THE DEFENDANT IS RESPONSIBLE FOR THE ENTIRE LOSS, AND THE SECOND CIRCUIT REVERSED ON THAT.

AND ALL THE SECOND CIRCUIT SAID IS DISTRICT COURT, COME UP WITH A METHODOLOGY THAT IS REASONABLE. THAT'S WHAT WE LEARNED FROM THAT CASE.

11:13AM	1	WE HAVE NO CASE LAW TO ESTABLISH WHAT A REASONABLE
11:13AM	2	METHODOLOGY IS. AND THIS CASE IN THIS COMPANY, AND BASED ON
11:13AM	3	ALL OF THESE INVESTORS WHO WERE INVESTING FOR DIFFERENT
11:13AM	4	REASONS, IT'S WAY TOO COMPLICATED AND SPECULATIVE TO ASCERTAIN
11:13AM	5	A REASONABLE AMOUNT OF LOSS.
11:13AM	6	THE GUIDELINES TELL US WHAT TO DO IN THOSE CIRCUMSTANCES.
11:13AM	7	WE LOOK TO WHAT THE DEFENDANT GAINED, AND WE ALL KNOW THAT
11:13AM	8	MR. BALWANI GAINED NOTHING FROM HIS TIME AT THERANOS. IN FACT,
11:13AM	9	HE LOST MONEY.
11:13AM	10	SO FOR THAT REASON, WE THINK THE LOSS ENHANCEMENT SHOULD
11:13AM	11	BE ZERO.
11:13AM	12	THE COURT: SO LET ME JUST CAPTURE THAT.
11:13AM	13	THE JURY HEARD THE EVIDENCE IN THE TRIAL, THEY CONVICTED
11:13AM	14	MR. BALWANI OF EVERY ONE OF THE CHARGES THAT WAS PRESENTED TO
11:13AM	15	THEM, INCLUDING THE WIRE FRAUD COUNTS, AND YOU BELIEVE THAT
11:14AM	16	THERE'S NO LOSS, THAT THE COURT SHOULD FIND NO LOSS? IS THAT
11:14AM	17	WHAT I'M HEARING YOU SAY?
11:14AM	18	MS. WALSH: THAT THERE SHOULD BE NO ADJUSTMENT FOR
11:14AM	19	LOSS, THAT'S RIGHT.
11:14AM	20	THE COURT: WHAT SHOULD THE LOSS AMOUNT BE IN YOUR
11:14AM	21	OPINION?
11:14AM	22	MS. WALSH: FOR MR. BALWANI, IT'S ZERO.
11:14AM	23	THE COURT: OKAY. OKAY.
11:14AM	24	MS. WALSH: YEAH.
11:14AM	25	THE COURT: OKAY. THANK YOU.

1 MR. LEACH.

11:14AM

11:14AM

11:14AM

11:14AM 4

11:14AM 5

11:14AM 6

11:14AM 7

11:14AM 8

11:14AM 9

11:14AM 10

11:14AM 11

11:14AM 12

11:15AM 13

11:15AM 14

11:15AM 15

11:15AM 16

11:15AM 17

11:15AM 18

11:15AM 19

11:15AM 20

11:15AM 21

11:15AM 22

11:15AM 23

11:15AM 24

11:15AM 25

3

MR. LEACH: THANK YOU, YOUR HONOR.

I'D LIKE TO ADDRESS EACH OF MS. WALSH'S POINT IF I COULD,
BUT I WOULD START BY SAYING THAT WE ARE NOT STARTING FROM A
BLANK SLATE HERE.

MOST, IF NOT ALL, OF THESE ARGUMENTS WERE MADE IN THE
HOLMES SENTENCING WHERE THE COURT MADE FINDINGS BASED ON THE
SABA REPORT, BASED ON MS. RAVITZ'S TESTIMONY. I THINK THE ONLY
NEW INFORMATION HERE THAT WE'RE DEALING WITH IS EXPERT
DECLARATIONS TENDERED BY MR. BALWANI. I'LL GET TO THOSE, BUT
MOST IF NOT EVERYTHING THAT HAS BEEN RAISED HERE WAS RAISED AND
CONSIDERED IN THE HOLMES SENTENCING UNDER IDENTICAL
CIRCUMSTANCES, AND THERE'S SIMPLY NOTHING NEW BESIDES THE
EXPERT DECLARATIONS THAT SHOULD ALTER THE COURT'S FINDINGS THAT
IT MADE IN THE HOLMES SENTENCING.

NOW, WE'VE ARGUED THAT THE LOSS IS THE FULL AMOUNT OF THE C1 AND C2 INVESTMENTS. WE RECOGNIZE THE COURT DISAGREED WITH THAT IN THE HOLMES SENTENCING.

WE PRESERVE OUR ARGUMENT ON THAT POINT, BUT I'M GOING TO FOCUS ON THE LOSS BASED ON THE COURT'S FINDINGS IN THE HOLMES SENTENCING BASED ON THE SABA REPORT, WHICH WE CONTINUE TO BELIEVE PROVIDE A SOUND AND RELIABLE BASIS TO CALCULATE THE LOSS IN THIS CASE.

AND IT'S IMPORTANT TO REMEMBER, YOUR HONOR, THE COURT'S

JOB HERE, THE COURT'S OBLIGATION IS TO HAVE A REASONABLE

1 11:15AM 2 11:15AM 3 11:15AM 11:15AM 4 11:16AM 11:16AM 11:16AM 7 8 11:16AM 11:16AM 9 11:16AM 10 11:16AM 11 11:16AM 12 11:16AM 13 11:16AM 14 11:16AM 15 11:16AM 16 11:16AM 17 11:16AM 18 11:16AM 19 11:16AM 20 11:16AM 21

11:17AM 22

11:17AM 23

11:17AM 24

11:17AM 25

ESTIMATE OF LOSS, NOT AN EXACT CALCULATION, AN ESTIMATE OF LOSS. THAT'S WHAT THE GUIDELINES CALL FOR.

AND THE GUIDELINES SAY THAT THIS IS A TASK BEST SUITED FOR THE DISTRICT JUDGE WHO OVERSAW THE TRIAL AND THAT THERE'S NOT A ONE-SIZE-FITS-ALL APPROACH. THERE'S A NUMBER OF FACTORS THAT THE COURT IS SUPPOSED TO CONSIDER, AND THE GUIDELINES RECOGNIZE THAT THERE'S NOT ONLY ONE WAY TO CALCULATE THE LOSS. THE JUDGE'S JOB IS TO FIND A REASONABLE ESTIMATE. THIS IS NOT AN EXACT SCIENCE.

WE KNOW HERE THAT THE INVESTORS IN THIS CASE LOST

EVERYTHING, EACH OF THE COUNTS OF CONVICTION, ALL OF THE

INVESTORS THAT WE SUBMITTED IN MY DECLARATION IN THE HOLMES

CASE. THIS ISN'T A CASE WHERE, YOU KNOW, THEY -- IF YOU VALUE

IT ON ONE DAY YOU HAVE X, IF THE STOCK KEEPS TRADING, THEY HAVE

Y. THEY LOST ALL OF THEIR MONEY.

AND THE POINT OF THE SABA EXERCISE IS TO TRY TO AFFIX A RESIDUAL VALUE TO THE STOCK ON A PARTICULAR DATE. THE DATE THAT THE COURT SELECTED IN THE HOLMES CASE WAS DECEMBER 31ST, 2014.

IT'S ALSO IMPORTANT TO REMEMBER IN TERMS OF THE BURDEN OF PROOF, I DIDN'T HEAR ANYTHING NEW FROM MS. WALSH IN TERMS OF THE CASES. THE LONICH CASE WAS CITED BY MS. HOLMES AND RELIED ON.

AND THE NINTH CIRCUIT IS CLEAR THROUGH THE <u>LAURIENTI</u> CASE

AND THE <u>BERGER</u> CASE THAT WHEN YOU'RE TALKING ABOUT COUNTS WHERE

1 11:17AM 2 11:17AM 3 11:17AM 11:17AM 4 11:17AM 11:17AM 11:17AM 11:17AM 8 11:17AM 9 11:17AM 10 11:17AM 11 11:18AM 12 11:18AM 13 11:18AM 14 11:18AM 15 11:18AM 16 11:18AM 17 11:18AM 18 11:18AM 19 11:18AM 20 11:18AM 21 11:18AM 22 11:18AM 23 11:18AM 24 11:18AM 25

YOU HAVE A CONVICTION, HERE WIRE FRAUD, HERE A CONSPIRACY TO DEFRAUD INVESTORS, THE APPROPRIATE STANDARD IS PREPONDERANCE OF EVIDENCE, AND THAT'S THE STANDARD THAT THE COURT APPLIED IN THE HOLMES SENTENCING. THERE'S NO NEW CASE LAW ON THIS, THERE'S NO NUANCE FOR MR. BALWANI THAT MAKES IT DIFFERENT, AND THE COURT SHOULD CONTINUE TO APPLY THAT PREPONDERANCE STANDARD.

I WOULD SUBMIT THAT WE MEET ANY STANDARD, YOUR HONOR, BUT PREPONDERANCE IS WHAT CONTROLS HERE.

IN TERMS OF THE NEW FACTS THAT MS. WALSH POINTED OUT, SHE RAISED A COUPLE RELIANCE ISSUES WITH RESPECT TO PARTICULAR INVESTORS. SHE MENTIONED MR. MURDOCH. THAT WAS AN INVESTOR WHERE THE COURT MADE FINDINGS IN THE HOLMES CASE.

THERE'S NO NEW FACTS IN THE RECORD BASED ON THAT. THE COURT HAS MS. RAVITZ'S SWORN TESTIMONY ON THIS POINT. AND SHE'S VERY MUCH IN THE SAME POSITION AS LISA PETERSON WAS FOR RDV, WHO THE COURT ALSO HEARD IN TWO TRIALS AND FOUND WAS A COMPETENT WITNESS TO TESTIFY OR PROVIDE INFORMATION ABOUT RELIANCE IN THIS PARTICULAR SETTING.

SHE WAS THE CHIEF OF STAFF FOR MR. MURDOCH. SHE SAT
THROUGH TWO MEETINGS WITH MS. HOLMES AND MR. BALWANI. SHE
RECEIVED THE TWO BINDERS OF DUE DILIGENCE MATERIALS. THE COURT
IS, BY NOW, VERY FAMILIAR WITH THE BINDERS THAT WERE PROVIDED
TO INVESTORS THAT WERE COMPILED BY MR. EDLIN. SHE HAD THOSE,
AND SHE REVIEWED THOSE ALONG WITH MR. MURDOCH. SHE HAD THE
SAME REVENUE PROJECTIONS THAT WENT TO INVESTORS, AND THOSE WERE

IN PART OF THE CALCULUS BEHIND THE INVESTMENTS.

SHE SAID THAT SHE AND MR. MURDOCH WERE TOLD AND THEY
THOUGHT THE WAG DEAL WAS GROWING AND GENERATING MILLIONS OF
DOLLARS IN REVENUE. THIS IS IMPORTANT BECAUSE IT'S IN DECEMBER
OF 2014, AND THIS IS A TIME PERIOD WHERE MR. BALWANI KNOWS FROM
MR. JHAVERI AND OTHERS AT WALGREENS THAT THEY'RE NOT GOING TO
EXPAND BEYOND THE 40 STORES BECAUSE THEY CAN'T GET THE RATIO OF
THE FINGERSTICK TESTING DOWN. THEY KNOW ALL OF THAT BY
DECEMBER 14TH, 2014 AND NONE OF THAT IS DISCLOSED TO MS. RAVITZ
OR TO MR. MURDOCH.

SHE WAS THERE WHEN MS. HOLMES AND MR. BALWANI SHOWED THEM
THE BOX THAT PURPORTEDLY WAS DOING ALL OF THE TESTING. SHE WAS
TOLD THAT THERE WERE USES IN THE MILITARY SITUATION.

CRITICALLY, SHE TESTIFIED TO QUESTIONS THAT MR. MURDOCH
WAS ASKED IN THESE MEETINGS. ONE OF THEM WAS DIRECTED RIGHT TO
MR. BALWANI, WHICH WAS HOW RELIABLE ARE THESE REVENUE
PROJECTIONS? AND MR. BALWANI SAID A MAXIMUM DOWNSIDE RISK OF
THESE HUNDRED MILLION DOLLAR PROJECTIONS IS 30 PERCENT.

THE COURT KNOWS FROM MS. RAVITZ'S TESTIMONY EXACTLY WHAT
WAS TOLD TO MR. MURDOCH. IT CAN DRAW INFERENCES BASED ON
TESTIMONY ABOUT WHAT WAS RELEVANT. THEY HAVEN'T CITED A SINGLE
CASE FOR THE PROPOSITION THAT IN SENTENCING WHERE CALCULATING
THE LOSS, YOU NEED TO CALL EACH AND EVERY INVESTOR IN THE
COMPANY, PUT THEM ON THE STAND, ASK THEM QUESTIONS AS YOU WOULD
IN A TRIAL IN ORDER TO DRAW THE REASONABLE ESTIMATE OF LOSS

1 11:20AM 2 11:20AM 3 11:20AM 11:20AM 4 11:20AM 11:20AM 6 11:20AM 7 11:20AM 8 11:21AM 9 11:21AM 10 11:21AM 11 11:21AM 12 11:21AM 13 11:21AM 14 11:21AM 15 11:21AM 16 11:21AM 17 11:21AM 18 11:21AM 19 11:21AM 20 11:21AM 21 11:21AM 22 11:21AM 23 11:21AM 24

11:22AM 25

THAT THE COURT MUST ASSESS IN SENTENCING.

WE HAVE MORE THAN MET OUR BURDEN ON THAT POINT.

THERE WAS ALSO SOME REFERENCE IN THE BRIEFING TO

MS. PETERSON, LIKE MS. HOLMES, THEY MAKE THIS ARGUMENT THAT

BECAUSE MS. PETERSON WAS NOT THE FINAL DECISION-MAKER AT RDV,

SHE'S INCOMPETENT TO TESTIFY TO RDV'S RELIANCE. THERE'S NO

CASE THAT SUPPORTS THAT.

AND MS. PETERSON'S TESTIMONY THROUGHOUT BOTH TRIALS IS
REPLETE WITH EVIDENCE SUPPORTING HER KNOWLEDGE OF WHAT WAS SAID
AND HER KNOWLEDGE OF WHAT WAS IMPORTANT TO RDV. AND I WOULD
DIRECT THE COURT TO IN THE HOLMES TRIAL, TRIAL TRANSCRIPT 4759
SHE TESTIFIED WE WERE RELYING ON WHAT WE WERE TOLD. SHE SAID
WE WERE RELYING ON WHAT WE WERE TOLD BY THEM ON THE ACCURACY OF
THE ANALYZER. SHE SAID THE PFIZER DOCUMENT WAS VERY IMPORTANT
TO THEM. SHE SAID SHE WAS NOT JUST RELYING ON WHAT WAS IN
WRITING, SHE WAS RELYING ON WHAT WE WERE TOLD.

AND SHE WAS ALSO THE ONE WHO PREPARED THE APPROVAL DOCUMENT FOR RDV MEMORIALIZING FOR THEIR RECORDS, YOU KNOW, WHAT THEY WERE TOLD, WHAT WAS IMPORTANT FOR THEM, AND WHAT THEY RELIED ON.

SO THE NOTION THAT YOU NEED TO HAVE SWORN TESTIMONY IN A
SENTENCING PROCEEDING WITH EACH AND EVERY INVESTOR SAYING "I
RELIED ON THIS" IS JUST NOT SUPPORTED BY THE CASES, AND THE
COURT HAS AMPLE FACTUAL INFORMATION IN THE RECORD TO SUPPORT
THE FINDINGS THAT IT MADE IN THE HOLMES SENTENCING WHICH SHOULD

1 APPLY EQUALLY HERE. 11:22AM THE COURT: LET ME ASK YOU -- PARDON ME, MR. LEACH. 2 11:22AM ARE THERE ANY VICTIMS PRESENT THAT WISH TO BE HEARD? 3 11:22AM 11:22AM 4 MR. LEACH: NOT TO MY KNOWLEDGE, YOUR HONOR. 11:22AM 5 THE COURT: ALL RIGHT. THANK YOU. MR. LEACH: LET ME TURN TO MR. SABA BECAUSE I THINK 11:22AM 6 11:22AM 7 THE ONLY REAL NEW FACTUAL INFORMATION THAT THE COURT HAS IS TWO EXPERT DECLARATIONS OR TWO FOR MR. WEINGUST AND ANOTHER ONE 11:22AM 8 FROM MR. REIFF. 11:22AM 9 11:22AM 10 I WANT TO START BY SAYING THAT THERE IS SOME DISPARITY IN 11:22AM 11 THE QUALIFICATIONS OF THE EXPERTS THAT MIGHT NOT BE OBVIOUS 11:22AM 12 FROM SOME OF THE MATERIALS, BUT I THINK ARE SIGNIFICANT IN EVALUATING PARTICULARLY MR. WEINGUST. 11:22AM 13 MR. SABA IS AN ACCREDITED SENIOR APPRAISER WITH THE 11:22AM 14 11:22AM 15 AMERICAN SOCIETY OF APPRAISERS. HE'S ALSO ACCREDITED IN BUSINESS VALUATIONS BY THE AICPA, THE PROFESSIONAL ACCOUNTING 11:23AM 16 11:23AM 17 ASSOCIATION. 11:23AM 18 AND WHAT THAT -- AND MR. WEINGUST HAS NEITHER OF THOSE 11:23AM 19 CERTIFICATIONS. 11:23AM 20 MR. WEINGUST IS A MEMBER OF ANOTHER ORGANIZATION CALLED A 11:23AM 21 NATIONAL ASSOCIATION OF CERTIFIED EVALUATORS AND ANALYSTS, BUT 11:23AM 22 HE'S NOT CERTIFIED BY THAT ORGANIZATION. MR. SABA IS. 11:23AM 23 AND WHY ARE THESE CERTIFICATIONS IMPORTANT? IT'S BECAUSE 11:23AM 24 IN DOING HIS REPORT, MR. SABA WAS REQUIRED TO COMPLY WITH THE 11:23AM 25 STANDARDS THAT APPLY TO THOSE EVALUATORS, AND YOU CAN SEE THIS

1 11:23AM 2 11:23AM 3 11:23AM 11:23AM 4 11:23AM 11:23AM 6 11:24AM 7 8 11:24AM 11:24AM 9 11:24AM 10 11:24AM 11 11:24AM 12 11:24AM 13 11:24AM 14 11:24AM 15 11:24AM 16 11:24AM 17 11:24AM 18 11:24AM 19 11:24AM 20 11:24AM 21 PARTICULAR DAY APPLYING THE STANDARDS. 11:24AM 22 11:24AM 23 11:25AM 24 THAT SAY THIS IS THE RIGHT DISCOUNT RATE TO APPLY, YOU SHOULD 11:25AM 25 APPLY THIS DISCOUNT RATE, AND THIS GENERATES A PARTICULAR

AT THE TAIL END OF MR. SABA'S INITIAL REPORT, HE SAYS, "I CERTIFY TO ALL OF THE FOLLOWING." THAT MEANS HE FOLLOWED THE STANDARDS OF THE AICPA IN PREPARING HIS REPORT, THAT MEANS HE FOLLOWED THE STANDARDS OF AMERICAN SOCIETY OF APPRAISERS IN PREPARING HIS REPORT, AND I THINK THAT CAN GIVE THE COURT ADDED ASSURANCE THAT BECAUSE MR. SABA IS COMPLYING WITH THE STANDARDS, DOING WHAT ACCOUNTANTS AND APPRAISERS DO EVERY DAY IN TRYING TO DO SOMETHING THAT IS VERY HARD, WHICH IS TO VALUE A COMPANY, AND PARTICULARLY HARD WHEN YOU'RE TRYING TO VALUE A COMPANY AND DISENTANGLE A RISK THAT I THINK THE COURT IS RIGHT IS NOT ACCOUNTED FOR BY INVESTORS OR BY -- AT LEAST THEY SHOULDN'T HAVE TO ACCOUNT FOR IT, AND THAT'S THE RISK OF FRAUD. SO THERE'S A VERY MEANINGFUL DIFFERENCE BETWEEN THE TWO EXPERTS THAT THE COURT HAS. WEINGUST IS A LAWYER, AND I'M NOT CASTING ANY ASPERSIONS ON HIS QUALIFICATIONS, BUT HE DIDN'T LOOK AT ANY DOCUMENTS, AS FAR AS I CAN TELL, OTHER THAN THE ARANCA REPORT THAT HE PROVIDED TO YOU. HE DIDN'T REVIEW THE VOLUME OF MATERIAL THAT MR. SABA ATTACHED TO HIS REPORT TO REALLY DIG INTO THE FORECAST, DIG INTO THE TESTIMONY TO TRY TO FIGURE OUT WHAT WAS THE VALUE OF THIS COMPANY ON THIS AND I HAVE TO TAKE ISSUE WITH SOMETHING MS. WALSH SAID EARLIER. I DON'T SEE ANYTHING IN MR. WEINGUST'S DECLARATIONS

VALUE.

HE'S CRITICAL OF WHAT MR. SABA DOES, BUT IF YOU PARSE THE DECLARATION, AND WE'VE LOOKED AT IT VERY CAREFULLY, YOUR HONOR, HE'S SAYING I THINK 45 PERCENT IS TOO HIGH. IF YOU WERE TO TAKE THIS 28 PERCENT NUMBER FROM THE SINGLE PEPPERDINE STUDY, THIS IS WHAT HAPPENS. AND IF YOU TAKE THE 20 PERCENT NUMBER IMPLIED BY ARANCA, THIS IS WHAT HAPPENS.

BUT MR. WEINGUST DOESN'T LOOK AT A SINGLE DOCUMENT OTHER
THAN THE ARANCA REPORT, HE DOESN'T REVIEW ANY OF THE TESTIMONY,
HE DOESN'T REVIEW ANYTHING ABOUT THE UNDERLYING TECHNOLOGY. HE
JUST SAYS, I HAVE A DIFFERENT -- YOU KNOW, I DISAGREED WITH
MR. SABA'S JUDGMENT ON THE 45 PERCENT, I'M NOT GOING TO TELL
YOU WHAT IT SHOULD BE, BUT IF YOU TAKE THESE OTHER TWO NUMBERS,
THIS IS WHAT YOU GET.

SO THIS ISN'T A SITUATION WHERE YOU HAVE AN EXPERT SAYING X AND ANOTHER ONE SAYING Y. IT'S REALLY THE Y BEING CRITICAL OF THE X, AND THE X HAS GONE THROUGH A VERY, VERY THOROUGH PROCESS, COMPLYING WITH THE APPROPRIATE STANDARDS.

THE 45 PERCENT IS A MATTER OF JUDGMENT, BUT HERE IT'S A MATTER OF JUDGMENT BASED ON VERY, VERY REASONABLE

CIRCUMSTANCES. LET ME EXPLAIN A LITTLE BIT WHY WE THINK THAT

IS SO AND WHY WE THINK THE COURT WAS RIGHT TO INCLUDE THAT IN

THE FIRST INSTANCE AND WHY MR. WEINGUST DOESN'T RAISE ANYTHING

TO MEANINGFULLY COUNTERACT THAT.

THE FIRST CRITIQUE I HEARD WAS HE'S USING THIS OLD DATA.

1 11:26AM 2 11:26AM 3 11:26AM 11:26AM 4 11:27AM 11:27AM 6 11:27AM 7 11:27AM 8 11:27AM 9 11:27AM 10 11:27AM 11 11:27AM 12 11:27AM 13 11:27AM 14 11:27AM 15 11:27AM 16 11:27AM 17 11:27AM 18 11:27AM 19 11:27AM 20 11:27AM 21 11:28AM 22 11:28AM 23 11:28AM 24 11:28AM 25

THIS SO-CALLED "OLD DATA" IS FROM A 2019 REPORT BY THE AICPA, WHICH MR. WEINGUST IS NOT A MEMBER OF, IS NOT CERTIFIED BY, AND THIS IS A TOOL ACCORDING TO MR. SABA THAT IS USED ROUTINELY IN VALUATIONS OF COMPANIES, BOTH PRIVATE AND PUBLIC, AND THIS IS DATA THAT IS IN AS AUTHORITATIVE LITERATURE AS YOU CAN GET IN THIS AREA.

SO WE APPRECIATE THAT MR. SABA THINKS IT'S OLD. IT'S HARD TO GET DATA ON PRIVATE VENTURE CAPITAL COMPANIES.

MR. WEINGUST WOULD HAVE YOU RELY ON ONE SINGLE REPORT FROM PEPPERDINE.

MR. SABA IS TAKING A MORE HOLISTIC APPROACH BASED ON DATA
THAT ISN'T OLD BUT IS DATA AUTHORITATIVELY RELIED UPON BY THE
AICPA.

THERE'S ALSO CRITICISM ON JUST USING THAT PEPPERDINE

NUMBER. THE COURT COMMENTED ON, WELL, DID HE USE THE 2021

NUMBERS OR THE 2015 NUMBERS? I HOPE WE MADE THIS CLEAR IN OUR

REPLY BRIEF, WHEN IT COMES TO THE PEPPERDINE STUDY, MR. SABA

WAS USING THE 25 -- THE 2015 NUMBERS.

IF YOU LOOK AT SOME OF THE SUPPORTING SCHEDULES AND YOU COMPARE THEM TO MR. WEINGUST'S DECLARATION, YOU'LL SEE THAT IT'S 2015 NUMBERS. THEY'RE APPLES TO APPLES. THERE IS A TYPO IN MR. SABA'S REPORT THAT SAYS 2021 MANUAL, BUT THE TYPO IS THE REFERENCE TO THE MANUAL, NOT THE USE OF THE PEPPERDINE STUDY.

SO I HEARD MS. WALSH SAYING SOMETHING SLIGHTLY DIFFERENT,
AND I JUST WANT TO MAKE SURE THAT WE'RE CLEAR ON THAT POINT.

1 11:28AM 2 11:28AM 3 11:28AM 11:28AM 4 11:28AM 11:28AM 6 11:28AM 7 11:28AM 8 11:28AM 9 11:29AM 10 11:29AM 11 11:29AM 12 11:29AM 13 11:29AM 14 11:29AM 15 11:29AM 16 11:29AM 17 11:29AM 18 11:29AM 19 11:29AM 20 11:29AM 21 11:29AM 22 11:29AM 23 11:29AM 24 11:29AM 25

WHY IS IT WRONG TO USE THE ARANCA NUMBERS, THE 20 PERCENT?

WELL, WE KNOW THAT ARANCA WAS LIED TO, YOUR HONOR. WE KNOW

THAT ARANCA IS A VALUATION COMPANY BASED IN INDIA. I THINK THE

CROSS-EXAMINATION OF MS. SPIVEY IN THE BALWANI TRIAL WAS ARANCA

IS NOT REALLY THAT -- THE COST FOR AN ARANCA REPORT IS NOT THE

SAME AS GETTING A VALUATION REPORT FROM DUFF & PHELPS, BUT NOW

MR. WEINGUST IS SAYING OR SUGGESTING THAT'S SOMETHING THAT THE

COURT SHOULD LOOK TO.

BUT IF YOU LOOK AT THE VALUATION REPORT FROM 2014, ARANCA IS ASSUMING, BASED ON WHAT THEY'RE TOLD BY MS. HOLMES AND MR. BALWANI, THAT THERANOS IS GOING TO GO FROM \$150,000 IN REVENUE IN DECEMBER OF 2014 TO \$113 MILLION IN REVENUE THE FOLLOWING YEAR.

NOT ONLY DO WE KNOW THAT DIDN'T HAPPEN, WE KNEW AT

DECEMBER 2014 THERE WAS NO WAY THAT WAS GOING TO HAPPEN BECAUSE

WALGREENS WAS SAYING WE'RE NOT GOING TO EXPAND PAST 40 STORES

UNTIL YOU CAN GET YOUR TECHNOLOGY TO DO THE FINGERSTICKS MORE

APPROPRIATELY. YOU DON'T SEE ANYTHING LIKE THAT IN THE ARANCA

REPORT.

MR. WEINGUST SAYS ARANCA DID ALL OF THIS DUE DILIGENCE.

THERE'S ZERO EVIDENCE IN THE RECORD ABOUT THE DILIGENCE THAT

ARANCA DID.

AND IF YOU LOOK CLOSELY AT THE FORECASTS THAT WERE

PROVIDED TO ARANCA, THESE ARE PIE IN THE SKY SUCCESS SCENARIO

PROJECTIONS UNDER THE BEST CASE, BASED ON EVERYTHING THAT WE

1 11:30AM 2 11:30AM 3 11:30AM 11:30AM 4 11:30AM 11:30AM 11:30AM 8 11:30AM 11:30AM 9 11:30AM 10 11:30AM 11 11:30AM 12 11:30AM 13 11:30AM 14 11:30AM 15 11:30AM 16 11:31AM 17 11:31AM 18 11:31AM 19 11:31AM 20 11:31AM 21 11:31AM 22 11:31AM 23 11:31AM 24 11:31AM 25

KNOW FROM THIS TRIAL, AND THAT'S NOTHING THAT MR. WEINGUST READ, CONSIDERED, THOUGHT ABOUT. YOU JUST CAN'T LOOK AT THE ARANCA REPORTS BASED ON WHAT WE KNOW AND BASED UPON WHAT WE HEARD IN THIS TRIAL AND THINK THAT THEY'RE ANYWHERE NEAR THE RIGHT NUMBERS THAT SHOULD GO INTO CALCULATING THE DISCOUNT RATE.

SO THE 45 PERCENT IS CONSIDERING THE PEPPERDINE REPORT,

ANOTHER BATCH OF COMPANIES FROM A WIDER PERIOD OF TIMEFRAME,

AND THE ACTUAL IMPLIED RATE OF RETURN THAT THE INVESTORS IN

THIS CASE THROUGH THEIR MODELING APPLIED.

I KNOW MR. WEINGUST IN HIS SUPPLEMENTAL DECLARATION

CRITIQUES THAT, BUT IT'S ACTUALLY IN THE SABA REPORT AND IN

WHAT HE DESCRIBED AS THE BUILD MODEL, LIKE YOU CAN SEE HIM

TAKING THE PROJECTIONS THAT WERE PROVIDED TO INVESTORS, TAKING

THE PRICE THAT THEY BOUGHT AT, AND USING THAT TO CALCULATE WHAT

WAS THEIR IMPLIED RATE OF RETURN, AND THAT'S PART OF THE MIX OF

INFORMATION THAT GOES INTO MR. SABA'S JUDGMENT, GIVING THE

DEFENDANTS EVERY BENEFIT OF THE DOUBT IN TERMS OF SOLVING ALL

OF THEIR TECHNOLOGY PROBLEMS, MEETING THESE PIE IN THE SKY

REVENUE PROJECTIONS, GETTING FDA APPROVAL, GETTING ALL OF THE

PROBLEMS FIXED IN THE LAB, GIVING ALL OF THOSE BENEFITS OF THE

DOUBT TO THE DEFENDANT, THAT'S HOW MR. SABA LANDS ON THIS

45 PERCENT, WHICH IS A MATTER OF JUDGMENT, BUT THERE IS

JUDGMENT IN THIS. THERE'S NO DOUBT ABOUT THAT, YOUR HONOR.

BUT IT'S A JUDGMENT WELL GROUNDED IN THE TRIAL RECORD AND IN

1 11:31AM 11:31AM 2 3 11:31AM 11:31AM 4 11:31AM 11:32AM 6 11:32AM 7 11:32AM 8 11:32AM 9 11:32AM 10 11:32AM 11 11:32AM 12 11:32AM 13 11:32AM 14 11:32AM 15 11:32AM 16 11:32AM 17 11:32AM 18 11:32AM 19 11:32AM 20 11:33AM 21 11:33AM 22 11:33AM 23 11:33AM 24

11:33AM 25

THE FACTS THAT THE COURT HEARD, AND IT'S COMPLETELY APPROPRIATE TO RELY ON.

MY COLLEAGUE ALSO BROUGHT UP THE FORTRESS TRANSACTION, AND I DO THINK THAT IS AN IMPORTANT DATA POINT FOR THE COURT TO CONSIDER IN TERMS OF IS 121 MILLION SOMEHOW, YOU KNOW, JUST NOT POSSIBLY THE LOSS IN THIS CASE. AND I THINK IT'S IMPORTANT TO UNDERSTAND EXACTLY WHAT THE FORTRESS TRANSACTION WAS.

THIS WAS IN DECEMBER OF 2017. FORTRESS LENT \$60 MILLION TO THERANOS SECURED BY ALL OF THE IP, ALL OF THE PATENTS THAT THE COURT HEARD ABOUT, ALL OF THE PATENTS THAT MR. WEINGUST TALKS ABOUT, A \$60 MILLION LOAN SECURED BY THE PATENTS, THE INTELLECTUAL PROPERTY.

AND IF THERANOS COULD MEET PARTICULAR MILESTONES, IT MIGHT GET AN ADDITIONAL 40 MILLION. THAT'S WHERE THE \$100 MILLION COMES IN.

AT THE END OF THE DAY, THERANOS DEFAULTED ON THAT LOAN,
FORTRESS TOOK ALL OF THE IP, AND I THINK THAT'S THE ONLY REAL
TRANSACTION THAT WE HAVE TO ASSESS, WELL, WHAT WAS THAT IP
WORTH? WHAT -- STRIP AWAY THE CASH, WHAT WAS THE IP WORTH?
THE MOST FORTRESS WOULD LEND WAS \$60 MILLION.

THE MOST FORTRESS WOOLD LEND WAS 700 MILLION.

NOW, LET'S SAY THAT THEY WERE DOUBLY COLLATERALIZED;

THAT'S \$120 MILLION. LET'S SAY THEY WERE TRIPLE

COLLATERALIZED; \$180 MILLION. FOUR TIMES COLLATERALIZED THAT

FORTRESS IS TAKING, YOU'RE AT 240 MILLION. ALL OF THESE

NUMBERS ARE SIGNIFICANTLY LESS THAN MR. SABA'S VALUATION,

1 11:33AM 11:33AM 2 3 11:33AM 11:33AM 4 11:33AM 11:33AM 6 11:33AM 7 11:33AM 8 11:34AM 9 11:34AM 10 11:34AM 11 11:34AM 12 11:34AM 13 11:34AM 14 11:34AM 15 11:34AM 16 11:34AM 17 11:34AM 18 11:34AM 19 11:34AM 20 11:34AM 21 11:34AM 22 11:34AM 23 11:34AM 24 11:34AM 25

GIVING THE DEFENDANTS ALL OF THE BENEFIT OF THE DOUBT.

THE FORTRESS TRANSACTION IS REMARKABLY HELPFUL IN TERMS OF ASSESSING WHETHER OR NOT THESE ARE LOSS ESTIMATES THAT ARE REALLY JUST SPECULATION OR ARE REALLY SOMETHING THAT ARE JUST GIVING THE BENEFIT OF THE DOUBT TO THE DEFENDANTS. IT'S MAGNITUDES OF VALUE LOWER.

MY COLLEAGUE ALSO TALKED ABOUT VOLATILITY AND HYPOTHETICAL EXIT USING THE OPM MODEL. MR. SABA ATTEMPTED TO ADDRESS THAT IN HIS SUPPLEMENTAL REPORT. YES, THIS IS HARD WORK. THERE ARE ASSUMPTIONS THAT HAVE TO GO INTO THIS. WE'RE TRYING TO CREATE A SCENARIO WHERE THERE WAS NO FRAUD, WHERE THERE WAS FULL TRANSPARENT INFORMATION. THAT IS A HARD EXERCISE. WE RECOGNIZE THAT.

BUT THE LEONARD CASE IN PARTICULAR SAYS THAT DOESN'T MEAN WE THROW UP OUR HANDS AND DON'T ESTIMATE WHAT THE LOSS IS. THE LEONARD CASE SAYS WE RECOGNIZE THIS IS A HARD JOB FOR DISTRICT COURTS, BUT THERE ARE TOOLS AVAILABLE. THERE ARE A NUMBER OF FACTORS TO GO THROUGH. AND I THINK THE COURT'S THOUGHTFUL ASSESSMENT OF THE INCOME APPROACH IN THE HOLMES SENTENCING WAS APPROPRIATE THEN AND IT'S APPROPRIATE NOW.

UNLESS THE COURT HAS FURTHER QUESTIONS, THE GOVERNMENT SUBMITS ON THE LOSS POINT.

THE COURT: THANK YOU.

MS. WALSH: JUST A COUPLE OF POINTS, YOUR HONOR.

SO I THINK IT'S WELL-KNOWN, AND MR. WEINGUST AND I THINK

11:35AM	1	MR. SABA WOULD AGREE WITH THIS, THAT VENTURE CAPITAL FIRMS BAKE
11:35AM	2	A FAILURE SCENARIO INTO THEIR MODELS FOR COMING UP WITH RATES
11:35AM	3	OF RETURN. SO TO SAY, WELL, I HAVE THIS RATE OF RETURN THAT
11:35AM	4	VENTURE CAPITAL FIRMS WERE INVESTING IN DURING THIS TIME
11:35AM	5	PERIOD, BUT I NEED TO MAKE ADJUSTMENTS BECAUSE THEY DIDN'T KNOW
11:35AM	6	ABOUT ALL OF THESE BAD THINGS ABOUT THERANOS, YOU'RE DOUBLE
11:35AM	7	COUNTING RISK.
11:35AM	8	THEY'VE ALREADY TAKEN INTO ACCOUNT THE RISK OF THE
11:35AM	9	BUSINESS FAILING. WHETHER IT FAILS FOR BAD MANAGEMENT,
11:35AM	10	MISTAKES OR FRAUD, IT'S AN ECONOMIC ANALYSIS, FAILURE IS
11:35AM	11	FAILURE, AND THEY HAVE TAKEN THAT INTO ACCOUNT.
11:35AM	12	THE COURT: THEY DO? IS THAT YOUR UNDERSTANDING IS
11:35AM	13	WHEN RISK ANALYSIS IS TAKEN, THEY ALSO LOOK AT WHAT IS THE
11:35AM	14	POSSIBILITY OF INTERIOR CRIMINAL CONDUCT THAT COULD RESULT IN A
11:35AM	15	FAILURE AND A DEBACLE OF THIS COMPANY? IS THAT SOMETHING THAT
11:36AM	16	THEY DO?
11:36AM	17	MS. WALSH: NO.
11:36AM	18	THE COURT: OH.
11:36AM	19	MS. WALSH: MY UNDERSTANDING IS THAT IT WOULD BE THE
11:36AM	20	OPPOSITE. THEY LOOK AT RISK OF FAILURE. THEY DON'T SAY WHY IS
11:36AM	21	THE BUSINESS FAILING.
11:36AM	22	THE COURT: IT'S JUST FAILURE.
11:36AM	23	MS. WALSH: IT'S ECONOMIC FAILURE.
11:36AM	24	THE COURT: I SEE. OKAY.
11:36AM	25	MS. WALSH: JUST TO RESPOND TO A POINT THAT

1 11:36AM 2 11:36AM 3 11:36AM 11:36AM 4 11:36AM 5 11:36AM 6 11:36AM 7 11:36AM 8 11:36AM 9 11:36AM 10 11:36AM 11 11:36AM 12 11:37AM 13 11:37AM 14 11:37AM 15 11:37AM 16 11:37AM 17 11:37AM 18 11:37AM 19 11:37AM 20 11:37AM 21 11:37AM 22 11:37AM 23 11:37AM 24 11:37AM 25

MR. LEACH MADE ABOUT ARANCA. HE SAYS, WELL, ARANCA WAS LIED TO, AND, THEREFORE, WE CAN'T RELY ON THAT DISCOUNT RATE OR THAT RATE OF RETURN THAT IS IN THAT REPORT.

WELL, IF ARANCA WAS LIED TO AND IT'S NOT RELIABLE TO RELY
ON THAT INFORMATION, THEN WHY IS MR. SABA RELYING ON ARANCA TO
ESTABLISH THE TIME PERIOD UNTIL A LIQUIDITY EVENT? HE'S
PICKING AND CHOOSING WHAT WITHIN THE ARANCA REPORT HE'S RELYING
ON, AND THAT'S NOT AN APPROPRIATE WAY TO METHODICALLY AND
NEUTRALLY COME UP WITH A VALUE.

THE COURT: SO WHAT SHOULD WE DO IF WE COMPLETELY
ELIMINATED THE ARANCA, SHOULD THERE BE EVEN ANOTHER ANALYSIS
THAT WE ELIMINATE ARANCA AND SAY CAN YOU MAKE A DECISION NOT
RELYING ON THAT, OR IS IT BETTER PRACTICE TO ANALYZE EVERYTHING
THAT IS ON THE TABLE AND THEN MAKE AT LEAST A BEST ESTIMATE?

MS. WALSH: SURE. I THINK IT IS BETTER TO ANALYZE EVERYTHING ON THE TABLE, BUT YOU CAN'T SAY ARANCA IS ON THE TABLE AND I'M GOING TO CHOOSE THE TIME PERIOD FOR A LIQUIDITY EVENT, THAT'S GOOD, THAT'S VALID, BUT, OH, NO, I'M GOING TO REJECT THE RATE OF RETURN BECAUSE ARANCA WAS LIED TO. YOU CAN'T HAVE IT BOTH WAYS.

THE COURT: OKAY.

MS. WALSH: OKAY. AND THEN JUST A COUPLE OF POINTS
ON MR. MURDOCH.

SO I DON'T THINK THAT NATALIE RAVITZ IS ANALOGOUS TO LISA PETERSON AT ALL.

1 11:37AM 2 11:37AM 3 11:38AM 11:38AM 4 11:38AM 11:38AM 6 11:38AM 7 11:38AM 8 11:38AM 9 11:38AM 10 11:38AM 11 11:38AM 12 11:38AM 13 11:38AM 14 11:38AM 15 11:38AM 16 11:38AM 17 11:39AM 18 11:39AM 19 11:39AM 20 11:39AM 21 11:39AM 22 11:39AM 23 11:39AM 24

11:39AM 25

MS. RAVITZ EXPRESSED IN HER S.E.C. TESTIMONY THAT SHE THOUGHT THAT THE HISTORICAL REVENUE WAS LOW, AND SHE DIDN'T NECESSARILY THINK IT WAS A GOOD INVESTMENT TO MAKE.

IT WAS MR. MURDOCH WHO PULLED THE TRIGGER ON THE INVESTMENT. HE WAS THE DECISION-MAKER. AND WE HAVE NOTHING IN THE RECORD, ZERO FROM HIM IN THE FORM OF TESTIMONY OR IN THE FORM OF A VICTIM IMPACT STATEMENT SAYING WHAT HE RELIED ON IN MAKING THAT DECISION. FOR THAT REASON, I THINK THE COURT HAS TO REJECT HIM AS AN INVESTOR TO BE INCLUDED IN THE GROUP.

THE COURT: OKAY. THANK YOU.

MS. WALSH: AND THEN FINALLY, THERE WAS SOMETHING
THAT MR. LEACH SAID THAT WAS INTERESTING ABOUT, WELL,
MR. WEINGUST IS NOT PROVIDING THE COURT WITH HIS OWN VALUATION.
HE'S NOT SAYING, HEY, THIS IS WHAT IT SHOULD BE. THAT'S TRUE.

IT'S THE GOVERNMENT'S BURDEN TO PROVE LOSS. IT'S NOT THE DEFENSE'S BURDEN, AND MR. WEINGUST HASN'T PROVIDED THE COURT WITH WHAT RATE OF RETURN OR ANYTHING ELSE OF VALUE, YOU KNOW, A FULSOME VALUATION. HE DIDN'T LOOK AT AS MANY DOCUMENTS PERHAPS AS MR. SABA, BUT THE BURDEN IS NOT ON US TO ESTABLISH LOSS.

WHAT HE DID DO, AND I THINK THIS IS THE WHOLE POINT OF
THIS EXERCISE, HE LOOKED AT MR. SABA'S REPORT AS AN EXPERT, AND
HE NOTICED THAT THERE WERE SOME VERY SERIOUS ERRORS IN EACH
APPROACH, AND THE INCOME APPROACH AND THE ASSET APPROACH.
WE'VE GONE OVER THOSE TODAY.

THE MAGNITUDE IN TERMS OF VALUING THERANOS AND THEN

ASCERTAINING LOSS, THE MAGNITUDE OF THOSE ERRORS ARE SO GREAT 1 11:39AM AND THEY RESULT IN SUCH SWINGS IN VALUE AND LOSS, THAT THE 2 11:39AM COURT SHOULD NOT RELY ON THE REPORT IN FASHIONING A REASONABLE 3 11:39AM 11:39AM 4 LOSS AMOUNT. 11:39AM 5 THE COURT: OKAY. THANK YOU. AND I THINK YOU'RE RIGHT, HIS REPORTS ARE CRITICAL, 11:39AM 6 11:39AM 7 THEY'RE CRITICISMS. THEY'RE LOOKING AT THE SABA REPORT, CRITICIZING SPECIFIC FINDINGS, PROTOCOLS THAT WERE ENGAGED AS 11:40AM 8 MR. REIFF -- IS IT MR. REIFF? 11:40AM 9 11:40AM 10 MS. WALSH: REIFF. 11:40AM 11 THE COURT: REIFF. HE DID THE SAME THING. BUT 11:40AM 12 NEITHER OF THEM COME UP WITH ANY FACTOR. I THINK MR. REIFF ACTUALLY SAYS, WELL, HE TALKS ABOUT THE 11:40AM 13 SABA REPORT AND SUGGESTS, WELL, IT'S REASONABLE, BUT HE DOES 11:40AM 14 11:40AM 15 CRITICIZE IT NONETHELESS. MS. WALSH: YEAH. AND I THINK WHAT HE SAYS IS THE 11:40AM 16 11:40AM 17 OCP METHOD OF ALLOCATION IS A COMMONLY USED METHOD, FINE, BUT 11:40AM 18 IN THESE CIRCUMSTANCES THERE ARE TWO FACTORS THAT ARE 11:40AM 19 INCREDIBLY SPECULATIVE. 11:40AM 20 THE COURT: AND IT WAS HELPFUL -- THANK YOU. AND I 11:40AM 21 WANT TO ASK MR. LEACH ABOUT ANYTHING HE WANTS TO SAY, 11:40AM 22 PARTICULARLY ABOUT THE ARANCA ISSUE. 11:40AM 23 BUT I DID LOOK AT THE RESUMES, THE CV'S OF THE EXPERTS 11:40AM 24 HERE AND MANY OF THEM, IT SEEMED, THAT HAD TESTIFIED IN 11:40AM 25 BUSINESS DISPUTES AND FAMILY LAW MATTERS. THERE WERE MANY OF

11:41AM	1	THEM I THINK YOUR EXPERTS TESTIFIED IN FAMILY LAW CASES
11:41AM	2	WHERE THERE WAS A DISSOLUTION OF THE COMMUNITY, I SUPPOSE, AND
11:41AM	3	THERE'S A DISAGREEMENT ABOUT THOSE ASSETS AND THINGS.
11:41AM	4	THERE WEREN'T TOO MANY SPECIFIC CRIMINAL CASES THAT WERE
11:41AM	5	NOTED IN THE CV'S OF THE PARTIES. I JUST NOTE THAT.
11:41AM	6	MR. LEACH.
11:41AM	7	MR. LEACH: JUST BRIEFLY ON THE ARANCA POINT.
11:41AM	8	YOUR HONOR, THIS EXIT DATE ONLY COMES INTO PLAY IN THE ASSET
11:41AM	9	APPROACH, WHICH I KNOW THE COURT DID NOT ADOPT.
11:41AM	10	AND I THINK THE POINT HERE IS, NOT TO BE CRITICAL OF
11:41AM	11	ARANCA, BUT TO TAKE A HARD LOOK AT WHAT INFORMATION ARANCA
11:41AM	12	ACTUALLY HAS AND WHETHER JUDGMENTS IT'S MAKING IN TERMS OF THE
11:41AM	13	FOUR YEAR HORIZON ARE REASONABLE OR NOT, NOT JUST WHOLLY
11:42AM	14	DISCOUNT IT, BUT TO BRING A CRITICAL EYE TO IT.
11:42AM	15	AND IT'S NOT SO MUCH THE ARANCA REPORT AS IT IS THE
11:42AM	16	FINANCIAL FORECAST THAT WERE THE SUBJECT OF MULTIPLE DAYS OF
11:42AM	17	TESTIMONY IN THIS CASE, AND WHETHER THOSE ARE REASONABLE OR
11:42AM	18	NOT, AND I THINK ANYBODY LOOKING AT THEM, PARTICULARLY WITH
11:42AM	19	INFORMATION NOW, HAS TO SEE THAT THESE ARE PIE IN THE SKY
11:42AM	20	PROJECTIONS THAT NEED SOME FORM OF DISCOUNT, WHATEVER ARANCA
11:42AM	21	THOUGHT OR WAS TOLD.
11:42AM	22	THE COURT: ANYTHING FURTHER?
11:42AM	23	MR. LEACH: NO, YOUR HONOR. THANK YOU.
11:42AM	24	MS. WALSH: JUST ONE POINT BASED ON WHAT MR. LEACH
11:42AM	25	SAID.

11:42AM	1	THE COURT: SURE.
11:42AM	2	MS. WALSH: I BELIEVE THE HOLDING PERIOD BEFORE THE
11:42AM	3	LIQUIDITY EVENT IS SOMETHING THAT MR. SABA ASCERTAINED IN
11:42AM	4	CONNECTION WITH THE ALLOCATION OF VALUE, NOT WITH THE ASSET
11:42AM	5	APPROACH.
11:42AM	6	SO YOU HAVE THE PAPERS AND YOU'LL SEE, BUT THAT'S MY
11:42AM	7	UNDERSTANDING. SO IT IS IMPORTANT BECAUSE EVEN IN THE INCOME
11:42AM	8	APPROACH YOU'RE GOING TO APPLY THE ALLOCATION METHOD TO THAT
11:42AM	9	APPROACH TO FIGURE OUT WHAT THE NUMBERS ARE FOR EACH INVESTOR.
11:42AM	10	THE COURT: OKAY. ANYTHING FURTHER ON LOSS
11:43AM	11	CALCULATION FROM EITHER SIDE?
11:43AM	12	MS. WALSH: NO, YOUR HONOR.
11:43AM	13	THE COURT: MR. LEACH?
11:43AM	14	MR. LEACH: NO, YOUR HONOR. THANK YOU.
11:43AM	15	THE COURT: WERE YOU ALSO SPEAKING FOR THAT VICTIM
11:43AM	16	COUNT, WERE YOU DOING THAT, MS. WALSH?
11:43AM	17	MS. WALSH: YES, YOUR HONOR. I THOUGHT I ADDRESSED
11:43AM	18	IT IN TERMS OF LOSS CAUSATION AND MURDOCH IS ONE OF THE
11:43AM	19	EXAMPLES.
11:43AM	20	THE COURT: ANYTHING FURTHER YOU WANT TO SAY ABOUT
11:43AM	21	THAT AS FAR AS THE GUIDELINE CALCULATION?
11:43AM	22	MS. WALSH: WE REST ON OUR PAPERS.
11:43AM	23	THE COURT: ALL RIGHT. OKAY.
11:43AM	24	ANYTHING FURTHER ABOUT THAT?
11:43AM	25	MR. LEACH: THE ONLY POINT I WOULD MAKE THERE,

11:43AM	1	YOUR HONOR, IS THAT THERE WERE SEVEN INVESTORS WHO ACTUALLY
11:43AM	2	TESTIFIED IN MR. BALWANI'S TRIAL. IN ADDITION, THERE ARE THE
11:43AM	3	INVESTORS WHO WE PROFFERED INFORMATION ABOUT, SUCH AS
11:43AM	4	MR. MURDOCH, PEER VENTURES, SOME OF THE ONES THAT THE COURT
11:43AM	5	FOUND IN THE HOLMES SENTENCING.
11:43AM	6	IN ADDITION TO THAT, YOU KNOW, THERE ARE PATIENT VICTIMS
11:44AM	7	HERE. THREE OF THEM TESTIFIED IN THE TRIAL. SO I'M NOT SURE
11:44AM	8	HOW THERE CAN BE A SCENARIO WHERE THERE WERE FEWER THAN TEN
11:44AM	9	VICTIMS MET. THAT IS SOMETHING THAT BECAUSE THE COURT DID NOT
11:44AM	10	CONSIDER ACQUITTED CONDUCT IN THE HOLMES SENTENCING IS
11:44AM	11	SOMETHING DIFFERENT HERE. I JUST WANTED TO MAKE SURE THAT WE
11:44AM	12	ADDRESSED THAT POINT.
11:44AM	13	THE COURT: THANK YOU. WELL, LET ME TALK ABOUT THE
11:44AM	14	OTHER GUIDELINE ENHANCEMENTS, IF YOU WILL NOW.
11:44AM	15	MR. LEACH: SURE, YOUR HONOR.
11:44AM	16	MS. WALSH: AND MR. COOPERSMITH IS GOING TO ADDRESS
11:44AM	17	THOSE.
11:44AM	18	THE COURT: SURE.
11:44AM	19	MS. WALSH: WE'LL DO ANOTHER SWITCH.
11:44AM	20	THE COURT: SURE. OKAY. AND I THINK WHAT WE'LL DO
11:44AM	21	IS GO THROUGH THESE OTHER TWO ENHANCEMENTS, WE'LL TAKE A BREAK,
11:44AM	22	AND THEN WE'LL COME BACK AND FINISH UP OUR GUIDELINE
11:44AM	23	CALCULATION AND THEN MOVE ON.
11:44AM	24	MR. LEACH: THANK YOU, YOUR HONOR.
11:44AM	25	THE COURT: I'M NOW AT OBJECTION TWENTY-FOUR, WHICH

1 11:44AM 2 11:45AM 3 11:45AM 11:45AM 4 11:45AM 11:45AM 6 11:45AM 7 11:45AM 8 11:45AM 9 11:45AM 10 11:45AM 11 11:45AM 12 11:45AM 13 11:45AM 14 11:45AM 15 11:45AM 16 11:46AM 17 11:46AM 18 11:46AM 19 11:46AM 20 11:46AM 21 11:46AM 22 11:46AM 23 11:46AM 24 11:46AM 25

IS THE AGGRAVATING ROLE, AND THIS IS THE 4 POINT ENHANCEMENT FOR ORGANIZER OR LEADER UNDER 3B1.1(A), AND EVERYBODY KNOWS I DID NOT FIND THAT IN THE COMPANION CASE.

MR. COOPERSMITH, DID YOU WANT TO BE HEARD ON THIS?

MR. COOPERSMITH: YOUR HONOR, I'M HAPPY TO BE HEARD.

TO TRY TO MAKE THIS AS EFFICIENT AS POSSIBLE, IF THE COURT IS

INCLINED TO APPLY THAT IN THE CASE OF MR. BALWANI, I CERTAINLY

WOULD HAVE A LOT TO SAY. IF THE COURT IS NOT INCLINED, I WILL

HAVE A LOT LESS TO SAY.

BUT I'LL SAY THIS IN BRIEF IS THAT AS I UNDERSTAND THE

COURT'S RULING IN ELIZABETH HOLMES'S CASE, THE COURT DID NOT

APPLY IT BECAUSE UNDER THE HOLDEN CASE IN THE NINTH CIRCUIT, IN

ORDER TO BE AN ORGANIZER OR LEADER, TO GET ANY OF THE

ADJUSTMENTS, WHETHER IT'S 2 POINTS OR 4 POINTS UNDER 3B1.1, YOU

WOULD HAVE TO BE DIRECTING, ORGANIZING, LEADING ANOTHER

CRIMINAL PARTICIPANT.

AND AS THE COURT NOTED IN THE HOLMES SENTENCING, THE ONLY CRIMINAL PARTICIPANTS AT ISSUE HERE ALLEGEDLY ARE MR. BALWANI AND MS. HOLMES.

THE COURT: WELL, THE JURY FOUND THAT.

MR. COOPERSMITH: YES, I UNDERSTAND THAT. AND FOR PURPOSES OF THE SENTENCING, WE OBVIOUSLY ARE RESPECTING THE VERDICT AND THAT'S WHY WE'RE HERE.

BUT WITH REGARD TO THE CRIMINAL PARTICIPANTS, WE HAVE MS. HOLMES AND MR. BALWANI.

THE COURT DID NOT BELIEVE THAT MS. HOLMES WAS LEADING 11:46AM 1 MR. BALWANI, ALTHOUGH THERE ARE INDICATIONS IN THIS CASE THAT 2 11:46AM THAT IS THE CASE, SHE WAS THE CEO, AND SHE HAD THE ABILITY TO 3 11:46AM 11:46AM 4 FIRE HIM AND SO FORTH. THE COURT: RIGHT. BUT THE JURY FOUND WHAT THEY DID 11:46AM 11:46AM 6 AND WE'RE HERE TO DETERMINE WHETHER OR NOT THIS COURT IN ITS 11:46AM 7 SENTENCING DECISION SHOULD APPLY A LEADERSHIP ROLE TO YOUR 11:46AM 8 CLIENT. I DIDN'T IN THE HOLMES CASE. AND MAYBE WE SHOULD -- I 11:46AM 9 11:46AM 10 DON'T MEAN TO INTERRUPT YOU, BUT MAYBE I'LL TAKE YOUR 11:46AM 11 INVITATION TO SAY, WELL, IF YOU'RE NOT GOING TO GIVE IT, I 11:46AM 12 DON'T HAVE ANYTHING TO SAY, JUDGE. SO LET'S TURN TO MR. LEACH. 11:46AM 13 MR. LEACH, SHOULD I GIVE THIS? SHOULD THIS APPLY? 11:46AM 14 11:47AM 15 MR. LEACH: I WAS HERE WHEN YOUR HONOR ELECTED NOT TO GIVE IT. SO I RESPECT THE COURT'S RULING, AND I DON'T WANT 11:47AM 16 TO REPEAT OURSELF, AND WE'RE NOT WRITING ON A BLANK SLATE HERE. 11:47AM 17 11:47AM 18 THE COURT: SURE. MR. LEACH: THE ONLY POINT I WOULD MAKE -- AND WE DO 11:47AM 19 11:47AM 20 WANT TO PRESERVE OUR ARGUMENTS ON THIS. THE COURT: YES, OF COURSE. 11:47AM 21 11:47AM 22 MR. LEACH: THE ONLY NUANCE I WOULD POINT OUT IS 11:47AM 23 THERE'S A COMPLICATED RELATIONSHIP BETWEEN ELIZABETH HOLMES AND 11:47AM 24 SUNNY BALWANI, AND I THINK THE TEXTS REVEAL AND THE EVIDENCE 11:47AM 25 REVEALS THAT THERE WERE TIMES PARTICULARLY WHEN YOU LOOK AT IT

11:47AM 1 2 11:47AM 3 11:47AM 11:47AM 4 11:47AM 11:47AM 6 11:47AM 7 11:47AM 8 11:47AM 9 11:47AM 10 11:48AM 11 11:48AM 12 11:48AM 13 11:48AM 14 11:48AM 15 11:48AM 16 11:48AM 17 11:48AM 18 11:48AM 19

11:48AM 20

11:48AM 21

11:48AM 22

11:48AM 23

11:48AM 24

11:48AM 25

COUNT BY COUNT WHERE MR. BALWANI WAS LEADING AND WHERE MS. HOLMES WAS LEADING.

TAKE, FOR EXAMPLE, PFM, MR. GROSSMAN, THERE WAS AN INITIAL MEETING BETWEEN MS. HOLMES AND MR. BALWANI AND THEN MUCH, IF NOT ALL, OF THE REMAINING ENGAGEMENT WAS BETWEEN MR. BALWANI AND MR. GROSSMAN. AND I THINK THERE'S A WAY TO LOOK AT THOSE FACTS AND SAY AT LEAST ON THAT COUNT, MR. BALWANI IS LEADING IN THAT SITUATION.

NOW, THAT'S NOT TO SAY THAT THEY DON'T HAVE

RESPONSIBILITY, THAT'S NOT TO SAY ONE IS CONTROLLING THE OTHER,

BUT IF YOU LOOK AT IT IN PARTICULAR SITUATIONS, THERE ARE TIMES

WHEN MS. HOLMES DEFERS TO HIM AND THERE ARE TIMES WHEN HE

DEFERS TO HER.

AND THERE'S JUST SOMETHING ODD ABOUT THIS CASE WHERE YOU HAVE THE CEO OF A COMPANY AND THE COO OF A COMPANY AND NEITHER ONE OF THEM IS THE LEADER.

BUT BEYOND THAT, I THINK THE COURT UNDERSTANDS THOSE

ISSUES. IT WAS A COMPLICATED RELATIONSHIP. WE MADE THE

ARGUMENT THAT IT WAS OTHERWISE EXTENSIVE. THE COURT WENT THE

OTHER WAY ON THAT POINT, AND WE UNDERSTAND THAT.

SO THOSE ARE THE ONLY NUANCES THAT I WANTED TO POINT OUT AND WITH THAT I'LL SUBMIT.

THE COURT: THANK YOU. AND THEY'RE APPROPRIATE. I
THINK ALL OF US AGREE THE CASE WAS COMPLICATED AND NUANCED IN
MANY WAYS, AND WE ALSO ARE GUIDED BY THE CASES THAT SAY THAT

UNITED STATES COURT REPORTERS

THERE CAN BE CO-LEADERS, AND IF THERE'S CO-LEADERS, 1 11:48AM 2 CO-CAPTAINS, THERE ISN'T A CAPTAIN DESIGNATED PER SE. 11:48AM ANYTHING ELSE YOU WANT TO SAY ABOUT THIS, MR. COOPERSMITH? 3 11:49AM 11:49AM 4 MR. COOPERSMITH: JUST BRIEFLY, YOUR HONOR. WE UNDERSTAND UNDER THE HOLDEN CASE AND IF THEY ARE IN 11:49AM 11:49AM 6 FACT CO-LEADERS, THAT THE ADJUSTMENT WOULD NOT BE APPLIED TO 11:49AM 7 MR. BALWANI JUST LIKE IT WAS NOT APPLIED TO MS. HOLMES. BUT I WILL SAY, AND THIS MAY BE COMING UP IN REMARKS 11:49AM 8 RELEVANT TO OTHER PORTIONS OF THE SENTENCING, YOUR HONOR, WE 11:49AM 9 11:49AM 10 REJECT THE IDEA THAT THEY WERE CO-LEADERS. 11:49AM 11 THE GOVERNMENT SAID OVER AND OVER AGAIN IN VARIOUS 11:49AM 12 CONTEXTS, INCLUDING THE SENTENCING MEMO IN MS. HOLMES'S CASE, 11:49AM 13 THAT MS. HOLMES WAS ULTIMATELY RESPONSIBLE. SHE WAS THE CEO, SHE WAS THE FACE OF THERANOS, SHE HAD THE ABILITY TO FIRE 11:49AM 14 11:49AM 15 MR. BALWANI. SO WE DON'T AGREE WITH THAT. 11:49AM 16 11:49AM 17 THE COURT: WELL, ALL OF THAT WAS TRUE. 11:49AM 18 MR. COOPERSMITH: ALL OF THAT WAS TRUE, YEAH. 11:49AM 19 THE COURT: RIGHT. 11:49AM 20 MR. COOPERSMITH: BUT FOR PURPOSES OF THIS GUIDELINE 11:49AM 21 ENHANCEMENT, IF THEY ARE CO-LEADERS, EVEN IF THAT WERE THE 11:49AM 22 CASE, THESE GUIDELINE ADJUSTMENTS WOULD NOT BE APPLIED. AND, 11:49AM 23 OF COURSE, IT CERTAINLY WOULDN'T BE APPLIED IF WHAT WE SAY IS RIGHT, IT WAS ACTUALLY MS. HOLMES WHO WAS THE LEADER OF THIS 11:49AM 24 11:49AM 25 COMPANY AND OF MR. BALWANI.

11:49AM	1	SO I THINK I'LL STOP THERE UNLESS THE COURT HAS MORE
11:50AM	2	QUESTIONS. WE DON'T THINK THE GUIDELINE ADJUSTMENT SHOULD BE
11:50AM	3	APPLIED.
11:50AM	4	THE COURT: OKAY. THANK YOU.
11:50AM	5	THANK YOU. LET'S TURN TO THE 2B1.1(B)(16), WHICH IS THE
11:50AM	6	SERIOUS BODILY INJURY ENHANCEMENT. THE GOVERNMENT IS URGING
11:50AM	7	THIS OR SUGGESTS THAT THE COURT SHOULD APPLY THIS.
11:50AM	8	I DONT THINK PROBATION DID YOU RECOMMEND THIS,
11:50AM	9	MS. GOLDSBERRY?
11:50AM	10	PROBATION OFFICER: NOT IN THE FINAL REPORT,
11:50AM	11	YOUR HONOR.
11:50AM	12	THE COURT: ALL RIGHT. THANK YOU.
11:50AM	13	SO, MR. LEACH, WHAT SHOULD I KNOW ABOUT THIS?
11:50AM	14	MR. LEACH: THERE'S A SIGNIFICANT DIFFERENCE BETWEEN
11:50AM	15	MS. HOLMES AND MR. BALWANI ON THIS POINT, YOUR HONOR, AND THAT
11:50AM	16	IS MR. BALWANI WAS CONVICTED OF A CONSPIRACY TO DEFRAUD
11:50AM	17	PATIENTS ABOUT THEIR BLOOD TESTS AND FOR FOUR INDIVIDUAL COUNTS
11:50AM	18	OF WIRE FRAUD WITH RESPECT TO THREE PATIENTS WHO TESTIFIED IN
11:50AM	19	AN AD TO THE MEDIA.
11:50AM	20	SO WE HAVE A FINDING BY THE JURY THAT MR. BALWANI ENGAGED
11:50AM	21	IN A CONSPIRACY TO PROVIDE FALSE AND MISLEADING INFORMATION TO
11:51AM	22	PAYING PATIENTS WHO ARE GOING TO RELY ON THESE BLOOD TESTS.
11:51AM	23	AND THERE'S A CASE THAT I KNOW THE COURT IS AND WE THINK
11:51AM	24	THIS FACTUAL SCENARIO FOUND BY THE JURY FALLS SQUARELY WITHIN
11:51AM	25	NINTH CIRCUIT CASE LAW.

I THINK THE JOHANSSON CASE, WHICH WE CITE --1 11:51AM THE COURT: 249 FED. 3D? 11:51AM 2 MR. LEACH: YES, YOUR HONOR. YOU'RE FASTER THAN I 3 11:51AM 11:51AM 4 AM. 11:51AM 5 I THINK THAT'S VERY INSTRUCTIVE. I MEAN, THAT'S WHERE 11:51AM 6 THERE WAS FALSIFICATION OF REPORTS ABOUT DRIVERS MEETING OR NOT 11:51AM 7 MEETING THE LIMIT, THE SLEEPING LIMIT BEFORE THEY HAD TO BE TAKEN OFF THE ROAD, AND THOSE DOCUMENTS WERE FALSIFIED. AND 11:51AM 8 THE NINTH CIRCUIT THERE FOUND THAT THERE WERE SUFFICIENT FACTS 11:51AM 9 11:51AM 10 TO SAY THAT THAT SCENARIO IS AN OFFENSE WITH A CONSCIOUS OR 11:51AM 11 RECKLESS DISREGARD OF SERIOUS BODILY INJURY. 11:51AM 12 I FAIL TO SEE THE DISTINCTION BETWEEN OUR TWO SITUATIONS 11:51AM 13 HERE. THERE WAS AMPLE EVIDENCE IN THE RECORD THAT THERANOS WAS PROVIDING FALSE AND MISLEADING BLOOD TESTS AND THAT MR. BALWANI 11:51AM 14 11:52AM 15 WAS CONSPIRING TO DO THAT TO PATIENTS. THE JURY FOUND THAT HE ACTED WILLFULLY WITH RESPECT TO 11:52AM 16 11:52AM 17 THAT AND WITH INTENT TO DEFRAUD. 11:52AM 18 THE RESPONSE I HEAR FROM MR. COOPERSMITH IS, WELL, 11:52AM 19 MR. BALWANI WAS TRYING TO FIX PROBLEMS AS THEY AROSE, AND IF HE 11:52AM 20 WOULD SEE THIS, HE REACTED TO THAT. 11:52AM 21 THAT MIGHT BE TRUE OR THAT MIGHT NOT BE TRUE ACCORDING TO 11:52AM 22 THE EVIDENCE, BUT IT DOESN'T SEEM TO US THAT THAT'S SOMETHING 11:52AM 23 THAT YOU CAN SAY IN LIGHT OF THE VERDICT, AND I THINK IT'S 11:52AM 24 IMPORTANT THAT COUNT TWELVE GOES TO THE TIME PERIOD AUGUST OF 11:52AM 25 2015 LATE INTO THE CONSPIRACY.

1 11:52AM 2 11:52AM 3 11:52AM 11:52AM 4 11:53AM 11:53AM 6 11:53AM 7 8 11:53AM 11:53AM 9 11:53AM 10 11:53AM 11 11:53AM 12 11:53AM 13 11:53AM 14 11:53AM 15 11:53AM 16 11:53AM 17 11:53AM 18 11:53AM 19 11:53AM 20 11:54AM 21 11:54AM 22 11:54AM 23 11:54AM 24 11:54AM 25

SO WHAT MR. BALWANI WAS OR WAS NOT DOING I'M NOT SURE IS
PARTICULARLY RELEVANT, AND OUR BRIEF LAYS FORTH SOME OF THE
FACTS IN TERMS OF THE CONCERNS THAT ERIKA CHEUNG WAS RAISING,
THE CONCERNS THAT TYLER SHULTZ WAS RAISING, THE CONCERNS THAT
DR. PANDORI WAS RAISING WHEN HE WAS TOLD BY MR. BALWANI WHEN HE
SAYS WE SHOULD STOP DOING THE EDISON, WE'RE NOT GOING THAT.
THERE'S AMPLE EVIDENCE IN THE RECORD WHERE MR. BALWANI IS
ADVISED OF PROBLEMS AND YET THE TESTS CONTINUE TO BE ISSUED.

AND I THINK ONE POINT WE MENTION IN OUR BRIEF IS THERE IS
AN INSTANCE WHERE DANIEL YOUNG IS RAISING SOME CONCERNS HE HAS
WITH TESTS, AND THE DEFENSE RAISED A LOT ABOUT DR. YOUNG AND
HIM NOT BEING CALLED IN THIS CASE, BUT THERE'S AN EMAIL FROM
HIM THAT SAID -- WHERE DR. YOUNG IS RAISING SOME OF THESE
CONCERNS, EVEN THE INDIVIDUALS THAT THE DEFENSE WAS POINTING TO
AS THEIR GO-TO PERSON FOR THEIR PROBLEMS. AND MR. BALWANI'S
RESPONSE TO THAT IS TELLING. HE'S TOLD BY DR. YOUNG THAT THERE
ARE PROBLEMS IN THE FALL OF 2014, AND HE FORWARDS THAT TO
MS. HOLMES AND HE SAYS, "ALWAYS ANOTHER STUDY AFTER THE FACT."

WHAT DOES THAT MEAN? THAT MEANS THAT HE KNOWS, TIME AND
TIME AGAIN, THERANOS IS GOING TO MARKET WITH SOMETHING BASED ON
A VALIDATION PROCESS THAT TURNS OUT NOT TO BE WORKING, ANOTHER
STUDY AFTER THE FACT.

DR. YOUNG IS PROPOSING, WELL, WE ALREADY WENT TO MARKET
WITH THIS PROBLEM, IT'S NOT WORKING. LET'S GO DO ANOTHER STUDY
TO TRY TO FIGURE OUT WHAT THE ISSUE IS. AND THAT'S NOT

HAPPENING WITH ONE ASSAY IN AUGUST OF 2014, THAT'S HAPPENING IN 1 11:54AM 11:54AM 2 MULTIPLE ASSAYS, AND MR. BALWANI KNOWS THIS. AND ALL OF THIS IS BEFORE THE SITUATION WHERE DR. ROSENDORFF LEAVES AFTER 3 11:54AM 11:54AM 4 TELLING MS. HOLMES IN A COMMUNICATION THAT GOES TO MR. BALWANI 11:54AM 5 THAT HE'S BEING ASKED TO VOUCH FOR TESTS THAT HE'S NOT 11:54AM 6 COMFORTABLE WITH, WHERE MR. BALWANI GOES TO THE LAB AND SAYS 11:54AM 7 IT'S AN F'ING DISASTER. SO THERE IS BEYOND A REASONABLE DOUBT EVIDENCE THAT 11:54AM 8 MR. BALWANI CONSPIRED TO DEFRAUD PATIENTS TO GIVE THEM FALSE 11:54AM 9 11:54AM 10 AND UNRELIABLE INFORMATION, AND THAT FACT COMPELS THE 11:54AM 11 FINDING -- A FINDING UNDER THIS GUIDELINE THAT THE OFFENSE 11:55AM 12 INVOLVED A CONSCIOUS OR A KNOWING RISK OF SERIOUS BODILY 11:55AM 13 INJURY. I JUST DON'T THINK WHATEVER HE IS DOING, YOU KNOW, IN 11:55AM 14 11:55AM 15 RESPONSE TO INDIVIDUAL ASSAYS MATTERS AT THE END OF THE DAY IN LIGHT OF THE JURY FINDING. 11:55AM 16 11:55AM 17 SO FOR THOSE REASONS WE THINK THIS ENHANCEMENT IS 11:55AM 18 APPROPRIATELY APPLIED. 11:55AM 19 THE COURT: THANK YOU. 11:55AM 20 MR. COOPERSMITH: THANK YOU, YOUR HONOR. 11:55AM 21 THIS IS ONE THAT THE PROBATION OFFICE GOT RIGHT BY NOT 11:55AM 22 RECOMMENDING THIS ADJUSTMENT, AND IT'S ALSO ONE THAT THE COURT 11:55AM 23 GOT RIGHT IN MS. HOLMES'S CASE. LET ME ADDRESS MR. LEACH'S 11:55AM 24 ARGUMENTS AND SAY A FEW OTHER THINGS. 11:55AM 25 FIRST OF ALL, WE'RE TALKING ABOUT GUIDELINE ADJUSTMENT FOR

1 11:55AM 2 11:55AM 3 11:55AM 11:55AM 4 11:55AM 11:56AM 11:56AM 7 11:56AM 8 11:56AM 9 11:56AM 10 11:56AM 11 11:56AM 12 11:56AM 13 11:56AM 14 11:56AM 15 11:56AM 16 11:56AM 17 11:56AM 18 11:56AM 19 11:56AM 20 11:56AM 21 11:57AM 22 11:57AM 23

11:57AM 24

11:57AM 25

CONSCIOUS RISK OF CREATING -- CONSCIOUS CREATION OF A RISK OF SERIOUS BODILY INJURY OR DEATH.

THE LAW ON THAT, JUST TO START WITH THAT, IS IT HAS TO BE EITHER KNOWING OR RECKLESS, WHICH UNDER THE NINTH CIRCUIT STANDARD, AND THIS IS ON PAGE 33 AND 34 OF OUR SENTENCING MEMORANDUM, IT HAS TO BE RECKLESS. IT IS SO OUTSIDE OF THE PALE THAT THE DEFENDANT MUST ACTUALLY KNOW. IT'S AS CLOSE AN ANALOGY THAT YOU COULD POSSIBLY GET.

SO IN THIS CASE WE'VE GOT A JURY VERDICT, AS MR. LEACH SAID, AND THE VERDICT WAS FINDING MR. BALWANI GUILTY OF PATIENT COUNTS AND OF CONSPIRACY. THAT IS TRUE, AND WE'RE NOT ARGUING THAT AGAIN TODAY, OF COURSE.

BUT THE JURY VERDICT IS A GENERAL VERDICT. AND AS WE
POINTED OUT IN OUR PAPERS, WE DON'T KNOW WHY THE JURY DECIDED
TO CONVICT MR. BALWANI ON THAT COUNT, BUT BY THAT SAME TOKEN,
WE DON'T KNOW WHY THE JURY DECIDED NOT TO CONVICT MS. HOLMES ON
THOSE SAME COUNTS, EVEN THOUGH THE GOVERNMENT'S PRESENTATION
WAS VIRTUALLY IDENTICAL IN BOTH CASES.

AND THE GOVERNMENT ARGUED IN MOTION PRACTICE AND IN

CLOSING ARGUMENT THAT ONE OF THE THEORIES OF WHY MR. BALWANI

WAS GUILTY OF THESE PATIENT COUNTS AND CONSPIRACY WAS THAT

PATIENTS HAD BEEN TOLD THERANOS LABORATORY RESULTS ARE MORE

ACCURATE, THEY'RE BETTER THAN OTHER COMPETITORS, YOU SHOULD GO

TO THERANOS. THEY ARGUED THAT. AND FOR ALL WE KNOW BASED ON

THE GENERAL VERDICT, THE JURY WOULD HAVE LATCHED ON TO THAT AND

SAID, OKAY, THAT'S A MISREPRESENTATION THAT WE'RE GOING TO FIND 1 11:57AM GUILT ON. 2 11:57AM SO THE VERDICT DOESN'T HELP US HERE IN TERMS OF WHETHER 3 11:57AM 11:57AM 4 THIS GUIDELINE ADJUSTMENT SHOULD BE APPLIED. AND WHEN WE TALK ABOUT SENTENCING IS THE PROVINCE OF THE 11:57AM COURT, NOT THE JURY, AND YOUR HONOR HAS TO DECIDE THESE 11:57AM 6 11:57AM 7 DIFFICULT QUESTIONS. I WENT BACK TO THIS COURT'S RULING ON OUR RULE 29 MOTION, 11:57AM 8 AND THAT'S DOCKET 1625, AND WHEN YOU LOOK AT THAT, ESPECIALLY 11:57AM 9 11:57AM 10 PAGE 9 AND 10, THERE'S A LOT OF POINTS THAT THIS COURT MADE 11:57AM 11 ABOUT WHY MS. HOLMES KNEW FULL WELL, ACCORDING TO THE COURT'S 11:58AM 12 OPINION, THAT THE LABORATORY HAD ALL OF THESE ISSUES. 11:58AM 13 SO THE SAME EVIDENCE APPLIED TO MS. HOLMES. FOR EXAMPLE, 11:58AM 14 IF THIS IS REALLY THE CASE, MR. LEACH POINTS OUT THAT 11:58AM 15 MR. BALWANI WROTE AN EMAIL TO MS. HOLMES AND SAID "ALWAYS ANOTHER STUDY AFTER THE FACT." 11:58AM 16 WELL, MS. HOLMES GOT THAT EMAIL. SO SHE HAS THE SAME 11:58AM 17 11:58AM 18 KNOWLEDGE AS MR. BALWANI IF THAT IS AN ISSUE. 11:58AM 19 WE DON'T THINK THAT'S WHAT IT MEANT. BUT GIVEN MR. LEACH'S ARGUMENT, WE DON'T UNDERSTAND HOW IT COULD BE 11:58AM 20 11:58AM 21 APPLIED TO MR. BALWANI AND NOT MS. HOLMES. AND THE COURT, OF 11:58AM 22 COURSE, MADE THAT RULING IN MS. HOLMES'S CASE. 11:58AM 23 BY THE SAME TOKEN, IF THE TEXT MESSAGE "NORMANDY IS AN 11:58AM 24 F'ING DISASTER" IS WHAT MR. LEACH THINKS IT IS, SHE HAD THAT 11:58AM 25 SAME TEXT MESSAGE. THE SAME EVIDENCE APPLIED TO HER AS IT WAS

11:58AM	1	TO MR. BALWANI, AND SHE WASN'T GIVEN THE ADJUSTMENT. SO OUT OF
11:58AM	2	BASIC FAIRNESS, IT SHOULDN'T APPLY TO MR. BALWANI.
11:58AM	3	AGAIN, WE DON'T NEED TO DEBATE THIS NOW, BUT WE DON'T
11:59AM	4	BELIEVE THAT TEXT MESSAGE MEANT WHAT THE GOVERNMENT SAID, BUT I
11:59AM	5	DON'T NEED TO GO INTO THAT FOR THIS PURPOSE.
11:59AM	6	SO WHY SHOULDN'T THE GUIDELINE ADJUSTMENT BE APPLIED? AND
11:59AM	7	THERE ARE A LOT OF REASONS.
11:59AM	8	FIRST OF ALL AND I WANT TO JUST HAND UP SOMETHING TO
11:59AM	9	THE COURT IF I CAN WITH YOUR PERMISSION, YOUR HONOR, AND I'LL
11:59AM	10	GIVE IT TO THE GOVERNMENT, TOO. BUT THIS HAD TO DO WITH THE
11:59AM	11	BLOOD TESTING THAT MR. BALWANI ARRANGED FOR HIS MOTHER TO
11:59AM	12	HAVE
11:59AM	13	THE COURT: YOU DON'T HAVE TO PASS THAT UP. I'VE
11:59AM	14	SEEN IT.
11:59AM	15	MR. COOPERSMITH: I DON'T THINK YOU'VE SEEN IT.
11:59AM	16	THE COURT: YOU PUT SOMETHING IN THE RECORD OR AT
11:59AM	17	LEAST ONE OF THE SUBMISSIONS WERE RELATIVE'S TESTS, BLOOD
11:59AM	18	TESTS.
11:59AM	19	MR. COOPERSMITH: YES, YOUR HONOR.
11:59AM	20	THE COURT: AND IF YOU'RE OFFERING THIS FOR AN
11:59AM	21	ARGUMENT TO SAY WOULD HE DO THIS TO A RELATIVE? WOULD HE ALLOW
11:59AM	22	A RELATIVE TO TAKE A TEST IF HE HAD CONSCIOUS KNOWLEDGE? IS
11:59AM	23	THAT WHAT THE PURPOSE OF THIS IS?
11:59AM	24	MR. COOPERSMITH: YES, YOUR HONOR.
11:59AM	25	THE COURT: I UNDERSTAND THAT.

MR. COOPERSMITH: WHAT I'LL SAY -- AND I WON'T HAND 1 11:59AM IT UP. BUT WHAT I WILL TELL THE COURT IS THAT WE LOOKED AT THE 2 11:59AM BLOOD TESTS THAT MR. BALWANI'S MOTHER ACTUALLY HAD BASED ON THE 3 11:59AM 12:00PM 4 REPORT THAT WE HAVE IN EXHIBIT 20, I BELIEVE, AND TO MY DECLARATION IN THE SENTENCING MEMORANDUM, WE LOOKED AT THE 12:00PM 12:00PM 6 ACTUAL BLOOD TEST SHE TOOK BECAUSE MR. LEACH SAID, WELL, WE DON'T KNOW IF IT'S ACTUALLY FINGERSTICK, RIGHT? 12:00PM 7 SO WE LOOKED AT ALL OF THE TESTS THAT SHE HAD, AND WE 8 12:00PM DETERMINED, AND THAT'S WHAT OUR HANDOUT SAYS, THAT EVERY SINGLE 12:00PM 9 12:00PM 10 ONE OF THOSE TESTS THAT HIS MOTHER HAD IN MARCH OF 2015 WERE 12:00PM 11 AVAILABLE AT THERANOS ON FINGERSTICK. 12:00PM 12 IN ADDITION, MR. BALWANI'S SISTER WHO SENT A LETTER TO THE 12:00PM 13 COURT, RUPA PAWANI, SAID SHE WAS THERE WHEN MR. BALWANI'S 12:00PM 14 MOTHER HAD FINGERSTICK. 12:00PM 15 AND THEN THE OTHER THING I'LL SAY ABOUT THAT, YOUR HONOR, IS THAT OF COURSE THERE'S NO EVIDENCE HERE THAT -- WE KNOW HIS 12:00PM 16 MOTHER DID HAVE THE BLOOD TEST. THE REPORT IS IN THE RECORD. 12:00PM 17 12:00PM 18 THERE'S NO EVIDENCE HERE THAT MR. BALWANI SOMEHOW TOLD THE 12:00PM 19 LAB, OH, YOU KNOW, WHATEVER YOU DO, DON'T DO FINGERSTICK. HIS 12:00PM 20 MOTHER HAD A BLOOD TEST, A SERIES OF BLOOD TESTS. THOSE WERE 12:01PM 21 DUTIFULLY DONE BY THE LAB, AND THE RESULTS WERE REPORTED. 12:01PM 22 AND THAT FACT ALONE, I THINK, NEGATES ANY SUGGESTION THAT 12:01PM 23 MR. BALWANI IS PUTTING PATIENTS CONSCIOUSLY OR RECKLESSLY IN 12:01PM 24 DANGER AS THE GOVERNMENT ARGUES BECAUSE HE'S NOT GOING TO DO 12:01PM 25 THAT TO HIS OWN MOTHER AND OBVIOUSLY THAT POINT THE COURT

UNDERSTANDS.

SO IN ADDITION, THOUGH, THERE'S A LOT MORE, YOUR HONOR, AND THAT IS WHAT ACTUALLY HAPPENED HERE. WHEN YOU LOOK AT THE WHOLE HISTORY OF THE THERANOS LABORATORY THAT WAS IN OPERATION BETWEEN 2013 TO 2015, IN HINDSIGHT YOU CAN LOOK AT THINGS LIKE THE CMS REPORT AND, YOU KNOW, SOME OF THE THINGS THAT DR. DAS SAID IN MS. HOLMES'S CASE AND SAY, WELL, MAYBE THEY SHOULD HAVE DONE THINGS A LITTLE DIFFERENTLY. BUT IN REAL TIME, THOSE AFTER-THE-FACT REPORTS DON'T BEAR ON WHAT MR. BALWANI WAS TRYING TO DO OR NOT DO AS FAR AS PATIENT RISK AT THE TIME.

WHEN YOU LOOK AT IT IN REAL TIME, EVERY SINGLE TIME THAT AN ISSUE WAS RAISED, MR. BALWANI DIDN'T SAY, WELL, SO WHAT, YOU KNOW, WE DON'T CARE. IT WAS, LET'S GET TO THE BOTTOM OF THIS.

WHEN THERE WERE EMAILS AFTER EMAILS WHERE LET'S FIGURE OUT WHAT IS GOING ON HERE, LET'S STOP TESTING UNTIL WE FIGURE OUT WHAT THE PROBLEM IS, LET'S DO STUDIES.

AND THERE ARE SOME EXAMPLES THAT I THINK REALLY JUMP OUT, AT LEAST FOR ME. FOR EXAMPLE, ON MAY 30TH, 2014, THE COURT PROBABLY REMEMBERS THIS, DR. ROSENDORFF SENT AN EMAIL THAT SAID STOP HCG TESTING ON THE THERANOS EDISON DEVICE, AND THAT'S THE PREGNANCY RELATED TEST THAT YOU'VE HEARD ABOUT.

WELL, WHAT HAPPENED? THEY DID STOP. AND THEY STOPPED UNTIL THE SCIENTIFIC TEAM AND THE LAB COULD LOOK AT WHAT WAS GOING ON, AND WITHIN A FEW DAYS, THEY HAD DONE SOME STUDIES, AND THE LABORATORY TEAM SENT EMAILS TO DR. ROSENDORFF, NOT

1 12:02PM 2 12:03PM 3 12:03PM 12:03PM 4 12:03PM 12:03PM 6 12:03PM 7 8 12:03PM 12:03PM 9 12:03PM 10 12:03PM 11 12:03PM 12 12:03PM 13 12:03PM 14 12:03PM 15 12:03PM 16 12:03PM 17 12:04PM 18 12:04PM 19 12:04PM 20 12:04PM 21 12:04PM 22 12:04PM 23 12:04PM 24 12:04PM 25

MR. BALWANI, AND SAID OKAY, WE'RE RELEASING THE RESULTS, WE THINK WE'VE GOT THIS, AND DR. ROSENDORFF DIDN'T DO ANYTHING. SO OKAY. RIGHT. SO THAT'S WHAT IS GOING ON HERE.

SO TO BLAME THIS ON MR. BALWANI WHERE HE'S CREATING A CONSCIOUS RISK, THAT'S THE LAST THING THAT ANYONE WOULD WANT TO DO RUNNING A COMPANY LIKE THIS. HE RELIED ON THE SCIENTIFIC TEAM. DR. ROSENDORFF TESTIFIED THAT HE STOOD BY HIS VALIDATION REPORTS. DR. ROSENDORFF SAID HE NEVER RELEASED, KNOWINGLY RELEASED A RESULT THAT HE THOUGHT WAS INACCURATE.

MR. BALWANI HAD A LOT OF DATA THAT WAS PRESENTED TO HIM, INCLUDING THE AAP REPORTS THAT YOU SAW AT TRIAL AND A LOT OF OTHER MATERIALS THAT ASSURED HIM THAT THE LAB WAS NOT RELEASING INACCURATE RESULTS TO PATIENTS.

AND THEN THE OC ISSUE WHICH THE GOVERNMENT MENTIONED IN THEIR PAPERS, OF COURSE QC, QUALITY CONTROL, IS SOMETHING THAT YOU DO. AND AS THE TESTIMONY AT TRIAL SHOWED, YOU DON'T RELEASE THE RESULT UNTIL -- UNLESS THE QUALITY CONTROL PASSES. SO THERE WAS NO EVIDENCE IN THIS CASE THAT MR. BALWANI DECIDED LET'S RELEASE RESULTS ANYWAY EVEN IF THE QUALITY CONTROL FAILS. THAT JUST NEVER HAPPENED.

SO I THINK FOR ALL OF THESE REASONS, INCLUDING THAT THERE WERE MILLIONS OF TESTS HERE AND THE GOVERNMENT PRESENTED A RELATIVELY SMALL HANDFUL, WE DON'T THINK THIS GUIDELINE ADJUSTMENT SHOULD BE APPLIED TO MR. BALWANI ANY MORE THAN IT COULD HAVE BEEN APPLIED TO MS. HOLMES, AND WE THINK THAT'S THE RIGHT ACTION IN THIS CASE.

1

2

3

12:04PM

12:04PM

12:04PM

12:04PM 4

12:04PM 5

12:04PM 6

12:04PM 7

12:04PM 8

12:04PM 9

12:05PM 10

12:05PM 11

12:05PM 12

12:05PM 13

12:05PM 14

12:05PM 15

12:05PM 16

12:05PM 17

12:05PM 18

12:05PM 19

12:05PM 20

12:05PM 21

12:05PM 22

12:05PM 23

12:05PM 24

12:05PM 25

THE COURT: OKAY. ANYTHING FURTHER, MR. LEACH? MR. LEACH: TWO BRIEF POINTS, YOUR HONOR.

THE FIRST IS AT LEAST IN THE CONTEXT OF SENTENCING FOR THIS GUIDELINE, THE COURT DOES NOT NEED TO FIND A MILLION TESTS WERE WRONG. THE COURT DOES NOT NEED A MILLION TESTS WERE WRONG. THE COURT NEEDS TO FIND THAT WITH RESPECT TO A PATIENT. WE HAVE MULTIPLE PATIENTS TESTIFY IN THE TRIAL. BRITTANY GOULD, THE COURT MAY RECALL, TESTIFIED ABOUT HER FALSE HCG TEST WHICH HAPPENED AFTER THE PROBLEMS WERE PURPORTEDLY FIXED THAT MR. COOPERSMITH DESCRIBE. SO TO SAY THAT THERE MIGHT HAVE BEEN SOME GOOD TESTS OUT THERE, DOES NOT RESPOND TO WHETHER THE GUIDELINE APPLIES OR DOESN'T APPLY.

THE OTHER POINT I WOULD MAKE IS WE KNOW FROM THE CMS REPORT AND FROM DR. DAS THAT THERANOS ITSELF CONCLUDED AT THE END OF THE DAY THERE WAS A POSSIBLE PATIENT IMPACT FOR EVERY ONE OF THE APPROXIMATELY 800,000 TESTS THAT WERE DONE ON THE EDISON BETWEEN SEPTEMBER 2013 AND JUNE OF 2015. ALL OF THOSE WERE VOIDED, AND THERANOS ITSELF SAID THERE'S A POSSIBLE PATIENT IMPACT.

SO WE HAVE FALSE DOCUMENTS GOING TO THE PATIENTS, WE HAVE A POSSIBLE PATIENT IMPACT ON ALL OF THEM, WE HAVE A DEFENDANT WHO IS CONVICTED OF WILLFULLY JOINING THE CONSPIRACY AND ACTING WITH AN INTENT TO DEFRAUD THOSE PATIENTS, AND EVERYTHING THAT MR. COOPERSMITH SAID IS A DISAGREEMENT WITH THE JURY'S FINDING

1 12:05PM 12:06PM 2 3 12:06PM 12:06PM 4 12:06PM 5 12:06PM 6 12:06PM 7 12:06PM 8 12:06PM 9 12:06PM 10 12:06PM 11 12:06PM 12 12:06PM 13 12:06PM 14 12:06PM 15 12:06PM 16 12:06PM 17 12:06PM 18 12:06PM 19 12:06PM 20 12:07PM 21 12:07PM 22 12:07PM 23 12:07PM 24 12:07PM 25

THERE, AND I JUST DON'T SEE ANYTHING HE SAID THAT CAN CONTRAVENE WHAT THE JURY HAS FOUND IN THIS CASE.

MR. COOPERSMITH: REALLY BRIEFLY, YOUR HONOR.

WE'RE NOT ARGUING THE JURY'S FINDING AT THIS MOMENT. WHAT WE'RE SAYING IS THAT THE VERDICT DOESN'T GOVERN THIS BECAUSE WE DON'T KNOW WHY THEY CONVICTED GIVEN THE GOVERNMENT'S ARGUMENTS THAT THEY WERE TOLD THAT THERANOS WAS MORE ACCURATE. AND IF IT WAS JUST AS ACCURATE AS EVERY OTHER LAB IN THE COUNTRY, THAT WOULD NOT BE A REASON TO APPLY THIS FACTOR OBVIOUSLY.

BUT JUST LET ME BRIEFLY MENTION BRITTANY GOULD SINCE MR. LEACH MENTIONED IT, AND ALSO DR. DAS.

SO, FIRST OF ALL, ON BRITTANY GOULD, THE EMAILS THAT WERE INTRODUCED AT TRIAL SHOWED THAT THE PROBLEMS WERE RAISED TO MR. BALWANI'S LEVEL WHERE THERE WAS A PROBLEM WITH BRITTANY GOULD'S TEST AND MR. BALWANI WAS TOLD THAT THERE WAS A DECIMAL POINT ERROR IN THE RESULTS THAT WERE REPORTED TO HER AND HER POSITION. SO THAT'S NOT A REASON WHY MR. BALWANI WAS PUTTING SOMEONE AT RISK.

AND AS I SAID BEFORE, THAT WAS AN HCG TEST WHICH OCCURRED SEVERAL MONTHS AFTER THAT INCIDENT THAT I JUST DESCRIBED WHERE DR. ROSENDORFF STOPPED THE TESTING, THERE WAS A STUDY DONE, AND THEN DR. ROSENDORFF ALLOWED IT TO GO BACK ON EDISON.

SO MONTHS -- A FEW MONTHS LATER, BRITTANY GOULD GOT THE RESULT, THAT'S VERY UNFORTUNATE, BUT THAT'S NOT BECAUSE

1 12:07PM 2 12:07PM 3 12:07PM 12:07PM 4 12:07PM 12:07PM 6 12:07PM 7 12:07PM 8 12:07PM 9 12:07PM 10 12:07PM 11 12:07PM 12 12:08PM 13 12:08PM 14 12:08PM 15 12:08PM 16 12:08PM 17 12:08PM 18 12:08PM 19 12:08PM 20 12:08PM 21 12:08PM 22 12:08PM 23 12:08PM 24

12:08PM 25

MR. BALWANI WAS TRYING TO CREATE A RISK OR KNEW HE WAS CREATING A RISK TO SOMEONE LIKE MS. GOULD OR SOMEONE SIMILARLY SITUATED.

ON THE ISSUE OF DR. DAS, DR. DAS DIDN'T TESTIFY IN MR. BALWANI'S CASE OBVIOUSLY, BUT MR. BALWANI WAS INVOLVED IN HIRING DR. DAS ALONG WITH MS. HOLMES. MR. BALWANI WAS STILL THERE AT THE COMPANY IN THE LATTER PART OF 2015, AND THE FIRST FEW MONTHS OF 2016 DR. DAS WAS HIRED. SO THIS WAS MR. BALWANI WORKING WITH MS. HOLMES TO TRY TO UNDERSTAND THE ISSUES THAT HAD BEEN RAISED BY CMS.

BUT IN ANY EVENT, THIS IS AFTER THE FACT, AND THAT DR. DAS COMES ALONG AND HAS A CERTAIN VIEW OF THE WORLD, MR. BALWANI IS WORKING WITH HIM, AND THAT DOESN'T SAY THAT BACK IN REAL TIME IN 2013 AND '14 OR EARLIER IN '15 THAT MR. BALWANI KNEW THAT HE WAS CREATING SOME KIND OF RISK TO PATIENTS.

IN FACT, WE SEE IN THE RECORD THAT DEVICES CAME OFFLINE. THE GOVERNMENT ITSELF PRESENTED AN EXHIBIT WHERE EARLY IN 2015, OR EVEN LATE IN '14, CERTAIN TESTS ON THE EDISON WAS STOPPED.

SO THIS WAS NOT A COMPANY THAT, AS MR. BALWANI WAS IN THE MANAGEMENT TEAM OF, WAS TRYING TO PROVIDE INACCURATE RESULTS TO PATIENTS. WE DON'T THINK THAT THE RECORD SUPPORTS THAT. THE COURT'S COMMENT IN MS. HOLMES'S CASE IS THE EVIDENCE DOESN'T SUPPORT THAT. WE THINK THAT'S A CORRECT OBSERVATION AND THIS GUIDELINE ADJUSTMENT SHOULD NOT BE APPLIED.

THE COURT: ALL RIGHT. THANK YOU.

I THINK THE CONNECTION HERE IS A LITTLE BIT GREATER. THE

1 12:08PM 2 12:08PM 3 12:08PM 12:09PM 4 12:09PM 5 12:09PM 6 12:09PM 7 12:09PM 8 12:09PM 9 12:09PM 10 12:09PM 11 12:09PM 12 12:09PM 13 12:09PM 14 12:09PM 15 12:10PM 16 12:10PM 17 12:10PM 18 12:10PM 19 12:10PM 20 12:10PM 21 12:10PM 22 12:10PM 23 12:10PM 24 12:10PM 25

EVIDENCE HERE AS TO YOUR CLIENT, MR. BALWANI'S INTIMACY WITH THE LAB IS SOMETHING THAT IT SEEMED TO ME THAT HE HAD PURVIEW OVER THE LAB. YOU INDICATE THAT HE HIRED OR HAD PART OF HIRING DR. DAS.

HE ALSO HIRED HIS DERMATOLOGIST AFTER DR. ROSENDORFF LEFT, WHICH SUGGESTS THAT HE HAD MORE CONTROL. I THINK THAT WAS THE GENERAL PRESENTATION AT THE TRIAL, AT THE TRIALS, THAT THE LAB WAS KIND OF HIS BABY IF YOU WILL.

HE HIRED MS. SAWYER CONCURRENT OR SHORTLY AFTER HE HIRED HIS DERMATOLOGIST TO BE THE LAB DIRECTORS IN THAT CASE. HE WAS THE ONE WHO HAD GREATER RESPONSIBILITY IT SEEMED FOR THE LAB. IF THERE WAS A DIVISION OF LABOR, THE LAB SEEMED TO BE HIS. AND HE HAD -- THERE WERE EMAILS. THERE WAS MS. CHEUNG, WHEN SHE HAD ISSUES WITH THE LAB, SHE WENT TO MR. BALWANI TO TALK TO HIM ABOUT IT, AND WE KNOW ABOUT THAT CONVERSATION AND HIS RESPONSE TO HER CONCERNS AND OTHERS.

SO I THINK THAT'S THE DISTINCTION THAT HIS INTIMACY IS A LITTLE BIT CLOSER TO THE LAB THAN PERHAPS MS. HOLMES AND PERHAPS THAT GIVES HIM A GREATER VISION OF RESPONSIBILITY FOR THE OUTPUT FROM THAT LAB, AND I THINK THAT'S THE BASIS OF WHAT -- ONE OF THE BASIS OF ARGUING WHY THIS SHOULD APPLY TO MR. BALWANI.

MR. COOPERSMITH: THANK YOU, YOUR HONOR.

I UNDERSTAND THE POINT. IT IS TRUE THAT MR. BALWANI HAD MORE DIRECT PURVIEW OF THE LAB, BUT IT'S ALSO TRUE THAT EACH OF

1 12:10PM 12:10PM 2 3 12:10PM 12:10PM 4 12:10PM 5 12:10PM 6 12:10PM 7 12:11PM 8 12:11PM 9 12:11PM 10 12:11PM 11 12:11PM 12 12:11PM 13 12:11PM 14 12:11PM 15 12:11PM 16 12:11PM 17 12:11PM 18 12:11PM 19 12:11PM 20 12:11PM 21 12:11PM 22 12:11PM 23 12:11PM 24 12:11PM 25

THESE IMPORTANT ISSUES THAT THE GOVERNMENT SAID ARE PROBLEMS, THAT MR. BALWANI SHOULD HAVE FIXED OR TAKEN INTO ACCOUNT TO STOP TESTING, MS. HOLMES ALSO KNEW ABOUT.

AND I'LL JUST READ FROM THE GOVERNMENT'S SENTENCING MEMO BRIEFLY. THEY SAY MS. HOLMES HAD ULTIMATE AUTHORITY OVER THE LAB OPERATIONS JUST LIKE SHE DID EVERY OTHER ASPECT OF THE COMPANY'S ACTIVITY. AN ORG CHART PRESENTED TO CMS BY THERANOS DISPLAYED MS. HOLMES AT THE TOP OF THE CLIA OPERATION OVERSEEING A GROUP COMPRISED OF MORE THAN 60 THERANOS EMPLOYEES INCLUDING --

THE COURT: YOU'VE GOT TO SLOW DOWN.

MR. COOPERSMITH: YEAH. -- OVERSEEING A GROUP COMPRISED OF MORE THAN 60 THERANOS EMPLOYEES, INCLUDING HER COCONSPIRATOR, RAMESH BALWANI.

AND EVEN MORE IMPORTANTLY, YOUR HONOR, GOING TO THE ISSUE OF HIRING DR. DHAWAN. SO HE WAS MR. BALWANI'S DERMATOLOGIST, BUT I THINK THAT'S SELLING HIM A LITTLE SHORT. HE ALSO WAS THE DIRECTOR OF THE CLINICAL LAB, AND HE WAS FULLY QUALIFIED. NO ONE HAS EVER DISPUTED THAT.

THE COURT: HIS OWN LAB.

MR. COOPERSMITH: HE WAS. AND HE WAS ALSO LICENSED AND HE SERVED AS THE LAB DIRECTOR.

BUT IN ADDITION -- AND WE PUT THESE DOCUMENTS INTO OUR SENTENCING BRIEF. THE RECORD HERE SHOWS THAT MR. BALWANI, RIGHT AFTER DR. ROSENDORFF LEFT IN NOVEMBER OF 2014, HE DIDN'T

1 12:11PM 2 12:11PM 3 12:12PM 12:12PM 4 12:12PM 12:12PM 6 12:12PM 7 12:12PM 8 12:12PM 9 12:12PM 10 12:12PM 11 12:12PM 12 12:12PM 13 12:12PM 14 12:12PM 15 12:12PM 16 12:12PM 17 12:12PM 18 12:12PM 19 12:12PM 20 12:13PM 21 12:13PM 22 12:13PM 23 12:13PM 24 12:13PM 25

JUST SAY, OH, LET'S GET MY DERMATOLOGIST IN HERE. HE WAS INVOLVED IN AN ACTIVE SEARCH, A VERY ACTIVE SEARCH FOR A FULL-TIME LAB DIRECTOR. HE PUT FORWARD DR. SAKSENA FOR THAT PURPOSE. HE HAD MADE SURE THAT DR. SAKSENA HAD TIME TO STUDY FOR THE TESTING HE HAD TO TAKE. THEY PUSHED THAT ISSUE WITH THE REGULATORS, THE CALIFORNIA REGULATORS TO MAKE SURE HE WOULD BE QUALIFIED. SO MR. BALWANI WAS NOT TRYING TO IGNORE THE PROBLEM.

OF COURSE EVEN WHILE THEY WERE DOING THIS VERY ACTIVE LAB DIRECTOR SEARCH AND DR. DHAWAN AND DR. SAWYER WERE FILLING IN AS TEMPORARY LAB DIRECTORS, ALL OF THE SCIENTIFIC TEAM, PH.D. LEVEL PEOPLE WERE STILL IN THE LAB. MR. BALWANI WAS NOT MAKING DECISIONS, AND THERE'S NO EVIDENCE OF THIS OF WHICH PATIENT RESULTS TO RELEASE AND WHICH PATIENT RESULTS NOT TO RELEASE.

SO WE THINK THAT IS A DISTINCTION THE COURT NOTED, BUT WE DON'T THINK THAT MAKES A DIFFERENCE IN THIS CASE GIVEN THE SUM TOTAL.

AGAIN, I WOULD JUST COME BACK TO WHAT I WOULD THINK WOULD BE VERY UNFAIR TO APPLY THIS RESULT TO MR. BALWANI, THIS ADJUSTMENT WHEN IT WASN'T APPLIED TO MS. HOLMES WHERE SHE HAD THE SAME KNOWLEDGE AS THE COURT POINTED OUT IN DOCKET 1635.

AGAIN, THE JURY VERDICT DOESN'T CONTROL HERE. IT'S THE PROVINCE OF THIS COURT TO MAKE THAT DECISION.

IF IT WAS SOMETHING IN THE VERDICT THAT WAS A SPECIAL VERDICT, WE WOULD JUST BE IN A DIFFERENT POSITION, BUT WE JUST DON'T HAVE THAT.

1

12:13PM

12:13PM 2

12:13PM 3

12:13PM 4

12:13PM 5

12:13PM 6

12:13PM 7

12:13PM 8

12:13PM 9

12:13PM 10

12:13PM 11

12:13PM 12

12:13PM 13

12:13PM 14

12:14PM 15

12:14PM 16

12:14PM 17

12:14PM 18

12:14PM 19

12:14PM 20

12:14PM 21

12:14PM 22

12:14PM 23

12:14PM 24

THE COURT: RIGHT. AND I THINK YOU WERE TALKING

ABOUT THE HISTORY OF WHEN PROBLEMS WOULD ARISE AND YOUR

CLIENT'S ATTENTION TO THEM, AND WE KNOW THAT AT THIS TIME THIS

WAS A CRITICAL STAGE, THERE WAS ROLLOUT HAPPENING. THIS WAS A

CRITICAL PART OF THE COMPANY'S EXISTENCE.

AND ANOTHER WAY OF LOOKING AT THE EVIDENCE, AND I DON'T KNOW WHAT THE JURY THOUGHT ABOUT, BUT ONE WAY OF LOOKING AT IT IS YOU LOSE YOUR LAB DIRECTOR, YOU'RE GOING TO LOSE CLIA, AND EVERYTHING IS GOING TO COLLAPSE. THE COMPANY WOULD CEASE TO EXIST.

SO, OF COURSE, THOSE RESPONSIBLE IN THE COMPANY, THE LEADERSHIP WOULD DO WHATEVER THEY COULD TO KEEP, TO KEEP THE COMPANY GOING. AND I THINK THIS IS WHAT YOUR POINT IS, HE REACHED OUT TO A LAB DIRECTOR THAT HE KNEW THAT HE COULD HIRE AS AN INTERIM PERHAPS TO KEEP THE COMPANY GOING.

AND WE ALL OBSERVED THE TESTIMONY OF THE DOCTOR AND WHEN
HE TESTIFIED ABOUT HIS WORK AND THE TIMES THAT HE SPENT ON SITE
AND THE NUMBER OF SIGNATURES THAT -- THE TRANCHES OF DOCUMENTS
THAT WERE PROVIDED TO HIM FOR HIS SIGNATURE AS LAB DIRECTOR
HAD TO SIGN OFF ON PROTOCOLS AND THINGS. HE TALKED ABOUT WHAT
HE DID, AND WE ALL RECALL THE DEMEANOR AND NATURE AND QUALITY
OF HIS TESTIMONY AS HE WAS EXAMINED ABOUT HIS WORK THERE. SO I
RECALL THAT.

I JUST SAY, THIS IS ANOTHER WAY OF LOOKING AT IT.

MR. LEACH MIGHT ARGUE THEY WERE DESPERATE AT THAT TIME TO 1 12:14PM 2 KEEP THE CONCERN GOING, AND THEY RECOGNIZED THAT PERHAPS THE 12:14PM EFFECTS OR THE INABILITY OF THE MACHINES WERE ABOUT TO BE 3 12:15PM 12:15PM 4 REVEALED AND THEY WANTED TO KEEP THAT GOING. MAYBE THAT'S WHAT THE GOVERNMENT'S POINT WAS. I DON'T KNOW. THEY DIDN'T ARGUE 12:15PM 12:15PM 6 THAT SPECIFICALLY. 12:15PM 7 BUT FOR PURPOSES OF THIS ALLOCATION OF THIS ENHANCEMENT, I THINK I TAKE YOUR POINT, I UNDERSTAND -- I DON'T THINK YOU 12:15PM 8 WOULD QUARREL WITH THE FACT THAT THE DIVISION OF LABOR WAS SUCH 12:15PM 9 12:15PM 10 THAT YOUR CLIENT HAD GREATER CONTROL, INTIMACY OR PROVINCE OVER 12:15PM 11 THE LAB. 12:15PM 12 MR. COOPERSMITH: I DO QUARREL WITH THE TERM "CONTROL," YOUR HONOR. AND JUST TO TAKE THE POINT THE COURT 12:15PM 13 12:15PM 14 JUST MADE --12:15PM 15 THE COURT: WELL, HE HIRED HIS DERMATOLOGIST FOR THE LAB DIRECTOR, MS. HOLMES DIDN'T. 12:15PM 16 12:15PM 17 MR. COOPERSMITH: WELL, MS. HOLMES WAS THE CEO OF 12:15PM 18 THE COMPANY. SHE KNEW FULL WELL WHO WAS BEING HIRED AS THE LAB 12:15PM 19 DIRECTOR. 12:15PM 20 THE COURT: HIS DERMATOLOGIST. MR. COOPERSMITH: ABSOLUTELY. SHE KNOWS ALL OF 12:15PM 21 12:15PM 22 THESE THINGS. AGAIN, THE ADJUSTMENT WASN'T APPLIED TO HER. 12:15PM 23 THE COURT'S POINT THAT WE DON'T AGREE WITH THIS, BUT 12:16PM 24 JUST TO PLAY IT OUT, THAT, WELL, AT THIS TIME THEY NEEDED A LAB 12:16PM 25 DIRECTOR AND SO TO KEEP THE COMPANY GOING THEY HAD TO GET THE

1 12:16PM 2 12:16PM 3 12:16PM 12:16PM 4 12:16PM 12:16PM 6 12:16PM 7 12:16PM 8 12:16PM 9 12:16PM 10 12:16PM 11 12:16PM 12 12:16PM 13 12:16PM 14 12:16PM 15 12:16PM 16 12:16PM 17 12:17PM 18 12:17PM 19 12:17PM 20 12:17PM 21 12:17PM 22 12:17PM 23 12:17PM 24 12:17PM 25

LAB DIRECTOR IN PLACE AND KEEP THE CLINICAL LAB GOING. IF
THAT'S WHAT HAPPENED, THAT'S EQUALLY ON MS. HOLMES AS THE CEO.
SO I DON'T UNDERSTAND WHY THAT WOULD BE MEANINGFUL HERE.

THE COURT: NO.

MR. COOPERSMITH: AND THE OTHER THING I'LL SAY IS THAT, OF COURSE, IN EARLY 2015 THE COMPANY OPENED AN ARIZONA LAB WITH DANIEL YOUNG AS THE LAB DIRECTOR WHO WAS QUALIFIED UNDER ARIZONA REQUIREMENTS, AND THAT LAB WAS DOING ALL FDA APPROVED COMMERCIAL TESTING.

AND IN THAT TIMEFRAME EVEN WHILE, AS THE COURT POINTED

OUT, DR. DHAWAN AND DR. SAWYER WERE IN PLACE OF LAB DIRECTORS

UP IN NEWARK, MORE AND MORE TESTING WAS BEING SHIFTED TO THE

COMMERCIAL MACHINES.

AND I UNDERSTAND THE GOVERNMENT HAS OTHER ISSUES WITH THAT ON THE INVESTMENT SIDE, BUT FOR THIS PURPOSE, THAT'S THE OPPOSITE OF TRYING TO CREATE A RISK TO PATIENTS WHEN THEY'RE ACTIVELY SPENDING MONEY AND TIME OPENING AN ARIZONA LAB AND IS GOING TO TEST PATIENTS, AND THERE REALLY IS NO EVIDENCE IN THE CASE OF COMMERCIAL TESTING IS SOMEHOW FLAWED AT LEAST AS FAR AS HOW MR. BALWANI SAW IT.

THE COURT: HOW SHOULD I INTERPRET THE CONDUCT OR

THE ACTION THAT -- I THINK IT IS DR. DAS WHEN HE WAS ON BOARD

AND HE SAID, YOU KNOW, THE ONLY THING THAT WE CAN DO IS TO

INVALIDATE ALL OF THOSE TESTS? WHAT MR. LEACH SUGGESTS IS THAT

THAT IS PER SE EVIDENCE.

1 12:17PM 2 12:17PM 3 12:17PM 12:17PM 4 12:17PM 12:17PM 6 12:17PM 7 12:17PM 8 12:17PM 9 12:18PM 10 12:18PM 11 12:18PM 12 12:18PM 13 12:18PM 14 12:18PM 15 12:18PM 16 12:18PM 17 12:18PM 18 12:18PM 19 12:18PM 20 12:18PM 21 12:18PM 22 12:18PM 23 12:18PM 24

12:18PM 25

MR. COOPERSMITH: WELL, FIRST OF ALL, OF COURSE THE ACTUAL LANGUAGE THAT DR. DAS USED WE POINT OUT AS AN ABUNDANCE OF CAUTION.

BUT EVEN IF YOU TAKE THIS AS GOSPEL THAT DR. DAS REALLY
BELIEVED THAT THIS HAD TO BE DONE AND THAT'S HIS DECISION, IT'S
AFTER THE FACT, YOUR HONOR. AND SO MR. BALWANI, AS I SAID, IS
INVOLVED WITH MS. HOLMES TO HIRE DR. DAS, A LAB DIRECTOR FROM
UCLA, A HIGHLY QUALIFIED GUY, COMES IN AND HE LOOKS AT THE
WHOLE ISSUE, AND THEY ALLOW HIM TO DO THAT. NO ONE WAS TELLING
HIM DON'T LOOK AT THIS OR DON'T LOOK UNDER THIS ROCK.

HE LOOKS AT THE LAB AND THE DOCUMENTATION, AND HE COMES UP WITH WHATEVER VIEW HE COMES UP WITH. BUT THE FACT THAT HE DID THAT LATER WHEN THERE WAS NO MORE FINGERSTICK TESTING GOING ON.

AS OF SEPTEMBER 2015 WHEN CMS CAME IN, THE EDISON HAD BEEN STOPPED FOR MONTHS AND EVEN THE MODIFIED PREDICATE MACHINES WHICH ALSO DID FINGERSTICK WERE STOPPED AT THAT POINT.

SO BY THE TIME THAT DR. DAS CAME IN, IT WAS ALL NOT BEING CONDUCTED ANYMORE. IT WAS ALL COMMERCIAL TESTING.

AND SO IT'S LIKE THE SAME AS IF YOU BRING IN AN EXPERT FOR ANY BUSINESS OR LABORATORY AFTER THE FACT AND HE MAKES SOME CONCLUSIONS ABOUT PROBLEMS, IT DOESN'T GO TO WHAT MR. BALWANI KNEW AT THE TIME THAT THE LAB WAS OPERATING WITH FINGERSTICK, AND IT JUST DOESN'T AFFECT THAT.

SO IT'S AFTER-THE-FACT INFORMATION.

WHAT WE HAVE TO DETERMINE FOR PURPOSES OF THIS GUIDELINE

12:19PM	1	ADJUSTMENT IS WHETHER AT THE TIME THESE RESULTS WERE GOING OUT
12:19PM	2	MR. BALWANI WAS CREATING CONSCIOUSLY OR RECKLESSLY A RISK OF
12:19PM	3	THIS PATIENT HARM, AND THE EVIDENCE HERE IS THAT HE WAS NOT
12:19PM	4	DOING THAT.
12:19PM	5	EVEN IF THE COURT THOUGHT, WELL, MAYBE IN SOME CASES
12:19PM	6	THAT'S WHAT HAPPENED, THAT WOULD NOT SHOW THAT MR. BALWANI WAS
12:19PM	7	DOING THAT CONSCIOUSLY OR RECKLESSLY. HE WAS TRYING TO DO WHAT
12:19PM	8	HE COULD, EVEN IF THE COURT THINKS IT'S INADEQUATE, DO WHAT HE
12:19PM	9	COULD TO FIX THE PROBLEMS AND MAKE SURE THAT THE SCIENTIFIC
12:19PM	10	TEAM WAS ON TOP OF THESE ISSUES SO THAT PATIENT RESULTS WERE AS
12:19PM	11	GOOD AS THEY COULD GET.
12:19PM	12	THE COURT: THAT'S YOUR INTERPRETATION?
12:19PM	13	MR. COOPERSMITH: YES, YOUR HONOR, I THINK THAT'S
12:19PM	14	FAIR FROM THE CASE IN THE CASE.
12:19PM	15	THE COURT: OKAY. THANK YOU.
12:19PM	16	LET'S TAKE ABOUT 20 MINUTES, AND THEN WE'LL COME BACK AND
12:19PM	17	WE WILL INCLUDE THE CALCULATIONS. THANK YOU.
12:19PM	18	MR. LEACH: THANK YOU, YOUR HONOR.
12:19PM	19	(RECESS FROM 12:19 P.M. UNTIL 12:50 P.M.)
12:50PM	20	THE COURT: WE'RE BACK ON THE RECORD IN THE BALWANI
12:50PM	21	MATTER. ALL PARTIES PREVIOUSLY PRESENT ARE PRESENT ONCE AGAIN.
12:50PM	22	I'D LIKE TO CONTINUE OUR CONVERSATION. WE MENTIONED THE
12:50PM	23	SUBMISSION BY THE DEFENSE YESTERDAY OF A DOCUMENT, AND I DON'T
12:50PM	24	THINK IT'S BEEN FORMALLY I THINK IT WAS SUBMITTED WITH YOUR
12:50PM	25	REQUEST, I THINK, TO BE

12:50PM	1	MR. COOPERSMITH: IT WAS AN ADMINISTRATIVE MOTION
12:50PM	2	FOR LEAVE TO FILE IT.
12:50PM	3	THE COURT: THAT'S RIGHT. IT HASN'T BEEN ACTED ON.
12:50PM	4	I'VE TALKED ABOUT IT. IT'S DOCUMENT 1677.
12:50PM	5	THANK YOU, MS. ROBINSON.
12:50PM	6	I'LL ADMIT THAT NOW JUST FOR THE RECORD.
12:51PM	7	ALL RIGHT. THANK YOU.
12:51PM	8	ANY OTHER COMMENT FROM COUNSEL ABOUT ANY OF THE LOSS
12:51PM	9	CALCULATIONS THAT WE HAVE TALKED ABOUT BEFORE THE BREAK,
12:51PM	10	MR. LEACH?
12:51PM	11	MR. LEACH: NO, YOUR HONOR. THANK YOU.
12:51PM	12	MR. COOPERSMITH: NO, YOUR HONOR. THANK YOU.
12:51PM	13	THE COURT: ALL RIGHT. THANK YOU VERY MUCH.
12:51PM	14	ALL RIGHT. THANK YOU.
12:51PM	15	WHAT I WOULD LIKE TO DO IS TO GIVE YOU THE COURT'S
12:51PM	16	DECISIONS ON THESE MATTERS SUCH THAT WE CAN PROCEED WITH THE
12:51PM	17	GUIDELINE CALCULATIONS AND GOING FORWARD.
12:51PM	18	FIRST OF ALL, AS TO THE LOSS CALCULATION MATTER AND THE
12:52PM	19	FIRST ISSUE IS WHAT IS THE STANDARD THAT THE COURT SHOULD APPLY
12:52PM	20	THAT IS PREPONDERANCE OR CLEAR AND CONVINCING?
12:52PM	21	THE COURT IS GOING TO FIND THAT IN THIS MATTER THE
12:52PM	22	PREPONDERANCE OF THE EVIDENCE LEVEL IS APPROPRIATE IN THIS
12:52PM	23	CASE, AND THE COURT WILL APPLY THAT STANDARD CITING <u>LAURIENTI</u> ,
12:52PM	24	611 FED. 3D, AND THE <u>BERGER</u> CASE AT 587 FED 3D.
12:52PM	25	I KNOW WE'VE TALKED ABOUT THE <u>LONICH</u> CASE. I DO THINK

1 12:52PM 2 12:52PM 3 12:52PM 12:52PM 4 12:52PM 12:52PM 6 12:52PM 7 12:53PM 8 12:53PM 9 12:53PM 10 12:53PM 11 12:53PM 12 12:53PM 13 12:53PM 14 12:53PM 15 12:53PM 16 12:53PM 17 12:54PM 18 12:54PM 19 12:54PM 20 12:54PM 21 12:54PM 22 12:54PM 23

12:54PM 24

12:54PM 25

LONICH IS DISTINGUISHABLE FROM OUR CASE HERE. OF COURSE,

LONICH INVOLVED -- AND I THINK, MS. WALSH, YOU'VE MENTIONED

THIS -- THERE'S AN ISSUE ABOUT THE TOTAL BANK FAILURE VIS-À-VIS

THE FRAUD ON THE INVESTORS AND THE STRUGGLE THAT THE COURT HAD

AND THE PARTIES HAD WITH TRYING TO MATCH THOSE TWO LOSSES.

THIS IS A VERY DIFFERENT FACT PATTERN, ALBEIT COMPLICATED

NONETHELESS, BUT IT'S DIFFERENT FROM LONICH. SO I DO FIND THAT

THE PREPONDERANCE OF THE EVIDENCE IS THE APPROPRIATE STANDARD

TO USE, AND THE COURT WILL USE THAT.

THERE WAS ANOTHER OBJECTION I WANTED TO MENTION THAT

MR. BALWANI SUGGESTED THAT -- REGARDING -- I THINK MS. WALSH

TALKED ABOUT INTERVENING CAUSES AND DISRUPTION OF A CAUSAL

CHAIN. I DO WANT TO INDICATE THAT THE COURT IS GOING TO -- ANY

ACTIONS THAT THERANOS TOOK AFTER MAY 2016 ARE NOT ATTRIBUTABLE,

AND THE COURT WON'T CONSIDER THOSE AS ATTRIBUTABLE AS TO

MR. BALWANI.

IN THE COURT'S LOSS CALCULATION, THE OFFSET OF TOTAL

INVESTOR LOSS AMOUNT IS THE VALUE OF THERANOS AT A POINT IN

TIME PRIOR TO THE DEFENDANT'S DEPARTURE. SO THAT SPECIFIC

OBJECTION IS REALLY NOT NECESSARY, AGAIN, UNDER FEDERAL RULE OF

CRIMINAL PROCEDURE 32(I)(3)(B) BECAUSE THE COURT IS NOT GOING

TO USE ANY POST 2016 CONDUCT AS ITS DETERMINATION OF THE

DEFENDANT'S SENTENCING.

TURNING TO THE SABA REPORT, AND I'LL JUST CALL IT THAT.

WE'VE HAD SOME ROBUST CONVERSATION ABOUT THAT.

1 12:54PM 2 12:54PM 3 12:54PM 12:54PM 4 12:54PM 12:55PM 6 12:55PM 7 12:55PM 8 12:55PM 9 12:55PM 10 12:55PM 11 12:55PM 12 12:55PM 13 12:55PM 14 12:55PM 15 12:55PM 16 12:55PM 17 12:55PM 18 12:56PM 19 12:56PM 20 12:56PM 21 12:56PM 22 12:56PM 23 12:56PM 24

12:56PM 25

WE KNOW, AS MR. LEACH POINTS OUT, AND I DON'T THINK THE DEFENSE PARTS COMPANY WITH, THAT THE COURT'S OBLIGATION IN THE LOSS CALCULATION IN THE SEARCH FOR A LOSS CALCULATION IS A REASONABLE, REALISTIC, AND ECONOMIC PROJECTION OF LOSS BASED ON THE EVIDENCE AND WEST COAST ALUMINUM TEACHES THAT AT 265 FED. 3D.

WE HAD SOME DISCUSSION ABOUT MR. SABA'S REPORT AND THE ANALYSIS THAT HE TOOK. THE SABA REPORT'S ESTIMATION OF VALUATION PROVIDES THREE DIFFERENT DATES REGARDING THE ANALYSIS AND FOR THE PURPOSES OF ITS LOSS CALCULATION THE COURT SELECTS THE DATE CLOSEST IN TIME AGAIN TO THE C INVESTMENTS, WHICH IS DECEMBER 31, 2014.

LET ME INDICATE, AS I DID IN THE COMPANION CASE, I AM
GOING TO TELL YOU THE COURT'S DECISIONS NOW FOR PURPOSES OF
INFORMATION FOR TODAY'S SENTENCING. I WILL ISSUE SHORTLY A
FORMAL ORDER THAT MEMORIALIZES THE COURT'S FINDINGS AND THE
REASONS AND BASIS FOR IT FOR YOUR BENEFIT AND FOR THE RECORD.
SO YOU'LL HAVE A MORE FULSOME ORDER THAT CAPTURES THE COURT'S
DECISION HERE AFTER TODAY.

AND THE COURT WILL ALSO SELECT THE INCOME METHOD. IT

FINDS THAT IT IS THE MOST APPROPRIATE FOR ONGOING COMPANIES AND

IT DOES PROVIDE -- ACTUALLY IN THE COURT'S ANALYSIS HERE, IT

DOES PROVIDE A HIGHER COMPANY VALUATION AGAIN AND AGAIN, NOTING

THAT THAT IS ACTUALLY MORE FAVORABLE TO THE DEFENSE.

THERE WAS AN ARGUMENT ABOUT THE SABA REPORT'S LOSS RANGE

1 12:56PM 2 12:56PM 3 12:56PM 4 12:56PM 12:56PM 12:56PM 6 12:57PM 7 8 12:57PM 12:57PM 9 12:57PM 10 12:57PM 11 12:57PM 12 12:57PM 13 12:57PM 14 12:57PM 15 12:57PM 16 12:57PM 17 12:57PM 18 12:57PM 19 12:58PM 20 12:58PM 21 12:58PM 22 12:58PM 23 12:58PM 24 12:58PM 25

BEING TOO BROAD. I THINK MS. WALSH POINTS US TO THAT AND SUGGESTS THAT THE LOSS CALCULATIONS WERE INCORRECT PROVIDING INFORMATION FROM WEINGUST, DR. WEINGUST, MR. WEINGUST AND OTHERS, MR. REIFF AS WELL.

AND I -- MR. SABA USED -- I THINK THE ALLEGATION WAS THAT SABA'S 45 PERCENT RATE WAS EXCESSIVE AND SHOULD HAVE USED PEPPERDINE STUDIES, AND I TALKED ABOUT WHAT THE COURT WAS DOING YESTERDAY AFTERNOON AFTER IT RECEIVED THE FILING AND THE EXPERT REPORTS AND THOSE THINGS.

AND WHILE I DON'T WANT TO SAY I'M TROUBLED BY THE BATTLE
OF QUANTUM EXPERTS, I APPRECIATE THAT THERE'S ROBUST ARGUMENT
FOR THIS. IT'S A VERY CRITICAL POINT FOR BOTH SIDES. I
APPRECIATE THAT, THAT ARGUMENT.

BUT AS I POINTED OUT, THE -- THIS IS A CRIMINAL CASE, NOT
A CIVIL CASE. MS. WALSH TELLS US THAT, TOO. IT HAS GREATER -OBVIOUSLY THERE'S LIBERTY INTERESTS HERE THAT OUTWEIGH ANY
CIVIL INTEREST, BUT, AGAIN, THE COURT'S TASK HERE, AIDED BY
YOUR REPORTS, YOUR COMMENTS AND YOUR ASSISTANCE, IS TO FIND A
REASONABLE -- IS TO USE REASONABLENESS TO FIND A REASONABLE
AMOUNT HERE.

WE'RE NOT IN A BUSINESS CONTEXT, AS MANY OF YOU ARE

FAMILIAR WITH, OR AS I POINTED OUT, SOME OF THE EXPERT'S WORK

IN THE PAST HAS BEEN TO PROVIDE SOME EQUITY AND DIVISION OF

COMMUNITY PROPERTY IN A DISSOLUTION PROCEEDING. THAT'S NOT THE

FUNCTION HERE. THAT PRECISENESS, AND I THINK YOU BOTH

1 12:58PM 2 12:58PM 3 12:58PM 12:58PM 4 12:58PM 12:58PM 6 12:58PM 7 8 12:59PM 12:59PM 9 12:59PM 10 12:59PM 11 12:59PM 12 12:59PM 13 12:59PM 14 12:59PM 15 12:59PM 16 12:59PM 17 12:59PM 18 12:59PM 19 12:59PM 20 01:00PM 21 01:00PM 22 01:00PM 23 01:00PM 24 01:00PM 25

RECOGNIZE, BOTH SIDES RECOGNIZE, IT'S NOT ALWAYS ASCERTAINABLE,

AND THAT'S WHY THE CASES TELL US THAT THE SEARCH IS REALLY

BASED ON REASONABLENESS, RECOGNIZING THE COMPLEXITY OF THESE

CASES THAT COME BEFORE COURTS.

THE COURT DOES FIND THAT MR. SABA DID CONSIDER A BROADER RANGE OF STUDIES AND DATA IN SELECTING THE 45 PERCENT NUMBER THAT HE DID REACH. HE LOOKED AT THE DATA FROM THE PEPPERDINE STUDIES, HE LOOKED AT ARANCA WITH ALL OF ITS CRITICISMS, HE USED THE INFORMATION THAT WAS, AS I MENTIONED TO MS. WALSH, ON THE TABLE, AND THE COURT FINDS THAT HIS REPORT, NOTWITHSTANDING THE CRITICISM OF THE OTHER EXPERTS, THAT ARE HELPFUL IN PROVIDING CONTEXT AND SUBJECTING THE SABA REPORT TO MORE CRITICAL REVIEW, THOSE REPORTS AND THOSE CRITICISMS DID NOT DISTURB THE COURT'S FINDING THAT THE SABA REPORT IS REASONABLE AND FOUNDED ON RELIABLE DATA AND ANALYSIS.

THE COURT FINDS THAT, AGAIN, THAT THE SABA PROTOCOL IS RELIABLE AND REASONABLY ESTIMATING THE RESULT FROM THIS FRAUD CONSPIRACY.

THERE WAS ANOTHER OBJECTION BY -- AND THE COURT WILL ACCEPT THE SABA REPORT AND USE THE SABA REPORT IN ITS ANALYSIS FOR ITS FINDINGS.

THERE WAS ANOTHER OBJECTION BY THE DEFENDANT ABOUT LOSS

SUSTAINED BY PATIENT VICTIMS. LET ME INDICATE THAT THE COURT

IS GOING TO FIND AGAIN UNDER 32(I)(3)(B) THAT THIS IS

UNNECESSARY. THE COURT IS NOT GOING TO CONSIDER PATIENT LOSSES

01:00PM	1	IN REGARDS TO THE TOTAL LOSS AMOUNTS FOR 2B1.1(B)(1).
01:00PM	2	MOVING TO THE VICTIM COUNT ENHANCEMENT. THIS IS
01:00PM	3	2B1.1(B)(2)(A)(I). THIS IS THE 2 POINT ENHANCEMENT FOR 10 OR
01:00PM	4	MORE VICTIMS. THE COURT FINDS THAT, AGAIN, UNDER A
01:01PM	5	PREPONDERANCE OF EVIDENCE STANDARD THAT THE EVIDENCE DOES
01:01PM	6	SUPPORT A FINDING OF AT LEAST 12 VICTIMS, INVESTOR VICTIMS WHO
01:01PM	7	MEET THE DEFINITION OF VICTIMS AND UNDER THE GUIDELINES. AND
01:01PM	8	THE COURT WILL IDENTIFY THOSE 12:
01:01PM	9	THE FIRST ONE IS PFM;
01:01PM	10	TWO IS MOSLEY FAMILY HOLDINGS;
01:01PM	11	THREE IS RDV CORPORATION;
01:01PM	12	FOURTH IS KEITH RUPERT MURDOCH;
01:01PM	13	FIVE IS RICHARD KOVACEVICH;
01:01PM	14	SIX IS PEER VENTURE GROUP;
01:01PM	15	SEVEN IS LUCAS VENTURE GROUP;
01:01PM	16	EIGHT IS MENDENHALL;
01:01PM	17	NINE IS HALL BLACK DIAMOND;
01:02PM	18	TEN IS BLACK DIAMOND VENTURE;
01:02PM	19	ELEVEN IS ALAN EISENMAN; AND,
01:02PM	20	TWELVE IS SHERRIE EISENMAN.
01:02PM	21	INVESTMENTS MADE BY EACH OF THESE VICTIMS ARE INCLUDED IN
01:02PM	22	THE LOSS CALCULATION, AND ACCORDINGLY THE COURT FINDS THAT A 2
01:02PM	23	LEVEL ENHANCEMENT IS APPROPRIATE UNDER 2B1.1(B)(2)(A)(I).
01:02PM	24	OBJECTION TWENTY-FOUR RELATES TO THE AGGRAVATING ROLE, AND
01:02PM	25	I'VE TALKED WITH COUNSEL ABOUT THIS. AND I THINK THE NINTH

1 01:02PM 2 01:02PM 3 01:02PM 01:02PM 4 01:02PM 01:03PM 01:03PM 7 01:03PM 8 01:03PM 9 01:03PM 10 01:03PM 11 01:03PM 12 01:03PM 13 01:03PM 14 01:03PM 15 01:03PM 16 01:03PM 17 01:03PM 18 01:04PM 19 01:04PM 20 01:04PM 21 01:04PM 22 01:04PM 23 01:04PM 24

01:04PM 25

CIRCUIT HOLDEN CASE, 908 FED. 3D CONTROLS HERE, AND THE COURT RECOGNIZING THAT IN OUR DISCUSSION THIS MORNING ABOUT CO-LEADERS AS A POSSIBILITY, THE COURT IS GOING TO NOT FIND THAT THIS ENHANCEMENT SHOULD BE GIVEN. SO IF THAT MEANS THAT I SUSTAIN THE DEFENSE OBJECTION, THAT'S WHAT I'VE DONE, AND I WON'T FIND THAT ENHANCEMENT APPLIES HERE.

UNDER 2B1.1(B)(16)(A), THIS IS THE SERIOUS BODILY INJURY ENHANCEMENT. WE HAD SOME ROBUST -- THIS IS VERY CLOSE, I THINK, VERY CLOSE INDEED. WE HAD CONVERSATION ABOUT MR. BALWANI'S WHAT I CALL INTIMACY WITH THE LAB, AND THE EVIDENCE SHOWED TO THE COURT THAT HE HAD CONTROL AND RESPONSIBILITY OVER THE LAB, AND THERE WERE ISSUES WITH THE TESTING ACCURACY AND RELIABILITY OF THE PROPRIETARY DEVICE AND THE TESTIMONY AT TRIAL SUGGESTED THAT. IT SUGGESTED THAT

IT APPEARED THAT HE WAS THE LEAD CONTACT PERSON, AT LEAST
IN THE ADMINISTRATIVE CHAIN OUTSIDE OF THE LABS AND LAB
DIRECTORS, AND HE HAD CONTROL OVER THAT. EMAILS WERE SENT TO
HIM REGARDING CONDUCT OF THE LAB, THE LAB'S ABILITY, THE
MACHINES, ISSUES WITH THE MACHINES. WE ALSO KNOW THE EVIDENCE
SHOWS THAT THERE WAS AT LEAST SOME INTEREST BY MR. BALWANI AND
PERHAPS HIS CODEFENDANT IN TRYING TO FIND OUT WHO WAS
RESPONSIBLE FOR LEAKING INFORMATION FROM THE LAB AND THAT ALSO
FELL UNDER HIS PURVIEW AND HE HAD GREAT CONCERNS ABOUT THAT,
WHICH DO SUGGEST THAT HE HAD GREATER OVERSIGHT AND CONTROL OVER

1 01:04PM 2 01:04PM 3 01:04PM 4 01:04PM 01:05PM 01:05PM 6 01:05PM 7 01:05PM 8 01:05PM 9 01:05PM 10 01:05PM 11 01:05PM 12 01:05PM 13 01:05PM 14 01:05PM 15 01:05PM 16 01:05PM 17 01:05PM 18 01:06PM 19 01:06PM 20 01:06PM 21 01:06PM 22 01:06PM 23 01:06PM 24

01:06PM 25

THE LAB SITUATION. AND MR. LEACH'S ARGUMENT SUGGESTS THAT THE FACT THAT THERE WAS DR. DAS INVALIDATED AND CANCELLED ALL OF THOSE TEST RESULTS IS PER SE EVIDENCE THAT THE COURT SHOULD USE IN IMPOSING AND OTHERWISE ALLOWING THIS ENHANCEMENT AS AGAINST MR. BALWANI.

AND, AGAIN, THIS IS A VERY CLOSE CALL. THE COURT HAS

CONSIDERED VERY CAREFULLY THOSE ARGUMENTS AS WELL AS ITS

OBSERVANCE OF THE EVIDENCE AT TRIAL, THE WAY THE EVIDENCE CAME

IN AT TRIAL, AND THE COURT IS, HOWEVER, NOT GOING TO IMPOSE

THIS. THE COURT IS GOING TO FIND THAT THERE'S INSUFFICIENT

EVIDENCE THAT REALLY DOES SHOW FACTUALLY THAT THERE WAS A

DISREGARDING OF THE RISK OR ACTUALLY A KNOWLEDGE OF THE RISK TO

PATIENTS OR AN ABILITY OR ACKNOWLEDGEMENT OF PROCEEDING WITH

THE TESTS NOTWITHSTANDING THAT.

IT'S VERY CLOSE, THOUGH, AND I THINK THE EVIDENCE COULD VERY WELL -- AN ARGUMENT COULD BE MADE THAT MIGHT SUPPORT IT.

I'M NOT GOING TO FIND IT IN THIS CASE, AND I WILL DECLINE TO APPLY THE 2 LEVEL ENHANCEMENT UNDER 2B1.1(B) (16) (A).

LET ME GO THROUGH THEN THE GUIDELINE CALCULATIONS FOR COUNSEL AND PROBATION. THESE ARE FOUND ON PAGE 22 OF MS. GOLDSBERRY'S REPORT.

THERE'S A GROUPING OF THE COUNTS FROM ONE TO TWELVE, AND PURSUANT TO 2B1.1(A)(1), AND THE COURT IS GOING TO FIND THAT THE BASE OFFENSE LEVEL IS 7.

THE COURT IS GOING TO FIND THAT AFTER LOOKING AT THE SABA

01:07PM	1	REPORT AND THAT ANALYSIS, THE COURT IS GOING TO FIND THE TOTAL
01:07PM	2	LOSS TO INVESTOR VICTIMS IS \$120 MILLION AND UNDER 2B1.1(M),
01:07PM	3	THIS IS A 24 LEVEL INCREASE.
01:07PM	4	THE COURT WILL FIND UNDER 2B1.(B)(2)(A)(I) THE NUMBER OF
01:07PM	5	VICTIMS IS A 2 LEVEL INCREASE.
01:07PM	6	AS I'VE SAID, THE COURT IS NOT GOING TO FIND IN
01:07PM	7	PARAGRAPH 76 THE ROLE ADJUSTMENT FOR LEADERSHIP. THE ADJUSTED
01:07PM	8	OFFENSE LEVEL THEREFORE IS 33.
01:08PM	9	THE CRIMINAL HISTORY CATEGORY IS I.
01:08PM	10	AND THAT THEN YIELDS A GUIDELINE RANGE OF 135 TO
01:08PM	11	168 MONTHS.
01:08PM	12	MS. GOLDSBERRY?
01:08PM	13	PROBATION OFFICER: YES, YOUR HONOR.
01:08PM	14	THE COURT: AND THAT'S THE COURTS'S FINDING FOR
01:08PM	15	GUIDELINE CALCULATION.
01:08PM	16	AGAIN, THE COURT IS GOING TO PROVIDE COUNSEL WITH AN ORDER
01:08PM	17	THAT PROVIDES THE COURT'S MORE FULSOME DETAILS OF THE COURT'S
01:08PM	18	FINDINGS FOR THE RECORD, BUT I WANTED TO STATE AN OVERVIEW THE
01:08PM	19	REASON FOR THE COURT'S GUIDELINE CALCULATIONS.
01:08PM	20	ANY QUESTIONS? MR. LEACH?
01:08PM	21	MR. LEACH: NO, YOUR HONOR.
01:08PM	22	MR. COOPERSMITH: WE UNDERSTAND THE COURT'S RULING.
01:08PM	23	THE COURT: ALL RIGHT. THANK YOU.
01:08PM	24	ANYTHING FURTHER BEFORE I ASK IF THE PARTIES WISH TO BE
01:08PM	25	HEARD AS TO SENTENCING?

01:08PM	1	MR. LEACH: NO, YOUR HONOR.
01:08PM	2	THE COURT: ALL RIGHT.
01:08PM	3	MR. COOPERSMITH: NO, YOUR HONOR.
01:08PM	4	THE COURT: ALL RIGHT. THANK YOU.
01:09PM	5	DOES THE GOVERNMENT WISH TO BE HEARD?
01:09PM	6	MR. SCHENK: GOOD MORNING, YES. THANK YOU,
01:09PM	7	YOUR HONOR.
01:09PM	8	IF I COULD START WITH WHAT THE COURT HAD CALLED
01:09PM	9	SUBSTANTIVE PSR OBJECTIONS, AND I JUST WANTED TO FOR THE RECORD
01:09PM	10	CONFIRM THAT I THINK THERE WERE TWO THAT I THINK THE COURT HAS
01:09PM	11	NOT RULED ON YET, TWENTY-TWO AND TWENTY-THREE.
01:09PM	12	BASED ON WHAT THE COURT JUST SAID, THOUGH, IT SOUNDS LIKE
01:09PM	13	IT IS DENYING THE OBJECTIONS OR OVERRULING THE OBJECTIONS.
01:09PM	14	THEY BOTH HAD SOMETHING TO DO WITH THE ENHANCEMENTS FOR THE
01:09PM	15	NUMBER OF VICTIMS OR LOSS RELATED TO VICTIMS.
01:09PM	16	THE COURT: THAT'S RIGHT. I HOPE I MADE THAT CLEAR
01:09PM	17	WHEN I SAID I WOULD GET TO THOSE EARLIER IN OUR GUIDELINE
01:09PM	18	CALCULATIONS, BUT THAT'S THE SPIRIT OF THE COURT'S FINDINGS,
01:09PM	19	YES. THANK YOU.
01:09PM	20	MR. SCHENK: THANK YOU.
01:09PM	21	YOUR HONOR, I INTEND TO ADDRESS THE 3553(A) FACTORS AND
01:09PM	22	WHY THE COURT SHOULD IMPOSE A SENTENCE OF 180 MONTHS IN CUSTODY
01:10PM	23	IN THIS CASE. THE COURT JUST NOTED ITS GUIDELINE RANGE AND THE
01:10PM	24	RANGE HERE AS THE COURT STATED IS 135 TO 168.
01:10PM	25	THE GOVERNMENT'S RECOMMENDATION IS ABOVE THE GUIDELINES

1 01:10PM 2 01:10PM 3 01:10PM 01:10PM 4 01:10PM 01:10PM 6 01:10PM 7 01:10PM 8 01:10PM 9 01:10PM 10 01:10PM 11 01:10PM 12 01:11PM 13 01:11PM 14 01:11PM 15 01:11PM 16 01:11PM 17 01:11PM 18 01:11PM 19 01:11PM 20 01:11PM 21 01:11PM 22 01:11PM 23 01:11PM 24 01:11PM 25

THAT THE COURT JUST DETERMINED, AND WE STAND BY THAT

RECOMMENDATION AND BELIEVE THAT AN APPROPRIATE SENTENCE IN THIS

CASE COMES FROM THE STATUTE, COMES FROM 3553(A), AND WHEN WE

ANALYZE THE FACTORS, WE SEE THAT A SENTENCE OF 15 YEARS IS

APPROPRIATE.

THE COURT SHOULD KEEP IN MIND TWO SORT OF OVERARCHING
THEMES THAT ARE RELEVANT WHEN SENTENCING MR. BALWANI. THE
FIRST IS THE SIGNIFICANT ROLE HE PLAYED IN DEFRAUDING
INVESTORS, AND I'LL GO THROUGH THAT A LITTLE BIT MORE, BUT IT
IS NOT ACCURATE TO SAY THAT MS. HOLMES DEFRAUDED INVESTORS AND
SUNNY BALWANI RAN THE LAB. THAT IS AN OVERSIMPLIFICATION AND
MORE SO JUST ISN'T TRUE.

MR. BALWANI PLAYED A SIGNIFICANT ROLE IN THE INVESTOR

FRAUD. MR. BALWANI CREATED THE FINANCIAL STATEMENTS THAT THE

COURT WILL RECALL WERE OFF BY ONE BILLION DOLLARS. THOSE

FINANCIAL STATEMENTS WERE PROVIDED TO INVESTORS, AND

MR. BALWANI KNEW THAT THOSE FINANCIAL STATEMENTS WERE PROVIDED

TO INVESTORS.

SO NOT ONLY DID HE DO WORK ON THE FINANCIAL SIDE, HE ALSO PLAYED A ROLE IN THE WALGREENS ROLLOUT. THE RELATIONSHIP WITH WALGREENS WAS RELEVANT TO THE PATIENT FRAUD BECAUSE THAT WAS THE LOCATION THAT THE PATIENTS WENT TO, TO RECEIVE THE BLOOD TESTS, BUT IT ALSO WAS RELEVANT ON THE INVESTOR SIDE.

INVESTORS WERE TOLD THAT THERANOS HAD THIS HEALTHY AND EXPANDING RELATIONSHIP WITH WALGREENS AND BECAUSE OF THAT HAD

1 01:11PM 2 01:11PM 3 01:11PM 01:12PM 4 01:12PM 01:12PM 6 01:12PM 7 01:12PM 8 01:12PM 9 01:12PM 10 01:12PM 11 01:12PM 12 01:12PM 13 01:12PM 14 01:12PM 15 01:12PM 16 01:12PM 17 01:12PM 18 01:12PM 19 01:13PM 20 01:13PM 21 01:13PM 22 01:13PM 23 01:13PM 24 01:13PM 25

MORE CONFIDENCE IN THE TECHNOLOGY, IN THE STABILITY OF THE COMPANY, AND THOSE FACTS WERE COMMUNICATED TO INVESTORS.

MR. BALWANI PLAYED A ROLE IN THAT AND IN THE WALGREENS
RELATIONSHIP AND IN THE COMMUNICATION OF WALGREENS INFORMATION
TO INVESTORS.

FINALLY, THERE ARE CERTAIN INVESTORS THAT MR. BALWANI
PLAYED A SIGNIFICANT ROLE IN COMMUNICATING DIRECTLY WITH,
INDIVIDUALS LIKE BRIAN GROSSMAN AT PFM; INDIVIDUALS LIKE
ALAN EISENMAN WE'LL GET TO A LITTLE BIT LATER. MR. BALWANI
ALSO COMMUNICATED DIRECTLY WITH INVESTORS. SO HE PLAYED A
SIGNIFICANT ROLE IN THE INVESTOR SIDE.

ON THE PATIENT SIDE, AS THE COURT NOTED EARLIER THIS

MORNING, MR. BALWANI WAS INTIMATELY FAMILIAR WITH THE EVENTS IN

THE LAB. MR. BALWANI HIRED AND FIRED INDIVIDUALS IN THE LAB.

AND WHILE HE HAS ARGUED TO THE COURT THAT HE WAS UNDER

MS. HOLMES, MR. BALWANI HAD SIGNIFICANT AUTONOMY IN RUNNING THE

LAB. HE MADE DECISIONS THAT DIRECTLY IMPACTED THE INFORMATION

THAT WAS COMMUNICATED TO PATIENTS, AND IT IS IN THE LAB THAT

SOME OF THE GREATEST HARM OCCURRED, AND MR. BALWANI PLAYED A

SIGNIFICANT ROLE IN OVERSEEING THE CLINICAL LAB.

SO IT IS BOTH HIS ROLE IN THE PATIENT FRAUD AND HIS ROLE
IN THE INVESTOR FRAUD THAT SHOULD LEAVE THIS COURT TO DECIDE A
SIGNIFICANT CUSTODIAL SENTENCE SHOULD BE IMPOSED, AND THE
GOVERNMENT BELIEVES THAT THAT SENTENCE SHOULD BE 15 YEARS.

IN ORDER TO IMPOSE THAT SIGNIFICANT SENTENCE, THIS COURT

1 01:13PM 2 01:13PM 3 01:13PM 01:13PM 4 01:13PM 01:13PM 6 01:13PM 7 01:13PM 8 01:13PM 9 01:13PM 10 01:13PM 11 01:14PM 12 01:14PM 13 01:14PM 14 01:14PM 15 01:14PM 16 01:14PM 17 01:14PM 18 01:14PM 19 01:14PM 20 01:14PM 21 01:14PM 22 01:14PM 23 01:14PM 24 01:14PM 25

DOES NOT HAVE TO FIND THAT MR. BALWANI FOUNDED THERANOS. THE DEFENSE ARGUES THAT HE DID NOT PLAY THAT ROLE, AND, THEREFORE, HE SHOULD RECEIVE A SIGNIFICANT VARIANCE OR A PROBATIONARY SENTENCE.

IN ORDER TO SENTENCE MR. BALWANI TO A SIGNIFICANT
CUSTODIAL SENTENCE, THE COURT NEED NOT CONCLUDE THAT THAT IS
RESERVED FOR FACTORS. MR. BALWANI PLAYED A SIGNIFICANT ROLE IN
THE TWO FRAUDS ONCE HE ARRIVED AT THERANOS.

THE COURT ALSO, IN ORDER TO IMPOSE A SIGNIFICANT SENTENCE,
DOES NOT NEED TO CONCLUDE THAT MR. BALWANI INTENDED TO DEFRAUD
EITHER INVESTORS OR PATIENTS WHEN HE ARRIVED AT THERANOS AROUND
THE 2009 TIMEFRAME, JUST LIKE THE EVIDENCE AT TRIAL DID NOT
PROVE THAT ELIZABETH HOLMES STARTED THERANOS WITH THE INTENT TO
DEFRAUD, THE GOVERNMENT DID NOT PRESENT EVIDENCE AND IS NOT
ARGUING TO THE COURT THAT IT MUST CONCLUDE THAT HIS INITIAL
INTENT IN JOINING THERANOS WAS TO DEFRAUD.

INSTEAD WHAT HAPPENED HERE WAS BOTH HOLMES AND BALWANI
MADE A CHOICE TO DEFRAUD INVESTORS AND PATIENTS WHEN THEY SAW
THE RUNWAY, THE AMOUNT OF TIME THAT THERANOS HAD LEFT
DWINDLING. THEY COULD HAVE ALLOWED THERANOS TO FAIL. INSTEAD
THEY CHOSE TO COMMIT FRAUD BOTH TO INVESTORS AND PATIENTS, AND
THAT CHOICE WASN'T MADE WHEN MR. BALWANI JOINED THERANOS OR
WHEN MS. HOLMES FOUNDED THERANOS.

SO MY POINT HERE IS THERE ARE ARGUMENTS THAT THE DEFENSE IS MAKING TO THE COURT IN ADVANCING THEIR SENTENCING

1 01:14PM 2 01:15PM 3 01:15PM 01:15PM 4 01:15PM 01:15PM 6 01:15PM 7 01:15PM 8 01:15PM 9 01:15PM 10 01:15PM 11 01:15PM 12 01:15PM 13 01:15PM 14 01:15PM 15 01:15PM 16 01:15PM 17 01:16PM 18 01:16PM 19 01:16PM 20 01:16PM 21 01:16PM 22 01:16PM 23 01:16PM 24 01:16PM 25

RECOMMENDATION, AND THEY ARE RED HERRINGS. THE COURT NEED NOT REACH THESE CONCLUSIONS, THAT HE FOUNDED THERANOS OR THAT HE INITIALLY INTENDED TO DEFRAUD IN ORDER TO SENTENCE HIM TO A SIGNIFICANT CUSTODIAL TIME.

HIS ACTIONS DURING THE CONSPIRACY PERIODS, 2010 OR SO, WERE SUFFICIENTLY BAD TO JUSTIFY THIS SIGNIFICANT CUSTODIAL SENTENCE. WE NEED NOT LOOK FURTHER OR EARLIER IN TIME TO FIND ADDITIONAL HARM IN ORDER TO JUSTIFY A SIGNIFICANT CUSTODIAL SENTENCE.

THE 3553(A) FACTOR THAT THE COURT IS SUPPOSED TO CONSIDER ARE THE NATURE AND CIRCUMSTANCES OF THE OFFENSE. THIS IS A VERY AGGRAVATING FACTOR HERE FOR THE COURT TO CONSIDER AND WEIGH.

WHAT HAPPENED HERE IS NOT A DISCRETE BAD DECISION ON AN INDIVIDUAL DAY. INSTEAD, MR. BALWANI CAME TO WORK DAY AFTER DAY AND MADE MISREPRESENTATIONS TO INVESTORS. HE CREATED DOCUMENTS LIKE THE FINANCIAL STATEMENTS, AND HE ENGAGED WITH WALGREENS, AND BOTH WERE DONE DECEPTIVELY.

BUT THE DECEPTION DIDN'T END THERE. BOTH WERE THEN, THE FINANCIAL STATEMENTS AND THE HEALTH OF THE WALGREENS RELATIONSHIP, WERE USED AS TOOLS TO DEFRAUD INVESTORS. THEY WERE BOTH COMMUNICATED TO INVESTORS SO THAT INVESTORS BELIEVED THAT THEY WERE INVESTING IN A DIFFERENT COMPANY BASED ON REPRESENTATIONS THAT INVESTORS RECEIVED FROM MR. BALWANI. INVESTORS BELIEVED THAT THEY WERE INVESTING IN A COMPANY THAT

1 01:16PM 2 01:16PM 3 01:16PM 01:16PM 4 01:16PM 01:16PM 6 01:16PM 7 01:16PM 8 01:17PM 9 01:17PM 10 01:17PM 11 01:17PM 12 01:17PM 13 01:17PM 14 01:17PM 15 01:17PM 16 01:17PM 17 01:17PM 18 01:17PM 19 01:17PM 20 01:17PM 21 01:17PM 22 01:17PM 23 01:17PM 24 01:17PM 25

WAS GOING TO ACHIEVE SIGNIFICANT REVENUE, SIGNIFICANT INCOME IN THE VERY NEAR TERM, A BILLION DOLLARS IN 2015 IS WHAT INVESTORS WERE TOLD SHORTLY BEFORE 2015.

INVESTORS WERE TOLD BASED ON REPRESENTATIONS DIRECTLY FROM MR. BALWANI THAT THEY WERE INVESTING IN A COMPANY THAT HAD A HEALTHY AND EXPANDING RELATIONSHIP WITH WALGREENS. THAT'S NOT WHAT MR. BALWANI WAS TOLD.

MR. BALWANI WAS TOLD BY MR. JHAVERI, WHO THE COURT HEARD FROM DURING TRIAL, THAT WALGREENS WAS CONCERNED ABOUT THE FINGERSTICK DRAW PERCENTAGE AND WOULD NOT EXPAND BEYOND ARIZONA UNTIL THAT NUMBER CAME -- INCREASED, THE NUMBER OF FINGERSTICK DRAWS INCREASED.

THAT'S WHAT MR. BALWANI HEARD FROM WALGREENS. THAT IS NOT WHAT INVESTORS HEARD FROM MR. BALWANI.

WHAT INVESTORS HEARD WAS THAT THERANOS WAS IN A HEALTHY
AND EXPANDING RELATIONSHIP WITH WALGREENS AND IT IS SO HEALTHY,
LOOK AT OUR FINANCIAL PROJECTIONS IN THE VERY NEAR TERM, 2014
AND 2015, THAT ARE BASED ON A GREATLY INCREASED NUMBER OF
STORES THAT THERANOS CLAIMS THAT IT WOULD BE PRESENT WITHIN
WALGREENS STORES GOING NATIONWIDE IN A VERY SHORT PERIOD OF
TIME.

AGAIN, THAT'S NOT WHAT MR. BALWANI KNEW FROM WALGREENS,
BUT INSTEAD THAT'S WHAT MR. BALWANI KNEW THAT HE HAD TO
COMMUNICATE TO INVESTORS IN ORDER TO ENCOURAGE THEM TO INVEST.

MR. BALWANI DIDN'T ONLY MISLEAD THE INVESTORS BEFORE THEY

INVESTED, BUT THERE'S A GOOD EXAMPLE. THE COURT WILL REMEMBER 1 01:18PM 2 01:18PM 3 01:18PM 01:18PM 4 01:18PM 01:18PM 6 01:18PM 7 FOR THE COURT PRECISELY THESE CONCLUSIONS. 01:18PM 8 01:18PM 9 01:18PM 10 01:18PM 11 01:18PM 12 AN UNINFORMED CONSULTANT. 01:18PM 13 01:18PM 14 01:19PM 15 01:19PM 16 01:19PM 17 COLLAPSE. 01:19PM 18 01:19PM 19 01:19PM 20

01:19PM 21

01:19PM 22

01:19PM 23

01:19PM 24

01:19PM 25

TRIAL EXHIBIT 2057 IN THE BALWANI TRIAL IN -- AT THAT TIME ALAN EISENMAN FOUND A REPORT BY A CONSULTANT AT UBS. AND IN THAT REPORT THE CONSULTANT REACHES SOME CONCLUSIONS ABOUT THERANOS, AND ALAN EISENMAN FOUND THOSE CONCLUSIONS INTERESTING. I'LL COME BACK TO THIS IN A MOMENT AND IDENTIFY

BUT THESE CONCLUSIONS IN A PUBLICALLY AVAILABLE SOURCE DOCUMENT WERE COMMUNICATED TO MR. BALWANI, THEY WERE SURPRISING TO ALAN EISENMAN, AND WHEN CONFRONTED WITH THESE FACTS, MR. BALWANI TOLD ALAN EISENMAN THAT IT SOUNDS LIKE THIS IS FROM

MR. BALWANI KNEW AND NOT ONLY THAT INVESTORS NEEDED TO BE DECEIVED ON THE FRONT IN ORDER FOR THEM TO INVEST, BUT ALSO THE DECEPTION MUST CONTINUE. THE TRUTH OF WHAT WAS HAPPENING AT THERANOS COULD NOT GET OUT, OTHERWISE THE HOUSE OF CARDS WOULD

SO THERE'S INSTANCES BOTH OF MR. BALWANI MISLEADING INVESTORS BEFORE THEY INVEST, BUT ALSO PERPETUATING THE FRAUD EVEN POST INVESTMENT LIKE THIS EXAMPLE. MR. BALWANI ALSO, TO CONTINUE THIS NATURE AND CIRCUMSTANCES OF THE OFFENSE ARGUMENT, PLAYED A SIGNIFICANT ROLE IN THE CLINICAL LAB BY REMOVING DISSENT.

WHEN ERIKA CHEUNG GOES TO MR. BALWANI AND SAID THAT SHE WAS CONCERNED ABOUT THE TEST RESULTS, SOME OF THE QC DATA, WHAT 1

2

3

4

01:19PM

01:19PM

01:19PM

01:19PM

01:20PM

01:20PM 6

01:20PM 7

01:20PM 8

01:20PM 9

01:20PM 10

01:20PM 11

01:20PM 12

01:20PM 13

01:20PM 14

01:20PM 15

01:20PM 16

01:20PM 17

01:20PM 18

01:20PM 19

01:20PM 20

01:20PM 21

01:21PM 22

01:21PM 23

01:21PM 24

01:21PM 25

ERIKA CHEUNG TOLD THIS JURY WAS THAT MR. BALWANI TOLD HER THAT WASN'T HER JOB. HER JOB WAS TO PROCESS PATIENT SAMPLES AND NOT ASK QUESTIONS.

AND WHEN INDIVIDUALS LIKE ERIKA CHEUNG OR TYLER SHULTZ OR DR. ROSENDORFF RAISED CONCERNS, WHEN THEY WERE UNCOMFORTABLE WITH WHAT THEY WERE BEING ASKED TO DO AT THERANOS, THERE WAS ONLY ONE PLACE FOR THEM, AND THAT WAS THE EXIT. THEY, BECAUSE THEY WORKED UNDER SUNNY BALWANI, KNEW THEY COULDN'T STAY AT THERANOS, AND THEY WERE ALL GIVEN THE OPTION: PROCESS PATIENT SAMPLES OR LEAVE.

AND WHEN SOMEONE LIKE DR. ROSENDORFF LEFT, YOU CAN SEE WHAT MR. BALWANI DESIRED THROUGH WHO HE HIRES TO REPLACE HIM. WE HAD A DISCUSSION ABOUT THIS EARLIER THIS MORNING.

MR. BALWANI HIRES DHAWAN AND SAWYER, TWO LARGELY ABSENTEE LAB DIRECTORS, BECAUSE SOMEONE WHO WAS PRESENT WOULD HAVE ASKED TOO MANY QUESTIONS AT THAT POINT. THERE WASN'T A WAY TO KEEP THERANOS GOING AND HAVE AN ENGAGED ADAM ROSENDORFF-LIKE LAB DIRECTOR. SO INSTEAD HE TURNED TO INDIVIDUALS THAT HE KNEW HE COULD KEEP IN THE DARK, AND MR. BALWANI WOULD ACT AS THE DE FACTO LAB DIRECTOR.

YOU HEARD TESTIMONY IN TRIAL FROM SAWYER AND DHAWAN ABOUT NOT JUST THE NUMBER OF HOURS OR THE LACK OF HOURS THAT THEY SPENT AT THE LAB, BUT THEIR LACK OF KNOWLEDGE REGARDING EVEN THE TESTING PLATFORMS AT THERANOS. THEY DIDN'T KNOW THAT THERANOS WAS USING THERANOS DEVICES TO RUN TESTS.

UNITED STATES COURT REPORTERS

1 01:21PM 01:21PM 2 3 01:21PM 01:21PM 4 01:21PM 5 01:21PM 6 01:21PM 7 01:21PM 8 01:21PM 9 01:21PM 10 01:21PM 11 01:21PM 12 01:21PM 13 01:22PM 14 01:22PM 15 01:22PM 16 01:22PM 17 01:22PM 18 01:22PM 19 01:22PM 20 01:22PM 21 01:22PM 22 01:22PM 23 01:22PM 24 01:22PM 25

MR. BALWANI WOULD HAVE YOU BELIEVE THAT THAT WAS A TEMPORARY FIX, THAT HIS HOPE WAS THAT AN EMPLOYEE AT THERANOS WOULD EVENTUALLY BECOME QUALIFIED TO BECOME THE LAB DIRECTOR, THAT SHOULD GIVE THIS COURT NO COMFORT.

DURING THAT PERIOD OF TIME, THEY WERE TESTING PATIENT'S BLOOD JUST LIKE THEY WERE WHEN ADAM ROSENDORFF WAS THERE, JUST LIKE THEY WERE AFTER DHAWAN AND SAWYER LEFT.

TO SAY THIS WAS A TEMPORARY FIX ONLY MATTERS IF THEY STOPPED TESTING DURING THAT PERIOD OF TIME. BUT THERE WAS NO ADJUSTMENT TO THE WAY THEY TREATED INDIVIDUAL PATIENTS WHO TRUSTED THERANOS TO ASSIST THEM IN MAKING MEDICAL DECISIONS.

MR. BALWANI HAD A CHOICE IN THAT MOMENT, TO CONTINUE TO HAVE ENGAGED LAB DIRECTORS LIKE DR. ROSENDORFF, OR NOT. AND HE KNEW WHAT WOULD HAPPEN IF HE CONTINUED TO HAVE ENGAGED LAB DIRECTORS, AND HE MADE A DIFFERENT CHOICE. AND IT IS THAT CHOICE AND HIS MANY OTHER CHOICES THAT SHOULD LEAD THIS COURT TO CONCLUDE THAT THE NATURE AND CIRCUMSTANCES OF THE OFFENSE ARE A SIGNIFICANTLY AGGRAVATING FACTOR AND SHOULD LEAD THE COURT TO IMPOSE A SIGNIFICANT CUSTODIAL SENTENCE.

ON THE SAME POINT, THE DEFENSE HAS ARGUED TO THE COURT THAT MR. BALWANI RECEIVED NO FINANCIAL BENEFIT FROM THE FRAUD AND FOR THAT REASON THIS SHOULD BE A MITIGATING FACTOR. I WANT TO BE CLEAR ABOUT THIS. IF THE COURT CONCLUDED THE WAY THAT THE GOVERNMENT ADVOCATED THE GUIDELINES, THAT IS, THE GOVERNMENT'S VIEW OF THE GUIDELINES ARE MR. BALWANI UNDER THE

1 01:22PM 2 01:22PM 3 01:22PM 01:22PM 4 01:22PM 01:23PM 6 01:23PM 7 01:23PM 8 01:23PM 9 01:23PM 10 01:23PM 11 01:23PM 12 01:23PM 13 01:23PM 14 01:23PM 15 01:23PM 16 01:23PM 17 01:23PM 18 01:23PM 19 01:24PM 20 01:24PM 21 01:24PM 22 01:24PM 23 01:24PM 24 01:24PM 25

GUIDELINES SHOULD GET A LIFE SENTENCE, THAT HE'S AN ADJUSTED OFFENSE LEVEL 43, CRIMINAL HISTORY CATEGORY I, THEREFORE, THE COURT SHOULD IMPOSE LIFE ACCORDING TO THE GUIDELINES. THE GOVERNMENT BELIEVES THAT THE LACK OF A FINANCIAL MOTIVE IS A BASIS TO VARY AND NOT JUST THE FINANCIAL MOTIVE, BUT TO BE MORE SPECIFIC, THE DELTA BETWEEN MR. BALWANI'S GAIN AND INVESTOR LOSSES WOULD BE A BASIS TO VARY FROM A GUIDELINE OF LIFE. THAT IS NOT WHERE THE COURT HAS COME DOWN, THOUGH.

SO WHEN THE COURT USES ITS GUIDELINE RANGE 135 TO 168, THIS FACTOR IS NO LONGER A FACTOR THAT THE COURT NEEDS TO BASE A VARIANCE UPON BECAUSE THIS NEW GUIDELINE RANGE, 135 TO 168, IS LOWER THAN WHAT 3553(A) SUGGESTS THE COURT SHOULD IMPOSE.

3553(A) SUGGESTS THAT THE COURT SHOULD IMPOSE A 15 YEAR SENTENCE, SO AS A RESULT IT IS NO LONGER NECESSARY TO VARY BASED ON THE LACK OF FINANCIAL GAIN TO MR. BALWANI.

THE NEXT 3553(A) FACTOR THE COURT IS ASKED TO CONSIDER ARE THE HISTORY AND CHARACTERISTICS OF MR. BALWANI. IN MANY INSTANCES, IN MANY CASES THIS WOULD BE A BASIS TO VARY OR A FACTOR IN MITIGATION. IT ISN'T TRUE HERE, AND IT ISN'T TRUE FOR A COUPLE OF REASONS.

FIRST, THE MOST SIGNIFICANT FACTOR IN MR. BALWANI'S FAVOR, THE LACK OF CRIMINAL HISTORY IS COVERED BY THE GUIDELINES. THERE'S SOME INSTANCES IN WHICH THE ADJUSTED OFFENSE LEVEL IS SO HIGH HE GETS NO BENEFIT, IF HE'S IN CRIMINAL HISTORY CATEGORY I OR II, FOR INSTANCE, THE GUIDELINE ADVOCATED BY THE

1 01:24PM 01:24PM 2 3 01:24PM 01:24PM 4 01:24PM 5 01:24PM 6 01:24PM 7 01:24PM 8 01:24PM 9 01:24PM 10 01:24PM 11 01:25PM 12 01:25PM 13 01:25PM 14 01:25PM 15 01:25PM 16 01:25PM 17 01:25PM 18 01:25PM 19 01:25PM 20 01:25PM 21 01:25PM 22 01:25PM 23 01:25PM 24 01:25PM 25

GOVERNMENT, THERE'S NO BENEFIT IF HE'S IN CATEGORY I OR II FOR CRIMINAL HISTORY, SO THE COURT MIGHT THEN THINK IT IS NECESSARY TO INTERVENE AND CREATE A VARIANCE BECAUSE OF THIS MITIGATING FACTOR. THAT ISN'T THE CASE ANY LONGER.

THE COURT'S GUIDELINE AT ADJUSTED OFFENSE LEVEL 33 HAS DISTINCTIONS BETWEEN CRIMINAL HISTORY CATEGORIES, SO MR. BALWANI'S NATURE AND HISTORY, HIS PERSONAL CIRCUMSTANCES ACTUALLY CAN BE ACCOUNTED FOR NOW IN THE GUIDELINES.

THERE'S ANOTHER REASON, THOUGH, THE COURT SHOULD NOT FIND AS A MITIGATING FACTOR, AND THAT IS THAT MR. BALWANI'S LETTERS OF SUPPORT DEMONSTRATE THE EXISTENCE OF A SUPPORT NETWORK. THAT SUPPORT NETWORK EXISTED DURING THE FRAUD.

THE SUPPORT NETWORKS GENERALLY HELP REDUCE RECIDIVISM. WE THINK THAT INDIVIDUALS WHO HAVE THE SUPPORT OF FAMILY OR THEIR LOCAL COMMUNITY WILL BE LESS LIKELY TO TURN TO CRIME POST RELEASE. THAT ISN'T THE CASE HERE, THOUGH. THAT SUPPORT NETWORK EXISTED WHILE MR. BALWANI WAS ENGAGED IN THIS MULTIYEAR FRAUD. AS A RESULT THE COURT SHOULD NOT FIND THAT HIS NATURE AND CIRCUMSTANCES ARE A MITIGATING FACTOR AND CERTAINLY NOT ONE THAT REQUIRES THE COURT TO VARY FROM THE GUIDELINE RANGE THAT IT FOUND.

IF WE CONTINUE IN 3553(A) NOW (A)(2), WE'RE ASKED TO LOOK AT THE NEED FOR THE SENTENCE IMPOSED, NOT SOME COLLATERAL CONSEQUENCES OF THIS CASE BUT RATHER THE NEED FOR THE SENTENCE IMPOSED TO REFLECT THE SERIOUSNESS OF THE OFFENSE AND IT IS

FROM THIS PART OF THE STATUTE THAT WE BEGIN OUR DISCUSSION OF GENERAL DETERRENCE.

IN THIS CASE THERE HAS BEEN SIGNIFICANT MEDIA ATTENTION AND AS THE CASES SUGGEST, WHITE COLLAR CRIME IS ALSO A PARTICULAR TYPE OF CRIME THAT CAN BE DETERRED THROUGH GENERAL DETERRENCE, THIS IS AN AREA IN WHICH THE COURT SHOULD GIVE PARTICULAR WEIGHT OR EMPHASIS TO GENERAL DETERRENCE BECAUSE A CALCULATION IS MADE BY THOSE WHO ARE CONTEMPLATING COMMITTING FRAUD AND TO SOME EXTENT IT'S A ROUGH MATHEMATICAL CALCULATION, THE RISK OF BEING CAUGHT AND THE POTENTIAL PUNISHMENT VERSUS THE FINANCIAL GAIN OR THE BENEFIT OF COMMITTING THE CRIME.

THE MEDIA ATTENTION MAGNIFIES THE BENEFITS OF GENERAL DETERRENCE AND IN SOME INSTANCES THE COURT MAY BE UNCOMFORTABLE WITH IMPOSING A SIGNIFICANT CUSTODIAL SENTENCE ON AN INDIVIDUAL IN A CASE WITH MEDIA ATTENTION BECAUSE IT'S HARD FOR THEM TO CONTROL THE MEDIA ATTENTION. THEY RECEIVE A SIGNIFICANT SENTENCE IN A CASE FOR A REASON THAT THEY DIDN'T HAVE MUCH CONTROL OVER.

AS THE COURT KNOWS, THOUGH, THAT ISN'T THE CASE HERE. IN THIS INSTANCE BOTH MS. HOLMES AND MR. BALWANI USED THE MEDIA TO PERPETRATE THEIR FRAUD. "THE WALL STREET JOURNAL" ARTICLE IN 2013 THAT THE COURT HEARD ABOUT IN MR. BALWANI'S TRIAL WAS SENT TO MS. HOLMES AND MR. BALWANI BEFORE IT WAS PUBLISHED, AND IT WAS REVIEWED, APPROVED, PUBLISHED, CONTAINED FALSE STATEMENTS, AND THEN WERE SENT, THOSE COPIES OF THE ARTICLE WERE SENT TO

INDIVIDUAL INVESTORS.

MS. HOLMES AND MR. BALWANI USED THE MEDIA AS PART OF THE FRAUD TO PROVIDE A MEASURE OF LEGITIMACY OR OF CORROBORATION TO STATEMENTS THAT THEY HAD MADE TO INVESTORS AND AS A RESULT HE SHOULDN'T HAVE IT BOTH WAYS. HE SHOULDN'T GET THE BENEFIT FROM HIS USE OF THE MEDIA DURING THE FRAUD BUT NOW AVOID THE OPPORTUNITY THAT IS AVAILABLE TO THE COURT THROUGH GENERAL DETERRENCE AND THE IMPOSITION OF A SIGNIFICANT CUSTODIAL SENTENCE.

HIS USE OF THE MEDIA, THOUGH, DOESN'T END THERE. I MENTIONED A MOMENT AGO TRIAL EXHIBIT 2057, THAT'S THE UBS EMAIL THAT ALAN EISENMAN SENT TO MR. BALWANI. AND HERE I WANT TO NOTE JUST SOME OF THE THINGS THAT WERE IN THE UBS CONSULTANT STATEMENTS THAT MR. BALWANI CLAIMED WERE FROM AN UNINFORMED CONSULTANT.

ALAN EISENMAN IN HIS UBS REPORT LEARNED THAT BLOOD SAMPLES HAD TO BE SENT TO PALO ALTO. THAT'S TRUE. MR. BALWANI TELLS ALAN EISENMAN THAT THAT SOUNDS LIKE IT'S COMING FROM AN UNINFORMED CONSULTANT.

MR. EISENMAN ALSO LEARNED THAT THERANOS TESTING WAS LESS RELIABLE THAN TRADITIONAL TESTING, THAT THAT WAS IN THE UBS REPORT. AGAIN, MR. BALWANI SAYS THAT'S FROM AN UNINFORMED CONSULTANT, EVEN THOUGH WE NOW KNOW THAT TO BE TRUE.

AND FINALLY, THE TURN-AROUND TIME WAS OVER 24 HOURS. THE UBS CONSULTANT WRITES THAT. ALAN EISENMAN IS SURPRISED BY THAT

BECAUSE THAT'S DIFFERENT THAN WHAT HE UNDERSTOOD WHEN HE WAS MAKING THE DECISION TO INVEST.

AND MR. BALWANI, WHEN HE'S CONFRONTED WITH THAT AGAIN, INFORMS MR. EISENMAN THAT THAT ALSO MUST BE FROM AN UNINFORMED CONSULTANT.

MR. BALWANI'S USE OF THE MEDIA DOESN'T END THERE. IN HIS ENGAGEMENTS WITH WALGREENS HE SENDS INFORMATION THAT HE FINDS PUBLICALLY AVAILABLE. IT'S TRIAL EXHIBIT 1254. THAT WAS AN ARTICLE THAT APPEARED IN NOVEMBER OF 2013, RIGHT AT THE TIME THAT THERANOS AND WALGREENS ARE GOING LIVE. AND IN THIS PUBLISHED STORY MR. BALWANI READS QUOTE, "NO BOTCHED STICKS, NO PHLEBOTOMISTS, ONLY MACHINES IN THERANOS LABS." MR. BALWANI TAKES THIS ARTICLE AND SENDS IT TO WALGREENS.

SO THE USE OF THE MEDIA, THE MANIPULATION OF THE MEDIA TO PERPETUATE THE FRAUD WAS NOT THE EXCLUSIVE PROVINCE OF ELIZABETH HOLMES. MR. BALWANI DID IT ALSO AND DID IT TO GREAT EFFECT. BECAUSE OF THAT THE COURT SHOULD FEEL COMFORTABLE BELIEVING THAT A SENTENCE, A SIGNIFICANT CUSTODIAL SENTENCE HERE WILL SATISFY THE AIMS OF GENERAL DETERRENCE, AND THOSE AIMS WILL BE MAGNIFIED THROUGH THE ADDITIONAL COVERAGE.

WE'RE ALSO ASKED UNDER THIS PART OF 3553(A) TO CONSIDER SPECIFIC DETERRENCE. THE DEFENSE IN THEIR FILING ESSENTIALLY GIVES THIS THE BACK OF THE HAND AND SAYS THAT MR. BALWANI, THERE'S NO RISK OF FUTURE FRAUD, AND THAT THE COURT SHOULD PUT NO WEIGHT ON SPECIFIC DETERRENCE. THAT'S WRONG FOR THREE

1

3

01:29PM

01:29PM

01:29PM 2

01:29PM 4

01:29PM 5

01:29PM 6

01:29PM 7

01:29PM 8

01:29PM 9

01:29PM 10

01:29PM 11

01:29PM 12

01:29PM 13

01:29PM 14

01:29РМ 15

01:29PM 16

01:30PM 17

01:30PM 18

01:30PM 19

01:30PM 20

01:30PM 21

01:30PM 22

01:30PM 23

01:30PM 24

REASONS.

FIRST, MR. BALWANI HAS NOT ACKNOWLEDGED HIS ROLE IN THE FRAUD, AND THAT SHOULD PROVIDE SOME MEASURE OF CONCERN TO THE COURT. I'M NOT SAYING THAT THE COURT PUNISHES AN INDIVIDUAL FOR GOING TO TRIAL. IT'S A DIFFERENT ARGUMENT. THE ARGUMENT HERE IS THAT WHEN THE COURT IS DECIDING WHETHER THIS INDIVIDUAL IS LIKELY TO COMMIT FUTURE CRIMES, THE COURT USES THE INFORMATION THAT IS AVAILABLE TO IT TO REACH THAT CONCLUSION. AND SOME OF THE INFORMATION THAT IS AVAILABLE TO THIS COURT IS THAT THIS IS A DEFENDANT WHO HAS NOT ACKNOWLEDGED NOT JUST THAT HE DIDN'T HAVE A ROLE IN A FRAUD, BUT HE'S GOING FURTHER.

AND THIS IS MY SECOND POINT. IN THE DEFENSE'S SENTENCING MEMO, THIS IS AT PAGES 25 AND 28, AND AGAIN THIS MORNING THEY'VE REPEATED THIS ARGUMENT. AND IT GOES LIKE THIS, MR. BALWANI LEFT THERANOS AT A TIME WHEN IT HAD X DOLLARS, \$300 MILLION IN THE BANK, AND HE ISN'T RESPONSIBLE FOR WHAT HAPPENED TO THAT MONEY. IN FACT, MS. HOLMES, THE BOARD OF DIRECTORS, AND THE INVESTORS ARE THE ONES WHO DECIDED HOW TO SPEND THAT MONEY, AND IT IS THEIR FAULT THAT MORE OF THE LOSSES WEREN'T RECOUPED, THAT THE LOSSES TO THE INVESTORS ARE THE RESULT OF THE ACTIONS OF THE INDIVIDUALS WHO REMAINED AT THERANOS AFTER MR. BALWANI LEFT.

MR. BALWANI ISN'T EVEN ACKNOWLEDGING TO THE COURT THAT HE WAS PRESENT AT THE SCENE OF A CRIME. IT'S A DIFFERENT THING TO SAY I HAD A ROLE IN THE FRAUD, AND HE CERTAINLY ISN'T SAYING

01:32PM 25

1

3

01:32PM

01:32PM

01:32PM

01:32PM

01:32PM

01:32PM 8

01:32PM 9

01:32PM 10

01:32PM 11

01:32PM 12

01:32PM 13

01:32PM 14

01:32PM 15

01:33PM 16

01:33PM 17

01:33PM 18

01:33PM 19

01:33PM 20

01:33PM 21

01:33PM 22

01:33PM 23

01:33PM 24

01:33PM 25

THAT, BUT HE'S NOW GONE ONE FURTHER AND IS TELLING THIS COURT 2 THERANOS WAS NOT THE SCENE OF THE CRIME UNTIL I LEFT. UNTIL I LEFT, THERE WAS \$300 MILLION LEFT IN THE BANK, AND THAT COULD 4 HAVE BEEN USED TO PAY BACK THE INVESTORS SO THERE WOULD HAVE BEEN NO LOSS HERE. 01:32PM 6 WHEN HE GOES FURTHER AND MAKES THIS ARGUMENT TO THE COURT, 01:32PM 7 THE COURT SHOULD BE ADDITIONALLY CONCERNED ABOUT WHETHER A

SPECIFIC DETERRENCE IS NECESSARY, BECAUSE HE WON'T ACKNOWLEDGE THAT THE MONEY IN THE BANK WAS THE RESULT OF FRAUD. HE CAN STILL MAINTAIN HIS POSITION THAT HE DIDN'T COMMIT FRAUD OR THAT HE DIDN'T HAVE A ROLE IN IT AND THAT WAS ALL MS. HOLMES OR SOME OTHER VERSION, BUT HE'S ACTUALLY GONE FURTHER NOW AND IS TELLING THE COURT THAT MONEY IN THE BANK WAS MONEY THAT THERANOS WAS ENTITLED TO HAVE AND SHOULD HAVE BEEN OR COULD HAVE BEEN DISBURSED TO INVESTORS, AND AMONG THESE INDIVIDUALS, AMONG THE GROUPS THAT HE BLAMES FOR NOT DOING THE RIGHT THING WITH THAT MONEY IS THE INVESTORS THEMSELVES. AND THE COURT SHOULD BE CONCERNED ABOUT THAT KIND OF ARGUMENT WHEN IT'S THINKING ABOUT WHETHER SPECIFIC DETERRENCE IS RELEVANT, IS A FACTOR THAT IT SHOULD USE TO EITHER AGGRAVATE OR MITIGATE A SENTENCE OUTSIDE OR WITHIN THE GUIDELINES.

THE THIRD REASON WHY A SPECIFIC DETERRENCE MATTERS IS A REASON -- AN ARGUMENT I MADE A MOMENT AGO, SO I'LL TOUCH IT BRIEFLY, AND THAT IS THE EXTENSIVE SUPPORT NETWORK THAT EXISTED DURING THE TIME OF THE FRAUD HAS RELEVANCE TO SPECIFIC

1 01:33PM 01:33PM 2 3 01:33PM 01:33PM 4 01:33PM 01:34PM 6 01:34PM 7 01:34PM 8 01:34PM 9 01:34PM 10 01:34PM 11 01:34PM 12 01:34PM 13 01:34PM 14 01:34PM 15 01:34PM 16 01:34PM 17 01:34PM 18 01:34PM 19 01:34PM 20 01:34PM 21 01:34PM 22 01:34PM 23

01:35PM 24

01:35PM 25

DETERRENCE. THE EXTENSIVE NETWORK EXISTED DURING THE FRAUD, DID NOT DETER THE FRAUD, AND AS A RESULT, ONE OF THE CHECKS THAT THE COURT MAY HAVE TO FEEL COMFORTABLE THAT SPECIFIC DETERRENCE ISN'T NECESSARY IN SOME CASES IS ABSENT HERE, THE NETWORK EXISTED AND DID NOT PREVENT THE FRAUD.

I WANT TO MOVE ON TO THE NEXT FACTOR WHICH IS PROMOTING RESPECT FOR THE LAW AND PROVIDING JUST PUNISHMENT FOR THE OFFENSE. AND FOR THIS ONE I WANT TO REMIND THE COURT OF THE REAL HARMS THAT OCCURRED HERE. FOR THE INVESTOR SIDE, THE INVESTORS LOST MILLIONS OF DOLLARS. THAT IS ITSELF A SIGNIFICANT HARM DESERVING OF A SIGNIFICANT CUSTODIAL SENTENCE, BUT IT ALSO HAS A ROLE BECAUSE THE MONEY THAT WAS INVESTED HERE HAD SIGNIFICANT OPPORTUNITY COST. MUCH OF THE MONEY THAT WAS INVESTED IN THERANOS, IF IT DIDN'T GO TO THERANOS, IT COULD HAVE GONE TO OTHER LEGITIMATE TECHNOLOGICAL INNOVATIONS WITH COMPANIES, ESPECIALLY COMPANIES HERE IN SILICON VALLEY, THAT HAD REAL COMPANIES, THAT COULD DO REAL GOOD IN THE WORLD.

THE INVESTORS THOUGHT THAT WHAT THEY WERE INVESTING IN WAS ONE OF THOSE COMPANIES. AND THE REASONS THEY THOUGHT THAT IS BECAUSE SOME OF THE STATEMENTS THAT MR. BALWANI HIMSELF MADE TO INVESTORS WERE CREATED, WERE BIRTHED WITH THAT IDEA IN MIND TO MAKE INVESTORS THINK THAT WHAT THEY WERE INVESTING IN WAS A COMPANY WITH REAL TECHNOLOGY THAT COULD AFFECT THE FUTURE OF HEALTH CARE. INSTEAD INVESTORS INVESTED IN A FRAUD. THEIR MONEY COULD HAVE GONE TO A REAL COMPANY THAT COULD HAVE

AFFECTED HEALTH CARE IN THE FUTURE.

THERE'S ALSO REAL HARM ON THE PATIENT SIDE. THE COURT HEARD FROM PATIENTS DURING MR. BALWANI'S TRIAL WHO TESTIFIED ABOUT THEIR EXPERIENCES. I WON'T REPEAT ALL OF THEM, BUT THE COURT KNOWS THAT INDIVIDUALS WHO RECEIVED BLOOD TEST RESULTS FROM THERANOS MADE MEDICAL DECISIONS BASED ON THOSE BLOOD TEST RESULTS.

IT IS NOT AN INTELLECTUAL LEAP TO SEE THE HARM. IT IS THE DIRECT RESULT. ONE CAUSE OR IMPLIED THE OTHER IN THIS CASE. AND INDIVIDUALS RECEIVED TEST RESULTS THAT WERE INCORRECT AND MADE MEDICAL DECISIONS BASED UPON THAT INCORRECT INFORMATION. THAT, TOO, IS A SIGNIFICANT REAL HARM THAT THIS COURT MUST ADDRESS THROUGH ITS SIGNIFICANT CUSTODIAL SENTENCE.

THE LAST FACTOR I WANT TO TURN TO IS (A)(6), 3553(A)(6). AND THE REASON I WANT TO TOUCH ON THIS ONE IS BECAUSE WE NOW HAVE THE SENTENCE IMPOSED IN MS. HOLMES'S CASE. AND THIS FACTOR INFORMS US THAT WE SHOULD AVOID UNWARRANTED SENTENCE DISPARITIES AMONG DEFENDANTS WITH SIMILAR RECORDS WHO HAVE BEEN FOUND GUILTY OF SIMILAR CONDUCT.

UNWARRANTED IS THE IMPORTANT WORD HERE. MS. HOLMES RECEIVED A SENTENCE OF 135 MONTHS. THE GOVERNMENT IS ASKING THE COURT TO SENTENCE MR. BALWANI HIGHER THAN THAT, TO A SENTENCE OF 180 MONTHS, AND THAT IS A DISPARITY. THOSE NUMBERS ARE DIFFERENT, IT IS NOT UNWARRANTED, AND IT IS NOT UNWARRANTED FOR SEVERAL REASONS.

1 01:36PM 2 01:36PM 3 01:36PM 01:37PM 4 01:37PM 01:37PM 6 01:37PM 7 01:37PM 8 01:37PM 9 01:37PM 10 01:37PM 11 01:37PM 12 01:37PM 13 01:37PM 14 01:37PM 15 01:37PM 16 01:37PM 17 01:37PM 18 01:37PM 19 01:37PM 20 01:38PM 21 01:38PM 22 01:38PM 23 01:38PM 24

01:38PM 25

FIRST, MR. BALWANI PLAYED A SIGNIFICANT ROLE IN BOTH THE PATIENT FRAUD AND ALSO THE INVESTOR FRAUD. I'VE IDENTIFIED SPECIFIC PLACES OR SPECIFIC ROLES THAT MR. BALWANI PLAYED, SO I'M NOT GOING TO REPEAT THOSE NOW, BUT IT IS RELEVANT AS THE COURT ANALYZES WHETHER THERE'S A WARRANTED OR AN UNWARRANTED DISPARITY BETWEEN MS. HOLMES AND MR. BALWANI SHOULD THE COURT IMPOSE A SENTENCE LIKE THE ONE THAT THE GOVERNMENT IS ADVOCATING FOR.

THE REASON THAT IT WOULD NOT BE UNWARRANTED IS BECAUSE WHEN THE COURT SENTENCED MS. HOLMES, EVEN THOUGH IT COULD CONSIDER AS RELEVANT CONDUCT ACQUITTED CONDUCT, THE COURT CHOSE NOT TO. THE COURT CHOSE TO SENTENCE MS. HOLMES BASED UPON THE CONVICTED CONDUCT THAT WAS LIMITED TO THE INVESTOR FRAUD.

MR. BALWANI, AS THE COURT KNOWS, WAS CONVICTED OF ALL COUNTS IN THE INDICTMENT. THAT INCLUDED THE PATIENT FRAUD. AND IT IS NOT JUST THE COUNTS OF CONVICTION THAT MATTERED, BUT THE COURT SAW THE EVIDENCE IN THE CASE. THE COURT SAW THE ROLE THAT MR. BALWANI PLAYED IN THE LAB.

MR. BALWANI FIRED INDIVIDUALS WHO EXPRESSED DISSENT, HE TOLD INDIVIDUALS WHO EXPRESSED DISSENT THAT THEIR JOB WAS SIMPLY TO PROCESS PATIENT SAMPLES, HE REPLACED ENGAGED LAB DIRECTORS WITH UNENGAGED LAB DIRECTORS, AND IT'S ALL OF THOSE REASONS WHY THE COURT SHOULD FEEL COMFORTABLE THAT MR. BALWANI SHOULD RECEIVE A MORE SIGNIFICANT SENTENCE THAN MS. HOLMES AND THAT DISPARITY WOULD NOT BE UNWARRANTED.

1 01:38PM 2 01:38PM 3 01:38PM 01:38PM 4 01:38PM 01:38PM 6 01:38PM 7 01:38PM 8 01:38PM 9 01:38PM 10 01:39PM 11 01:39PM 12 01:39PM 13 01:39PM 14 01:39PM 15 01:39PM 16 01:39PM 17 01:39PM 18 01:39PM 19 01:39PM 20 01:39PM 21 01:39PM 22 01:39PM 23 01:39PM 24 01:39PM 25

MR. BALWANI ALSO PLAYED, AND I WANT TO HIGHLIGHT THIS, A ROLE IN THE WALGREENS ROLLOUT THAT THE COURT HEARD SIGNIFICANT EVIDENCE IN HIS TRIAL ABOUT.

MR. BALWANI WAS THE POINT PERSON AT THERANOS, AND MR. JHAVERI WAS THE POINT PERSON AT WALGREENS, AND THE TWO OF THEM WORKED TO OPERATIONALIZE THE ROLLOUT. THAT ROLLOUT PLAYED A SIGNIFICANT ROLE IN BOTH FRAUDS.

I TOUCHED ON THIS EARLIER THAT INVESTORS INVESTED BECAUSE THEY SAW AND HEARD THAT THE ROLLOUT WITH WALGREENS WAS GOING WELL, AND THEY WERE TOLD THAT THE ROLLOUT WITH WALGREENS WAS EXPANDING.

THEY ALSO -- THE WALGREENS ROLLOUT ALSO CREATED THE OPPORTUNITY FOR THE PATIENTS TO BE DEFRAUDED, TO GET THE INACCURATE BLOOD TEST RESULTS.

MR. BALWANI'S ROLE, THE INTEGRAL ROLE THAT HE PLAYED IN THE WALGREENS ROLLOUT AFFECTED BOTH FRAUDS, THE PATIENT FRAUD AND THE INVESTOR FRAUD AND BECAUSE THAT PLAYED SUCH A SIGNIFICANT ROLE IN BOTH FRAUDS, THE COURT SHOULD FEEL COMFORTABLE IMPOSING A MORE SIGNIFICANT CUSTODIAL SENTENCE ON MR. BALWANI THAN IT DID ON MS. HOLMES, AND THAT THAT DIFFERENCE WOULD NOT BE AN UNWARRANTED SENTENCE DISPARITY.

THE LAST ISSUE I'LL TOUCH ON IS MR. BALWANI ADDRESSES BASES FOR VARIANCE IN HIS MEMO, AND HE ESSENTIALLY SAYS THAT HE INVESTED HIS OWN MONEY, THE MILLIONS OF DOLLARS, AND HE NEVER SOUGHT FAME OR RECOGNITION, AND THAT HE HAS A LONG HISTORY OF

CHARITABLE GIVING. IT IS THESE THREE PILLARS UPON WHICH THE DEFENSE'S VARIANCE REQUEST IS BASED.

THE COURT SHOULD REJECT THEM AND DETERMINE THAT A SENTENCE WITHIN THE GUIDELINE, WITHIN THE GUIDELINES THAT THE GOVERNMENT RECOMMENDED WOULD BE LIFE. THE GUIDELINES THAT THE COURT FOUND 135 TO 168 ARE MORE APPROPRIATE THAN ONE LIKE THE DEFENSE IS ASKING FOR, WHICH IS A SENTENCE OF PROBATION. NOT ONLY WOULD A SENTENCE OF PROBATION IGNORE ALL OF THE PRIOR 3553(A) FACTORS THAT I JUST COVERED WITH THE COURT, BUT IT ALSO ASSUMES THAT THESE ARE PROPER BASES FOR VARIANCE, THAT MR. BALWANI'S INVESTMENT OF HIS OWN MONEY, HE ARGUES, UNLIKE ELIZABETH HOLMES, MR. BALWANI INVESTED HIS OWN MONEY.

THE COURT KNOWS FROM INFORMATION THAT IT RECEIVED DURING THE COURSE OF THE TRIAL, MR. BALWANI HAD THE ABILITY TO INVEST HIS OWN MONEY. IT SHOULD NOT REWARD HIM FOR THAT. IT, IN FACT, SHOULD CAUSE THE COURT TO QUESTION HOW MR. BALWANI COULD HAVE MADE THESE CHOICES. WHY IT IS THAT MR. BALWANI, WHEN FACED WITH THERANOS POTENTIALLY RUNNING OUT OF ITS RUNWAY, WHY HE CHOSE TO DEFRAUD INVESTORS, WHY HE CHOSE TO DEFRAUD PATIENTS? THERE SIMPLY IS NO ANSWER TO THAT QUESTION.

THAT HE DID NOT SEEK FAME OR RECOGNITION IS NOT SOMETHING THAT AT THIS STAGE HE SHOULD GET CREDIT FOR.

MR. BALWANI HELD ON TO HIS SHARES BECAUSE WHEN HE HAD --BECAUSE WHEN HE POSSESSED THEM DURING THE FRAUD, THEY WERE WORTH HUNDREDS OF MILLIONS OF DOLLARS, AND MR. BALWANI WANTED

1

2

3

4

8

01:39PM

01:39PM

01:40PM

01:40PM

01:40PM

01:40PM

01:40PM

01:40PM 7

01:40PM 9

01:40PM 10

01:40PM 11

01:40PM 12

01:40PM 13

01:40PM 14

01:40PM 15

01:40PM 16

01:40PM 17

01:40PM 18

01:41PM 19

01:41PM 20

01:41PM 21

01:41PM 22

01:41PM 23

01:41PM 24

BILLIONS OF DOLLARS. HE HELD ON TO THEM BECAUSE HE ASSUMED, HE 1 01:41PM 2 THOUGHT THAT THERANOS WOULD OUTLIVE THE FRAUD, THAT EVENTUALLY 01:41PM THERANOS COULD BECOME WHAT HE WAS TELLING INDIVIDUALS THERANOS 3 01:41PM 01:41PM 4 WAS, AND IF HE WAS SUCCESSFUL, HE WAS TAKING A RISK AND HE WAS PLAYING THE GAME THAT EVENTUALLY WE WILL BE WHAT WE CLAIM TO BE 01:41PM 01:41PM 6 AND I WILL HAVE SHARES THAT ARE WORTH BILLIONS OF DOLLARS 01:41PM 7 INSTEAD OF MILLIONS. SO THAT HE DID NOT SEEK FAME OR SOUGHT TO RECEIVE SOME 01:41PM 8 MEASURE OF RECOGNITION FOR IT IS NOT A BASIS FOR THE COURT NOW 01:41PM 9 01:42PM 10 TO DETERMINE HE DESERVES A VARIANCE AND CERTAINLY NOT ONE TO 01:42PM 11 PROBATION, WHICH IS WHAT THE DEFENSE IS ASKING FOR. 01:42PM 12 HIS HISTORY OF CHARITABLE GIVING IS CERTAINLY LAUDABLE. I 01:42PM 13 DON'T HAVE ANY ADDITIONAL WORDS TO SAY ON THAT OTHER THAN IT IS NOT A BASIS TO VARY OUTSIDE OF THE GUIDELINES THAT THE COURT 01:42PM 14 01:42PM 15 HAS FOUND, IT IS NOT A BASIS TO VARY BEYOND THE 180 MONTHS THAT THE GOVERNMENT IS ASKING THE COURT TO IMPOSE, AND IT IS 01:42PM 16 CERTAINLY NOT A BASIS TO VARY DOWN TO PROBATION AS THE DEFENSE 01:42PM 17 01:42PM 18 IS ASKING FOR. 01:42PM 19 BEYOND THAT, I'LL SUBMIT AND ENCOURAGE THE COURT TO IMPOSE 01:42PM 20 A SIGNIFICANT CUSTODIAL SENTENCE REQUESTED BY THE GOVERNMENT. 01:42PM 21 THANK YOU. 01:42PM 22 THE COURT: THANK YOU. 01:42PM 23 DOES DEFENSE WISH TO BE HEARD? 01:42PM 24 MR. COOPERSMITH: YES, YOUR HONOR. THANK YOU. 01:43PM 25 SO THANK YOU FOR THE OPPORTUNITY, YOUR HONOR. AND AFTER

1 01:43PM 2 01:43PM 3 01:43PM 01:43PM 4 01:43PM 5 01:43PM 6 01:43PM 7 01:43PM 8 01:43PM 9 01:43PM 10 01:43PM 11 01:43PM 12 01:43PM 13 01:43PM 14 01:43PM 15 01:43PM 16 01:44PM 17 01:44PM 18 01:44PM 19 01:44PM 20 01:44PM 21 01:44PM 22 01:44PM 23 01:44PM 24 01:44PM 25

ALL OF THIS TIME, WE'VE FINALLY REACHED THIS POINT. THIS IS OBVIOUSLY A DECISION THAT AFFECTS A REAL HUMAN BEING, MR. BALWANI. THIS IS, AT THIS TIME, NOT A MATTER OF CALCULATING DECIMAL POINTS AND NUMBERS. IT'S ABOUT WHO MR. BALWANI IS AND WHAT SENTENCE HE SHOULD RECEIVE.

THE REASON I SAY THAT IN PART, YOUR HONOR, IS BECAUSE IN LISTENING TO MR. SCHENK, I FEEL LIKE WE'RE BACK IN THE PRE-BOOKER WORLD WHERE SOMEHOW THE GUIDELINES ARE PRESUMED REASONABLE AND THEY'RE OVERRIDINGLY THE MOST IMPORTANT THING, AND THEN WE HAVE TO JUSTIFY VARIANCES.

I UNDERSTAND THE GUIDELINES UNDER THE PRECEDENT THAT EXIST ARE A STARTING POINT. FOR THE RECORD, WE DON'T EVEN AGREE WITH THAT, THAT THEY SHOULD BE. BUT WE UNDERSTAND THAT'S WHERE THE COURT STARTS.

BUT THEY ARE A STARTING POINT. THERE'S NO PRESUMPTION THAT THEY'RE REASONABLE. THEY'RE JUST ONE FACTOR AMONG ALL OF THE 3553(A) FACTORS.

SO WHEN MR. SCHENK SAYS, WELL, HE THINKS THE GUIDELINES ARE LIFE AND HE'S DOING US A FAVOR BY RECOMMENDING 15 YEARS, THAT'S JUST OVERLY RELATED TO THE GUIDELINES AND NOT APPROPRIATE IN TODAY'S SENTENCING WORLD.

THE OTHER THING THAT I WANT TO JUST OBSERVE IN GENERAL IS THAT THE GOVERNMENT SAID A LOT OF THINGS AT TRIAL. AND AS THE COURT REMEMBERED, THERE WERE A LOT OF THINGS THAT THE GOVERNMENT DID, AND THEY ARE ENTITLED TO MAKE A STRATEGIC

CHOICE WHERE THEY DECIDED TO PRESENT EVIDENCE AND NOT PRESENT 1 01:44PM THE OTHER SIDE. THEY DIDN'T, IN OTHER WORDS, FRONT THINGS AS 01:44PM 2 SOMETIMES LAWYERS DO. 3 01:44PM 01:44PM 4

AND THEY ARE NOW ASSUMING BECAUSE OF THE JURY VERDICT, WHICH IS AGAIN A GENERAL VERDICT, THAT EVERY SINGLE FACT THAT THEY PUT INTO PLAY AT TRIAL IS SOMEHOW FOUND BEYOND A REASONABLE DOUBT. THAT IS NOT THE CASE.

AND THEY'RE DOING THAT TODAY, AND THEY'VE DONE THAT REPEATEDLY.

SO, FOR EXAMPLE, WHEN THE GOVERNMENT SAYS THAT MR. BALWANI DIDN'T HAVE ANY BASIS TO THINK THAT THE WALGREENS RELATIONSHIP WOULD CONTINUE TO GROW AFTER -- GIVEN HIS DEALINGS WITH MR. JHAVERI AT WALGREENS, IN FACT, MR. JHAVERI SENT MR. BALWANI AN EMAIL THAT SAID IN AUGUST OF 2014, SAID WE ARE GOING TO TOUCH 2500 STORES IN 2015. AND MR. JHAVERI DID THAT WITH FULL KNOWLEDGE OF WHAT THE FINGERSTICK PERCENTAGES WERE AND SOME OF THE DIFFICULTIES IN GETTING THAT FINGERSTICK PERCENTAGE DOWN TO WHERE BOTH SIDES WANTED TO TARGET IT, WHICH BY THE WAY IN THE EVIDENCE OF THE CASE WAS NOT REQUIRED BY WALGREENS UNTIL AUGUST OF 2015. SO THERE WAS PLENTY OF TIME.

BUT I ONLY RAISE THAT ONE THING, YOUR HONOR, AS AN ILLUSTRATION THAT NOT EVERYTHING THAT THE GOVERNMENT PRESENTED AT TRIAL IS TRUE. THERE WAS DEFENSE EVIDENCE AND THE GOVERNMENT IS TRYING TO IGNORE. SO THERE'S A MUCH MORE NUANCED BALANCED LOOK AT THIS THAT IS REQUIRED THAN WHAT THE GOVERNMENT

01:44PM

01:44PM 6

01:44PM 7

01:44PM 8

01:44PM 9

01:44PM 10

01:45PM 11

01:45PM 12

01:45PM 13

01:45PM 14

01:45PM 15

01:45PM 16

01:45PM 17

01:45PM 18

SAYS.

LET ME JUST SORT OF GO BACK TO FIRST PRINCIPLES. SO THE NATURE AND CIRCUMSTANCES OF THE OFFENSE. MR. BALWANI, AS MR. SCHENK HAS TO CONCEDE, DID NOT JOIN THERANOS BECAUSE HE WAS TRYING TO DEFRAUD ANYONE. IN FACT, BY THE TIME THAT MR. BALWANI JOINED THERANOS, HE HAD ACCOMPLISHED EDUCATIONAL ACHIEVEMENTS, HE HAD ACCOMPLISHED BUSINESS ACHIEVEMENTS, HE HAD OBTAINED DEGREES. HIS STORY IS REALLY A CLASSIC AMERICAN SUCCESS STORY OF A MAN WHO CAME HERE AS A YOUNG PERSON TO GO TO COLLEGE HERE IN THE UNITED STATES AND STUDIED HARD AND WORKED HARD AND MOVED HERE TO SILICON VALLEY AND STARTED A COMPANY AND WAS SUCCESSFUL.

AS MR. SCHENK SAID, HE LATER JOINED THERANOS IN 2009 NOT TO DEFRAUD ANYONE, SO RIGHT AWAY HE DOESN'T HAVE ANY KIND OF BACKGROUND IN THIS. MS. HOLMES OBVIOUSLY FOUNDED THE COMPANY MUCH EARLIER.

SO HE JOINS THERANOS. SO WHAT DOES HE DO? HE DOES SOME DUE DILIGENCE AS WE'VE POINTED OUT. HE DOES A LOT OF DUE DILIGENCE. HE ASKS A LOT OF QUESTIONS. HE MEETS WITH A LOT OF THE LEADING PEOPLE AT THERANOS. HE MEETS WITH CHANNING ROBERTSON, AN ENGINEER PROFESSOR AT STANFORD WHO TELLS HIM THINGS ARE GREAT, AND HE DECIDES TO JOIN.

ALL OF THE EVIDENCE HERE POINTS TO THE FACT THAT MR. BALWANI JOINED THIS COMPANY BECAUSE HE BELIEVED IN THE MISSION OF THERANOS, HE HAD SOME FAMILY HISTORY, HIS FATHER

DIED AT A RELATIVELY YOUNG AGE, AND HE HAD SOME FAMILY HISTORY 1 01:47PM THAT WANTED HIM TO CONTRIBUTE. 2 01:47PM AND THIS WAS NOT UNUSUAL FOR MR. BALWANI. HE HAD BEEN 3 01:47PM

01:47PM

01:47PM

01:47PM 6

01:47PM 7

01:47PM 8

01:47PM 9

01:47PM 10

01:47PM 11

01:48PM 12

01:48PM 13

01:48PM 14

01:48PM 15

01:48PM 16

01:48PM 17

01:48PM 18

01:48PM 19

01:48PM 20

01:48PM 21

01:48PM 22

01:48PM 23

01:48PM 24

01:48PM 25

4

CONTRIBUTING HIS WHOLE LIFE. AS THE COURT HAS SEEN FROM THE LETTERS THAT WE HAVE SUBMITTED, MR. BALWANI HAS A LONG HISTORY OF GIVING.

MR. SCHENK SAYS, WELL, THAT'S NOT A FACTOR THAT THE COURT SHOULD CONSIDER. IT'S LAUDABLE, BUT, YOU KNOW, IT'S ABOUT WHO MR. BALWANI IS. SO IT IS A VERY IMPORTANT FACTOR TO LOOK AT THE WHOLE PERSON HERE.

AND WHAT MR. BALWANI DID WITH HIS CHARITABLE GIVING LONG BEFORE THERANOS, AND INCLUDING WHILE HE WAS INVOLVED WITH THERANOS AND EVEN AFTER THAT, WAS HE TRIED TO -- YOU CAN SEE, IT'S HELPING AN ORGANIZATION BUILD A COMMUNITY KITCHEN TO FEED PEOPLE WHO NEEDED HELP, IT'S HELPING A VILLAGE GET A WATER PUMP SO IT CAN SUPPLY WATER TO ITS INHABITANTS, IT'S CONTRIBUTING MONEY SO THAT WHEELCHAIRS CAN BE PROVIDED TO PEOPLE WHO NEED TO USE WHEELCHAIRS, AND IT'S VOLUNTEERING IN A CHARITABLE KITCHEN TO ACTUALLY HELP HANDS ON FEED HOMELESS PEOPLE. HE DID ALL OF THAT WITHOUT ANY REQUEST FOR RECOGNITION. HE DIDN'T WANT HIS NAME ON A BUILDING. NOTHING. HE JUST WANTED TO HELP, AND THAT'S WHY HE JOINED THERANOS BECAUSE HE WANTED TO HELP. HE WANTED TO CONTRIBUTE.

NOW, HE NOT ONLY CONTRIBUTED BY JOINING AND WORKING AND ROLLING UP HIS SLEEVES AND TRY TO MAKE THIS COMPANY AS GOOD AS

1 01:48PM 2 01:49PM 3 01:49PM 01:49PM 4 01:49PM 01:49PM 6 01:49PM 7 01:49PM 8 01:49PM 9 01:49PM 10 01:49PM 11 01:49PM 12 01:49PM 13 01:49PM 14 01:49PM 15 01:49PM 16 01:49PM 17 01:49PM 18 01:50PM 19 01:50PM 20 01:50PM 21 01:50PM 22 01:50PM 23 01:50PM 24

01:50PM 25

COULD BE, HE ALSO INVESTED A LOT OF MONEY. SO HE NOT ONLY TALKED THE TALK, HE WALKED THE WALK. HE PUT IN, AS THE COURT SAW, WELL OVER \$4 AND A HALF MILLION. HE ALSO GUARANTEED A LOAN WHICH SOHAN SPIVEY TESTIFIED AT TRIAL WAS THE SAME ECONOMICALLY AS MR. BALWANI LOANING MONEY TO THE COMPANY.

SO HE LOANS MONEY. HE'S ON THE HOOK FOR \$12 MILLION AND THAT HE COULD HAVE LOST AND FORTUNATELY HE DIDN'T LOSE THAT MONEY. HE DID LOSE THE 4 AND A HALF MILLION, MORE THAN THAT THAT, HE INVESTED, PLUS THE MONEY THAT HE GAVE MS. HOLMES SO SHE COULD BUY COMPANY STOCK. SO MR. BALWANI ACTUALLY INVESTED THAT MONEY.

MR. SCHENK SAYS, WELL, IT IS TRUE THAT HE NEVER SOLD A SHARE, THAT IS TRUE, BUT SOMEHOW MR. SCHENK TURNS THAT AROUND INTO AN AGGRAVATING FACTOR BECAUSE HE WAS SOMEHOW GREEDY WHERE HE WANTED EVEN MORE BILLIONS SO HE WASN'T EVEN WILLING TO PART WITH A SINGLE SHARE. THERE'S NO EVIDENCE OF THAT. IT'S POOR SPECULATION.

NOTHING IN MR. BALWANI'S HISTORY FROM THE FACT THAT HE GAVE OVER AND OVER AGAIN FOR A LONG PERIOD OF TIME WITH CHARITABLE GIVING WITHOUT ASKING FOR ANYTHING. HE INVESTED IN THERANOS, HE ASKED FOR A SALARY OF ONE DOLLAR WHEN HE JOINED THERANOS. NOTHING IN THIS RECORD SUPPORTS THE IDEA THAT MR. BALWANI IS GREEDY, AND THE REASON HE DIDN'T SELL SHARES IS BECAUSE HE WANTED TO MAKE MORE BILLIONS. AND IT'S NOT ALL OR NOTHING BY THE WAY, YOUR HONOR.

1 01:50PM 2 01:50PM 3 01:50PM 01:50PM 4 01:50PM 01:50PM 6 01:50PM 7 01:50PM 8 01:50PM 9 01:50PM 10 01:51PM 11 01:51PM 12 01:51PM 13 01:51PM 14 01:51PM 15 01:51PM 16 01:51PM 17 01:51PM 18 01:51PM 19 01:51PM 20 01:51PM 21 01:51PM 22 01:51PM 23 01:51PM 24 01:51PM 25

MR. SCHENK AND THE GOVERNMENT POINT TO, WELL, MR. BALWANI'S INVESTMENT IN THERANOS WAS RELATIVELY EARLY, IN 2009 AND 2010, AND SO WHAT ABOUT 2013, 2014, 2015? MR. BALWANI HAD ALL OF THESE SHARES WORTH HALF A BILLION DOLLARS, AND IF YOU'RE TRYING TO DEFRAUD PEOPLE, COULD YOU HAVE SOLD ONE SHARE? TEN SHARES? A HUNDRED SHARES? FIVE THOUSAND SHARES? IT WOULD BE A BASIC. NO ONE WOULD BAT AN EYELASH IF SOMEONE WHO OWNED THAT MANY SHARES IN A COMPANY THAT'S A HOT COMPANY AT THE TIME WANTED TO DIVERSIFY THEIR PORTFOLIO A BIT YOU HAD TO SELL EVERY SINGLE SHARE.

THIS IDEA THAT HE HELD ON TO THE SHARES BECAUSE HE WANTED TO MAKE EVEN MORE BILLIONS, MR. SCHENK SAID THAT'S AN AGGRAVATING FACTOR, THERE'S NO EVIDENCE OF THAT. IT'S BASICALLY MADE UP.

WHAT WE'VE GOT HERE AND THE REASON I'M TELLING YOU THIS, YOUR HONOR, AND THE COURT KNOWS THIS FROM TRIAL IS THAT WE HAVE A CASE THAT IS VERY UNUSUAL HERE. IT'S OUTSIDE OF THE HEARTLAND. IT'S ATYPICAL OF THE FRAUD CASES THAT THIS COURT AND COURTS ALL OVER THIS COUNTRY SEE EVERY SINGLE DAY, AND THAT IS THE PRIMARY DRIVING MOTIVE OF FRAUD IS GREED, IS TO PUT YOURSELF FIRST, IS TO MAKE MONEY BEFORE OTHERS.

THERE ARE MANY DEFENDANTS THAT I'M SURE THIS COURT HAS SEEN AND CERTAINLY I HAVE SEEN AS AN ATTORNEY WHERE IF YOU GET THE VICTIM'S MONEY, IT'S A WIN. AND IF YOU ARE ABLE TO BUY A HOUSE OR A BOAT OR TAKE A GREAT VACATION, THAT'S A WIN.

1 01:51PM 01:51PM 2 3 01:51PM 01:52PM 4 01:52PM 5 01:52PM 6 01:52PM 7 01:52PM 8 01:52PM 9 01:52PM 10 01:52PM 11 01:52PM 12 01:52PM 13 01:52PM 14 01:52PM 15 01:52PM 16 01:52PM 17 01:52PM 18 01:52PM 19 01:52PM 20 01:52PM 21 01:53PM 22 01:53PM 23 01:53PM 24

01:53PM 25

THERE IS NOTHING IN THIS RECORD THAT SUPPORTS IN ANY WAY THAT MR. BALWANI WAS MOTIVATED BY THOSE THINGS. HE DIDN'T DO THOSE THINGS. HE DIDN'T MAKE ANYTHING AT THERANOS. IN FACT, HE WAS AN INVESTOR IN THERANOS WHO LOST A LOT OF MONEY, AND OBVIOUSLY HE WORKED FOR THE COMPANY AS WELL, AND WE CAN TALK ABOUT THAT.

BUT THERE'S NO GREED FACTOR HERE. THERE IS NO FINANCIAL BENEFIT. AND MR. SCHENK SAYS, WELL, MAYBE THAT'S A REASON TO DEPART FROM LIFE. AGAIN, THAT'S PUTTING THE GUIDELINES INTO AN EXALTED PLACE THAT THEY ARE NOT DESERVING OF UNDER THE LAW, BUT THEY ARE A REASON FOR A SIGNIFICANTLY LOWER SENTENCE HERE NOT ONLY COMPARED TO THE GUIDELINE RANGE THAT THE COURT CALCULATED, BUT ALSO COMPARED TO MS. HOLMES WHO DID NOT DO THAT. SHE DID NOT INVEST HER OWN MONEY.

THE OTHER THING I'LL SAY ABOUT THAT IN TERMS OF DISPARITY, AND I'M JUMPING AROUND BUT I HOPE IT FLOWS LOGICALLY, YOUR HONOR, MS. HOLMES RECEIVED A VERY HARSH SENTENCE, 11 YEARS AND 3 MONTHS. I THINK IT WAS 135 MONTHS.

AND WHAT THE GOVERNMENT ARGUED IN MS. HOLMES'S CASE, AMONG OTHER THINGS, IS THAT YOU SHOULD SEND A MESSAGE TO THE COMMUNITY THROUGH THE VEHICLE THAT YOU HAVE HERE, BECAUSE YOU HAVE THE PRESS GATHERED WHO HAVE BEEN REPORTING ON THIS CASE EXTENSIVELY FOR MANY YEARS NOW, AND YOU HAVE THIS BASIC MOUTHPIECE TO GET THE WORD OUT IN THE COMMUNITY THAT IF YOU'RE GOING TO COMMIT FRAUD, YOU'RE GOING TO GET A VERY HARSH

SENTENCE.

1

3

4

01:53PM

01:53PM

01:53PM

01:53PM

01:53PM

01:53PM 6

01:53PM 7

01:53PM 8

01:53PM 9

01:53PM 10

01:53PM 11

01:53PM 12

01:53PM 13

01:54PM 14

01:54PM 15

01:54PM 16

01:54PM 17

AND WHAT THE GOVERNMENT SAID IN THE CASE OF MS. HOLMES IS THAT ORDINARILY YOU MIGHT THINK THAT IS NOT FAIR BECAUSE THE DEFENDANT REALLY HAS NO CONTROL OVER THAT, BUT HERE THE GOVERNMENT SAID MS. HOLMES ACTUALLY COURTED THE PRESS, AND, THEREFORE, IT'S FAIR IN THIS CASE TO USE THAT MOUTHPIECE, IF YOU WILL, TO GET THE WORD OUT, THE GENERAL DETERRENCE WORD.

AND THEN THEY TRIED TO PUT THIS ROUND PEG OF MR. BALWANI INTO A ROUND HOLE OF THIS MEDIA ISSUE WHICH DOESN'T EXIST FOR MR. BALWANI.

EVEN IF YOU THINK THAT MS. HOLMES WAS ICARUS AND FLEW TOO CLOSE TO THE SUN, MR. BALWANI DID NOT SEEK THE SUN. HE WAS NOT ON THE COVER OF MAGAZINES, HE DID NOT GIVE INTERVIEWS, AND HE DID NOT GO AROUND THE COUNTRY ACCEPTING AWARDS, AND HE DID NOT SERVE ON THE BOARD OF PRESTIGIOUS INSTITUTIONS LIKE HARVARD UNIVERSITY. HE DIDN'T ASK FOR ANY OF THAT. ALL HE ASKED FOR WAS A DOLLAR AND A CHANCE TO WORK HARD, AND HE IS VERY DIFFERENT FROM MS. HOLMES.

SOME OF THE EVIDENCE THAT THE JURY FOUND WAS THE MOST SIGNIFICANT EVIDENCE IN MS. HOLMES'S CASE, THE EVIDENCE THAT MS. HOLMES FALSIFIED PHARMACEUTICAL REPORTS, AND SHE SAID THIS ON THE STAND, THERE WAS REALLY NO DISPUTE ABOUT THAT, SHE SAID THAT SHE DIDN'T THINK SHE WAS DOING ANYTHING WRONG.

BUT MR. BALWANI KNEW NOTHING ABOUT MS. HOLMES PUTTING LOGOS ON PHARMA REPORTS THAT SHOULDN'T HAVE BEEN ON THERE OR

01:54PM 24

01:54PM 25

1 01:54PM 01:54PM 2 01:54PM 3 01:54PM 4 01:54PM 5 01:54PM 6 01:54PM 7 01:55PM 8 01:55PM 9 01:55PM 10 01:55PM 11 01:55PM 12 01:55PM 13 01:55PM 14 01:55PM 15 01:55PM 16 01:55PM 17 01:55PM 18 01:55PM 19 01:55PM 20 01:55PM 21 01:55PM 22 01:55PM 23 01:55PM 24 01:56PM 25

CHANGING WORDING IN THE REPORTS. MR. BALWANI DIDN'T DO THAT.

SO EVEN IF YOU THINK -- AND THE JURY APPARENTLY MAY HAVE THOUGHT IN MS. HOLMES'S CASE THAT THAT'S AN ISSUE FOR MS. HOLMES. THAT'S NOT WHAT MR. BALWANI DID. HE DIDN'T SEEK THE MEDIA.

AND I WANT TO POINT OUT A FEW THINGS THAT MR. SCHENK OMITTED. SO THERE'S AN ARTICLE THAT THE COURT IS VERY FAMILIAR WITH NOW HAVING SAT THROUGH TWO TRIALS AND THAT'S THE "FORTUNE" MAGAZINE ARTICLE AUTHORED BY ROGER PARLOFF. AND MS. HOLMES IS ON THE COVER OF THAT "FORTUNE" ISSUE, YOU MIGHT RECALL.

THE GOVERNMENT PLAYED TAPES OF MS. HOLMES TALKING TO ROGER PARLOFF AND MADE A CASE THAT THERE WERE FRAUDULENT REPRESENTATIONS IN THERE.

WHAT THE GOVERNMENT DIDN'T TELL YOU IS THAT MR. BALWANI ALSO SAT FOR A MUCH BRIEFER INTERVIEW WITH MR. PARLOFF, AND THE GOVERNMENT DIDN'T PLAY THAT TAPE AT TRIAL. AND THE REASON IS BECAUSE THERE'S NOTHING IN THERE WHERE MR. BALWANI MAKES ANY MISREPRESENTATIONS TO MR. PARLOFF.

SO EVEN WHEN MR. BALWANI HAD THE OPPORTUNITY, WHICH WAS RARE, BY THE WAY, I CAN'T EVEN THINK OF ANOTHER TIME WHEN HE GAVE AN INTERVIEW, EVEN WHEN HE HAD THE OPPORTUNITY TO HAVE A DIRECT VEHICLE WITH MR. PARLOFF TO SAY WHATEVER HE WANTED TO SAY THAT THE GOVERNMENT CLAIMS HE'S GOING TO SAY FRAUDULENT THINGS, HE DIDN'T DO IT. HE DIDN'T SAY ANYTHING FRAUDULENT, AND THE GOVERNMENT DIDN'T PLAY THE TAPE.

1 01:56PM 2 01:56PM 3 01:56PM 01:56PM 4 01:56PM 01:56PM 6 01:56PM 7 01:56PM 8 01:56PM 9 01:56PM 10 01:56PM 11 01:56PM 12 01:56PM 13 01:56PM 14 01:56PM 15 01:57PM 16 01:57PM 17 01:57PM 18 01:57PM 19 01:57PM 20 01:57PM 21 01:57PM 22 01:57PM 23 01:57PM 24 01:57PM 25

SO FOR THE GOVERNMENT TO SAY THAT SOMEHOW THE MEDIA ISSUES ARE EQUIVALENT BETWEEN THESE TWO DEFENDANTS AND THEY USE THAT AS A REASON TO GIVE MS. HOLMES A HARSHER SENTENCE, THAT IS ABSOLUTELY NOT APPLICABLE TO MR. BALWANI AND FOR THE SAME REASON THAT THE GOVERNMENT ARGUED IT'S AN AGGRAVATING FACTOR IN MS. HOLMES'S CASE, IT IS A MITIGATING FACTOR IN THIS CASE.

LET'S MOVE ON TO SOME OTHER THINGS. STILL ON THE NATURE AND CIRCUMSTANCES OF THE OFFENSE, YOUR HONOR.

SO MR. BALWANI, THERE'S NO DISPUTE, WANTED THIS COMPANY TO SUCCEED. MR. BOSTIC SAID THAT DURING CLOSING ARGUMENT THAT HE WANTED THEM TO SUCCEED. AGAIN, IT'S SOMETHING THAT TAKES US OUT OF THE HEARTLAND. THERE'S LOTS OF CASES WHERE THERE IS NO INVESTMENT, IT'S A SCAM. THIS WAS A COMPANY THAT MR. BALWANI WAS TRYING TO BUILD.

AND IN ORDER TO BUILD IT, HE HAD A LOT OF DATA POINTS, RIGHT? HE KNEW THAT THE SCIENTIFIC TEAM HAD DONE HOURS AND HOURS OF WORK TO SUBMIT AN FDA APPLICATION TO GET THEIR 4.0 DEVICE APPROVED. AND, YOU KNOW, IF YOU'RE GOING TO COMMIT A FRAUD, WHY GO THROUGH THE EFFORTS? I MEAN, THIS WAS -- HE WAS GETTING THE DATA AND THE COMPANY WAS WORKING ON THESE THINGS, AND THAT THE SCIENCE WAS REAL, AND THAT IT IS GOING TO BE SUCCESSFUL.

AND IN ORDER TO TRY TO MAKE IT AS SUCCESSFUL AS HE COULD, HE TOOK RISKS. HE WENT TO THAILAND AND MEXICO DURING THE HEIGHT OF THE H1N1 FLU SCARE, THAT WAS A VERY DANGEROUS DISEASE

1 01:57PM 2 01:57PM 3 01:57PM 01:57PM 4 01:57PM 01:58PM 01:58PM 7 8 01:58PM 01:58PM 9 01:58PM 10 01:58PM 11 01:58PM 12 01:58PM 13 01:58PM 14 01:58PM 15 01:58PM 16 01:58PM 17 01:58PM 18 01:58PM 19 01:58PM 20 01:59PM 21 01:59PM 22 01:59PM 23 01:59PM 24

01:59PM 25

AT THE TIME, AND HE WENT THERE SO HE COULD TRY TO GET THE DEVICE TESTED IN HOSPITALS IN THOSE PLACES. AND EVEN LATER HE WENT TO COLUMBIA WHERE AT THAT POINT WAS THE HOTBED OF THE ZIKA DISEASE PANIC. HE WENT TO COLUMBIA, AND AGAIN, TRYING TO GET THE DEVICE TESTED SO IT COULD EVENTUALLY BE USED FOR ZIKA TESTING. HE WENT TO THOSE HOTBED AREAS BECAUSE HE WANTED THE COMPANY TO SUCCEED. THAT'S AT PERSONAL RISK, RIGHT? AND HE LOST A LOT HERE, YOUR HONOR, AND IT'S NOT JUST THE MONEY.

SO MR. BALWANI WAS THE SECOND IN COMMAND. I KNOW THE COURT HAS SAID THAT, WELL, MAYBE THEY WERE COEQUALS HERE. IN SOME WAYS THEY WERE, BUT THERE IS NO DOUBT THAT IT WAS MS. HOLMES WHO WAS IN CHARGE, THAT SHE WAS THE CEO, THAT SHE HAD THE POWER TO FIRE MR. BALWANI, THAT IF SHE DIDN'T LIKE WHAT HE WAS DOING, SHE COULD HAVE FIRED HIM, SHE COULD HAVE TOLD HIM TO DO SOMETHING DIFFERENT, SHE COULD HAVE DEMOTED HIM, ANY OF THOSE THINGS.

AND THE GOVERNMENT HAS ARGUED REPEATEDLY JUST THAT POINT, THAT MS. HOLMES IS THE FACE OF THE COMPANY, SHE'S THE CEO, THE BUCK STOPPED THERE, AND THAT SHE HAD THE POWER TO FIRE MR. BALWANI. SO NOW THAT HER SENTENCING IS OVER, THEY'RE PERHAPS TAKING A DIFFERENT VIEW OF THE WORLD.

LET ME GO OVER A FEW POINTS THAT MR. SCHENK MADE THAT I THINK ARE IMPORTANT TO ADDRESS, YOUR HONOR.

WE HAVE TALKED ABOUT IN OUR SENTENCING MEMO THE NATURE OF THE SENTENCING GUIDELINES. AND AS I SAID BEFORE, I THINK THE

1 01:59PM 2 01:59PM 3 01:59PM 01:59PM 4 01:59PM 01:59PM 01:59PM 7 8 01:59PM 02:00PM 9 02:00PM 10 02:00PM 11 02:00PM 12 02:00PM 13 02:00PM 14 02:00PM 15 02:00PM 16 02:00PM 17 02:00PM 18 02:00PM 19 02:00PM 20 02:00PM 21 02:00PM 22 02:00PM 23 02:00PM 24 02:01PM 25

GOVERNMENT IS FAR TOO WEDDED, MORE THAN THE LAW ALLOWS, WEDDED TO THE SENTENCING GUIDELINES IN THIS CASE. THE FRAUD LOSS AMOUNT, AS WE SAID IN OUR PAPERS, THEY DON'T DISTINGUISH BETWEEN A DEFENDANT LIKE MR. BALWANI AND A DEFENDANT WHO IS JUST RUNNING A FICTITIOUS COMPANY THAT HAS NOTHING, NEVER HAD ANYTHING, AND IT'S JUST A COMPLETE SCAM. THERE'S NO DISTINGUISHING BETWEEN THOSE TYPES OF DEFENDANTS.

AND SO WHAT THE LOSS AMOUNT TABLE DOES IS ASSIGNS A CERTAIN NUMBER TO A CERTAIN LOSS AMOUNT, AND I UNDERSTAND THE COURT HAS MADE THOSE FINDINGS THIS MORNING OR THIS AFTERNOON.

SO EVEN THOUGH THAT'S WHAT THE GUIDELINES REQUIRE, THERE IS SO MUCH OF A DISPARITY BETWEEN DIFFERENT DEFENDANTS IN DIFFERENT CASES, AND I THINK THE COURT HAS TO LOOK AT THE FIRST PERSON AS AN INDIVIDUAL AND WHAT REALLY HAPPENED, AND NOT ONLY WHAT HAPPENED IN THE OFFENSE CONDUCT, BUT ALSO THE ENTIRE HEALTH CARE, THE ENTIRE PERSONA, THE ENTIRE HISTORY AND MAKE A DECISION BASED ON THAT AND NOT JUST ON THE GUIDELINES.

THE POINT I'M MAKING, YOUR HONOR, THE GUIDELINES, WE HAVE POINTED OUT MANY SCHOLARS HAVE COMMENTED, ESPECIALLY IN A CASE LIKE THIS, THEY CAN YIELD ABSURD RESULTS, AND WE THINK THAT WOULD BE THE CASE HERE FOR MR. BALWANI.

THE GOVERNMENT SAYS THAT IT'S AN AGGRAVATING FACTOR THAT MR. BALWANI HAS A SUPPORT NETWORK. I THINK THAT'S THE FIRST TIME THAT I HAVE HEARD THAT KIND OF ARGUMENT. USUALLY THE PRESENCE OF A SUPPORT NETWORK IS A REASON WHY THE DEFENDANT

WON'T BE A DANGER IN THE FUTURE. AND THERE REALLY ISN'T ANY EVIDENCE THAT HE WOULD BE.

FIRST OF ALL, HE'S ALREADY IN HIS LATE 50S, AND ALL OF THE STUDIES ARE THAT PEOPLE IN THAT AGE RANGE ARE NOT LIKELY TO REPEAT OFFENSES. AND ALSO, WHEN YOU LOOK AT THE UNIQUE CIRCUMSTANCES OF THIS CASE, THERE'S NO CHANCE THAT MR. BALWANI WILL HAVE ANOTHER CRACK AT A COMPANY LIKE THERANOS. YOU KNOW, HE'S BASICALLY AND VERY UNFORTUNATELY RADIOACTIVE AS A RESULT OF THIS WHOLE AFFAIR.

BUT THE SUPPORT NETWORK, YOU KNOW, THE REASON HE HAS A SUPPORT NETWORK IS BECAUSE HE'S BEEN SO GIVING OVER THE YEARS. I MEAN, HE HAS A DEVOTED FAMILY WHO ARE HERE IN COURT TODAY, FIVE PEOPLE. NOT EVERYONE COULD MAKE IT. SOME OF THE FAMILY MEMBERS ARE IN INDIA, SOME ARE ON THE EAST COAST AS THE COURT HAS HEARD BEFORE.

BUT THE REASON THAT HE HAS A LOVING FAMILY SUPPORTING HIM AND ALL OF THESE PEOPLE WRITING LETTERS -- THE PEOPLE WHO WROTE LETTERS ARE NOT TRYING TO EXCUSE THE CONDUCT THAT THE JURY FOUND. THEY'RE JUST TRYING TO PRESENT TO THE COURT THE FULL PICTURE OF MR. BALWANI AND ABOUT WHO HE IS.

AND THE REASON HE HAS THAT SUPPORT NETWORK IS BECAUSE OF HOW CHARITABLE AND HOW SELFLESS HE'S BEEN FOR HIS ENTIRE LIFE. AND FOR MR. SCHENK AND THE GOVERNMENT TO SAY THAT'S SOMEHOW AN AGGRAVATING FACTOR, WELL, THAT'S JUST PUZZLING, YOUR HONOR. I DON'T GET THAT. AND I THINK THAT'S A REASON TO LOOK AT

1

3

02:01PM

02:01PM

02:01PM 2

02:01PM 4

02:01PM 5

02:01PM 6

02:01PM 7

02:01PM 8

02:01PM 9

02:01PM 10

02:01PM 11

02:01PM 12

02:01PM 13

02:01PM 14

02:02PM 15

02:02PM 16

02:02PM 17

02:02PM 18

02:02PM 19

02:02PM 20

02:02PM 21

02:02PM 22

02:02PM 23

02:02PM 24

1 02:02PM 02:02PM 2 3 02:02PM 02:02PM 4 02:02PM 5 02:02PM 6 02:02PM 7 02:02PM 8 02:03PM 9 02:03PM 10 02:03PM 11 02:03PM 12 02:03PM 13 02:03PM 14 02:03PM 15 02:03PM 16 02:03PM 17 02:03PM 18 02:03PM 19 02:03PM 20 02:03PM 21 02:03PM 22 02:03PM 23 02:03PM 24 02:03PM 25

MR. BALWANI AS A CANDIDATE FOR LENIENCY AND NOT THE OTHER WAY AROUND.

I WANT TO ADDRESS ONE REALLY IMPORTANT THING, YOUR HONOR, AND THAT IS MR. SCHENK'S ARGUMENT THAT SOMEHOW MR. BALWANI HAS NOT ACCEPTED RESPONSIBILITY AND THAT'S ANOTHER AGGRAVATING FACTOR HE CLAIMS.

SO THERE IS A GUIDELINE ADJUSTMENT. WE HAVE NOT ARGUED FOR THAT ADJUSTMENT. THE COURT IS NOT APPLYING THE 3 POINT REDUCTION FOR ACCEPTANCE OF RESPONSIBILITY. WE HAVE NOT ASKED FOR THAT.

MR. BALWANI EXERCISED HIS FIFTH AMENDMENT RIGHT NOT TO TESTIFY AT TRIAL. AND FOR MR. SCHENK TO SAY THAT SOMEHOW THE FACT THAT HE HASN'T ACCEPTED RESPONSIBILITY IN A CASE THAT HE WENT TO TRIAL AND EXERCISED THAT FIFTH AMENDMENT RIGHT, I BELIEVE MR. SCHENK'S POINT IS AN IMPROPER COMMENT ON MR. BALWANI'S FIFTH AMENDMENT RIGHT BECAUSE HE HAS NO OPPORTUNITY TO ACCEPT RESPONSIBILITY UNLESS HE WAIVES THAT RIGHT.

THE OTHER THING THAT MR. SCHENK SAYS ABOUT THAT IS SOMEHOW OUR ARGUMENT THAT MR. BALWANI IS BLAMING INVESTORS FOR WHAT HAPPENED AFTER HE LEFT THE COMPANY IS A REASON WHY HE'S NOT ACCEPTING RESPONSIBILITY. I WANT TO JUST CLARIFY THE RECORD ON THAT BECAUSE I THINK THAT IS A TWISTED WAY TO LOOK AT THIS.

WHAT OUR ARGUMENT IS, IS NOT THAT INVESTORS ARE TO BLAME SOMEHOW. WHAT WE HAVE SAID ABOUT THAT HAD TO DO WITH THE LOSS

CALCULATION. I DON'T WANT TO REPEAT THOSE ARGUMENTS, BUT IT'S 1 02:04PM 2 IMPORTANT BECAUSE MR. SCHENK MENTIONED THIS, IS THAT WHEN 02:04PM MR. BALWANI LEFT THE COMPANY, THE COMPANY HAD \$350 MILLION IN 3 02:04PM THE BANK. THAT'S NOT DISPUTED. HE ALSO HAD IP, WHICH THE 02:04PM 4 THINGS WE PUT IN THE RECORD SHOW WE BELIEVE WERE WORTH MANY, 02:04PM 02:04PM 6 MANY HUNDREDS OF MILLIONS OF DOLLARS, AND THE GOVERNMENT HAS A DIFFERENT VIEW OF THAT. BUT WHATEVER YOU THINK ABOUT THAT, 02:04PM 7 MR. BALWANI AND HIS DEFENSE TEAM HAS NEVER ARGUED THAT THERANOS 02:04PM 8 WAS ENTITLED TO \$350 MILLION AND SOMEHOW YOU WOULD BE DOING 02:04PM 9 02:04PM 10 PEOPLE A FAVOR IF THEY RETURN IT TO INVESTORS. NO. 02:04PM 11 THE POINT WAS THAT WHEN MR. BALWANI LEFT THE COMPANY, THE 02:04PM 12 COMPANY DID HAVE \$350 MILLION AND HAD THE IP, AND INSTEAD OF 02:04PM 13 TRYING TO OPERATE FOR ANOTHER TWO YEARS AND MAKE A GO OF IT AS A COMPANY, THEY COULD HAVE CLOSED THEIR DOORS RIGHT THEN AND 02:04PM 14 02:04PM 15 DISTRIBUTED WHATEVER THEY COULD DISTRIBUTE, INCLUDING THE CASH THAT CAME FROM THE INVESTORS IN THE FIRST PLACE, DISTRIBUTED 02:04PM 16 02:04PM 17 THAT BACK TO INVESTORS, ALONG WITH WHATEVER THEY COULD GET FROM 02:05PM 18 THE IP. AND THAT ARGUMENT HAS NOTHING TO DO WITH WHETHER 02:05PM 19 MR. BALWANI ACCEPTED RESPONSIBILITY. WE HAVE NOT ASKED FOR THE GUIDELINE ADJUSTMENT, AS I'VE SAID. 02:05PM 20

02:05PM 21

02:05PM 22

02:05PM 23

02:05PM 24

02:05PM 25

BUT FOR MR. SCHENK TO SAY WE SHOULD GIVE HIM A HARSHER SENTENCE BECAUSE HE DIDN'T ACCEPT RESPONSIBILITY WHEN YOU PUT ASIDE WHAT I CONSIDER UNFOUNDED ARGUMENT ABOUT THE 350 MILLION AND THE TIME AFTER MR. BALWANI LEFT, WHEN YOU PUT THAT ASIDE, WHICH YOU SHOULD, YOU END UP WITH WHAT I THINK IS AN IMPROPER

COMMENT ON HIS FIFTH AMENDMENT RIGHTS.

THE COURT: WELL, PARDON ME FOR INTERRUPTING AND LET ME DO SO NOW TO TELL YOU THAT THIS COURT IS NOT GOING TO IN ITS SENTENCE -- AND I AM GOING TO SENTENCE YOUR CLIENT. YOU KNOW THAT. THAT'S WHY WE'RE HERE. BUT I AM NOT GOING TO SENTENCE HIM IN ANY WAY CONSIDERING THE FACT THAT HE CHOSE TO EXERCISE HIS UNITED STATES CONSTITUTIONAL RIGHT TO NOT TESTIFY AND REMAIN SILENT. THAT'S A CHERISHED RIGHT THAT WE ALL ENJOY, AND HE EXERCISED THAT RIGHT. THERE'S NO PUNITIVE ACTION ON EXERCISING A CONSTITUTIONAL RIGHT. I DON'T TAKE MR. SCHENK'S COMMENT THAT WAY THAT HE WAS SUGGESTING THAT.

I UNDERSTAND HOW IT COULD BE INTERPRETED THAT WAY. IT'S NOT HOW THE COURT RECEIVED IT, AND IT'S CERTAINLY NOT HOW THE COURT IS GOING TO EVALUATE THE APPROPRIATE SENTENCE IN THIS CASE. YOUR CLIENT HAS THE ABSOLUTE RIGHT NOT TO TESTIFY. HE WILL NOT BE PUNISHED FOR THE EXERCISE OF THAT.

YOU'RE COMPLETELY CORRECT THE GUIDELINES DO PROVIDE UNDER 3E1(A) AND (B) THE OPPORTUNITY, SHOULD A DEFENDANT CHOOSE TO EXERCISE THAT OPPORTUNITY, TO RECEIVE A 3 LEVEL REDUCTION SHOULD THEY WISH TO DO SO AND IF THEY OTHERWISE QUALIFY, AND HE CHOSE NOT TO DO THAT.

SO TO YOUR POINT, HE IS NOT ENTITLED TO THE GUIDELINE REDUCTION. BUT I AM NOT GOING TO EVEN CONSIDER THE FACT THAT HE DID NOT TESTIFY NOR THAT HE -- I THINK IT WAS IN -- I CAN'T REMEMBER WHAT PARAGRAPH IT WAS IN THE PSR, BUT MS. GOLDSBERRY

UNITED STATES COURT REPORTERS

02:07PM 25

1

2

3

4

02:05PM

02:05PM

02:05PM

02:05PM

1 02:07PM 2 02:07PM 3 02:07PM 02:07PM 4 02:07PM 02:07PM 6 02:07PM 7 02:07PM 8 02:07PM 9 02:07PM 10 02:07PM 11 02:07PM 12 02:07PM 13 02:07PM 14 02:07PM 15 02:07PM 16 02:08PM 17 02:08PM 18 02:08PM 19 02:08PM 20 02:08PM 21 02:08PM 22 02:08PM 23 02:08PM 24

02:08PM 25

NOTES THAT HE DID NOT MAKE ANY STATEMENT AS FAR AS ACCEPTANCE OF RESPONSIBILITY, AND FOR PURPOSES OF HER REPORT CALCULATING THE GUIDELINE CALCULATIONS THAT WAS AN IMPORTANT INQUIRY, BUT FOR THAT REASON ONLY.

MR. COOPERSMITH: YOUR HONOR, I REALLY APPRECIATE THE COURT'S COMMENTS, AND I'M, OF COURSE, NOT SURPRISED, BUT ALSO GLAD TO HEAR IT.

AND THE POINT I'M MAKING IS NOT THAT I THOUGHT THE COURT WOULD PUNISH MR. BALWANI FOR THAT, AND, OF COURSE, THE COURT WOULDN'T DO THAT AND SHOULDN'T. IT'S JUST THAT MR. SCHENK'S ARGUMENT NEEDS TO BE THROWN OUT BECAUSE THE IDEA THAT HE'S NOT ACCEPTING RESPONSIBILITY, THAT'S A REASON TO IMPOSE MORE PRISON TIME, THAT JUST I DON'T THINK FLIES.

BUT LET ME MOVE ON, YOUR HONOR.

MR. SCHENK MENTIONED, YOU KNOW, CERTAIN HARMS THAT WERE CAUSED, RIGHT? SO ONE THING HE COMMENTED ON WAS THE INVESTOR HARM. AND IF YOU BELIEVE THERE IS INVESTOR LOSS, AND I UNDERSTAND THE COURT SO FOUND, THEN THAT IS A HARM IN THE CASE.

BUT BASICALLY THIS IS A DOUBLE COUNTING OR MAYBE IT'S QUADRUPLE COUNTING OR QUINTUPLE COUNTING. THE IDEA IS THAT THE GUIDELINE MR. SCHENK IS TRYING TO TAKE ADVANTAGE OF ALREADY ACCOUNT FOR A VERY LENGTHY SENTENCE JUST FROM THAT ONE FACTOR UNDER 3553(A) FACTORS OF THE GUIDELINES WOULD DICTATE A CERTAIN GUIDELINE RANGE, WHICH IS OBVIOUSLY ADVISORY.

BUT MR. SCHENK WANTS TO THEN DOUBLE COUNT THAT ARGUMENT

AGAIN IN ARGUING FOR A SENTENCE EVEN ABOVE THE GUIDELINE RANGE THE COURT CALCULATED.

AND THEN PATIENT HARM. THE COURT ALREADY, AND WE APPRECIATE, DID NOT FIND THE FACTOR OF MR. BALWANI CONSCIOUSLY OR RECKLESSLY CAUSING PATIENT HARM. ALL OF US MAKE ERRORS OBVIOUSLY. WE POINTED TO THE EXAMPLE IN THE BRIEF, THE CLEVELAND CLINIC EXAMPLE. THIS IS ALL PUBLIC, THAT THE CLEVELAND CLINIC WAS FOUND TO BE IN IMMEDIATE JEOPARDY BY THE CMS LABORATORY REGULATORS ON MANY SCORES, AND IN FACT SOME OF THE SAME THINGS THAT THERANOS WAS FOUND FOR, AND THEY HAD TO CORRECT THE PROBLEMS, AND NO ONE WAS PROSECUTED.

BUT I BRING THAT UP BECAUSE WE'RE NOT IN THAT CASE, BUT ALL LABS MAKE ERRORS. IN FACT, DR. BURNS ON THE STAND SAID, WELL, HE HAD SOME PROBLEMS WITH OTHERS LABS.

SO THAT'S WHAT HAPPENED. SO BY DEFINITION ANY LABORATORY CASE, WHETHER IT'S CRIMINAL OR CIVIL OR REGULATORY, IS GOING TO INVOLVE SOME ERROR THAT A LAB MADE, AND, OF COURSE, THERE'S ALWAYS THAT HARM.

SO MR. BALWANI NEVER WANTED THAT. THERE'S NO EVIDENCE, AS WE'VE SAID BEFORE AND I WON'T REPEAT THOSE ARGUMENTS, BUT NEVER WANTED ANYONE TO BE HARMED. HE WOULDN'T HARM A FLY.

INSTEAD, WHAT MR. BALWANI HAS DEMONSTRATED HIS ENTIRE LIFE WAS THAT HE WANTS TO GIVE. HE'S GRATEFUL TO BE HERE, HE'S GRATEFUL TO BE A UNITED STATES CITIZEN, HE'S GRATEFUL TO HAVE HAD THE OPPORTUNITY TO GIVE TO HIS COMMUNITY. HE'S DONE THAT

1

02:08PM

OVER AND OVER AGAIN. HE'S DEMONSTRATED HIS CHARACTER.

OBVIOUSLY HE WAS CONVICTED BY A JURY OF FRAUD AND THE COURT HAS TO SENTENCE HIM OF COURSE, AND THAT'S WHY WE'RE HERE, BUT HE IS DESERVING OF A LENIENT SENTENCE. HE'S NOT MS. HOLMES. HE DID NOT PURSUE THE SAME PATH AS SHE DID. HE DID NOT PURSUE FAME AND FORTUNE AND RECOGNITION AND GLORY. HE DID NOT SELL A SINGLE SHARE. HE DID NOT TRY TO PROFIT. HE DID NOT TRY TO HARM ANYBODY, AND, YES, THE COURT HAS TO SENTENCE HIM, BUT NOT TO THE RANGE THAT THE GOVERNMENT IS RECOMMENDING OR PROBATION IS RECOMMENDING, OR MS. HOLMES RECEIVED BY THIS COURT.

NOT ALL DEFENDANTS ARE THE SAME. IT'S AN INDIVIDUALIZED DETERMINATION.

AND WITH THAT, YOUR HONOR, THANK YOU.

THE COURT: THANK YOU.

AND I INTERRUPTED YOUR PRESENTATION WITH MY COMMENTS, AND I DIDN'T MEAN TO SUGGEST IN ANY WAY THAT YOU SHOULD IN ANY WAY RETREAT FROM ANY COMMENTS. SO IF YOU HAVE ANYTHING YOU DIDN'T GET A CHANCE TO SAY BECAUSE OF MY INTERRUPTION, YOU CERTAINLY SHOULD GO FORWARD NOW. I WANT YOU TO GIVE YOUR FULSOME RESPONSE TO BOTH THE GOVERNMENT'S AND YOUR FULSOME POSITION. SO I RARELY INTERRUPT SOMEONE DURING THEIR PRESENTATION. I DID SO BECAUSE I WANTED YOU TO KNOW THE COURT'S FEELINGS ABOUT YOUR CLIENT'S EXERCISE OF HIS RIGHTS, BUT I DIDN'T MEAN TO INTERRUPT YOU.

02:11PM	1	SO IF YOU HAD SOMETHING ELSE YOU WANTED TO SAY, REVIEW
02:11PM	2	YOUR NOTES AND LET ME KNOW, PLEASE.
02:11PM	3	MR. COOPERSMITH: YEAH, I MIGHT TAKE A MOMENT TO
02:11PM	4	CONFER WITH MY TEAM, YOUR HONOR.
02:11PM	5	THE COURT: SURE. GO RIGHT AHEAD.
02:11PM	6	MR. COOPERSMITH: AND I MIGHT AS WELL BE THOROUGH
02:11PM	7	WHILE WE'RE HERE.
02:11PM	8	THE COURT: ABSOLUTELY.
02:12PM	9	(DISCUSSION OFF THE RECORD.)
02:12PM	10	MR. COOPERSMITH: THANK YOU FOR THE COURT'S
02:12PM	11	INDULGENCE. I APPRECIATE IT.
02:12PM	12	THE COURT: OF COURSE.
02:12PM	13	MR. COOPERSMITH: A FEW OTHER THINGS I'M REMINDED I
02:12PM	14	SHOULD SAY FOR COMPLETENESS, AND I THINK THESE THINGS ARE
02:12PM	15	IMPORTANT.
02:12PM	16	FIRST OF ALL, ONE THING THE GOVERNMENT SAID, I WROTE IN MY
02:12PM	17	NOTES AND I THINK IT IS WORTH RESPONDING TO, AND THAT IS THEY
02:12PM	18	SAY MR. BALWANI WAS THE QUOTE, "DE FACTO LAB DIRECTOR" AFTER
02:12PM	19	DR. ROSENDORFF LEFT. I DON'T THINK THERE'S ANY BASIS FOR THAT.
02:12PM	20	MR. BALWANI WAS NOT THE DE FACTO LAB DIRECTOR.
02:12PM	21	THERE WERE, FIRST OF ALL, AS I SAID BEFORE, AN ENTIRE
02:12PM	22	SCIENTIFIC TEAM AT THERANOS, INCLUDING DR. SAKSENA WHO WERE
02:12PM	23	INVOLVED IN THE LAB. EVEN IF DR. DHAWAN AND DR. SAWYER WERE
02:13PM	24	NOT AS INVOLVED AS YOU MIGHT LIKE, THERE WAS A WHOLE TEAM OF
02:13PM	25	SCIENTISTS WHO WERE THERE, AND THEY WERE THERE TO MAKE SURE THE

LAB RESULTS WERE AS GOOD AS THEY COULD BE AND THEY WERE RUNNING SMOOTHLY.

AT THE SAME TIME, AS I SAID BEFORE, THE COMPANY WAS PHASING OUT THE EDISON DEVICES AND USING MORE COMMERCIAL DEVICES. IN FACT, THEY OPENED UP THIS LAB IN ARIZONA, AND DR. YOUNG WAS PUT IN CHARGE OF THE LAB, NOT MR. BALWANI, AND DR. YOUNG WAS QUALIFIED AS A LAB DIRECTOR.

THE IDEA THAT HE WAS ALL OF THE SUDDEN TAKING IT UPON HIMSELF TO OVERSEE WHAT RESULTS WERE BEING RELEASED TO PATIENTS, THAT'S JUST NOT THE CASE. THERE IS NOT A SINGLE TIME THAT MR. BALWANI SIGNED OFF ON RELEASING A RESULT TO A PATIENT. THAT JUST DIDN'T HAPPEN, AND HE'S NOT THE DE FACTO LAB DIRECTOR. HE WAS OPERATIONALLY INVOLVED IN THE LAB AS THE COURT KNOWS.

IN ADDITION, JUST A WORD ABOUT STIFLING DISSENT I THINK IS HOW THE GOVERNMENT PUT IT. AND, YOU KNOW, THE COURT HEARD FROM ERIKA CHEUNG, AND SHE GOT TO THERANOS AS A YOUNG GRADUATE OF THE UNIVERSITY OF CALIFORNIA AND WAS EXCITED TO WORK THERE, AND THEN SHE RAISED SOME ISSUES.

WELL, MR. BALWANI, THE GOVERNMENT WOULD HAVE YOU BELIEVE, YOUR HONOR, THAT SHE RAISED ISSUES AND MR. BALWANI TOLD HER, I DON'T WANT TO HEAR IT, JUST DO YOUR JOB, RUN THE SAMPLES, DON'T TALK TO ME.

THAT IS NOT AT ALL WHAT HAPPENED. WHEN IT GOT TO THE POINT OF MR. BALWANI, ACCORDING TO MS. CHEUNG, SAYING YOUR JOB

1

2

3

4

02:13PM

02:13PM

02:13PM

02:13PM

02:13PM

02:13PM 6

02:13PM 7

02:13PM 8

02:13PM 9

02:13PM 10

02:13PM 11

02:13PM 12

02:13PM 13

02:13PM 14

02:13PM 15

02:14PM 16

02:14PM 17

02:14PM 18

02:14PM 19

02:14PM 20

02:14PM 21

02:14PM 22

02:14PM 23

02:14PM 24

02:14PM 25

IS TO RUN SAMPLES, BY THAT TIME THERE HAD BEEN SCIENTIST AFTER 1 SCIENTIST, ESPECIALLY DR. YOUNG, WHO LOOKED AT HER CLAIMS AND 2 LOOKED AT WHAT SHE SAID ABOUT QC AND LOOKED AT WHAT SHE SAID 3 4 ABOUT PROFICIENCY TESTS. THE COURT MIGHT REMEMBER THERE WAS AN EXHIBIT, AND I DON'T

HAVE THE NUMBER, BUT THE COURT PROBABLY REMEMBERS IT WAS A TABLE OF NUMBERS SHOWING A COMPARISON BETWEEN THERANOS DEVICES AND MODIFIED PREDICATE -- I'M SORRY, ACTUAL PREDICATE MACHINES, FDA MACHINES, AND SOME OF THE NUMBERS ACCORDING TO THE GOVERNMENT WERE A LITTLE OFF.

DR. ROSENDORFF TESTIFIED THAT THAT WAS NOT A PROPER EXPERIMENT, IT DIDN'T SHOW A FAILURE. DR. PANDORI PUT TOGETHER A WHOLE POWERPOINT ABOUT HOW THIS ALTERNATIVE ASSESSMENT PROCEDURE WAS THE RIGHT WAY TO GO AND THAT WAS NOT THE CORRECT WAY TO ANALYZE THINGS.

SO BY THE TIME THAT MR. BALWANI ALLEGEDLY HAD A CONVERSATION WITH MS. CHEUNG WHERE SHE CLAIMED HE SAID JUST DO YOUR JOB, AND HE ALREADY HAD SCIENTISTS LOOK AT THIS, INCLUDING DR. YOUNG, ON EVERY SINGLE CLAIM. SO THIS WAS THE OPPOSITE OF A MANAGER NOT WANTING TO HEAR FROM MS. CHEUNG. HE SPENT A LOT OF TIME, A LOT OF COMPANY TIME, A LOT OF HIS EMPLOYEE'S TIME TRYING TO UNDERSTAND WHERE SHE WAS COMING FROM AND TO ADDRESS THE CONCERNS AS BEST AS HE COULD.

SO THAT IDEA OF SHUTTING PEOPLE DOWN I THINK IS -- THERE'S A SORT OF MYTH THAT'S DEVELOPED ABOUT MR. BALWANI. I THINK IF

02:14PM

02:14PM

02:14PM

02:14PM

02:14PM

02:15PM 6

02:15PM 7

02:15PM 8

02:15PM 9

02:15PM 10

02:15PM 11

02:15PM 12

02:15PM 13

02:15PM 14

02:15PM 15

02:15PM 16

02:15PM 17

02:15PM 18

02:15PM 19

02:15PM 20

02:15PM 21

02:15PM 22

02:15PM 23

02:15PM 24

YOU READ THE MEDIA, HE'S SOME KIND OF ENFORCER. IF YOU READ 1 THE LETTERS FROM EMPLOYEES, THAT'S NOT HOW HE WAS PERCEIVED, AT LEAST NOT BY EVERYBODY. AND THIS IDEA THAT HE'S SHUTTING 3 MS. CHEUNG DOWN IS JUST NOT CONSISTENT WITH THE FACTS. THE OTHER THING I WANTED TO SAY, AND WE PUT THIS IN OUR SENTENCING PAPERS AND I MENTIONED THIS BEFORE, HE DID IN FACT HAVE HIS FAMILY TESTED AT THERANOS. AND IT WAS NOT JUST HIS

MOM, IT WAS HIS SIBLINGS AND OTHERS. WHY WOULD YOU DO THAT IF YOU THOUGHT THAT THE LAB WAS SO BAD? I'M NOT SAYING THAT TO ARGUE IT AGAINST THE JURY'S VERDICT, BECAUSE WE'RE HERE BECAUSE OF A JURY VERDICT. BUT IT SHOWS YOU THAT NOT EVERYTHING THAT THE GOVERNMENT SAYS ABOUT MR. BALWANI AND NOT EVERYTHING THEY SHOWED AT TRIAL IS NECESSARILY TRUE. AND THERE'S NO BETTER TIME TO THINK ABOUT IT OF HOW MR. BALWANI WANTED THE COMPANY TO BE AND WHY HE HAD CONFIDENCE IN THE LAB. HE WAS NOT TRYING TO CREATE PATIENT HARM. THERE'S NO BETTER EVIDENCE HERE REALLY THAN THE FACT THAT HE HAS HIS OWN FAMILY TESTED THERE. NOBODY WOULD DO THAT. HE'S BELOVED BY HIS FAMILY, AND HE LOVES THEM, AND IT JUST DOESN'T WORK THAT WAY.

SO, AGAIN, I'M NOT TRYING TO SAY THAT WE SHOULD IGNORE THE VERDICT. WE CAN'T DO THAT. BUT I THINK IT IS A MITIGATING FACTOR THAT THE COURT SHOULD CONSIDER.

SO THANK YOU FOR THE EXTRA TIME, YOUR HONOR. I APPRECIATE IT.

THE COURT: OF COURSE.

02:17PM 25

MR. COOPERSMITH: I'M SURE WITH A COMPLICATED CASE 1 02:17PM 02:17PM 2 LIKE THIS I COULD GO ON FOR HOURS OR DAYS AS I DID DURING CLOSING ARGUMENT, BUT I DO WANT THE COURT TO TAKE THESE THINGS 3 02:17PM 02:17PM 4 INTO CONSIDERATION. OBVIOUSLY, WE'VE SUBMITTED A LOT OF 02:17PM 5 MATERIAL THAT THE COURT HAS READ, AND WE DO THINK THAT 02:17PM 6 MR. BALWANI IS DESERVING OF LENIENCY, AND THAT'S WHAT WE ASK THE COURT TO DO. 02:17PM 7 THE COURT: THANK YOU. 02:17PM 8 ANYTHING FURTHER FROM THE GOVERNMENT? 02:17PM 9 02:17PM 10 MR. SCHENK: NO. THANK YOU, YOUR HONOR. THE COURT: PROBATION, ANYTHING FURTHER? 02:17PM 11 02:17PM 12 PROBATION OFFICER: NO, YOUR HONOR. 02:17PM 13 THE COURT: ALL RIGHT. THANK YOU. IN JUST A MOMENT I'M GOING TO CALL UPON MR. BALWANI TO ASK 02:17PM 14 02:18PM 15 02:18PM 16 02:18PM 17 02:18PM 18 02:18PM 19

02:18PM 20

02:18PM 21

02:18PM 22

02:18PM 23

02:18PM 24

02:18PM 25

IF HE WISHES TO BE HEARD, BUT I'LL TAKE A MOMENT OF PERSONAL PRIVILEGE, IF I MAY, AND I SHOULD HAVE DONE THIS AT THE OUTSET TO THANK ALL COUNSEL, THANK YOU. WE WERE TOGETHER FOR A LONG TIME IN THIS TRIAL. IT WAS HARD FOUGHT ON BOTH SIDES. IT WAS MY GREAT PRIVILEGE TO WORK WITH ALL OF YOU, AND I APPRECIATE THAT.

AS MR. COOPERSMITH POINTS OUT, THE JURY HAS SPOKEN. THE REASON WE'RE HERE TODAY IS FOR THE SENTENCING. YOU ALL KNOW THAT SENTENCING IS THE MOST DIFFICULT THING THAT YOU DO AS LITIGATORS. IT'S CERTAINLY THE MOST DIFFICULT THING THAT A JUDGE DOES WHEN SHE IMPOSES A SENTENCE ON AN INDIVIDUAL.

02:18PM	1	BUT, AGAIN, I JUST WANTED TO THANK YOU ALL FOR YOUR
02:18PM	2	COURTESY THROUGHOUT THE TRIAL.
02:18PM	3	MR. BALWANI, SIR, YOU HAVE THE RIGHT TO BE HEARD AT YOUR
02:18PM	4	SENTENCING.
02:18PM	5	IS THERE ANYTHING YOU WOULD LIKE TO SAY OR ANYTHING YOU
02:18PM	6	WOULD LIKE ME TO KNOW BEFORE I IMPOSE SENTENCE?
02:18PM	7	MR. COOPERSMITH: YOUR HONOR, I WOULD JUST TELL THE
02:18PM	8	COURT THAT MR. BALWANI APPRECIATES THE INVITATION TO SPEAK, AND
02:19PM	9	WE KNOW HE HAS THAT RIGHT. HE ALSO HAS THE RIGHT NOT TO SPEAK,
02:19PM	10	AND HE CHOOSES TO EXERCISE HIS RIGHT NOT TO SPEAK.
02:19PM	11	THE COURT: OKAY. IS THAT CORRECT, MR. BALWANI?
02:19PM	12	THE DEFENDANT: YES, YOUR HONOR.
02:19PM	13	THE COURT: ALL RIGHT. THANK YOU VERY MUCH, SIR.
02:19PM	14	THANK YOU.
02:19PM	15	ALL RIGHT. ANYTHING FURTHER FROM EITHER SIDE?
02:19PM	16	MR. SCHENK: NO, YOUR HONOR.
02:19PM	17	MR. COOPERSMITH: NO, YOUR HONOR.
02:19PM	18	PROBATION OFFICER: NO, YOUR HONOR.
02:19PM	19	THE COURT: ALL RIGHT. THANK YOU VERY MUCH. AND
02:19PM	20	THANK YOU, COUNSEL, FOR THE TIME SPENT THIS MORNING. THIS WAS
02:19PM	21	HELPFUL TO THE COURT.
02:19PM	22	WE SPENT A LOT OF TIME GOING THROUGH THE NUANCES ABOUT THE
02:19PM	23	PRELIMINARY INFORMATION THAT MUST BE RESOLVED PRIOR TO THE
02:19PM	24	IMPOSITION OF A SENTENCE, AND AS I SAID, WE ALL KNOW WHY WE'RE
02:19PM	25	HERE. I'VE READ THE PSR. LET ME SAY I HAVE READ THE LETTERS

1 02:19PM 2 02:19PM 3 02:19PM 02:19PM 4 02:19PM 02:20PM 6 02:20PM 7 8 02:20PM 02:20PM 9 02:20PM 10 02:20PM 11 02:20PM 12 02:20PM 13 02:20PM 14 02:20PM 15 02:20PM 16 02:20PM 17 02:21PM 18 02:21PM 19 02:21PM 20 02:21PM 21 02:21PM 22 02:21PM 23 02:21PM 24

02:21PM 25

AND THE DOCUMENTS THAT HAVE BEEN SUPPLIED TO THE COURT, THE INFORMATION BOTH FROM THE GOVERNMENT AND THEIR EXPERTS, THEIR SENTENCING MEMORANDUM, AS WELL AS THE SENTENCING MEMORANDUM FROM THE DEFENDANT.

I'VE READ THE LETTERS THAT WERE PRESENTED TO THE COURT THAT SPEAK IN SUPPORT OF MR. BALWANI AND SPEAK TO HIS BACKGROUND. THEY SPEAK TO THE NATURE OF THEIR RELATIONSHIP WITH HIM, THEIR KNOWLEDGE OF HIM.

THERE WERE PHOTOGRAPHS, WEREN'T THERE, THAT SHOW MANY PUSH CARTS FROM PAKISTAN, I BELIEVE, AND INDIA THAT SHOW THE WORK OF THE CONTRIBUTIONS THAT MR. BALWANI HAS MADE AND THE EFFORTS THAT INDIVIDUALS WHO HAVE CHANGED THEIR LIVES, THEY'VE BEEN ABLE TO ESTABLISH BUSINESSES WITH PUSH CARTS, SELLING FRUITS, SELLING BEVERAGES, AND OTHER MATTERS TO IMPROVE THEIR LIVES.

SO TO MR. COOPERSMITH'S POINT, THESE ARE THINGS THAT AN INDIVIDUAL LOOKS AT, AND THEY HAVE A GREAT IMPRESSION, POSITIVE IMPRESSION ON THE COURT AS DO THE FAMILY SUPPORT, THE MANY LETTERS THAT SPOKE ABOUT THEIR RELATIONSHIP WITH MR. BALWANI AND THEIR SPECIAL CONNECTION WITH HIM, NOT JUST A BLOOD RELATIONSHIP BUT MORE.

I BELIEVE HIS BROTHERS ARE IN COURT, AND THEY ARE GRATEFUL TO HIM BECAUSE HE PAID FOR THEIR COLLEGE TUITION, HE PAID FOR THE TUITION THAT ALLOWED THEM TO GO TO COLLEGE, AND PERHAPS WHAT I HAVE LEARNED FROM HIM IN THE PSR WAS THAT HE WAS THE SON WHO WAS SENT FORWARD TO ACCOMPLISH MUCH AND TO RETURN MUCH TO

HIS FAMILY. HE DID THAT WITH HIS FAMILY. HE CONSISTENTLY SUPPORTED HIS FAMILY.

1

3

02:21PM

02:21PM

02:21PM 2

02:21PM 4

02:21PM 5

02:21PM 6

02:22PM 7

02:22PM 8

02:22PM 9

02:22PM 10

02:22PM 11

02:22PM 12

02:22PM 13

02:22PM 14

02:22PM 15

02:22PM 16

02:22PM 17

02:22PM 18

02:22PM 19

02:22PM 20

02:22PM 21

02:22PM 22

02:23PM 23

02:23PM 24

02:23PM 25

WE'RE TOLD ABOUT THE CHARITABLE GIFTS THAT HE MADE AND SOME OF THOSE WERE BEFORE HIS INVOLVEMENT WITH THE COMPANY. MANY OF THEM WERE AFTER HIS INVOLVEMENT WITH THE COMPANY AND CONTINUED INTO THE 2020, I THINK, WAS ONE DATE THAT I NOTED WHERE HE CONTINUED TO SUPPORT BOTH HIS -- THE TEMPLE THAT HE WORSHIPS AT. I THINK THAT'S WHERE THE -- I BELIEVE THAT'S WHERE THE WELL WAS IN MILPITAS, CALIFORNIA, TO ASSIST THE TEMPLE THERE IF I'M NOT MISTAKEN AND THAT'S MY RECOLLECTION.

BUT THAT SHOWS ANOTHER SIDE OF HIM, AND I THINK THAT WAS YOUR POINT, MR. COOPERSMITH.

AND TO YOUR POINT, MR. COOPERSMITH, SENTENCING IS ALWAYS INDIVIDUALIZED.

THE COURT NEEDS TO LOOK AT -- WE'VE TALKED ABOUT MS. HOLMES. SHE'S PART OF THIS CASE, BUT SHE'S NOT PART OF THIS SENTENCE. THE SENTENCE THAT THE COURT MUST CONSIDER IN THIS CASE IS INDIVIDUALIZED TO MR. BALWANI, AND THAT'S WHAT THE COURT INTENDS TO DO AND TALKING A LITTLE BIT ABOUT THE THINGS THAT I'VE LEARNED ABOUT HIM FROM THE PSR AND THAT HE SHARED WITH THE PROBATION OFFICER.

BUT WE KNOW THAT THE JURY SAT THROUGH THIS TRIAL FOR MONTHS, THEY HEARD THE VARIOUS WITNESSES, THEY HEARD THE ARGUMENTS OF COUNSEL, THEY HEARD THE CLOSING ARGUMENTS, THEY HEARD THE EVIDENCE, AND THEY LOOKED AT THE EVIDENCE VERY

UNITED STATES COURT REPORTERS

1 02:23PM 02:23PM 3 02:23PM 02:23PM 4 02:23PM 02:23PM 6 02:23PM 7 02:23PM 8 02:23PM 9 02:23PM 10 02:24PM 11 02:24PM 12 02:24PM 13 02:24PM 14 02:24PM 15 02:24PM 16 02:24PM 17 02:24PM 18 02:24PM 19 02:24PM 20 02:24PM 21 02:24PM 22 02:24PM 23 02:24PM 24

02:25PM 25

CAREFULLY. THERE WERE MANY, MANY EXHIBITS THAT WERE PRESENTED.

AS I'VE SAID PREVIOUSLY, A JURY THAT WAS SELECTED BY BOTH SIDES IS A REPRESENTATIVE OF THE COMMUNITY, AND WE ASKED THIS JURY TO COME IN AS THE COMMUNITY TO HEAR AND JUDGE AND TEST THE EVIDENCE THAT THE GOVERNMENT PUTS FORWARD THROUGH AN INDICTMENT AND IN THAT WAY TO RENDER THE COMMUNITY'S DECISION AS TO WHETHER OR NOT THERE HAVE BEEN VIOLATIONS THAT THE GOVERNMENT HAS PROVED BY PROOF BEYOND A REASONABLE DOUBT.

IN THIS CASE THIS JURY DID RETURN VERDICTS OF GUILT AS TO EACH OF THE COUNTS THAT WERE ALLEGED IN THE INDICTMENT, AND THAT BRINGS US TO THIS DATE TODAY.

THE OTHER THINGS THAT I LEARNED ABOUT MR. BALWANI WERE HIS GREAT SUCCESS IN EDUCATION AND THEN FOLLOWING HIS EDUCATION WHAT HE DID WITH THAT EDUCATION, HE WENT FORWARD. HE WAS A SUCCESS IN BUSINESS. HE WORKED AT MICROSOFT FOR A WHILE, BUT THEN HE LEFT AND HE STARTED HIS OWN BUSINESS, AND AS WE KNOW IN SILICON VALLEY HERE, IT IS NOT UNUSUAL, IT'S QUITE THE NORM FOR SOMEONE TO START A BUSINESS, A STARTUP. THAT'S A PHRASE THAT WE ALL KNOW ABOUT. AND WE KNOW WHAT HAPPENS WITH THOSE STARTUPS. OFTENTIMES THE PEOPLE WHO BEGIN THOSE COMPANIES, THEY LOOK FORWARD TO BEING ACQUIRED AND THE ACQUISITION IS SOMETHING THAT PEOPLE SEEK, AND THAT'S CERTAINLY WHAT HAPPENED WITH MR. BALWANI.

THE INVESTIGATION IN THE PROBATION REPORT REFLECTS THAT HE HAD STARTED A BUSINESS, AND THAT HE SOLD THE BUSINESS AT GREAT

1 02:25PM 2 02:25PM 3 02:25PM 02:25PM 4 02:25PM 02:25PM 6 02:25PM 7 02:25PM 8 02:25PM 9 02:25PM 10 02:26PM 11 02:26PM 12 02:26PM 13 02:26PM 14 02:26PM 15 02:26PM 16 02:26PM 17 02:26PM 18 02:26PM 19 02:26PM 20 02:26PM 21 02:26PM 22 02:26PM 23 02:26PM 24 02:27PM 25

PROFIT TO HIMSELF. THAT'S SOMETHING THAT IS VERY COMMON IN THIS VALLEY. AND I WAS GOING TO SAY IT'S INTERESTING, OR PERHAPS TRAGIC IS A BETTER WORD, TO LOOK AT THE PATH OF THIS CASE AND TO REALIZE THAT THAT PATH HAS COME FULL CIRCLE. INSTEAD OF IN A LARGE BUILDING, AN OFFICE BUILDING, A CAMPUS WITH R&D AND LABS AND THINGS AND ENGINEERS, WHAT HAS HAPPENED NOW IS ALL OF THAT HAS COME BACK TO A COURTROOM BECAUSE OF THE JURY'S FINDINGS, BECAUSE OF THE INDICTMENT THAT THE COMMUNITY, AT THE GUIDANCE OF THE GOVERNMENT, THE COMMUNITY ALSO WAS RESPONSIBLE FOR THE INDICTMENT AND THE COMMUNITY HEARD THE TRIAL, AND WE COME BACK TO THIS.

IS THAT WHAT WAS HAPPENING HERE?

MR. COOPERSMITH, YOU SUGGEST THAT THIS WAS A GREAT IDEA, AND YOUR CLIENT WAS ALL IN ON IT. THIS WAS TECHNOLOGY THAT COULD CHANGE THE WORLD, IT COULD CHANGE THE WAY THAT HEALTH CARE IS DISTRIBUTED AND ADMINISTERED, AND YOUR CLIENT HAS SAID HE WAS ALL IN. HE TRAVELLED. THAT WASN'T BEFORE THE JURY. I THINK THIS IS SOMETHING THAT THE PROBATION DEPARTMENT GLEANED FROM HIM. THE JURY CERTAINLY DIDN'T HEAR ANY OF THAT, BUT HIS TRAVEL WAS TO PERHAPS MARKET THE DEVICE AND PROVIDE THAT DEVICE FOR OTHER COUNTRIES, POOR COUNTRIES.

BUT, AGAIN, WE COME FULL CIRCLE. HOW DID THAT HAPPEN? WHAT WAS THE DISRUPTION BETWEEN THIS GENIUS IDEA AND WHAT WAS IT THAT DISRUPTED THAT MACHINE, THAT TECHNOLOGY, THAT BENEFIT TO SO MANY COUNTRIES? AND WHAT THE JURY FOUND WAS THAT IT WAS

1 02:27PM 2 02:27PM 3 02:27PM 02:27PM 4 02:27PM 5 02:27PM 6 02:27PM 7 02:27PM 8 02:27PM 9 02:28PM 10 02:28PM 11 02:28PM 12 02:28PM 13 02:28PM 14 02:28PM 15 02:28PM 16 02:28PM 17 02:28PM 18 02:28PM 19 02:28PM 20 02:28PM 21 02:28PM 22 02:29PM 23 02:29PM 24

02:29PM 25

FRAUD, IT WAS WIRE FRAUD. AND FOR SOME REASON THAT HAPPENED. WE DON'T KNOW WHAT IT WAS. THE JURY HEARD THE EVIDENCE. I SUPPOSE THE JURY HEARD THE EVIDENCE, AND THEY FOUND THAT THE CONDUCT WAS FRAUDULENT.

WHAT I'M SUGGESTING IS WHY DID THAT HAVE TO HAPPEN? AND THIS WAS A SUCCESSFUL BUSINESS. THE IDEA WAS STRONG. THERE WERE MANY INVESTORS GOING, AND THEN THERE WERE PROBLEMS, AS THERE ARE IN EVERYTHING IN LIFE.

AND IN THIS NEW VENTURE PROBLEMS STARTED TO ARISE. THERE WAS A LOT OF, I THINK IT WAS CALLED -- WHAT WAS IT CALLED? IT WAS GHOST OPERATION FOR TEN YEARS AND UNTIL THE MACHINE AND EVERYTHING DEVELOPED. MR. BALWANI CAME INTO THE COMPANY IN 2009 AND THEN THINGS STARTED TO GO FORWARD, BUT THEN THERE WERE PROBLEMS.

AND NOTWITHSTANDING THOSE PROBLEMS, THE DEFENDANTS CHOSE TO GO FORWARD AND CONTINUE WITH DECEPTION I'LL CALL IT, MISLEADING INFORMATION, ACTIVE, MISLEADING AND CONTINUING TO PERPETUATE THE FRAUD EVEN WHEN THEY KNEW THAT THE EVIDENCE INTERNALLY INFORMED THEM THAT THEY COULD NOT PRODUCE WHAT THEY SAID THEY WERE GOING TO PRODUCE TO THEIR INVESTORS. AND THAT'S THE WIRE FRAUD, ISN'T IT? THAT'S THE FRAUD ON THE INVESTORS.

THEY KNEW THERE WERE ISSUES. THEY CONCEALED, THEY MISLED INVESTORS, THEY MISLED PATIENTS. THEY CHOSE TO, FOR SOME REASON, TO IGNORE ALL OF THAT EVIDENCE AND TO GO FORWARD WITH THE INVESTMENTS. THAT'S THE DISRUPTION. THAT'S THE

1 02:29PM 2 02:29PM 3 02:29PM 02:29PM 4 02:29PM 02:29PM 6 02:29PM 7 02:29PM 8 02:29PM 9 02:29PM 10 02:30PM 11 02:30PM 12 02:30PM 13 02:30PM 14 02:30PM 15 02:30PM 16 02:30PM 17 02:30PM 18 02:30PM 19 02:30PM 20 02:30PM 21 02:30PM 22 02:30PM 23 02:30PM 24 02:30PM 25

SUPERSEDING INTERVENING ACTS THAT PREVENTED THERANOS FROM GOING FORWARD WITH THIS TECHNOLOGY THAT HAD SUCH GREAT PROMISE.

WE WONDER WHY, WHY DID THAT HAPPEN? WHAT WAS IT? WAS IT GREED? MR. COOPERSMITH SUGGESTS IT WASN'T BECAUSE HE, MR. BALWANI, WAS A SHAREHOLDER, AND HE LOST MILLIONS OF DOLLARS IN THIS EVENT.

AND MR. SCHENK SAYS, WELL, IT'S A LITTLE DIFFERENT BECAUSE HE'S A STAKEHOLDER, AND THERE WAS SOME HOPE THAT THE COMPANY WOULD, NOTWITHSTANDING THE FRAUD, COME TO FRUITION AND HE WOULD BE QUITE WEALTHY.

SOMEONE SAID, I THINK ONE OF THE LETTERS AND SOMEBODY SAID THAT, WELL, INVESTORS SHOULD ONLY INVEST WHAT THEY EXPECT TO LOSE. IS THAT WHAT HE DID? IS THAT MONEY THAT HE DID NOT HAVE WORRIES ABOUT OR WAS NOT CONCERNED ABOUT PARTING COMPANY WITH? WE DON'T KNOW. I DON'T KNOW, AND I'M NOT SUGGESTING THAT THERE WAS ANYTHING ON HIS PART, HIS CHOOSING NOT TO TESTIFY THAT SHOULD SUGGEST ANYTHING OTHERWISE, AND I'M NOT SUGGESTING IN ANY WAY THAT THERE'S A DEARTH OF EVIDENCE BECAUSE OF THAT AT ALL.

BUT I THINK IT'S JUST THAT ENDURING QUESTION ABOUT WHY DID SUCH A PROMISING COMPANY COME TO THIS END AND WHY DID MR. BALWANI FIND HIMSELF IN THIS?

AND THE EVIDENCE SHOWED THAT HE KNEW ABOUT THE FRAUD. THERE WERE TEXT MESSAGES BETWEEN HE AND HIS CODEFENDANT, THERE WERE CONDUCT THAT WAS ENGAGED IN DIRECTLY BY MR. BALWANI WITH

1 02:31PM 02:31PM 2 3 02:31PM 02:31PM 02:31PM 5 02:31PM 6 02:31PM 7 02:31PM 8 02:31PM 9 02:31PM 10 02:31PM 11 02:31PM 12 02:31PM 13 02:32PM 14 02:32PM 15 02:32PM 16 02:32PM 17 02:32PM 18 02:32PM 19 02:32PM 20 02:32PM 21 02:32PM 22 02:32PM 23 02:32PM 24 02:32PM 25

INVESTORS WHEN HE MET WITH THEM, HE PROVIDED FINANCIAL PROJECTIONS THAT WERE NOT JUST UNREALISTIC, THEY WERE LIES, THEY WERE FRAUD.

AND WAS IT THE NECESSITY TO KEEP THE FINANCES GOING, TO KEEP THE COMPANY GOING JUST ONE MORE, JUST ONE MORE BLOCK, JUST ONE MORE BLOCK, WE'RE ALMOST THERE? IS THAT WHAT IT WAS?

WERE THOSE ACTS OF DESPERATION OR ACTS OF MANIPULATION? THAT CONDUCT IS CONCURRENT WITH THE FRAUD ON THE INVESTORS, AND REGRETTABLY WHAT THE JURY IN THIS CASE FOUND AND WHAT THEY SAW WAS MANIPULATION AND A TRUE FLIGHT FROM HONEST BUSINESS PRACTICES.

AND, OF COURSE, IN HINDSIGHT WHAT WE WOULD RECOGNIZE IS THE SOLUTION SHOULD HAVE BEEN AN INITIATION OF AN ACQUAINTANCE WITH AND A FULSOME RELATIONSHIP WITH HONESTY, TRUTH, AND CANDOR. FOR SOME REASON THAT WAS NOT ENGAGED HERE, AND PERHAPS THAT'S WHY WE ARE AT THIS REGRETTABLE STATE TODAY WHERE MR. BALWANI STANDS BEFORE THE COURT HAVING BEEN CONVICTED OF ALL OF THE COUNTS, INCLUDING THE PATIENT COUNTS IN THIS MATTER, AND THAT IS TROUBLING.

I CERTAINLY RESPECT AND I DO NOTE ALL OF THE GOOD WORKS THAT MR. BALWANI HAS DONE IN HIS LIFE WITH HIS FAMILY AND OTHERS.

THE COURT IS NOT GOING TO IGNORE THOSE FACTORS, AND THEY'RE IMPORTANT FACTORS THAT THE COURT CONSIDERS IN ITS 3553 ANALYSIS AS THE COURT MUST DO.

IN THIS MATTER, AGAIN, RECOGNIZING THAT THE INDIVIDUAL 1 02:32PM BEFORE THE COURT AND HIS HISTORY, THE CHARACTERISTICS, 02:32PM 2 INCLUDING HIS CHARITY AND RECOGNIZING ALL OF THE GOOD THINGS 3 02:33PM 02:33PM 4 THAT HE HAS DONE, THE COURT IS GOING TO IMPOSE A SENTENCE IN 02:33PM 5 THIS MATTER. THE COURT, FIRST OF ALL, WILL ORDER A SPECIAL 02:33PM 6 ASSESSMENT OF \$1200. THAT'S \$100 PER COUNT IN THIS MATTER. 02:33PM 7 AS TO RESTITUTION, COUNSEL, I AM NOT GOING TO ORDER RESTITUTION TODAY. I'M GOING TO DEFER THAT FOR ANOTHER DATE, 02:33PM 8 AND I'LL ASK COUNSEL TO MEET AND CONFER ABOUT A SCHEDULE FOR A 02:33PM 9 02:33PM 10 RESTITUTION HEARING. 02:33PM 11 I'D ALSO INVITE YOU TO CONFER WITH THE CODEFENDANT'S 02:33PM 12 COUNSEL HERE, TOO, TO SEE IF THAT IS A HEARING THAT YOU WOULD 02:33PM 13 LIKE TO ENGAGE IN JOINTLY. AS YOU MIGHT KNOW, I CONTINUED -- I DID NOT MAKE A 02:33PM 14 02:33PM 15 RESTITUTION FINDING IN MS. HOLMES'S CASES. I ASKED COUNSEL TO MEET AND CONFER ABOUT A SCHEDULE FOR THAT. I WOULD INVITE YOU 02:33PM 16 02:34PM 17 ALL TO TALK ABOUT WHETHER OR NOT IT MAKES SENSE TO HAVE ONE 02:34PM 18 RESTITUTION HEARING OR IF YOU WOULD LIKE TO HAVE TWO SEPARATE 02:34PM 19 RESTITUTION HEARINGS OR JUST THE PROTOCOLS FOR THAT, AND THEN 02:34PM 20 YOU CAN CONTACT MS. ROBINSON ABOUT THAT.

02:34PM 21

02:34PM 22

02:34PM 23

02:34PM 24

02:34PM 25

SO I AM DEFERRING RESTITUTION AT THIS TIME, MS. GOLDSBERRY.

IN THIS MATTER THE COURT WILL IMPOSE A FINE OF \$25,000 AS TO COUNTS ONE THROUGH TWELVE. THAT'S CONCURRENT AS TO EACH COUNT, MS. GOLDSBERRY.

1 02:34PM 2 02:34PM 3 02:34PM 02:34PM 4 02:34PM 02:34PM 6 02:35PM 7 8 02:35PM 02:35PM 9 02:35PM 10 02:35PM 11 02:35PM 12 02:35PM 13 02:35PM 14 02:35PM 15 02:35PM 16 02:35PM 17 02:35PM 18 02:35PM 19 02:35PM 20 02:35PM 21 02:36PM 22 02:36PM 23 02:36PM 24

02:36PM 25

I AM NOT GOING TO IMPOSE A SENTENCE OF PROBATION IN THIS MATTER. THE COURT IS GOING TO FIND THAT THERE'S A SUPERVISED RELEASE TERM OF THREE YEARS AS TO EACH COUNT, AND THOSE SHALL RUN CONCURRENT, CONCURRENT TO ONE ANOTHER.

IN THIS MATTER, RECOGNIZING THAT MR. BALWANI WAS CONVICTED OF ALL OF THE COUNTS IN THIS MATTER, AND AGAIN, CONSIDERING THE HISTORY AND CHARACTERISTICS, INCLUDING HIS CHARITY AND GOOD WORKS AND RECOGNIZING ALL OF THAT, THE COURT IS GOING TO IMPOSE A SENTENCE, A GUIDELINE SENTENCE, AND THE COURT FINDS IT'S APPROPRIATE TO IMPOSE A GUIDELINE SENTENCE. THE COURT WILL IMPOSE A GUIDELINE SENTENCE OF 155 MONTHS, AND IN IMPOSING THIS SENTENCE THE COURT FINDS THAT IT IS SUFFICIENT BUT NOT GREATER THAN NECESSARY TO COMPLY WITH THE PURPOSES OF 18 UNITED STATES CODE SECTION 3553.

THE COURT HAS CONSIDERED THE HISTORY AND THE CHARACTERISTICS OF THE DEFENDANT, THE NATURE AND CIRCUMSTANCES OF THE OFFENSE, INCLUDING THE NEED FOR THE SENTENCE IMPOSED TO REFLECT THE SERIOUSNESS OF THE OFFENSE, TO PROMOTE RESPECT FOR THE LAW, TO PROVIDE JUST PUNISHMENT FOR THE OFFENSE, TO AFFORD ADEQUATE DETERRENCE IN CRIMINAL CONDUCT AND ALSO TO AVOID DISPARITY IN SENTENCES OF CO-DEFENDANTS.

THE COURT IMPOSES THIS SENTENCE AFTER CONSULTING THE UNITED STATES SENTENCING GUIDELINES AND IN LIGHT OF THE STATUTORY CONCERNS EXPRESSED IN 18 UNITED STATES CODE 3553(A). MR. BALWANI, SIR, YOU HAVE THE RIGHT TO FILE AN APPEAL.

ANY APPEAL MUST BE FILED WITHIN 14 DAYS. 1 02:36PM 02:36PM 2 DO YOU UNDERSTAND THAT, SIR? THE DEFENDANT: I DO, YOUR HONOR. 3 02:36PM 02:36PM 4 THE COURT: THANK YOU. 02:36PM 5 AS TO A SURRENDER DATE. MR. COOPERSMITH, I WAS GOING TO 02:36PM 6 SUGGEST A SURRENDER DATE SOME TIME IN MARCH, AND I WAS GOING TO IDENTIFY MARCH, EITHER -- LET'S SEE, THE 15TH, NO LATER THAN 02:36PM 7 2:00 P.M., MARCH 15TH, 2023, NO LATER THAN 2:00 P.M. I DIDN'T 02:36PM 8 ASK THE GOVERNMENT IF THEY WANTED TO BE HEARD ON THE SURRENDER 02:36PM 9 02:36PM 10 DATE. PARDON ME. 02:36PM 11 MR. SCHENK: NOTHING FURTHER. THANK YOU. 02:36PM 12 THE COURT: ALL RIGHT. THANK YOU. 02:36PM 13 DID YOU HAVE A DESIRE TO ASK THE COURT TO MAKE A RECOMMENDATION TO THE BUREAU OF PRISON AS TO A LOCATION? 02:37PM 14 02:37PM 15 MR. COOPERSMITH: YES, YOUR HONOR. WE'VE DONE THE LOOKING AT THE VARIOUS FACTORS. WE WOULD ASK THE COURT TO 02:37PM 16 RECOMMEND THE MINIMUM SECURITY SATELLITE CAMP AT LOMPOC. 02:37PM 17 02:37PM 18 THE COURT: ALL RIGHT. 02:37PM 19 MR. COOPERSMITH: AND WE HAVE PARTICULAR LANGUAGE WE 02:37PM 20 WOULD LIKE THE COURT TO CONSIDER USING IN THE JUDGMENT, AND I 02:37PM 21 CAN CITE THAT NOW. 02:37PM 22 THE COURT: LET ME SAY THAT I WAS GOING TO RECOGNIZE 02:37PM 23 THAT THIS WAS A NONVIOLENT OFFENSE, AND THAT MR. BALWANI 02:37PM 24 PRESENTS NO HISTORY OF VIOLENCE. HE HAS NO RECORD, CRIMINAL 02:37PM 25 RECORD. HE'S NOT -- THERE'S NO RECORD OF ANY SUBSTANCE ABUSE

NOR IS THERE ANY RECORD OF VIOLENCE IN HIS BACKGROUND SUCH THAT 1 02:37PM 2 A RECOMMENDATION TO A MINIMUM SECURITY CAMP LIKE FACILITY WOULD 02:37PM BE APPROPRIATE, AND THE COURT WOULD RECOMMEND TO THE BUREAU OF 3 02:38PM 02:38PM 4 PRISONS THAT IT LOCATE HIM AT A FACILITY SUCH AS THAT THAT IS CLOSEST AS POSSIBLE TO ALAMEDA COUNTY OR THE SOUTHERN PART OF 02:38PM 02:38PM 6 SANTA CLARA COUNTY TO AFFORD FOR FAMILY VISITATION BECAUSE THE 02:38PM 7 COURT FINDS THAT FAMILY VISITATION ENHANCES REHABILITATION. THAT'S WHAT I WAS GOING TO STATE. 02:38PM 8 DO YOU WANT TO AUGMENT THAT? 02:38PM 9 02:38PM 10 MR. COOPERSMITH: YES, YOUR HONOR. 02:38PM 11 AND THE CAMP FACILITY THAT WE'RE AWARE OF THAT WOULD FIT 02:38PM 12 THE DESCRIPTION THE COURT JUST GAVE WOULD BE THE SATELLITE CAMP 02:38PM 13 AT ATWATER, BUT WE ARE ASKING THE COURT TO RECOMMEND ASSIGNMENT OF MR. BALWANI TO THE MINIMUM SECURITY CAMP AT LOMPOC, AND THE 02:38PM 14 02:38PM 15 REASON IS THAT IT IS A LITTLE FURTHER AWAY. I THINK IT'S A FOUR HOUR DRIVE INSTEAD OF A TWO HOUR DRIVE FROM HIS CURRENT 02:38PM 16 02:38PM 17 RESIDENCE, BUT NONETHELESS, IT'S A FACILITY THAT HAS MUCH MORE 02:38PM 18 PROGRAMMING AND I THINK IS MORE SUITABLE FOR MR. BALWANI, AND 02:39PM 19 HOPEFULLY HE CAN BE PRODUCTIVE IF THAT'S WHERE HE ENDS UP.

THE COURT: OKAY.

02:39PM 20

02:39PM 21

02:39PM 22

02:39PM 23

02:39PM 24

02:39PM 25

MR. COOPERSMITH: SO WE WOULD LIKE THE COURT TO RECOMMEND THE MINIMUM SECURITY CAMP AT LOMPOC, AND THE COURT HAS ALREADY MADE THE FINDING THAT HIS SECURITY NEEDS DON'T REFLECT THE NEED TO BE CONFINED ABOVE THE CAMP LEVEL, AND I UNDERSTAND THAT'S WHAT THE COURT HAS SAID; IS THAT CORRECT?

02:39PM	1	THE COURT: YES, YES. THE ONE THING I DIDN'T,
02:39PM	2	THERE'S ALSO NO EVIDENCE OF ANY GANG ACTIVITY THAT THE BUREAU
02:39PM	3	OF PRISONS NEEDS TO BE CONCERNED ABOUT.
02:39PM	4	MR. COOPERSMITH: OKAY. SO THAT'S OUR
02:39PM	5	RECOMMENDATION, YOUR HONOR.
02:39PM	6	THE COURT: OKAY. THANK YOU. I WOULD RECOMMEND IF
02:39PM	7	THE LOMPOC CAMP IS AVAILABLE, AFTER THEY EVALUATE MR. BALWANI,
02:39PM	8	I HAVE NO OBJECTION TO THAT BEING HIS SITE.
02:39PM	9	MR. COOPERSMITH: THANK YOU, YOUR HONOR.
02:39PM	10	IN PARTICULAR, IT'S THE SATELLITE CAMP BECAUSE THERE'S
02:39PM	11	ACTUALLY ANOTHER HIGHER SECURITY LEVEL PRISON THERE AS WELL.
02:39PM	12	SO IT'S THE SATELLITE CAMP.
02:40PM	13	THE COURT: IT'S THE MINIMUM SECURITY SATELLITE
02:40PM	14	CAMP.
02:40PM	15	MR. COOPERSMITH: CORRECT, YOUR HONOR.
02:40PM	16	THE COURT: RIGHT. OKAY. ANYTHING FURTHER?
02:40PM	17	MR. SCHENK: NO, YOUR HONOR. THANK YOU.
02:40PM	18	THE COURT: MR. COOPERSMITH, ANYTHING FURTHER?
02:40PM	19	MR. COOPERSMITH: I'M JUST LOOKING AT MY NOTES.
02:40PM	20	NO, YOUR HONOR, NOTHING FURTHER.
02:40PM	21	THE COURT: ALL RIGHT. THANK YOU VERY MUCH. THANK
02:40PM	22	YOU.
02:40PM	23	THANK YOU, COUNSEL.
02:40PM	24	(COURT CONCLUDED AT 2:40 P.M.)
	25	

1	
2	
3	CERTIFICATE OF REPORTER
4	
5	
6	
7	I, THE UNDERSIGNED OFFICIAL COURT REPORTER OF THE
8	UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF
9	CALIFORNIA, 280 SOUTH FIRST STREET, SAN JOSE, CALIFORNIA, DO
10	HEREBY CERTIFY:
11	THAT THE FOREGOING TRANSCRIPT, CERTIFICATE INCLUSIVE, IS
12	A CORRECT TRANSCRIPT FROM THE RECORD OF PROCEEDINGS IN THE
13	ABOVE-ENTITLED MATTER.
14	Ovene Rodriguez
15	Char Lycon And
16	IRENE RODRIGUEZ, CSR, RMR, CRR CERTIFICATE NUMBER 8074
17	
18	DATED: DECEMBER 12, 2022
19	
20	
21	
22	
23	
24	
25	

# **EXHIBIT B**

# To

# Declaration of Jeffrey B. Coopersmith

#### EXCHANGE AND RELEASE AGREEMENT

This **EXCHANGE AND RELEASE AGREEMENT** (this "*Agreement*"), is made and entered into as of May 15, 2017, by and among **THERANOS, INC.**, a Delaware corporation (the "*Company*"), those certain holders of the Company's Series C-1 Preferred Stock ("*Series C-1 Preferred*") and Series C-2 Preferred Stock ("*Series C-2 Preferred*") who are parties hereto (each a "*Holder*" and, collectively, the "*Holders*"), and Elizabeth Holmes.

#### RECITALS

- **A.** Prior to the date hereof, the Company issued and sold in a series of transactions its Series C-1 Preferred and Series C-2 Preferred to certain of the Holders (such transactions, the "*Preferred Stock Financings*").
- B. The Board of Directors of the Company (the "Board") has determined that it is in the best interests of the Company and its stockholders to provide an opportunity for (i) existing holders of the Series C-1 Preferred who purchased Series C-1 Preferred for \$3.00 per share (the "First Series C-1 Preferred," and such Holders, the "First C-1 Holders") to exchange such shares of Series C-1 Preferred into an equivalent number of shares of newly-created Series C-1A Preferred Stock (the "Series C-1A Preferred"), (ii) existing holders of the Series C-1 Preferred who purchased Series C-1 Preferred for \$15.00 per share (the "Second Series C-1 Preferred," and such Holders, the "Second C-1 Holders") to exchange such shares of Series C-1B Preferred") and (iii) existing holders of the Series C-2 Preferred (the "C-2 Holders") to exchange such shares of Series C-2 Preferred into an equivalent number of shares of newly-created Series C-2A Preferred Stock (the "Series C-2A Preferred," and together with the exchange of the First Series C-1 Preferred and the Second Series C-1 Preferred, the "Exchange"), in each case in consideration for a release of claims against the Company.
- **C.** Each of the undersigned First C-1 Holders desires to exchange each share of First Series C-1 Preferred held by such First C-1 Holder for one share of Series C-1A Preferred, in accordance with the terms and conditions of this Agreement.
- **D.** Each of the undersigned Second C-1 Holders desires to exchange each share of Second Series C-1 Preferred held by such Second C-1 Holder for one share of Series C-1B Preferred, in accordance with the terms and conditions of this Agreement.
- **E.** Each of the undersigned C-2 Holders desires to exchange each share of Series C-2 Preferred held by such C-2 Holder (and together with any exchanged shares of First Series C-1 Preferred and Second Series C-1 Preferred, the "*Exchanged Shares*") for one share of Series C-2A Preferred (and together with any shares of Series C-1A Preferred and Series C-1B Preferred, the "*Adjusted Shares*"), in accordance with the terms and conditions of this Agreement.

#### **AGREEMENT**

In consideration of the foregoing premises and the mutual covenants and agreements hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company, each Holder and Elizabeth Holmes agree as follows:

#### 1. Exchange of Shares.

- **1.1.** Prior to the Closing (defined below), the Company shall have adopted and filed with the Secretary of State of the State of Delaware the Amended and Restated Certificate of Incorporation of the Company in the form of Exhibit A attached to this Agreement (the "**Restated Certificate**").
- 1.2. The Company has commenced an exchange offer to each holder of First Series C-1 Preferred, Second Series C-1 Preferred, or Series C-2 Preferred, in compliance with all applicable laws and regulations, offering such holders of First Series C-1 Preferred, Second Series C-1 Preferred, or Series C-2 Preferred the right to participate in the Exchange on the same terms and conditions as those contained in this Agreement, provided that (a) such exchange offer shall close no earlier than twenty (20) business days after commencement thereof (the "Completion Date"); and (b) each holder of First Series C-1 Preferred, Second Series C-1 Preferred, or Series C-2 Preferred that elects to participate in the Exchange shall become a party to this Agreement as a Holder. The Exchange is conditioned upon a minimum of 66 2/3% of the outstanding shares of the Second Series C-1 Preferred and the Series C-2 Preferred (together as a single class) (the "Minimum Holders") electing to participate. If the Minimum Holders do not participate, the Exchange will not be consummated.
- 1.3. On the date that is no later than two (2) business days after the Completion Date, the closing of the Exchange (the "Closing") shall take place whereby each of the Holders will transfer the Exchanged Shares held by such Holder by delivery of the original stock certificates underlying such Exchanged Shares or by executing a form of stock power transferring such Exchanged Shares, and the Company shall issue to each such Holder the Adjusted Shares. Immediately following the Closing, the Exchanged Shares will be cancelled by the Company and shall not be re-issued. This Agreement shall become effective at 5:00 p.m. Pacific Daylight Time on the date on which the Closing occurs (the "Effective Time"). At the Effective Time, each of the undersigned Holders who previously held Exchanged Shares shall then hold Adjusted Shares, in accordance with the terms and conditions of this Agreement. If the Closing does not take place within sixty (60) days after the date of this Agreement, this Agreement, including the provisions set forth in Section 2 of this Agreement (the "Release"), shall automatically terminate and be of no further force and effect. At any time prior to the Effective Time, the Company may, in its discretion, rescind the offer to complete the Exchange.
- 1.4. For United States federal (and applicable state and local) income tax purposes the parties intend that the transactions contemplated by this Agreement be treated as an adjustment to the purchase price paid by the Holders for the First Series C-1 Preferred, Second Series C-1 Preferred, and Series C-2 Preferred, as applicable, and that the transactions not be treated as a taxable event with respect to the Company or any Holder. Without limiting the foregoing, the parties intend that neither the Exchange nor the adjustment to the applicable Conversion Rate (as defined in the Restated Certificate) applicable to a Holder be treated as a distribution for purposes of Section 305 of the Internal Revenue Code of 1986, as amended (the "Code"). The Company shall file (or cause to be filed) all tax returns (including information returns, supplements or other tax filing obligations) in accordance with this Section 1.4 and shall take (or cause to be taken) no position contrary thereto or inconsistent therewith on any tax return or in the course of any audit, litigation or otherwise or make or file any statement or declaration inconsistent therewith unless otherwise required pursuant to a final determination within the meaning of Section 1313 of the Code.
- 1.5. As soon as practicable following the Closing, the Company shall deliver to each Holder participating in the Exchange a certificate or book-entry security entitlement representing the Adjusted Shares being issued to such Holder upon receipt from such Holder of the certificate

representing such Holder's Exchanged Shares (or an affidavit of lost certificate acceptable to the Company) for cancellation. The Company hereby acknowledges, covenants and agrees that in no event shall it issue any Adjusted Shares other than pursuant to this Agreement or in connection with another exchange transaction where holders of First Series C-1 Preferred, Second Series C-1 Preferred, or Series C-2 Preferred are permitted to exchange such shares for Series C-1A Preferred, Series C-1B Preferred, or Series C-2A Preferred, as applicable, subject to the provisions of Section 5 of this Agreement.

1.6. At or prior to the Closing, each of the Company and the Holders shall take such actions and execute such additional documents, certificates and instruments and take such other steps as shall be required to consummate the Exchange expeditiously, and shall take such actions following the Closing as may be required in connection with the agreements and covenants contained herein.

#### 2. Release of Claims.

2.1. Contingent upon and effective as of the Effective Time, each Holder on behalf of itself and its direct or indirect affiliates, agents, trustees, beneficiaries, directors, officers, subsidiaries, estates, successors, assigns, members and partners (collectively, "Releasors"), solely in their capacity as a stockholder of the Company, hereby fully, finally, and forever waives, releases, relinquishes, and discharges the Company and (a) its current and former officers and employees, and each of its and their affiliates, contractors, consultants, auditors, accountants, financial advisors, professional advisors, attorneys, investment bankers, representatives, insurers, trustees, trustors, agents, professionals, spouses, immediate family members, predecessors, successors, assigns, heirs, executors, or administrators, (b) its current and former directors, and each of their affiliates, contractors, consultants, auditors, accountants, financial advisors, professional advisors, attorneys, investment bankers, representatives, insurers, trustees, trustors, agents, professionals, spouses, immediate family members, predecessors, successors, assigns, heirs, executors, or administrators, (c) other stockholders (and any of their affiliates) who execute this Agreement, and (d) their respective successors and assigns, (individually, a "Releasee" and collectively, "Releasees") from any and all claims, demands, losses, rights, obligations, debts, liabilities, and causes of action of any nature whatsoever, whether known or unknown, suspected or unsuspected, direct or derivative, and that have been or could in the future be asserted in any forum, whether foreign or domestic, whether arising under federal, state, common, or foreign law or in equity, which Releasors now have or have ever had or may hereafter have directly or indirectly against any Releasee arising out of, based on, or relating in any way to any transaction with the Company or to their capacity as a stockholder of the Company that has occurred up until and including the date hereof, including, without limitation, any claim, demand, cause of action, obligation, debt and liability arising out of or relating to (i) the ownership of the shares purchased in the Preferred Stock Financings or in connection with the holding, acquisition, or disposition of any securities of the Company, (ii) any purchase agreement and related disclosures associated with the Preferred Stock Financings or the holding, acquisition, or disposition of any securities of the Company, including any agreement based upon or incorporating the Company's representations, warranties and disclosures as set forth in such purchase agreement, as well as any representations, omissions, acts, or facts that have been made by the Company or any of the Releasees up until and including the date hereof, (iii) any alleged violation by the Releasees of any federal, state, local or foreign regulation, rule, or statute regulating securities, including, without limitation, any alleged violation of the Securities Act of 1933, as amended, and the rules and regulations thereunder and any alleged violation of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, and any alleged claim of fraud, fraudulent inducement, negligent misrepresentation, or breach of contract, that arises out of or is related to the Preferred Stock Financings or in connection with the holding, acquisition, or disposition of any securities of the Company, (iv) any breach of fiduciary duty, (v) any actions of, or failures to take an action by, the Board and any committee of the Board in connection with the sale of any shares of the capital stock of the Company, (vi) any claim related to (A) the Company's compliance with applicable healthcare regulatory

laws (B) the Preferred Stock Financings, or (C) the holding, acquisition, or disposition of any securities of the Company, and (vii) any other claim arising out of or related in any manner to the Preferred Stock Financings or in connection with the holding, acquisition, or disposition of any securities of the Company (each a "Holder's Released Claim" and, collectively, the "Holders' Released Claims"). For the avoidance of doubt, nothing contained herein shall release any Releasee from any and all claims, demands, causes of action, obligations, debts and liabilities arising out of or relating to any actions taken by the Releasees that occur after the Effective Time.

**2.2. Release of Unknown Claims**. Each of the Holders hereby waives the benefits of Section 1542 of the California Civil Code (and any comparable law applicable in another jurisdiction), which provides as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

Each of the Holders may hereafter discover facts in addition to or different from those which he, she or it now knows or believes to be true with respect to the subject matter of the Holders' Released Claims or the Releasees, but each Holder expressly, fully, finally and forever settles and releases any and all Holders' Released Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. Each Holder acknowledges that such additional or different facts could materially affect the claims that are being released and the desirability of entering this Agreement. Each Holder further acknowledges that this release of unknown claims was separately bargained for and was a material element of this Agreement.

- **2.3.** Covenant Not to Assert Claim. Each of the Holders hereby irrevocably covenants to refrain from, directly or indirectly, asserting any claim or demand, or commencing, instituting or causing to be commenced, any suit or proceeding of any kind against any Releasee, based upon any matter purported to be released hereby.
- **2.4. No Liability**. Nothing herein shall be construed as an admission of liability by any party.
- 2.5. Final Release. Each party agrees that the releases and discharges contained in this Agreement are given for good and adequate consideration, freely and voluntarily. Each party has had the right to consult with counsel of its choosing in connection with this Agreement and has had ample opportunity to do so. If a party has not consulted with counsel in connection herewith, such party has knowingly and willingly elected not to do so. Each Holder agrees that this Agreement represents a full and final release and discharge of all of the Holders' Released Claims. Each Holder represents and warrants that, other than the Holders' Released Claims, such Holder does not have actual knowledge of any claims, demands, causes of action, obligations, debts or liabilities whatsoever, whether at law or in equity, of such Holder against the Company as of the date hereof.
- **3. Representations and Warranties of the Holders**. Each Holder hereby represents and warrants to the Company, severally and not jointly, that:

- **3.1. Authorization**. The Holder has full power and authority to enter into this Agreement and when executed and delivered by the Holder, this Agreement will constitute valid and legally binding obligations of the Holder, enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors' rights generally, and (b) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.
- 3.2. Purchase for Own Account. The Holder represents that it acquired the Exchanged Shares and is acquiring the Adjusted Shares solely for its own account and beneficial interest for investment and not for sale or with a view to distribution of the Adjusted Shares or any part thereof, has no present intention of selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate a change in such intention. By executing this Agreement, the Holder further represents that the Holder does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Adjusted Shares.
- **3.3. Information and Sophistication**. The Holder hereby: (a) acknowledges that it has received all the information it has requested that it considers necessary or appropriate for deciding whether to exchange its Exchanged Shares for the Adjusted Shares, (b) represents that it has had an opportunity to ask questions and receive answers regarding the terms and conditions of the Exchange and to obtain any additional information necessary to verify the accuracy of the information given to such Holder and (c) further represents that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risk of this transaction and its investment in the Adjusted Shares.
- 3.4. Non-Reliance. The Holder (a) disclaims the existence of and reliance upon any representation or warranty, express or implied, by the Company and/or the Company's Related Parties (as defined below), except as expressly set forth herein, regarding any aspect of this Agreement, the Exchange, the operation or financial condition of the Company, the viability or approvability of its technologies, the commercialization of its technologies, the value of the Company's stock or any other matter relevant to such Holder's determination to enter into this Agreement and to participate in the Exchange, (b) represents that it is not relying upon the Company or any of the Company's Related Parties, or any representation or warranty (or the completeness or accuracy thereof) of the Company or its Related Parties except as set forth herein, in making its decision to exchange shares pursuant to this Agreement, and (c) acknowledges that the Company is relying upon the truth of the representations and warranties in this Section 3.4 in connection with this Agreement. For purposes of this Agreement, "Related Parties" shall mean current and former directors, officers, partners, employees, attorneys, agents, successors, assigns, current and former stockholders (including current and former limited partners, general partners and management companies), owners, representatives, predecessors, parents, affiliates, associates and subsidiaries.
- **3.5. Ability to Bear Economic Risk**. The Holder acknowledges that investment in the Adjusted Shares involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold the Adjusted Shares for an indefinite period of time and to suffer a complete loss of its investment.
- **3.6. Further Limitations on Disposition**. Without in any way limiting or affecting the representations set forth above or any other agreements that exist between the Company and any

Holder, the Holder further agrees not to make any disposition of all or any portion of the Adjusted Shares unless and until:

- (a) there is then in effect a registration statement under the U.S. Securities Act of 1933, as amended (the "Act"), covering such proposed disposition and such disposition is made in accordance with such registration statement; or
- (b) the Holder shall have notified the Company of the proposed disposition and, if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration under the Act or any applicable state securities laws, provided that no such opinion shall be required for dispositions in compliance with Rule 144, except in unusual circumstances.

Notwithstanding the provisions of subsections (a) and (b) above, and without limiting or affecting any agreements that exist between the Company and any Holder, no such registration statement or opinion of counsel shall be necessary for a transfer by such Holder to a partner (or retired partner) or member (or retired member) of such Holder in accordance with partnership or limited liability company interests, or transfers by gift, will or intestate succession to any spouse or lineal descendants or ancestors, if all transferees agree in writing to be subject to the terms hereof to the same extent as if they were a Holder hereunder.

- **3.7. Accredited Investor Status.** Holder is an "accredited investor" as such term is defined in Rule 501 under the Act.
- **Restricted Securities.** The Holder understands that the Adjusted Shares have 3.8. not been, and will not be, registered under the Act, by reason of a specific exemption from the registration provisions of the Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Holder's representations as expressed herein. The Holder understands that the Adjusted Shares are "restricted securities" under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Holder must hold the Adjusted Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Holder acknowledges that the Company has no obligation to register or qualify the Adjusted Shares for resale except as set forth in that certain Amended and Restated Investors' Rights Agreement, dated as of an even date herewith. The Holder further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Adjusted Shares, and on requirements relating to the Company which are outside of the Holder's control, and which the Company is under no obligation and may not be able to satisfy.
- **3.9. No Public Market.** The Holder understands that no public market now exists for any of the securities issued by the Company, and that the Company has made no assurances that a public market will ever exist for the Adjusted Shares.
- **3.10. Legends.** The Holder understands that the Adjusted Shares, and any securities issued in respect thereof or exchange therefor, may bear one or all of the legends substantially in the form set forth below:
  - (a) "THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR

INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933."

- (b) Any legend required by the securities laws of any state to the extent such laws are applicable to the shares represented by the certificate so legended.
- 3.11. Ownership. The Holder owns (of record and beneficially) the Exchanged Shares free and clear of any restrictions on transfer, mortgage, charge, pledge, lien option restriction, right of first refusal, right of pre-emption or third party right or interest other than pursuant to an agreement to which the Company is a party. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any foreign, state or local government authority or other party on the part of such Holder is required in connection with the consummation of the transactions contemplated by this Agreement. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will cause such Holder to be in violation or breach of, or default under, any term or provision of any mortgage, indebtedness, indenture, contract, agreement, instrument, judgment or decree to which it is a party or by which it is bound.
- **3.12.** Tax Advisors. The Holder has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax consequences of this transaction and the transactions contemplated Exchange. With respect to such matters, such Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this Agreement or the transactions contemplated hereby.
- **4. Representations and Warranties of the Company.** The Company hereby represents and warrants to the Holders as follows:
- **4.1. Authorization.** All corporate action on the part of the Company and its directors, officers and stockholders necessary for the authorization, execution and delivery of this Agreement by the Company, the authorization, issuance and delivery of the Series C-1A Preferred, Series C-1B Preferred and Series C-2A Preferred, and the performance of all of the Company's obligations under this Agreement has been taken or will be taken prior to the Closing. The Agreement, when executed and delivered by the Company, shall constitute valid and binding obligations of the Company, enforceable in accordance with their terms, except (i) as limited by laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (ii) as limited by rules of law governing specific performance, injunctive relief or other equitable remedies and by general principles of equity.

#### 4.2. Capitalization.

(a) Immediately prior to the Closing, the authorized capital stock of the Company will consist of (1) 1,010,012,813 shares of Common Stock, (i) 759,354,758 of which are designated Class A Common Stock (the "Class A Common"), 51,761,205 of which are issued and outstanding, and (ii) 250,658,055 of which of which are designated Class B Common Stock, 250,658,055 of which are issued and outstanding; and (2) 308,068,771 shares of Preferred Stock, (i) 46,320,045 of which are designated Series A Preferred Stock, 46,320,045 of which are issued and outstanding, (ii) 53,494,262 of which are designated Series B Preferred Stock, 53,494,262 of which are issued and

outstanding, (iii) 58,810,045 of which are designated Series C Preferred Stock, 58,810,045 of which are issued and outstanding; (iv) 23,008,367 of which are designated Series C-1 Preferred Stock, 23,008,367 of which are issued and outstanding; (v) 18,508,335 of which are designated Series C-1A Preferred Stock, none of which are issued and outstanding; (vi) 4,500,032 of which are designated Series C-1B Preferred Stock, none of which are issued and outstanding; (vii) 32,975,872 of which are designated Series C-2 Preferred Stock, 32,975,872 of which are issued and outstanding; (viii) 32,975,872 of which are designated Series C-1B\* Preferred Stock, none of which are issued and outstanding; (x) 32,975,872 of which are designated Series C-1B\* Preferred Stock, none of which are issued and outstanding; (x) 32,975,872 of which are designated Series C-2A\* Preferred Stock, none of which are issued and outstanding; and (xi) 37 of which are designated Series D-2A Preferred Stock, 37 of which are issued and outstanding. The Common Stock and the Preferred Stock shall have the rights, preferences, privileges and restrictions set forth in the Restated Certificate.

- (b) The outstanding shares have been duly authorized and validly issued in compliance with applicable laws, and are fully paid and nonassessable.
  - (c) The Company has reserved:
    - (i) the Adjusted Shares for issuance pursuant to the Exchange;
- (ii) shares of Class A Common Stock (as may be adjusted in accordance with the provisions of the Restated Certificate) for issuance upon conversion of the Adjusted Shares (the "Conversion Shares");
- (iii) up to an aggregate of 43,681,485 shares proposed to be issued pursuant to one or more equity grants, 39,070,955 of which are to be issued to Elizabeth Holmes (the shares to be issued to Elizabeth Holmes, the "**Proposed Equity**"); and
- (iv) 104,209,647 shares of Class A Common authorized for issuance to employees, consultants and directors pursuant to its 2004 Stock Plan and 2013 Stock Plan, under which options to purchase an aggregate of 2,620,384 shares of Class A Common are issued and outstanding as of the date of this Agreement and restricted stock units amounting to 2,542,995 shares of Class A Common have been granted as of the date of this Agreement.
- (d) The Adjusted Shares, when issued and delivered and paid for in compliance with the provisions of the will be validly issued, fully paid and nonassessable. The Conversion Shares have been duly and validly reserved and, when issued in compliance with the provisions of this Agreement, the Restated Certificate and applicable law, will be validly issued, fully paid and nonassessable.
- **4.3. Governmental Consent.** No consent, approval or authorization of or designation, declaration or filing with any governmental authority on the part of the Company is required in connection with the valid execution and delivery of this Agreement, or the offer or issuance of the Adjusted Shares and the Conversion Shares, or the consummation of any other transaction contemplated by this Agreement, except (i) filing of the Restated Certificate with the office of the Secretary of State of the State of Delaware, (ii) the filing of such notices as may be required under the Securities Act of 1933, as amended (the "Securities Act") and (iii) such filings as may be required under applicable state securities laws.

- 5. Most Favored Terms. In the event that the Company, within the four (4) years following the Closing, enters into an equity transaction involving the issuance of equity securities by the Company with holders of First Series C-1 Preferred, Second Series C-1 Preferred, or Series C-2 Preferred, as applicable, who are not parties to this Agreement ("Nonparticipating Holders") that provides such Nonparticipating Holders with a more favorable conversion rate adjustment, a more favorable adjusted First Series C-1 Preferred, Second Series C-1 Preferred, or Series C-2 Preferred liquidation preference, as applicable, or otherwise reduces the effective investment price of the First Series C-1 Preferred, Second Series C-1 Preferred, as applicable, held by such Nonparticipating Holders as compared to that provided in the Exchange, then the Company shall allow the Holder to participate in such equity transaction on the same terms.
- 6. Relinquishment of Equity. Elizabeth Holmes hereby agrees that she shall, at her election, waive any right to receive the Proposed Equity and/or contribute to the Company shares of Company capital stock owned by her, in an amount equal, in the aggregate and on an as-converted to Class A Common basis, to the sum of (i) the number of additional shares of Class A Common issuable upon conversion of the Series C-2A Preferred actually issued pursuant to the Exchange as a result of the reduction of the conversion price to \$5.00 from \$17.00 for the Series C-2 Preferred exchanged and (ii) the number of additional shares of Class A Common issuable upon conversion of the Series C-1B Preferred actually issued pursuant to the Exchange as a result of the reduction of the conversion price to \$5.00 from \$15.00 for the Second Series C-1 Preferred exchanged (the "Founder Waiver"). Such waiver and/or contribution will occur upon the earlier of (x) September 30, 2017, (y) promptly following receipt by the Company of a 409A valuation for the Company's common stock and determination by the Board of the fair market value of the Company's common stock, and (z) or a Change of Control of the Company. For purposes of this Section 6, a "Change of Control" means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of the Company immediately prior to such consolidation, merger or reorganization, continue to represent a majority of the voting power of the surviving, resulting or acquiring entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related transactions to which the Company is a party in which in excess of 50% of the Company's voting power is transferred; or (iii) the sale or transfer of all or substantially all of the Company's assets, or the exclusive license of all or substantially all of the Company's material intellectual property; provided that a Change of Control shall not include any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any successor, indebtedness of the Company is cancelled or converted, or a combination thereof. Ms. Holmes has elected to provide the Founder Waiver so that the additional shares issuable upon conversion of the new Series C-1B Preferred and Series C-2A Preferred of the Company do not result in dilution of the interest in the Company held by employees, investors and other stockholders.
- 7. Confidentiality. The parties agree that this Agreement and the transactions contemplated hereby (including the Exchange) shall constitute material nonpublic information of the Company and confidential information pursuant to Section 3.2 of that certain Amended and Restated Investors' Rights Agreement dated as of even date herewith, by and among the Company and the other parties thereto, and shall be subject to the confidentiality obligations set forth therein.

#### 8. Governing Law.

**8.1. Choice of Law.** This Agreement and any claim, cause of action, dispute, suit or other proceeding among the parties arising out of or related in any manner to the Agreement shall be

governed, construed and interpreted in accordance with the laws of the state of Delaware, without giving effect to principles of conflicts of law.

- 8.2. Exclusive Forum. EACH PARTY HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE FOR THE PURPOSE OF ANY CLAIM, CAUSE OF ACTION, DISPUTE, SUIT OR OTHER PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT.
- 8.3. Judgment Enforceability. EACH PARTY AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE WILL BE CONCLUSIVE AND MAY BE ENFORCED IN ANY OTHER JURISDICTION (INCLUDING, WITHOUT LIMITATION, THE APPROPRIATE COURTS OF THE JURISDICTION IN WHICH IT IS RESIDENT OR IN WHICH ANY OF ITS PROPERTY OR OFFICES IS LOCATED) BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. EACH PARTY HEREBY CONSENTS TO PERSONAL JURISDICTION AND VENUE BY SUCH COURT OVER SUCH PARTY AND WAIVES ANY DEFENSE OF INCONVENIENT FORUM WITH RESPECT THERETO.
- **9. Revocation.** Once the Holder executes and submits the Agreement to the Company, it hereby covenants not to revoke its participation in the Exchange.
- 10. Successors and Assigns. This Agreement will be binding upon each Holder and its successors and assigns (if any).
- 11. Severability. In the event that any provision of this Agreement, or the application of any such provision to any person or set of circumstances, will be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by law.
- 12. Entire Agreement. This Agreement, including the Release, constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof and supersedes any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof. No party will be liable for or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth in this Agreement.
- 13. Amendments. This Agreement may not be amended, modified, altered or supplemented other than by means of a written instrument duly executed and delivered on behalf of the Company and the holders of a majority of the shares of First Series C-1 Preferred, Second Series C-1 Preferred, and Series C-2 Preferred together as a single class held (or after the execution hereof, previously held) by the Holders; *provided*, *however*, that Section 6 of this Agreement may not be amended or waived without the written consent of Elizabeth Holmes. Notwithstanding the foregoing, the Company may amend this Agreement without consent to add additional holders of Series C-1 Preferred and Series C-2 Preferred hereunder. Notwithstanding anything to the contrary contained herein, at any time prior to the Effective Time, the Company may, in its discretion, rescind its offer to complete the Exchange and this Agreement will not become effective.

- 14. Expenses. Each party shall pay all costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of the Agreement; provided, however, that the Company shall, at the Closing, reimburse the reasonable fees of and expenses of one special counsel to the Holders up to a previously agreed limit and shall reimburse the reasonable fees and expenses of special counsel to Elizabeth Holmes.
- Waiver of Conflicts. Each Holder acknowledges that: (a) it has read this Agreement; 15. (b) it has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of its own choice or has voluntarily declined to seek such counsel; and (c) it understands the terms and consequences of this Agreement and is fully aware of the legal and binding effect of this Agreement. Each Holder understands that Elizabeth Holmes has been represented by Cooley LLP in the preparation, negotiation and execution of this Agreement and that Madrone Partners, L.P. and Soda Springs Partners, LLC have also been represented by Cooley LLP in the preparation, negotiation and execution of this Agreement. Each Holder also understands that Cooley LLP has represented, currently represents, or may in the future represent one or more Holders or their affiliates in matters unrelated to the transactions contemplated by this Agreement, although such matters may be of a nature similar to those contemplated by this Agreement. Each Holder understands that with respect to this Agreement, Cooley LLP has represented only Ms. Holmes, on the one hand, and Madrone Partners, L.P. and Soda Springs Partners, LLC, on the other hand, and not any other Holder or party to this Agreement. The Company and each Holder hereby acknowledge that they have had an opportunity to ask for and have obtained information relevant to such representations, including disclosure of the reasonably foreseeable adverse consequences of such representations, and hereby waives any conflict arising out of such representations with respect to the matters contemplated by this Agreement.
- 16. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, *e.g.*, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

[Signature Page Follows]

COMPANY:

THERANOS, INC.

Ву:

Name: Elizabeth Holmes

Title: Chief Executive Officer

ELIZABETH HOLMES

Ву:\_\_\_\_

Entity Name:		
By: Name: Title:		_
Address:		
HOLDER (IF A	n Individual):	
By:	Olan asennin	
Name:	Alow Elsenman	_
Address:		

Entity Name:				
By:				
Name:				
Title:				
Address:				
HOLDER (IF A	AN INDIVIDUAL):			
By:				
Name:	Andreas	C	Dracopundos	
Address:				

Entity Name:	Bendel Fund
Ву:	E. Rolles
Name:	Christian Bolleter
Title:	Asset Manager
Address:	LGT Fondsleitung AG
	Herrengasse 12
	FL-9490 Vaduz
Ву:	n Individual):
Name:	
Address:	

Entity Name:	Black Diamond Ventures XII-B, L	L
By:		
Name:	Christopher B. Lucar	====
Title:	Managing Director	_
Address:	400 N. Bread Blvd. Suite 950	
	Glandale CA 9/203	
HOLDER (IF A	AN INDIVIDUAL):	
By:		
Name:		-
Address:		_
		_

## Case 5:18-cr-00258-EJD Document 1728-2 Filed 02/10/23 Page 173 of 213

The parties have caused this Exchange and Release Agreement to be executed and delivered as of the date first above written.

HOLDER (IF AN ENTITY):

Address:

Entity Name:	Blue (1055 Bleveshield Venture Pa
By:	
Name:	JOHN Banta
Title:	Managing Director
Address:	225 North Michigan Aver Chitago, Illinois 60601-76
HOLDER (IF A	AN INDIVIDUAL):
By:	
Nama.	

Entity Name:	BOIES, SCHALER ? FISHNER LLP
By: Name: Title:	Any Habie
Address:	2200 CORPORATE BLVD, NW Swite 400 BOLG RATION, FL 33431
HOLDER (IF A	N INDIVIDUAL):
By:	
Name:	
Address:	

Entity Name:	Central Valley Administrators, Inc.
By:	Come Warm.
Name:	Anne Wymer
Title:	Authorized Signatory
Address:	3115 Ocean Front Walk, Suite 301
	Marina del Rey, CA 90292
HOLDER (IF A	AN INDIVIDUAL):
i i i i i i i i i i i i i i i i i i i	
By:	
Name:	
Address:	<u>-                                      </u>

Entity Name:	100
D	
Ву:	
Name:	
Title:	Net file."
	The Contract
Address:	232
	6. 7° 7
70	V 4 V
A 19	at the terminal termi
	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
320 12	
O.	A A
HOLDER (IF AN INDIX	/IDHAL):
HOLDER (IF AN INDIV	VIDUAL):
HOLDER (IF AN INDIV	VIDUAL):
NO	VIDUAL):
Ву:	Selfut
NO	OLIN CAN TEN
Ву:	Selfut

Entity Name:	Cox Investment Holdings, Inc.
By: Name: Title:	Dallas Clement  Dallas Clement  Authorized Signatory
Address:	6250 Peachtree Dunwoody Road Atlanta, GA 30328
HOLDER (IF A	an Individual):
By:	
Name:	
Address:	

#### **HOLDER (IF AN ENTITY):**

Entity Name:	Crofton Capital
By:	Frank & Gordon
Name:	Frank E Gordon
Title:	Managing Partner
Address:	3102 West End Avenue
	Suite 650
	Nashville, TN 37203

#### HOLDER (IF AN INDIVIDUAL):

By:	
Name:	
Address:	

Address:

HOLDER (IF AN	ENTITY):	
Entity Name:		
By:		
Name:		
Title:		
Address:		
HOLDER (IF A	n Individual):	
	() - ()	
By:	David Brien	
Name:	David Boies	

Entity Name:		
By: Name:		
Title:		
Address:		
-		
HOLDER (IF AN INDIVIDUAL):		
Davi	Saniel Carter	
By: Name:	Daniel Carter DANFEL CARTER	
Address:		

HOLDER (IF AN	NENTITY):
	BY ROV CARPARATION, 18 MANAGER
Entity Name:	By POV CORPORATION, 18 MANAGER
By:	Selle elle
Name:	JERRY L JUBERGEN
Title:	CEP )
Address:	al ottowa ALG NW
ridaress.	Grand Rapids MI 49543
	G N.
	- C
HOLDER (IF	AN INDIVIDUAL):
1000	A STATE OF THE STA
By:	P. W.
Name:	Net
Address:	
Address.	<u> </u>
5 N. W.	

HOLDER (IF AN	entity):
Entity Name	EOSon INVESTMENTS M Ltd
By.	2
Name:	HI HITTOHO
Title:	Dilack
Address:	Tyntall Hace Ti-79 Birlis Prood Drughis, Isle of Man
HOLDER (IF	an Individual):
By:	
Name:	AC
Address	

(	
Entity Name:	FOSOn INVESTMENTS N Ltd
By⊬	12-
	HT HZTRONOD
Title:	Director
Address:	Tyrcall Have 17-79 Burks Road Daglas, we of Man
HOLDER (IF	an Individual):
By:	
Name:	
Address:	

### Case 5:18-cr-00258-EJD Document 1728-2 Filed 02/10/23 Page 184 of 213

The parties have caused this Exchange and Release Agreement to be executed and delivered as of the date first above written.

HOLDER (	(IF AN	ENTITY	):

Entity Name: _	
Bv:	
By: _ Name:	
Title:	
Address:	

HOLDER (IF AN INDIVIDUAL):

By: George F. Shutz

Name: Geoge P. Shultz

Address:

Entity Name: _	GORDON	FAMILY	- (Peus
By:			
Name:	TAPPLE	X 13. ]	DNES
Title:	TRUS	FE /	
Address:			
-			
HOLDER (IF A	N INDIVIDUAL):		
By:			
Name:	= 1		
Address:	V.		

Entity Name:	Henry A.	KILLINA	n 201	4 Gran	obiliter
By:	Dodnh	~ +		Trust	
Name:	- of the	O , ,	Mach		=
Title:	TM	star	, , , , ,	,	=
Address:	clo Dan	rel L	LOM.	lun	
	Cravet	A, SWA	-NL &	nova	LLP
	825	Eight	t fru	m	
	mM	NAUCT	un	10019	
HOLDER (IF A	AN INDIVIDUAL):				
D					
By:					-
Name:		-			=0
Address:					_

HOLDER (IF AN	ENTITY):
Entity Name:	MENSORA BOXEO, SA. DE CV.
By:	
Name:	Virta Maine Durilinez Légez
Title:	Altorney is fact.
Address:	
Actor Cos.	
How man (re-	
HOLDER (IF A	n individual):
्र । । । । । । । । । । । । । । । । । । ।	and the second s
Name:	
Address:	·-
보다. 생활	

Entity Name:		
D <sub>vv</sub>		
By:		
Name:		
Title:		
Address:		
Address.		
HOLDER (IF A	AN INDIVIDUAL):	
	DocuSigned by:	
By:	Kendra Jadil	
Name:	Kendra Fadil	
Address:		

Entity Name:	LUCAS VENTURE GROUP IV, LP BY NO GPIVILLE ITS MANAGING MEMBER
L.	NO 6P IVILLE ITS MANAGING MEMBER
By:	Tandl A
Name:	DONALD.A.LUCAS
Title:	MANA BING MEMBER
Address:	545 MIDDLEFIELD ROSTE 220
	MENLO PARK, CA 94025
HOLDER (IF A	n Individual):
By:	
Name:	,>
Address:	

HOLDER (IF AN ENTITY):

Address:

Entity Name: LUCAS VENTUPE BROUP XI, LUC BY
LVE GP IV, LUC ITS MANAGING MEMBER

By: Don of L A (1007)
Name: DONALD A · LUCAS
Title: MANAGING MEMBER

Address: 545 MIDDLEFIELD P.D. STE 220
MENLO PAPK CA 94025

HOLDER (IF AN INDIVIDUAL):

By:
Name:

HOLDER (IF AN	(ENTITY):
Entity Name:	Madrore Partner L. F
D	
By:	2007 KKY
Name:	hong A. Katale
Title:	Maragery Menors
Address:	3. 9 3
HOLDER (IF A	N INDIVIDUAL):
D.,,	
By:	
Name:	
A d duo aa.	
Address:	

Entity Name:	Mondenhall Tf farther
By:	Man Man de la company de la co
Name:	Dates M. MENTIER W.
Title:	GONELAL PART
Address:	Z7 W. TELLACE
	Houston TX 77007
HOLDER (IF A	AN INDIVIDUAL):
D	
By:	
Name:	
Address:	

Case 5:18-cr-00258-EJD Doci	ument 1728-2	Filed 02/10/23	Page 193 of 213
-----------------------------	--------------	----------------	-----------------

**HOLDER (IF AN ENTITY):** 

# By: Daniel L Mosley Name: Daniel L Mosley Title: Martyr Address: Up Crarke Small Share Li 825 Eight Aware Nu York Ny 1419 HOLDER (IF AN INDIVIDUAL): By: Name: Address:

HOLDER (IF AN	NENTITY):
Entity Name:	PEEN VENTURES GROUP III.P.
By	
Name:	JAMES MUTCHZUES
Title:	Marie Porce to
Address:	300 SALO MERE Rd. 3-125
	MENOPANY, SA 94025
HOLDER (IF A	N INDIVIDUAL):
By:	
Name:	
Address:	

Entity Name:	PER VENTORES Group IV. L.V.
By:	
Name:	Janes MUTZUMS
Title:	Manyon Dreceor
Address:	3000 Soud Hele Rd, 3-12
HOLDER (IF A	an Individual):
_	
By:	
Name:	
Address:	

**HOLDER (IF AN ENTITY):** 

# Entity Name:

By:
Name:
Title:

Address:

HOLDER (IF AN INDIVIDUAL):

Name: Richard M. Horocevich

Address:

Entity Name:	
By:	
Name:	
Title:	
Address:	
HOLDER (IF A	N INDIVIDUAL):
11000011(	1
	1.5 11/
By:	City 1. Becker
Name:	PULLEY VIBE CETTEL
ranio.	1.5
Address:	
Madress.	

Entity Name:	Robert K, Kraft LLC
By:	1/3wlst My A
Name:	Robert M. Kraft
Title:	Sole Director of its Manager
Address:	C/O The Kraft Group, One Patriot Place
	Foxborough, MA 02035
en Tri	
HOLDER (IF A	n Individual):
By:	
Name:	
	A <sub>1</sub>
Address:	
	***************************************
12 MeV	

Entity Name:	28%
By:	
Name: Title:	34
Title:	
Address:	
Holder (IF	n Individual):
<b>B</b> y:	X Shen D Esses
Name:	Sharrie EISERMan
Address	
	No.
	·
	•
<u>.</u>	

Entity Name:	SANDBOX CO-INVESTMENT FUND I, LLC
·	DocuSigned by:
By:	
1 (01110)	Ma-bithewso Browns
Title:	Managing Director
Address:	1000 West Fulton Market, Suite 213
	Chicago, IL 60607
HOLDER (IF A	N INDIVIDUAL):
By:	
Name:	
Address:	
Addicss.	
	-
*	

*	
Entity Name:	Soda Springs Partners, LLC
n.	1.01/
By:	pur 1 to p
Name:	Richard D. Chapman
Title:	Vice President
•	
Address:	110 NW 2nd Street, Suite 300
	Bentonville, AR 72712
HOLDER (IF A	AN INDIVIDUAL):
•	
By:	
Name:	
Address:	

Entity Name:	IETON CAPITAL
/By:	In with
Name:	LARRY GEROES
Title:	GEN, STUR
Address:	3000 SANDHILL Pel
	Mento Prone, Ca. 9402
	•
HOLDER (IF	'AN INDIVIDUAL):
By:	
Name:	
Address:	

# **EXHIBIT C**

# To

# Declaration of Jeffrey B. Coopersmith

### Case 5:18-cr-00258-EJD Document 1728-2 Filed 02/10/23 Page 204 of 213

From:

Bob Gordon

To:

Heather King (hking@theranos.com)

Sent:

7/9/2016 12:10:30 AM

Subject:


Theranos - Termination Agreement

Attachments:

Theranos SWY Termination Agmt - Executed 7-8-16.pdf

Executed version attached.

HIGHLY CONFIDENTIAL TREATMENT REQUESTED BY SAFEWAY, INC.



SWYSEC\_000002684

CONFIDENTIAL SBCOLMAN008860

## AGREEMENT TERMINATING MASTER PURCHASE AGREEMENT AND RELEASING CLAIMS

This Agreement Terminating the Master Purchase Agreement and Releasing Claims ("Agreement") is entered into effective as of July 8, 2016 by and between Safeway Inc., a Delaware corporation ("Safeway"), and Theranos, Inc., a Delaware corporation ("Theranos"). Safeway and Theranos are referred to collectively in this Agreement as the "Parties" and each individually as a "Party."

WHEREAS, Safeway and Theranos are parties to that certain Theranos Master Purchase Agreement dated as of September 20, 2010 (the "MPA");

WHEREAS, each Party has undertaken efforts to perform services under the MPA;

WHEREAS, the Parties have disputes about the obligations of the MPA, the ability to perform under the MPA, and the adequacy of such performance;

WHEREAS, the Parties seek to avoid litigation with respect to the performance of their respective obligations under the MPA;

WHEREAS, to resolve any potential legal dispute between the Parties, Safeway and Theranos desire to terminate the MPA, the Option Agreement, dated July 30, 2010, issued in connection therewith, and the Initial Note and Additional Note (the "Notes") issued in connection therewith (the MPA, the Option Agreement and the Notes, collectively, the "Subject Agreements"), to provide for the specified payment, and to release all claims the Parties may have against each other in connection with the Subject Agreements, together with all other claims known and unknown.

NOW, THEREFORE, the Parties agree as follows:

- 1. Termination of MPA. Effective as of July 8, 2016 (the "Effective Date"), the Subject Agreements shall be terminated in their entirety and shall be of no further force or effect, notwithstanding any provision in the Subject Agreements to the contrary, including Section 26.e. of Schedule B to the MPA. Safeway and Theranos acknowledge and agree that upon such termination, (i) the Notes shall be deemed fully paid and discharged for all purposes and all obligations of Theranos under the Notes shall be deemed satisfied in full for all purposes and (ii) all obligations of Theranos with respect to inventory payments under the MPA, including the repayment thereof, shall be deemed satisfied in full for all purposes.
- 2. Payment by Theranos. Within 10 calendar days of the Effective Date, Theranos shall pay to Safeway, in immediately available funds, the aggregate amount of 15 million five hundred thousand dollars (\$15,500,000.00). Such funds shall be paid by wire transfer, to the following account:

1

HIGHLY CONFIDENTIAL FOIA CONFIDENTIAL TREATMENT REQUESTED BY SAFEWAY, INC.

SWYSEC 000002685

Bank of America ABA# 0260-09593 Credit: Safeway Inc. Acct.#: 12333-03048

Notwithstanding any other provision herein to the contrary, the Parties agree that any failure by Theranos to timely complete this required payment will be a material breach of this Agreement. The Parties agree that in the event of such material breach, Safeway shall have the option, in its sole discretion, to enforce this Agreement and take legal action to recover the payment, which is a material term of this Agreement, or to rescind this Agreement rendering the Agreement void ab initio.

Release by Theranos. In consideration of the terms set forth in this Agreement, Theranos and its respective past, present and future parents, subsidiaries, affiliates, stockholders, officers, directors, partners, agents, servants, employees, representatives, family members, attorneys, heirs, executors, conservators, assigns, insurers, trustees, receivers, administrators, predecessors-in-interest, successors-in-interest, and any person claiming, purporting to claim, who can claim or who could have claimed, by, through or under, whether directly or indirectly (the "Theranos Releasors"), hereby irrevocably, unconditionally and fully release and forever discharge to the maximum extent possible, as of the Effective Date, Safeway and its respective past, present and future parents, subsidiaries, stockholders, officers, directors, partners, principals, agents, servants, employees, attorneys, conservators, insurers, trustees, predecessorsin-interest and successors-in-interest (the "Safeway Releasees") from any and all Claims. For the avoidance of doubt, the Claims released here include but are not limited to any claims relating in any way to the Subject Agreements, the relationship of the Parties under the Subject Agreements, any status, term or condition of the Subject Agreements or the termination of the Subject Agreements, or any inventory payment, promissory or convertible note, debt, equity or other obligation or interest. This release extends to and includes, but is not limited to, any Claims by the releasing Party, however denominated, for: breach of any express or implied written or oral contract, including, without limitation, the Subject Agreements; impairment of economic activities or opportunities; defamation; breach of any express or implied covenant of good faith and fair dealing; and any and all other common law or statutory contract and/or tort claims. "Claims" means, individually or collectively, as applicable, any and all actions, causes of action, counterclaims, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, extents, executions, rights, claims, demands, liabilities, setoffs, recoupments, losses, and rights to reimbursement, subrogation, contribution, indemnification or other payment, costs or expenses (including attorneys' fees), in each case whether arising under contract, in law or in equity or by operation of law, of any nature whatsoever, known or unknown, suspected or unsuspected, fixed or contingent, and whether representing a past, present or future obligation, in each case that are connected with, arise out of, relate to or are otherwise based as a whole or in part on any acts, omissions, facts, matters, transactions or occurrences prior to the Effective Date, directly or indirectly, relating to any or all of (i) the Subject Agreements, any ancillary document entered into in connection therewith, any of the transactions contemplated by any of the foregoing, and any actions, inactions or omissions by any personthereunder and (ii) any aspect of any of the dealings or relationships between or among any of

the Safeway Releasees, on the one hand, and any or all of the Theranos Releasees, on the other hand, prior to the Effective Date. Notwithstanding anything contained herein to the contrary, nothing in this definition of "Claims" shall be construed to include any claims or rights to which the Parties are entitled in connection with a breach of any provision, representation, warranty, covenant or agreement contained in this Agreement, or in any concurrently executed or future agreement between the Parties.

The Theranos Releasors acknowledge and understand that hereafter they may discover or appreciate claims, facts, issues or concerns in addition to or different from those that they now know or believe to exist with respect to the subject matter of this Agreement that, if known or suspected at the time of execution of this Agreement, might have materially affected the termination embodied herein. The Theranos Releasors nevertheless agree that the release and waiver described above applies to any such additional or different claims, facts, issues or concerns.

Theranos acknowledges that it is familiar with the provisions of California Civil Code section 1542 ("A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his settlement with the debtor") and specifically waives all rights and releases such claims as referenced therein and in any similar statute or law.

Theranos agrees never to institute a claim of any kind against any Safeway Releasee for any claim, demand, action and/or cause of action released herein. If any Theranos Releasor violates this Agreement by instituting any such claim, then such Theranos Releasor agrees to pay all costs and expenses of defending against the claim incurred by the Safeway Releasee, including reasonable attorney fees, and all further costs and fees, incurred in connection with the defense of the claim.

Release by Safeway. In consideration of the terms set forth in this Agreement, Safeway and its respective past, present and future parents, subsidiaries, affiliates, stockholders, officers, directors, partners, agents, servants, employees, representatives, family members, attorneys, heirs, executors, conservators, assigns, insurers, trustees, receivers, administrators, predecessors-in-interest, successors-in-interest, and any person claiming, purporting to claim, who can claim or who could have claimed, by, through or under, whether directly or indirectly (the "Safeway Releasors"), hereby irrevocably, unconditionally and fully release and forever discharge to the maximum extent possible, as of the Effective Date, Theranos and its respective past, present and future parents, subsidiaries, stockholders, officers, directors, partners, principals, agents, servants, employees, attorneys, conservators, insurers, trustees, predecessorsin-interest and successors-in-interest (the "Theranos Releasees") from any and all Claims. For the avoidance of doubt, the Claims released here include but are not limited to any claims relating in any way to the Subject Agreements, the relationship of the Parties under the Subject Agreements, any status, term or condition of the Subject Agreements or the termination of the Subject Agreements, or any inventory payment, promissory or convertible note, debt, equity or other obligation or interest. This release extends to and includes, but is not limited to, any Claims by the releasing Party, however denominated, for: breach of any express or implied

written or oral contract, including, without limitation, the Subject Agreements; impairment of economic activities or opportunities; defamation; breach of any express or implied covenant of good faith and fair dealing; and any and all other common law or statutory contract and/or tort claims.

The Safeway Releasors acknowledge and understand that hereafter they may discover or appreciate claims, facts, issues or concerns in addition to or different from those that they now know or believe to exist with respect to the subject matter of this Agreement that, if known or suspected at the time of execution of this Agreement, might have materially affected the termination embodied herein. The Safeway Releasors nevertheless agree that the release and waiver described above applies to any such additional or different claims, facts, issues or concerns.

Safeway acknowledges that it is familiar with the provisions of California Civil Code section 1542 ("A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his settlement with the debtor") and specifically waives all rights and releases such claims as referenced therein and in any similar statute or law.

Safeway agrees never to institute a claim of any kind against any Theranos Releasee for any claim, demand, action and/or cause of action released herein. If any Safeway Releasor violates this Agreement by instituting any such claim, then such Safeway Releasor agrees to pay all costs and expenses of defending against the claim incurred by the Theranos Releasee, including reasonable attorney fees, and all further costs and fees, incurred in connection with the defense of the claim.

5. Covenant Not To Sue. Each Party covenants and agrees never to commence, aid in any way, prosecute or cause or permit to be commenced or prosecuted against the other Party any action or other proceeding based upon any claim which is covered by this Agreement and the foregoing release, excluding, however, either Party's right to enforce this Agreement.

### No Reliance, No Duty to Disclose, No Admission.

(a) No Reliance and No Duty to Disclose. Each of the Parties hereto, on behalf of itself and its respective Theranos Releasors and Safeway Releasors, in any capacity, agrees and acknowledges that (a) except as expressly provided in this Agreement, no other Party hereto or any other Releasee, in any capacity, has warranted or otherwise made any representations to it or any of its Releasors or Releasees concerning any Claim released in this Agreement (including any representation concerning the existence, nonexistence, validity or invalidity of any Claim released in this Agreement) and no Releasor has relied on any Releasee in providing the releases and covenants not to sue in this Agreement, (b) the validity and effectiveness of the foregoing releases and covenants not to sue in this Agreement do not depend in any way on any such representations or warranties or the accuracy, completeness or validity thereof, (c) no other Party hereto or any other Releasee, in any capacity, has any duty to disclose or provide any facts or documents (whether material or immaterial, known or unknown,

4

HIGHLY CONFIDENTIAL FOIA CONFIDENTIAL TREATMENT REQUESTED BY SAFEWAY, INC.

SWYSEC\_000002688

suspected or unsuspected) to it or any other Releasor, including any facts or documents which, if known by any Releasor, might have caused such Releasor or any Party to which such Releasor is affiliated not to execute and deliver this Agreement, and (d) each such release and covenant not to sue shall remain in full force and effect even if any facts or documents (whether material or immaterial, known or unknown, suspected or unsuspected) were not disclosed or provided (whether intentionally, unintentionally or otherwise) by any Release to any Releasor, which facts or documents, if known by such Releasor, might have caused such Releasor or any Party to which such Releasor is affiliated not to execute and deliver this Agreement. Nothing contained herein is intended to impair or otherwise derogate from any of the representations, warranties or covenants expressly set forth in this Agreement. "Releasees" means the Safeway Releasees and the Theranos Releasors. "Releasors" means the Safeway Releasors and the Theranos Releasors.

- (b) No Admission. Nothing in this Agreement shall be construed as an admission by any Releasor or Releasee of the existence of any Claim released in this Agreement or of any liability with respect to any or all of such Claim released in this Agreement or any other past or future act, omission, fact, matter, transaction or occurrence.
- 7. Sole Right To Claims. Each Party represents and warrants that no other person or party had or has any interest in the claims referred to in this Agreement; that it has the sole right and exclusive authority to execute this Agreement; and that it has not sold, assigned, transferred, conveyed or otherwise disposed of any claim or demand relating to any matter covered by this Agreement.

### Confidentiality.

The Parties agree to keep the terms of this Agreement confidential and agree not to disclose the terms of this Agreement (1) except as necessary to enforce its terms; and (2) except that the Parties may disclose in confidence to their respective attorneys, officers, agents, insurers, tax advisors and tax return preparers, who need to know them and have agreed, either as a condition to employment or in order to obtain such terms and conditions, or have a professional duty, to be bound by terms and conditions substantially similar to those of this Agreement, the terms of this Agreement and any amounts paid and/or received hereunder; and (3) except as otherwise required by law, rule or regulation, or as required by a court or in response to a lawful request by a governmental authority, or is otherwise necessary to establish rights or enforce obligations under this Agreement, but, in each case, only to the extent that any such disclosure is necessary. Notwithstanding the foregoing, no Party shall disclose or use any Confidential Information of the other Party for any purpose without the other Party's prior written consent, including Confidential Information acquired prior to the Effective Date. All Confidential Information shall remain the property of the Party that disclosed such Confidential Information (or its licensors, as applicable), including any right to make, use or sell any product embodying any Confidential Information. "Confidential Information" means the Subject Agreements, all documents, instruments and agreements related thereto, and all information disclosed by either Party in connection with the Subject Agreements, either prior, on or after the date hereof. "Confidential Information" does not include information which: (i) prior to disclosure by the Party disclosing such information, is or becomes generally known through no fault of the Party receiving such information; (ii) is known to the Party receiving such information at the time of

disclosure, as evidenced by its records; (iii) is furnished to the Party receiving such information by a third party as a matter of right and without restriction on disclosure; (iv) is independently developed by the Party receiving such information without any breach of the Subject Agreements; or (v) is otherwise necessary to establish rights or enforce obligations under this Agreement, but, in each case, only to the extent that any such disclosure is necessary. In the event the receiving Party receives a court order, or is otherwise required by law, to disclose any Confidential Information, the receiving Party will (a) notify Discloser promptly upon receipt of such court order or other request for disclosure, such that Discloser has time to object and/or move for a protective order or confidential treatment and (b) to the extent the information to be disclosed in response to a court order must be filed in court, file any information disclosed in response to such order under seal and/or request that the court seal such Confidential Information. Except as may ultimately be required by such court order or law, the receiving Party's obligations with regard to such Confidential Information, as set forth above, will remain in full force and effect.

For the avoidance of doubt, the provisions of this Paragraph 8(a) apply to the Party as of the Effective Date but do not apply to and cannot be enforced against the Party based on the acts or omissions of any persons who are former employees as of the time of an alleged breach of this provision.

- (b) Promptly following the Effective Date, the Parties will provide written instructions to their respective senior executives (Senior Vice Presidents or more senior) that they shall not make, either directly or indirectly, any oral or written disparaging statements or representations of or concerning the other Party or its affiliates, or any of their businesses, or any of their current or former officers, directors, employees, shareholders, managers or investors, relating to the Subject Agreements or this Agreement; provided, however, that nothing herein shall prohibit (i) necessary communications between the Parties in connection with this Agreement, (ii) either Party from disclosing truthful information if legally required (whether by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process including cooperation with any law enforcement agencies) or (iii) either Party from acting in good faith to enforce such Party's rights under this Agreement. The Parties agree that providing the written instruction to senior executives described in this subparagraph will discharge their respective obligations under this subparagraph.
- (c) Promptly following the Effective Date, the Parties will work together in good faith to establish an agreed upon message that each Party will use if asked to comment on the Parties' relationship.

### 9. Medical Restriction Waiver.

In some locations (e.g., shopping centers) where Safeway operates, there are restrictions against clinics or facilities that specialize in the delivery of medical services and/or advice, or businesses that are engaged in routine, diagnostic or prognostic testing or screening services of the type conducted by medical laboratories, or in the taking, collecting or receiving at such premises specimens or samples for such purposes ("Medical Service Business," the restriction on

6

HIGHLY CONFIDENTIAL FOIA CONFIDENTIAL TREATMENT REQUESTED BY SAFEWAY, INC.

SWYSEC\_000002690

which is hereinafter referred to as a "Medical Service Business Restriction"). With respect to such locations that have a Medical Service Business Restriction, there may be instances where Theranos seeks the assistance of Safeway in removing the restriction so that Theranos can place its business in such a location. In such circumstances, the following provisions shall apply:

- (a) In locations where Safeway has a Lab Business on its premises at the time of Theranos' request, or where a Lab Business has executed an agreement to occupy such Safeway premises, Safeway shall have no obligation to Theranos with respect to any such Medical Service Business Restriction. Where Safeway has entered into a letter of Intent with a Lab Business for locating in such Safeway premises at the time of Theranos' request, Safeway must so notify Theranos no later than 10 days from the request, and Safeway will have 180 days from Theranos' request to execute a definitive agreement at such Safeway premises with such Lab Business. If such definitive agreement is not executed within such 180-day period, Safeway will waive any such Medical Service Business Restriction as to Theranos, and so notify the landlord of its waiver within 10 days of the end of the 180-day period. A "Lab Business" means a Medical Service Business that engages in routine, diagnostic or prognostic testing or screening services provided by a CLIA-certified laboratory, or in the taking, collecting or receiving specimens or samples for such purposes.
- In all other locations, after Theranos has discovered that a specific location where Theranos intends to place its business has a Medical Service Business Restriction, where Theranos provides Safeway with written notice that it has entered into a letter of intent with the applicable landlord for the placement of its business in a such location, Safeway will waive any such Medical Service Business Restriction as to Theranos that is contained in its lease, and so notify the landlord of its waiver within 10 days of Theranos' notice to Safeway. If the restriction arises from a source other than its lease, Safeway shall notify the landlord within 10 days of Theranos' notice to Safeway that it has no objection to Theranos occupying space in such location. For each such location where Safeway has granted a waiver and/or notified the landlord, Theranos shall have 180 days from the date of such notification to the landlord within which to execute a definitive agreement or definitive lease at such location. In the event Theranos has not executed a definitive agreement or definitive lease within such 180-day period, Safeway may withdraw its waiver and/or notify the landlord and Theranos that it no longer seeks to have the Medical Service Business Restriction lifted, and Safeway shall have no further obligation to Theranos with respect to such location.

Except as set forth in this Paragraph 9, Safeway shall have no other duties or obligations with respect to Theranos' requests or efforts to locate its business in locations where there is a Medical Service Business Restriction, including but not limited to giving up other occupancy, signage or parking rights, or seeking or obtaining consents or approvals from government bodies, third parties, or any other person or entity.

10. Governing Law. The construction, interpretation and enforcement of this Agreement shall be governed by the internal laws of the State of California applicable to

7

HIGHLY CONFIDENTIAL FOIA CONFIDENTIAL TREATMENT REQUESTED BY SAFEWAY, INC.

SWYSEC 000002691

contracts made and to be performed wholly within such state, without regard to the conflict of laws rules of any jurisdiction.

### 11. Dispute resolution.

- Except as set forth in Paragraph 11(b), regarding a material breach arising from Theranos's failure to timely pay amounts owed as set forth in Paragraph 2, any dispute, claim or controversy arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate, shall be determined by arbitration in San Francisco County, California, before three (3) neutral arbitrator(s). The arbitration shall be administered by JAMS pursuant to its Comprehensive Arbitration Rules & Procedures, except that the Parties shall agree to (or the arbitration panel shall determine) the scope of discovery and discovery schedule, including with respect to the timing and extent of document production, expert disclosures, and number of depositions. Within thirty (30) days of service of the demand for arbitration, each Party shall appoint one arbitrator and the two Party-appointed arbitrators shall, within twenty (20) days of the appointment of the second arbitrator, appoint the third arbitrator, who shall chair the arbitral tribunal. The Parties shall have no ex parte communications with potential arbitrators and the arbitrators shall not know which party appointed them. The Panel shall have the right to grant legal and equitable relief (including injunctive relief and specific performance) and shall award costs, including reasonable legal fees and costs of arbitration, and interest to the prevailing party. The arbitration proceeding and all testimony, filings, documents, award, and any information relating to or presented during the proceedings shall be deemed to be confidential information not to be disclosed to any other party. Judgment on the award may be entered in any court having jurisdiction.
- (b) In the event of a material breach arising from Theranos's failure to timely pay amounts owed as set forth in Paragraph 2, and in the event Safeway elects in its sole discretion to enforce rather than terminate this Agreement, the Parties agree that Safeway shall have the option, in its sole discretion, to take legal action to recover the amounts owed in any court of competent jurisdiction, or in accordance with the arbitration provisions of Paragraph 11(a). The parties further agree that if Safeway elects to enforce this Agreement in any Court of competent jurisdiction, that Court shall award costs, including reasonable legal fees and interest, to the prevailing party.
- 12. <u>Severability.</u> In case any provision of this Agreement shall be determined to be invalid, illegal or unenforceable for any reason, the remaining provisions of this Agreement shall be unaffected and unimpaired thereby and shall remain in full force and effect to the fullest extent permitted by law.
- 13. <u>Counterparts.</u> This Agreement may be signed in counterpart originals with the same force and effect as though a single original were executed.
- 14. Entire Agreement. This Agreement constitutes the entire agreement of the Parties hereto with respect to the subject matter of this Agreement, and this Agreement supersedes all

Q

HIGHLY CONFIDENTIAL FOIA CONFIDENTIAL TREATMENT REQUESTED BY SAFEWAY, INC.

SWYSEC 000002692

prior agreements between the Parties with respect to the subject matter covered herein, whether written or oral, except as otherwise expressly provided herein.

15. Notices. All notices, requests and other communications hereunder must be in writing and shall be deemed effective upon actual receipt if delivered personally; on the date receipt is acknowledged or refused if mailed by certified mail, postage prepaid, return receipt requested; on the next business day if by overnight delivery by a nationally recognized, reputable, overnight courier; and in any case shall be addressed to the parties at the following addresses:

if to Theranos, to:

Theranos, Inc.
1701 Page Mill Road
Palo Alto, CA 93404
Attention: Heather King
email: hking@theranos.com

if to Safeway, to:

Safeway 11555 Dublin Canyon Road Pleasanton, CA 94588 Attention: Bob Gordon Email: bob.gordon@albertsons.com

IN WITNESS WHEREOF, each of the Parties has executed this Agreement Terminating Master Purchase Agreement and Releasing of Claims as of the date specified next to such Party's signature below.

Dated: July 8 ,2016

Safeway Inc.

Name: R.A. Gordon

Its: EVP General Guestie

Dated: July 8 , 2016

Theranos Inc.

Name: Heather King
Its: General Counse

9